04 University of Plymouth Research Theses

01 Research Theses Main Collection

2023

## Investigating the genomic distribution and potential contribution of retrotransposable elements in relation to their potential impact on genome function and predisposition to human diseases.

## Ali, Randa Aweis

http://hdl.handle.net/10026.1/20184

http://dx.doi.org/10.24382/1020 University of Plymouth

All content in PEARL is protected by copyright law. Author manuscripts are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.

This copy of the thesis has been supplied on condition that anyone who consults it is understood to recognise that its copyright rests with its author and that no quotation from the thesis and no information derived from it may be published without the author's prior consent.



# UNIVERSITY OF PLYMOUTH

## INVESTIGATING THE GENOMIC DISTRIBUTION AND POTENTIAL CONTRIBUTION OF RETROTRANSPOSABLE ELEMENTS IN RELATION TO THEIR POTENTIAL IMPACT ON GENOME FUNCTION AND PREDISPOSITION TO HUMAN DISEASES.

Bу

RANDA AWEIS ALI BSc (Hons)

A thesis submitted to the University of Plymouth in partial fulfilment for the degree of

### DOCTOR OF PHILOSOPHY

School of Biomedical Sciences

October 2021

## Acknowledgements

Praise is to Allah by whose grace good deeds are completed. First and foremost, I would like to extend my greatest gratitude and appreciation to my esteemed supervisor Dr. Elaine Green, whom I would not have gotten this far in my academic journey without her continuous support and encouragement. Thank you for always believing in me and motivating me to carry on, especially at the times when I was doubting myself. You have truly been an excellent mentor. I would also like to extend my deepest appreciation to Dr. Vasilis Lenis for being the best big brother I could have asked for. I cannot thank you enough for always coming to my aid no matter how busy you were and for your continued support, whether with coding issues or life in general. With special thanks to Roxane Dunbar, for helping with this research project and for putting up with my occasionally distracting behaviours in the office. I will always cherish the memories and the fun times we shared during what has been some of the most challenging years of our life so far.

Thank you to all my friends at Plymouth University, with special appreciation to Dr. Doaa Althalathini, Dr. Zainab Bu Sinnah, and Dr. Suhailah Ali, for their friendship, invaluable advice, and continuous support. I am eternally grateful for all the meals you have cooked for me, and I hope our friendship lasts a lifetime, no matter where each of us is around the world.

Hats off to my childhood friends, with special appreciation to Camilla Scanlan and Muna Rahman, who made my transition back to Plymouth so much easier than I could have ever imagined. I do not know how I would have survived without you guys keeping me sane! I do not have the words to express how much I cherish your friendship. All I can say is that I am truly blessed for having you in my life. With thanks from the bottom of my heart to my friend Jeannie Campbell for taking the time to patiently check through sections of my thesis, even the very long one you called "the beast"! I owe you big time!

A huge thank you to my family for being so incredibly kind and supportive, and for always cheering me on and believing in me. I am truly blessed with the best family I could have asked for. With special gratitude to my darling sister Nihad, for also being my best friend. Thank you for always knowing what to say, and for being a source of comfort and joy in what has been a difficult time in my life.

With special thanks to my husband Zaid Al-Hamdi, for being the best life partner, and for putting up with me with patience, kindness, and love. I will always appreciate everything you have done and continue to do for me.

Saving the best for last, with the biggest and most special appreciation to my parents, for I would not be the person I am today without them. To my mum, Zahra Ali Bafadhel, the dedicated housewife who always put us before herself. And to my Dad, Ali Aweis Bafadhel, for putting up with so much to make sure we always had everything we needed. I truly appreciate all the sacrifices you both have made for us so that we could enjoy a better life.

### Author's Declaration

At no time during the registration for the degree of Doctor of Philosophy has the author been registered for any other University award without prior agreement of the Doctoral College Quality Sub-Committee.

The database submitted for this research degree has formed part of Roxane Dunbar's doctor of philosophy degree at the University of Plymouth.

A programme of advanced study was undertaken, which included: BIOM5001 Molecular Biology: Genomics, Transcriptomics, and Proteomics.

Presentations at conferences:

Poster presentation: Plymouth university annual research event 2017

Poster presentation: Plymouth university annual research event 2018

Poster presentation: CSHL Transposable Elements, New York 2018

Poster presentation: Plymouth university annual research event 2019

Word count of main body of thesis: 32,874

Kardant

Signed:

Date: 11/01/2023

#### Abstract

Investigating the genomic distribution and potential contribution of retrotransposable elements in relation to their potential impact on genome function and predisposition to human diseases.

#### Randa Aweis Ali

Active retrotransposable elements (RTEs) provide a continuous source of genomic diversity in humans. The potential impact of a novel RTE insertion depends on its genomic location. Previous studies investigating the landscape of polymorphic RTEs report their higher fraction in functional regions compared with fixed elements, thereby highlighting the potential impact of RTE activity on genome function (GF). However, studies have only recently begun incorporating RTE variants (RTEV) in association with complex human diseases. This study aimed to investigate the impact of RTEs activity on GF and the potential association of RTEV with disease susceptibility. A comprehensive database of all non-reference L1s, Alus, and SVA insertions reported in the literature to April 2019 was curated (n=39,798 RTEs). The curated database includes numerous singleton and rare RTE insertions. Such insertions potentially faced fewer selection pressures compared with common RTEs, thus are likely more representative of RTEs preferred integration site. The genomic distribution of the curated RTEs was compared with the distribution of ancient RTEs that are fixed in the human genome to hypothesise the likely effect of new RTE insertions. Nonreference insertions were found at higher frequencies in functional regions and had a more even genomic distribution than fixed RTEs, suggesting their ability to impact GF. The positional overlap between RTEs and trait-associated SNPs

(TASs) was investigated to determine the potential of RTEs as causal variants in GWAS risk loci. L1s, Alus, and SVA elements were significantly enriched in GWAS risk regions, suggesting the potential impact of RTEV on human health. Next, 354 novel RTE-TAS associations were identified via linkage analysis between RTEVs and genome-wide significant SNPs identified in European populations. Finally, SVA elements likely impose the highest impact on GF and human health based on their genomic accumulation in functional regions and their higher proportion in GWAS risk regions. Collectively, the results of this thesis depict the functional impact of RTEs on GF and human health, which have proven to be invaluable for future association studies to further the current knowledge regarding the aetiology of complex traits and disorders.

**Keywords:** Transposable elements; Polymorphic retrotransposable elements; Structural variants; Causative variant; GWAS; Genome function; Human health

## **Table of Contents**

| Acknowledgements  |
|---|
| Author's Declaration  |
| AbstractV   |
| List of Tables:XI   |
| List of Figures:  |
| List of Abbreviations:XVI   |
| 1. Introduction1  |
| 1.1. Transposable elements (TEs):1  |
| 1. 2. Retrotransposable elements (RTEs) 3                                   |
| 1.2.1. Classes of retrotransposable elements (RTEs)                         |
| 1.2.2. Structural organisation of non-LTR RTEs 4                            |
| <b>1.2.2.1.</b> LINE  |
| <b>1.2.2.2. SINE: Alu</b>   |
| <b>1.2.2.3. SVA</b>   |
| 1.2.3. Mechanism of L1 retrotransposition                                   |
| <b>1.2.4.</b> Alu and SVA elements hijack the L1 machinery9                 |
| <b>1.2.5. Effect of retrotransposition on genome function and integrity</b> |
| <b>1.2.6. Mechanisms of retrotransposition silencing</b>                    |
| <b>1.3. Functional role of TE activity in genome evolution</b>              |
| 1.4. RTEs as structural variants  |
| <b>1.3.1. RTE variants and their detection in the human genome</b>          |
| <b>1.4.2.</b> The effect of RTE variants on human health and disease        |
| 1.5. Summary of current study   |
| <b>1.6.</b> Aims and Objectives   |
| 1.6.1. Research Aims:   |
| <b>1.6.2. Main Objectives:</b> 19   |
| 2. Database curation  |
| 20  |
| 21.1.1. Early methods of RTE discovery:                                     |
| 22 22 22 22 22 22 22 22 22 22 22 22 22                                      |
| 25 2.1.3. Limitations of RTE discovery using NGS data:                      |
| 25 2.1.4. Online databases for non-reference RTE insertions:                |

| 2.1.5.             | Study aims:  | 26              |
|--------------------|--|-----------------|
| 2.2. Me            | thods:   | 27              |
| 2.2.1.             | Criteria of RTE database curation:                                       | 27              |
| 2.2.2.             | Study selection:   | 28              |
| 2.2.3.             | Data curation:   | 32              |
| 2.2.4.             | Quality control:   | 34              |
| 2.2.5.             | Addressing duplicate RTE profiles from the database by individual: .     | 35              |
| 2.3. Res           | sults:   | 37              |
| 2.3.1.             | Study selection:   | 37              |
| 2.3.2.             | Database structure/content:  | 38              |
| 2.3.3.             | General database:  | 39              |
| 2.3.4. D           | atabases by individual for L1Hs, AluY, and SVA_E/F:                      | 40              |
| 2.4. Dis           | cussion:   | 45              |
| 2.4.1.             | Study database vs. existing online databases                             | 45              |
| 2.4.2. Is          | sues with current methods of RTE detection                               | 46              |
| 2.4.3.<br>spectru  | Correlations between population growth rate and allele frequency m       | 47              |
| 2.4.4.<br>selectio | Correlations between population growth rate and efficiency of naturation | <b>al</b><br>48 |
| 2.4.5.             | Study overview   | 49              |
| 3. Geno            | mic Distribution of non-LTR RTEs   | 50              |
| 3.1. Intr          | oduction   | 50              |
| 3.1.1.             | Retrotransposition of L1s, Alus, and SVAs                                | 50              |
| 3.1.2. D           | istribution of endogenous RTEs   | 51              |
| 3.1.3.             | Effects of RTE activity on genome function                               | 52              |
| 3.1.4.             | Effects of RTE activity on human health                                  | 52              |
| 3.1.4.1.           | RTEs and monogenic diseases  | 52              |
| 3.1.4.2.           | RTEs and complex diseases  | 53              |
| 3.1.5.             | Genomic distribution of recent RTE insertions                            | 54              |
| 3.2. Me            | thods  | 61              |
| 3.2.1.             | RTE Datasets   | 61              |
| 3.2.1.             | 1. Non-reference database:   | 61              |
| 3.2.1.             | 2. Reference database:   | 61              |
| 3.2.2.             | Genomic Distribution analyses  | 63              |
| 3.2.2.             | 1. Chromosomal distribution  | 63              |
| 3.2.2.             | 2. Local GC content  | 64              |

|         | 3.2.2.          | 3.        | Distribution in functional regions                      | 65             |
|---------|-----------------|-----------|---|----------------|
|         | 3.2.2.          | 4.        | Local recombination rate                                | 67             |
|         | 3.2.2.          | 5.        | RTEs Enrichment in functional regions and accessible ch | romatin        |
|         | doma            | ains      | 69  |                |
| 3.3.    | Re              | sults     |   | 72             |
| 3       | .3.1.           | Chi       | romosomal distribution                                  | 72             |
|         | 3.3.1.<br>densi | 1.<br>ity | Linear regression analysis of RTE and chromosome size73 | or gene        |
| 3       | .3.2.           | Loc       | al GC content   | 80             |
| 3       | .3.3.           | Dis       | tribution in functional regions                         | 85             |
| 3       | .3.4.           | Loc       | al recombination rate                                   | 92             |
| 3       | .3.5.           | Loc       | al chromatin accessibility                              |                |
| 3.4.    | Dis             | cus       | sion  | 104            |
| 3       | .4.1.           | Chi       | omosomal distribution                                   | 105            |
| 3       | .4.2.           | Loc       | al GC content   | 108            |
| 3       | .4.3.           | Dis       | tribution in genomic regions of functional relevance    | 109            |
| 3       | .4.4.           | Loc       | al recombination rate                                   | 111            |
| 3       | .4.5.           | Loc       | al chromatin accessibility                              | 112            |
| 3       | .4.6.           | Stu       | dy overview and concluding remarks                      | 113            |
| 4. R    | RTEs a          | s po      | tential variants of disease                             | 115            |
| 4       | .1. Intr        | odu       | ction   | 115            |
| 4       | .1.1.           | The       | e missing heritability of complex traits:               | 115            |
| 4       | .1.2.           | Str       | uctural variants and complex traits:                    | 117            |
| 4       | .1.3.           | RTI       | E insertions as SV:                                     | 117            |
| 4       | .1.4.           | RTI       | E-mediated SVs and Complex traits:                      | 119            |
| 4       | .1.5.           | Stu       | dy overview:  | 120            |
| 4.2.    | Me              | thod      | S   | 121            |
| 4       | .2.1.           | Ove       | erview of methods:                                      | 121            |
| 4       | .2.2.           | Dat       | asets:  | 122            |
|         | 4.2.2.          | 1.        | Polymorphic retrotransposable element (RTE) insertions: | 122            |
| 4.2.2.2 |                 | 2.        | Trait associated SNPs:                                  | 123            |
| 4.2.2.3 |                 | 3.        | SNP and RTE genotype files from the 1000 genome project | <b>:t:</b> 123 |
|         | 4.2.2.          | 4.        | Functional regions file:                                | 125            |
| 4       | .2.3.           | Met       | thod of data analyses                                   | 125            |
|         | 4.2.3.          | 1.        | Overlapping RTEs with TAS LD-blocks                     | 125            |
|         | 4.2.3.          | 2.        | Enrichment of RTE variants in GWAS risk loci            | 126            |

| 4.2.3                | .3. LD between RTEs and TAS:   | 127         |
|----------------------|--|-------------|
| 4.3. Re              | sults  | 128         |
| 4.3.1.               | TAS Linkage disequilibrium blocks (LD-blocks):   | 128         |
| 4.3.2.               | Overlapping RTEs with TAS LD-blocks:   | 129         |
| 4.3.3.               | Enrichment of RTEs in TAS LD-blocks:   | 130         |
| 4.3.4.               | LD between RTEs and TAS:   | 133         |
| 4.3.5.<br>regions    | The distribution of RTEs in LD with TAS in functional genomic<br>s:136                       |             |
| 4.4. Dis             | scussion   | 140         |
| 4.4.1.               | RTEs overlap and enrichment in GWAS risk loci  | 140         |
| 4.4.2.               | LD analysis in comparison to previous reports in the literature.                             | 141         |
| 4.4.3.               | Distribution of RTEs in LD with TAS:   | 142         |
| 4.4.4.               | RTEs as causative variants affecting gene expression:  | 143         |
| 4.4.5.               | Study overview and concluding remarks  | 144         |
| 5. Genera            | al discussion and future directions  | 145         |
| 5.1. Da              | tabase curation  | 146         |
| 5.1.1                | . Reflections and limitations  | 148         |
| 5.2. Ge              | nomic distribution of RTEs   | 149         |
| 5.2.1                | . Study limitations  | 152         |
| 5.3. Co              | rrelation between RTEs and TASs  | 153         |
| 5.3.1                | . Study limitations  | 155         |
| 5.4. Su              | mmary of key findings  | 156         |
| 5.5. Fu              | ture directions  | 157         |
| Referenc             | es   | 159         |
| Appendix<br>database | <b>(1:</b> Additional information about the 45 studies included in the curated of this study | d<br>182    |
| Appendix             | <b>2:</b> Full list of RTEs in LD with TAS   | 184         |
| Appendix<br>study    | <b>3:</b> RTE-TAS associations in the literature compared to the results of                  | this<br>194 |

## List of Tables:

| Table 1: Summary of the inclusion and exclusion criteria for curating a        |
|--|
| comprehensive database of retrotransposable element insertions that contribute |
| to the inter-individual genomic diversity28                                    |
| Table 2: Search terms used for extract studies identifying retrotransposable   |
| element insertions in the human genome from PubMed29                           |
| Table 3: Principle investigators queried in PubMed to extract potentially non- |
| indexed recent studies identifying retrotransposable element insertions in the |
| human genome   |
| Table 4: Studies included in the curated non-reference retrotransposable       |
| element (RTE) databases, including the database by individual (db-individual), |
| along with the total number of samples and RTEs pre- and post- quality control |
| (QC) steps   |
| Table 5: Counts of retrotransposable elements (RTE) curated from 45            |
| studies  |
| Table 6: Counts of duplicate RTE profiles in the database-by-individual (db-   |
| individual)41  |
| Table 7: Count and frequency of singleton RTE insertions identified in each of |
| the ethnic groups within the curated database44                                |
| Table 8: Summary of the genomic distribution of old RTEs that are fixed in the |
| human genome, in comparison to the distribution of polymorphic RTE             |
| elements57   |

| Table 9: Count of Reference and Non-Reference LINE 1, Alu, and SVAs per                      |
|--|
| chromosome displaying percentage of the whole genome taken from the                          |
| curated RTE databases72  |
| Table 10: Counts and percentages of RTEs located within intergenic and                       |
| intragenic regions   |
| Table 11: Counts and percentages of RTEs located within enhancer regions of                  |
| the GeneHancer database87  |
| Table 12: Z-test statistics for the distribution of RTEs located within intergenic           |
| and intragenic regions of the NCBI RefSeq genes in comparison with a random                  |
| database including 1,000x iterations88   |
| Table 13: Counts and percentages of RTEs located within recombination                        |
| regions using the standardised sex-averaged (female and male) recombination                  |
| map described by Kong et al., (2010)93   |
| Table 14: Counts and percentages of RTEs located within recombination                        |
| regions using the standardised sex-averaged (female and male) recombination                  |
| map described by Kong et al., (2010)94   |
| Table 15: Empirical P values for the enrichment of RTEs located within                       |
| euchromatin domains using the H3K4me3 profiles of the Roadmap project.                       |
| RTEs are polymorphic insertions curated in-house from published                              |
| studies100   |
| Table 26: The overlap between polymorphic RTEs and the LD-blocks of                          |
| genome-wide significance (P $\leq$ 5x10 <sup>-8</sup> ) TASs. LD blocks were generated using |
| tagging SNPs ( $r^2 \ge 0.8$ ) in PLINK129   |

| Table 17: Polymorphic RTEs in LD ( $r^2 \ge 0.8$ ) with GWAS                            |
|---|
| TAS134  |
| Table 18: A list of the overlap between gene regions and RTEs in LD ( $r^2 > 0.6$ )     |
| with TAS137   |
| Table 19: List of RTEs in LD with TAS that overlap with enhancer                        |
| regions   |
| Table 20: Comparing the list of polymorphic RTEs in LD ( $r^2 > 0.6$ ) with GWAS        |
| TAS identified by previous similar studies with the list of RTE-TAS associations        |
| identified by the current study142  |
| Table 21: Studies included in the curated non-reference retrotransposable               |
| element (RTE) databases, including name of the detection tool used by each              |
| study, information about sensitivity/validation, and source file from which the         |
| insertions in the database got extracted from159  |
| Table 22: Full list of RTEs in LD with TAS  |
| Table 23: List of RTEs in LD ( $r^2 > 0.6$ ) with TAS identified by previous studies in |
| the literature and how it compares to RTE-TAS associations identified by this           |
| study171  |

## List of Figures:

| Figure 1: Components of the human genome2  |
|--|
| Figure 2: Schematic representation for the structural organization of (A) LINE1, |
| (B) Alu, and (C) SVA elements and multiple sequence alignment from various       |
| subfamilies of each element7   |
| Figure 3: L1 retrotransposition cycle8   |
| Figure 4: Schematic representation of polymorphic retrotransposable elements     |
| (RTE) detection using next-generation sequencing data                            |
| Figure 5: Overview of study selection process for curating a comprehensive       |
| database of retrotransposable elements (RTE) insertions                          |
| Figure 6: An overview of the procedure applied for selecting one                 |
| retrotransposable element (RTE) profile for inclusion in the database by         |
| individual when duplicate RTE profiles for the same individual (individual x)    |
| were produced by two studies (study A and B)36                                   |
| Figure 7: Genomic Distribution workflow62  |
| Figure 8: Schematic representation of RTEs enrichment in functional and          |
| accessible chromatin domains70   |
| Figure 9: Scatter plots of the distribution of L1 elements across chromosomes    |
| and gene density75   |
| Figure 10: Scatter plots of the distribution of Alu elements across chromosomes  |
| and gene density77   |

| Figure 11: Scatter plots of the distribution of SVA elements across                |
|--|
| chromosomes and gene density79   |
| Figure 12: Frequency distribution of L1 elements in different GC fractions of the  |
| human genome   |
| Figure 13: Frequency distribution of Alu elements in different GC fractions of the |
| human genome   |
| Figure 14: Frequency distribution of SVA elements in different GC fractions of     |
| the human genome   |
| Figure 15: Frequency distribution (%) of RTEs located within intergenic and        |
| intragenic regions   |
| Figure 16: Frequency distribution (%) of RTEs located within enhancer regions      |
| of the GeneHancer database91   |
| Figure 17: Frequency distribution (%) of RTEs located within different             |
| recombination regions using the standardised sex-averaged (female and male)        |
| recombination map described by Kong et al., (2010)93                               |
| Figure 18: Count of non-reference (polymorphic) RTEs enriched in the               |
| euchromatin domains of at least one epigenome reported in the Roadmap              |
| project  |
| Figure 19: Creating LD-blocks around each trait associated SNP (TAS) using         |
| tagging SNPs with an r2 ≥ 0.8126   |
| Figure 20: Density plot for the enrichment of polymorphic RTEs at GWAS risk        |
| loci131  |

## List of Abbreviations:

- 1KGP: The 1,000 genomes project
- AF: Allele frequency
- ALS: Amyotrophic lateral sclerosis
- ALS: Amyotrophic lateral sclerosis
- Bp: Base pair
- cDNA: Complementary DNA
- CNV: Copy number variation
- dbRIP: Database of Retrotransposon Insertion Polymorphisms
- DPs: Discordant read pairs
- DSBs: Double-strand breaks
- DXP: X-linked Dystonia-Parkinsonism
- EID: Epigenome identifier
- EN: Endonuclease
- eQTL: Expression quantitative trait loci
- ERVs: Endogenous retroviruses
- euL1db: The European database of L1HS retrotransposon insertions in humans
- FL-L1: Full-length L1
- GC-rich: DNA segments rich in guanine and cytosine nucleotides
- GoNL: The Genome of the Netherlands project
- GRC: Genome Reference Consortium
- GWAS: Genome-wide association studies
- GWS: Genome-wide significant
- HERVs: Human Endogenous retroviruses
- HLA: Human leukocyte antigen
- KAP1: KRAB-associated protein 1
- Kb: Kilo base, i.e. 1,000 base pairs

K-S test: Kolmogorov-Smirnov test

Kya: Thousand years ago

L1Hs: Human-specific L1

LD: Linkage disequilibrium

LINE: Long interspersed nuclear element

LncRNA: Long non-coding RNA

LTR: Long terminal repeats

MAF: Minor allele frequency

MaLR: Mammalian apparent long terminal repeats

MaLR: Mammalian apparent LTR

Mb: Mega base i.e. 1,000,000 base pairs

MiRNA: Micro RNA

MRNA: Messenger RNA

NAHR: Non-allelic homologous recombination

NCBI: The National Centre for Biotechnology Information

NGS: Next-generation sequencing

NHGRI-EBI: National Human Genome Research Institute (NHGRI) & European Bioinformatics Institute (EBI).

ORF: Open reading frame

ORFp: Open reading frame protein

PCR: Polymerase chain reaction

PiRNA: Piwi-interacting RNA

Pls: Principal investigators

PMID: PubMed id

Poly(A) tail: Adenine-rich tail

QC: Quality control

RefSeq: The reference Sequence collection

RNP: Ribonucleoprotein

- RT: Reverse transcriptase
- RTE: Retrotransposable element
- SINE: short interspersed nuclear elements
- SiRNA: Small interfering RNA
- SNP: single nucleotide polymorphism
- SNV: Single nucleotide variant
- SR: Split sequencing reads
- SRP: Signal recognition particle
- SRR: Standardised recombination rate
- SV: structural variant
- SVA: SINE-VNTR-Alu
- TAS: Trait associated SNP
- TE: Transposable elements
- TF: Transcription factor
- TPRT: Target-primed reverse transcription
- UCSC: University of California, Santa Cruz
- UTR: Untranslated region
- VNTR: Variable number of tandem repeat
- WGS: Whole-genome sequencing
- XDP: X-linked Dystonia-Parkinsonism

#### 1. Introduction

#### 1.1. Transposable elements (TEs):

Transposable elements (TE) are a common genomic feature in the genomes of many organisms, including prokaryotic and eukaryotic organisms (Kleckner, 1981; Bowen and Jordan, 2002; Touchon and Rocha, 2007). They are genomic segments capable of relocating their position in the genome through one of two mechanisms depending on their class (Bire and Rouleux-Bonnin, 2012). Although the evolutionary origin of TEs in eukaryotes remain murky, numerous studies has suggested horizontal transfer as a common occurrence involved in the evolutionary history of all major TE class (Smit, 1996; Bourque et al., 2018; Zhang et al., 2020).

There are two major classes of TEs that are known to exist within the human genome: DNA transposons and retrotransposable elements (Lander et al., 2001). DNA transposons mobilise through a cut-and-paste mechanism that results in the parent element inserting elsewhere in the genome so that it is no longer present in its original genomic location (Muñoz-López and García-Pérez, 2010). In contrast, retrotransposable elements (RTEs) mobilise through a copy-and-paste mechanism via an RNA intermediate resulting in two elements: the parent element at the original genomic location and a new copy elsewhere in the genome (Boeke et al., 1985; Viollet et al., 2014).

The initial sequencing of the human genome has revealed that at least 45% of the genome is composed of TEs (Figure 1), with potentially more of the human genome owing to sequences derived from TE activity (Lander et al., 2001).

The majority of TEs in the human genome are remnants of ancient TE retrotransposition events that amplified in the genome throughout the evolutionary lineage of modern humans (Boissinot et al., 2004; Ewing and Kazazian, 2010).



Figure 1: Components of the human genome. Over 45% of the human genome is derived from transposable elements, the majority of which are from the non-LTR (long terminal repeat) retrotransposons including LINEs, SINEs, and SVA elements. Figure adapted from "Synergy between sequence and size in Large-scale genomics" by Gregory, 2005, Nature Reviews Genetics, 6(9), p.702; "Transposable elements and psychiatric disorders" by Guffanti et al., 2014, Am J Med Genet B Neuropsychiatr Genet, 165B(3), p. 203.

Ancient TEs are no longer capable of mobilising in the human genome due to the build-up of random inactivating mutations or internal rearrangements (Lander et al., 2001; Wei et al., 2001; Hancks and Kazazian, 2016). DNA transposon activity has reportedly been non-existent in the human genome for the past 50 million years (Lander et al., 2001). Still, several RTE subfamilies retain their ability to

transpose, thus creating insertional polymorphisms in human populations (Wang et al., 2005; Mills et al., 2007; Huang et al., 2010).

RTE insertional polymorphisms can interfere with the function of the human genome (Kazazian, 2004; Hancks and Kazazian, 2016; Bourque et al., 2018), yet the extent to which RTE polymorphisms contribute to human health and disease has not yet been fully explored. This study investigates the effect of relatively recent RTE insertions from the active RTE subfamilies on genome function and how RTE variants from these subfamilies may influence predisposition to complex diseases. It is first necessary to review some of the relevant features of retrotransposable .elements found within the human genome before describing the analyses of this study.

#### 1. 2. Retrotransposable elements (RTEs)

#### 1.2.1. Classes of retrotransposable elements (RTEs)

RTEs are classified depending on the presence or absence of flanking long terminal repeats (LTR). LTR retrotransposons include mammalian apparent LTR (MaLR) and three classes of endogenous retroviruses (ERVs): ERV-class I, ERV (K)-class II, and ERV (L)-class III (Lander et al., 2001). The non-LTR retrotransposons include long interspersed nuclear elements (LINE), short interspersed nuclear elements (SINE) encompassing Alu elements, and SINE-VNTR-Alu (SVA) elements (Lander et al., 2001; Cordaux and Batzer, 2009).

Each RTE subclass is further organized into families and subfamilies, reflecting the evolution of RTE propagation in the human genome (Lander et al., 2001; Cordaux and Batzer, 2009). RTE subfamilies are distinguishable by sequence

variations from the consensus sequence shared by all members of the same RTE subclass (Ovchinnikov et al., 2002; Price et al., 2004; Wang et al., 2005). RTEs of the non-LTR class are the most abundant in humans, which together comprise over a third of the human genome (Figure 1) (Lander et al., 2001; Cordaux and Batzer, 2009). The non-LTR retrotransposons are the main focus of this study, which is why a more detailed description of these RTEs is discussed below.

#### 1.2.2. Structural organisation of non-LTR RTEs

#### 1.2.2.1. LINE

Three LINE families exist in the human genome: LINE1, LINE2, and LINE3 (Lander et al., 2001). The LINE1 (or L1 for short) family is the most recently evolved LINE family and the most abundant TE type in the human genome comprising 16.9% of the genome (Lander et al., 2001). A typical LINE is about 6 kilobases (kb) long and consists of: an internal promoter for RNA polymerase II located in its 5' untranslated region (UTR), two open reading frames (ORF1 and ORF2), separated by 63 base pairs (bp), a 3' UTR and an adenine-rich tail i.e. poly(A) tail (Dombroski et al., 1991) (Figure 2A).

Members of the human-specific L1 subfamily (L1Hs) are the only type of LINE elements that remain active in the human genome (Kazazian et al., 1988). L1s are described as autonomous elements due to their ability to code for the proteins required for their mobilisation in the genome (Moran et al., 1996). SINEs and SVA elements, on the other hand, do not encode any proteins. Instead, they hijack the L1 machinery for their own retrotransposition (i.e. the mechanism of mobilisation), thus they are non-autonomous elements (Dewannieux et al., 2003; Ostertag et al., 2003).

#### 1.2.2.2. SINE: Alu

Alus are the most abundant RTEs in terms of copy number in the human genome, with over 1 million copies that accumulated in the genome from continuous retrotransposition over the past 80 million years of human evolution (Lander et al., 2001). Alu elements diverged from the 7SL RNA gene (Ullu and Tschudi, 1984). Three Alu families exist in the human genome, AluJ, AluS, and AluY, with AluJ showing the most sequence similarity to the 7SL RNA gene and AluY being the most diverged, representing the evolutionary age of the Alu families (Jurka and Smith, 1988; Price et al., 2004). Members of the AluY family, as well as a few subfamilies of AluS, remain active in the human genome (Bennett et al., 2008). A typical Alu element is about 300 bps and consists of two homologous monomers rich in guanine and cytosine nucleotides (GC-rich) and separated by an adenine-rich (A-rich) linker region. The 5' monomer contains A and B boxes, representing the internal promoter derived from the 7SL RNA gene for RNA polymerase III, and the 3' monomer is followed by a poly(A) tail (Figure 2B) (Fuhrman et al., 1981; Dewannieux et al., 2003).

#### 1.2.2.3. SVA

SVA composite elements are the evolutionary youngest TE type in the human genome that potentially evolved during the divergence between humans and the other great apes (Orangutans, Gorillas, and Chimpanzees) about 15 million years ago (Wang et al., 2005). SVAs are also the most recently discovered TE type identified in 1994 by Shen et al. during their investigation of the RP gene structure (Shen et al., 1994). Sequence divergence analysis revealed the existence of 6 SVA subfamilies in the human genome named alphabetically from oldest

(SVA\_A) to the most recently evolved (SVA\_F) (Wang et al., 2005). SVAs from the E and F subfamilies are human-specific and remain active in the human genome (Wang et al., 2005). A typical SVA element is about 2kb long and is composed of five components: a 5' (CCCTCT)n hexamer tandem repeat region, a region homologous to Alu elements (i.e. an Alu-like region consisting of two antisense Alu fragments), a variable number of tandem repeat (VNTR) region made up of between 35 and 50 bp repeats, a SINE region about 490 bp long derived from the human endogenous retrovirus (HERV)-K10, and a poly(A) tail (Figure 2C) (Shen et al., 1994; Ostertag et al., 2003). Unlike L1 and Alu elements, an internal promoter region for SVA elements has not been identified and it has been suggested that these elements rely on the promoter activity of the flanking genomic regions (Wang et al., 2005). Wang et al. (2005) suggested that SVA elements are potentially transcribed by RNA polymerase II, similar to L1 elements, which was later confirmed in the literature via cell culture retrotransposition reporter assays (Hancks et al., 2011; Raiz et al., 2012).



Figure 2: Schematic representation for the structural organization of (A) LINE1, (B) Alu, and (C) SVA elements and multiple sequence alignment from various subfamilies of each element. Sequence alignments are shown below each element, beginning with the oldest to the youngest subfamily that remain active in the human genome. The partial alignment shows the positions of some of the nucleotides that are diagnostic of each subfamily. A A typical full-length long interspersed nuclear element-1 (LINE1 or L1) is about 6 kilobases (kb) long and consists of a 5' untranslated region (UTR), open reading frame 1 (ORF-1), and 2 (ORF-2) encoding the proteins required for L1 transposition, a 3' UTR, and ends with a polyadenylation tail (A)n. B| The structural organisation of a fulllength Alu element. Alus are typically 300 base pairs (bp) long and consist of two homologous monomers separated by an adenine-rich (A-rich) linker region. The 5' monomer contains an internal promoter for RNA polymerase III (A and B boxes), while the 3' monomer ends with a polyadenylation tail (A)n. C| SVAs are composite elements consisting of 5 units: a 5' (CCCTCT)n hexamer tandem repeat region, an Alu-like region consisting of two antisense Alu fragments, a variable number of tandem repeat (VNTR), a SINE region derived from the endogenous HERV-K10 retrovirus, and a 3' polyadenylation tail (A)n. Figure adapted from "The insertional history of an active family of L1 retrotransposons in humans" by Boissinot et al., 2004, Genome Research, 14(7), p.1222; "Standardized nomenclature for Alu repeats" by Batzer et al., 1996, Journal of Molecular Evolution, 42(1), p.4; "Mobile DNA elements in the generation of diversity and complexity in the brain" by Erwin et al., 2014, Nature Reviews Neuroscience, 15(8), p.498; "Identification of polymorphic SVA retrotransposons using a mobile element scanning method for SVA (ME-Scan-SVA)" by Ha et al., 2016, Mobile DNA, 7(1), p.2.

#### 1.2.3. Mechanism of L1 retrotransposition



Figure 3: L1 retrotransposition cycle: A| Full- length L1 source element (FL-L1) is transcribed in the nucleus producing an L1 mRNA. B and C| The mRNA is exported into the cytoplasm, where its ORF1 and ORF2 proteins are translated into ORF1p and ORF2p. D| The translated proteins bind to the source L1 mRNA to form an RNP complex, which is imported back into the nucleus (E). F.| A new L1 that is a copy of the source L1 element is inserted into a new genomic location by target-primed reverse transcription. Figure adapted from "Mobile DNA elements in the generation of diversity and complexity in the brain" by Erwin et al., 2014, Nature Reviews Neuroscience, 15(8), p.498.

The L1 retrotransposition cycle begins with transcription of a full-length L1 source element (FL-L1) by RNA polymerase II from its internal promoter, generating a bicistronic (i.e. encoding two proteins) L1 messenger RNA (mRNA) (Figure 3.A). The generated mRNA is exported into the cytoplasm (B), where the two L1encoded proteins are translated (C). ORF1p is a small protein with RNA-binding properties, and ORF2p is a larger protein, with both endonuclease (EN) and reverse transcriptase (RT) activities. The source L1 mRNA and translated proteins bind to form a ribonucleoprotein complex (RNP) (D) that is imported into the nucleus (E). The EN domain of ORF2p creates a single-strand nick at the opposite strand of its target site (5'-TTTT/AA-3', where "/" indicates the site of EN cleavage). The cleavage exposes a 3'-OH which is used by the ORF2p-RT domain to prime reverse transcription of the L1 mRNA in the new genomic location (F), starting from its 3' -poly(A) tail end, through a process known as target-primed reverse transcription (TPRT). The outcome of this process is a novel L1 insertion, which is a copy of the original FL-L1 source element, at a second genomic location. The source FL-L1 element is capable of producing further L1 copies, flanked by target site duplications, which are characteristic of the retrotransposition process (Hancks, Kazazian and Jr., 2016; Scott and Devine, 2017).

#### 1.2.4. Alu and SVA elements hijack the L1 machinery

Alu and SVA insertions are typically flanked by target site duplications characteristic of the L1 retrotransposition process and suggest that these elements hijack the L1 machinery since they lack any open reading frames (Dewannieux et al., 2003; Wang et al., 2005). A model describing the process by which Alu elements hijack the L1 machinery was described by Dewannieux et al. (2003). This model explains how a domain of the 7SL gene that is conserved in Alu elements associates with the binding site of the signal recognition particle (SRP), a ribonucleoprotein complex that can bind to specific signal peptides. The Alu-bound SRP then interacts with the ribosome, positioning the Alu transcript in close proximity to the L1 mRNA, thus allowing it to capture the L1 ORF2 protein as it is being translated (Figure 3.C). Alu elements that successfully capture the

L1 ORF2 protein during its translation can then replace the L1 transcript with their own during the TPRT process (Figure 3.F) (Dewannieux et al., 2003). Note that the L1 ORF1 protein is not required for Alu retrotransposition, therefore L1 elements with a non-functional ORF1 gene but a functional ORF2 gene can still facilitate Alu mobilisation.

Compared to Alu elements, the process by which SVA transcripts replace the L1 mRNA during the TPRT process is not very well defined. Reporter assays in cell culture confirmed the requirement for both L1 ORF1 and L1 ORF2 proteins for SVA retrotransposition (Hancks et al., 2011; Raiz et al., 2012). The Alu-like domain of the SVA element has been hypothesised to anneal to the SVA transcript with Alu transcripts bound to the SRP ribonucleoprotein complex, which will potentially allow the SVA transcript to capture the L1 ORF2 protein (Mills et al., 2007). This hypothesis is consistent with the results of Raiz et al. (2012) that reported a decrease in the retrotransposition activity of SVA reporter elements with a deleted Alu-like domain in cell cultures by an average of 32-46%, compared with a full-length reporter element.

#### 1.2.5. Effect of retrotransposition on genome function and integrity

The L1 ORF2 protein activity is an obvious source for the potential negative impact of retrotransposition on genome integrity, as it is capable of inducing DNA breakage, as previously discussed. RTE activity can harm genome function and integrity through a variety of mechanisms (Cordaux and Batzer, 2009; Guffanti et al., 2014; Savage et al., 2019). The effect of a new RTE element on genome function depends on the location in which it is inserted. Insertions into gene regions can interfere with mRNA splicing or even introduce new exons within the

interrupted gene (Lev-Maor et al., 2008; Chénais, 2016). RTE insertions can also cause inactivating mutations through inserting into exonic regions (Kazazian et al., 1988; Hancks and Kazazian, 2016). The poly(A) tail of RTE elements can provide polyadenylation signals that can affect the elongation of gene transcription, either by resulting in premature termination or by reducing transcription, consequently reducing gene expression (Perepelitsa-Belancio and Deininger, 2003; Chen et al., 2009).

RTE insertions upstream of gene regions can also affect gene function in many ways. RTEs can induce local epigenetic modifications which could affect the expression of neighbouring genes (Goodier, 2016). Alu and L1 elements carry internal promoter regions that can modulate gene expression of nearby genes (Nigumann et al., 2002; Zhang et al., 2015). Although SVA elements do not have an internal promoter, they are still able to bind to transcription factors, thus are able to modulate the expression of nearby genes (Quinn and Bubb, 2014; Gianfrancesco et al., 2017).

RTE retrotransposition has the potential to destabilise local genomic stability and mediate post-insertional rearrangements. An *in vitro* study reported that the L1 ORF2 protein created more DNA double-strand breaks (DSBs) than the number associated with successful L1 insertions, suggesting the negative impact of L1 activity on genome stability (Gasior et al., 2006). DSBs can drastically effect genome function. Unrepaired DSBs can potentially result in cell death, while incorrectly repaired DSBs can create chromosomal abnormalities such as translocations (Jeggo and Löbrich, 2007).

RTE integration can also cause deletion of genomic DNA at the integration site (Callinan et al., 2005; Han et al., 2005; Lee et al., 2012). Significant deletions and

duplications, resulting from RTE-mediated homologous and non-allelic homologous recombination events, can occur due to the high copy number and sequence homology between RTE elements (Startek et al., 2015; Nazaryanpetersen et al., 2016). RTE elements are also able to duplicate 5' and 3' flanking genomic regions during their retrotransposition, a phenomenon known as sequence transduction. This occurs when RTE transcription starts or carries on outside the element itself as a result of transcription initiation, using a promoter located upstream of the element or transcription elongation past the polyadenylation signal of the element, resulting in 5'- and 3' transduction, respectively (Goodier et al., 2000; Xing et al., 2009). These and other various effects of RTE activity on genome function are extensively reviewed in the literature (Cordaux and Batzer, 2009; Beck et al., 2011; Hancks and Kazazian, 2012; Guffanti et al., 2014; Bourque et al., 2018; Savage et al., 2019).

#### 1.2.6. Mechanisms of retrotransposition silencing

The human genome evolved many methods that act at every stage of the retrotransposition process to suppress RTE activity due to the many negative impacts associated with its activity on genome function and integrity. Pre-transcriptional silencing methods include epigenetic silencing methods such as: repressive histone modifications, heavy methylation of CpG dinucleotides in the promoter region, and KRAB-associated protein 1 (KAP1) mediated chromatin remodelling (Bestor and Bourc'his, 2004; Garcia-Perez et al., 2010; Jacobs et al., 2014).

Post-transcriptional silencing methods include degradation of RTE transcripts through endonucleases guided by short non-coding RNAs (typically 20-30 bp)

such as small interfering and Piwi-interacting RNAs (siRNA and piRNAs, respectively) (De Fazio et al., 2011; Chen et al., 2012; Goodier, 2016).

Additional host defence mechanisms exist that appear to limit the size of RTE insertions during the final stage of integration (Perepelitsa-Belancio and Deininger, 2003; Coufal et al., 2011). A detailed explanation of the named silencing mechanisms plus additional silencing mechanisms are reviewed in the literature (Goodier, 2016; Hancks and Kazazian, 2016; Yang and Wang, 2016).

#### **1.3.** Functional role of TE activity in genome evolution

The persistence of TE activity in the human genome despite their potential to genome function and the negatively impact many mechanisms of retrotransposition silencing poses the question about their role in genome function and evolution. Empirical studies owed the continuity of TE activity throughout the evolutionary history of eukaryotic genomes to the selfish and parasitic properties of these elements, evident by their ability to replicate faster than their host (Doolittle and Sapienza, 1980; Orgel and Crick, 1980; Kidwell and Lisch, 2001). There is now growing evidence supporting the original perspective of Barbara McClintock, the scientist responsible for TE discovery, who suggested that TEs may contribute to gene regulation (McClintock, 1956). TEs are now believed to have provided the source for the evolution of the majority of regulatory elements in the human genome through exaptation, i.e., the process by which TEs are harnessed to provide new functions, thereby facilitating the adaptation of their host to defined selective pressures (Jacques et al., 2013; Su et al., 2014; Chuong et al., 2017; Bourgue et al., 2018).

Many mechanisms by which TE-derived sequences contribute towards the regulation of the human genome, both in cis and in trans, have been reported in the literature (Smalheiser and Torvik, 2005; Johnson and Guigó, 2014; Elbarbary et al., 2016; Trizzino et al., 2018). Genome-wide assays have revealed that most TE-derived regulatory elements originate from ancient insertions that are now fixed in the human genome (Lowe and Haussler, 2012; Lynch et al., 2015; Trizzino et al., 2018). TE-derived cis-regulatory sequences include promoters, enhancers, and transcription factor (TF) binding sites that can interact with regulatory elements such as activator and repressive elements (Jordan et al., 2003; Lowe and Haussler, 2012; Su et al., 2014). At least 475 experimentally validated promoters and ~20% of TF binding sites in the human genome contain sequences derived from TEs (Jordan et al., 2003; Sundaram et al., 2014). TEs also provided the source for many micro RNAs (miRNAs) and long non-coding RNAs (IncRNAs) that can act as cis- or trans-regulatory elements with the potential to modulating gene expression or contribute towards posttranscriptional regulation of many genes (Smalheiser and Torvik, 2005; Johnson and Guigó, 2014).

Qin et al. (2015) identified 409 miRNAs derived from TE sequences, while Kelley and Rinn (2012) reported that about 42% of >7,600 human IncRNA sequences are derived from TEs. Other TE-derived regulatory sequences include transcription terminators (Conley and Jordan, 2012) and chromatin looping binding sites (Diehl et al., 2020). In addition to donating regulatory elements, TEs can also source and modulate regulatory networks that control complex biological pathways (Wray et al., 2003; Feschotte, 2008; Sundaram et al., 2014).

Studies have demonstrated the contribution of TE elements in mediating novel regulatory networks in the uterus during the evolution of mammalian pregnancy (Lynch et al., 2011; Lynch et al., 2015). Genome-wide ChIP analysis revealed that about one-third of the p53 regulatory protein binding sites are mediated by primate-specific ERV TEs, suggesting the role of TE elements in mediating species-specific transcriptional networks (Wang et al., 2007). An integrated genome-wide analysis has also confirmed the greater impact of species-specific TEs in mediating gene regulations (Zeng et al., 2018). Taken together, the process by which TEs contribute towards their host adaptation to selective pressures by providing the source for novel gene regulations is still ambiguous. One of the main challenges in achieving this knowledge is working backward, to study events that have already taken place millions of years ago, to understand the specific steps that led to TEs exaptation.

#### **1.4.** RTEs as structural variants

#### 1.3.1. RTE variants and their detection in the human genome

Despite the many genomic mechanisms to suppress RTE activity, some active elements escape such that individual genomes acquire additional RTE copies (Kazazian et al., 1988; Wang et al., 2005; Bennett et al., 2008; Guffanti et al., 2014; Hancks and Kazazian, 2016). When this occurs in tissues, the active RTEs create intra-individual somatic variations, which are not inherited by future generations (Reilly et al., 2013; Scott et al., 2017; Faulkner and Billon, 2018). In contrast, active RTEs that escape genome suppression in the germline create inter-individual variations that are inherited by future generations (Huang et al.,

2010; Akagi et al., 2013). Such insertions can create structural polymorphisms within and between populations depending on the time of their integration with respect to human evolution (Rishishwar et al., 2015). Initial studies investigating the rate of new RTE insertions per generation estimated that 1 new L1, Alu, and SVA elements occur in every 20-270, 20, and 900 births, respectively (Cordaux et al., 2006; Xing et al., 2009; Ewing and Kazazian, 2010; Beck et al., 2011). More recent pedigree-based estimates for the rate of new RTE elements are 1 new L1 and SVA elements for every 63 births, and 1 new Alu element per 40 births (Feusier et al., 2019). These new estimates suggest that SVA elements are more active while Alu elements are not as active in the human genome as previously thought. RTEs are often neglected in genomic studies despite their ongoing contribution to creating structural variations in humans, because of their repetitive nature and high sequence homology, which makes them difficult to detect and study (Rishishwar et al., 2017; Bourgue et al., 2018). Detection of RTE variants from next-generation sequencing (NGS) data requires specialised computational tools (Ewing, 2015; Goerner-potvin and Bourgue, 2018). Currently, the most accessible method of RTE detection rely on short-read NGS data and computational detection tools such as MELT (Gardner et al., 2017) and Mobster (Thung et al., 2014). These tools are designed with the consideration of the uniqueness of short-read NGS data alignment to the reference human genome and to RTE consensus sequences (Goerner-potvin and Bourque, 2018). However, different tools analysing the same sample produce varying results, despite the similarity in the fundamental algorithmic design (Rishishwar et al., 2016). Consequently, the full scope of structural variations mediated by RTE insertions is still under-represented in RTE detection studies.

Long-reads from sequencing technologies such as PacBio (Pacific Biosciences; Rhoads and Au, 2015) and MinION (Oxford Nanopore; Lu et al., 2016) are more likely to span the entire length of an RTE insertion plus their flanking genomic sequences. As such, the increasing length of NGS reads plus the continuous improvement of RTE detection tools is likely to resolve the issues of accuracy and precision of RTE detection within the human genome.

#### 1.4.2. The effect of RTE variants on human health and disease

RTE elements that are fixed in the human genome tend to accumulate in nonfunctional genomic regions (Lander et al., 2001) yet *de novo* germline RTE insertions do insert in functional regions. Such insertions are responsible for ~1/1000 disease-causing mutations (Lutz et al., 2003), and about 124 germline RTE-mediated insertional mutations that are known to cause monogenic diseases are reported in the literature (Hancks and Kazazian, 2016). The lack of RTE fixation in coding regions, despite their ability to integrate into functional regions, supports the role of natural selection in shaping the genomic landscape of ancient insertions (Medstrand et al., 2002; Abrusán and Krambeck, 2006; Kvikstad and Makova, 2010; Zhang et al., 2011).

In contrast, the landscape of recent RTE insertions is unlikely shaped by selection, a slow process that takes place over many generations (Huang et al., 2010). Conflicting results about the genomic distribution of recent RTE insertions have been reported in the literature (Ovchinnikov et al., 2001; Medstrand et al., 2002; Boissinot et al., 2004; Beck et al., 2010). The integration of active RTEs into coding regions suggests the negative impact of retrotransposition on genome function and the potential implication of recent insertions with regards to human health and disease. Indeed, recent studies have shown that somatic RTE
insertions in epithelial cells frequently drive tumorigenesis, so much so that it is now believed to be a hallmark feature of epithelial cancers in humans (Shukla et al., 2013; Scott et al., 2016; Zampella et al., 2016). Moreover, accumulating evidence supporting the role of somatic retrotransposition in neuronal plasticity and possibly in neuropsychiatric disorders has been published (Baillie et al., 2011; Erwin et al., 2014; Upton et al., 2015; Doyle et al., 2017). Structural variants derived from germline RTE insertions are also likely contributors towards phenotypic variations and individual predisposition to complex disorders. RTE variants are often in linkage disequilibrium with nearby SNPs (Higashino et al., 2014; Kuhn et al., 2014), and they can modulate the expression of nearby genes (Wang et al., 2017; Spirito et al., 2019). This suggests that they may cause differential gene expression between individuals in the population. Nevertheless, the relationship between germline RTE variants and predisposition to complex disorders remains ambiguous.

# 1.5. Summary of current study

Active RTE elements are an ongoing source of threat to the human genome given their disruptive nature and ability to impact genome regulation, yet the full scope of their integration, genomic distribution, and contribution towards complex disorders remains ambiguous. A comprehensive database of polymorphic RTE insertions was curated using online RTE databases and peer-reviewed publications in the literature. The curated database was used to investigate the genomic distribution of polymorphic RTEs by comparing it with the distribution of fixed RTE elements. The distribution analysis revealed the extent of RTE retrotransposition impact on genome function. Polymorphic RTEs in linkage disequilibrium with SNPs significantly associated with risk of various complex

traits and disorders were identified, providing a list of putative causative variants in risk loci.

# 1.6. Aims and Objectives

# 1.6.1. Research Aims:

Several RTE elements retain their ability to transpose in the human genome, thereby creating new insertions that contribute to the genomic diversity of humans. Yet, the extent of the continuous effect of RTE activity on genome function and the potential contribution of recent insertional polymorphisms as causative variants of diseases remains an open question. This thesis aimed to investigate the impact of RTE activity on genome function and the potential susceptibility. To this end, the landscape of recent RTE insertions and their positional overlap with trait-associated SNPs has been investigated to establish whether RTE activity may pose a high risk to genome function and contribute to human health and disease.

# 1.6.2. Main Objectives:

- Curate a comprehensive database of known RTE variants from the active L1, Alu, and SVA subfamilies using publicly available online databases plus peer-reviewed journal articles.
- Use the curated database to investigate the potential effect of RTE activity on genome function by comparing the genomic distribution of polymorphic RTE insertions against the distribution of endogenous RTE elements fixed in the human genome.

- Investigate the enrichment of polymorphic RTE elements in GWAS risk loci to establish the potential contribution of polymorphic RTEs as causative variants of complex diseases.
- 4. Curate a list of RTE variants in linkage disequilibrium with trait-associated SNPs that could potentially be causative variants of complex disease.

#### 2. Database curation

### 2.1. Introduction:

The average human genome is composed of 17% L1s, 11% Alus, and 0.13% SVA elements, the majority of which are remnants of ancient retrotransposition events that took place throughout the evolutionary lineage of modern humans (Lander et al., 2001; Gregory, 2005; Quinn and Bubb, 2014). RTE insertions of ancient subfamilies are now fixed in the genome of individuals from all races i.e. they are present in the same location in the genome of all individuals in all populations (Lander et al., 2001; Ewing and Kazazian, 2010). These ancient RTE subfamilies are no longer capable of retrotransposition due to 5' and 3' truncations. build-up of random inactivating mutations. or internal rearrangements (Lander et al., 2001; Wei et al., 2001; Hancks and Kazazian, 2016). Only the youngest, most recently evolved RTE subfamilies remain capable of active retrotransposition in humans including elements from the L1Hs (for human-specific), AluY, and SVA E/F subfamilies (Myers et al., 2002; Wang et al., 2005; Feusier et al., 2017). The evolutionary young and active RTE subfamilies are distinguishable from ancient subfamilies by sequence variations that deviate from the consensus sequence (Myers et al., 2002; Raiz et al., 2012;

Witherspoon et al., 2013; Konkel et al., 2015) as previously shown on Figure 2 (Chapter 1, page 7).

The average human genome is estimated to carry between 80-100 L1Hs elements (Brouha et al., 2003), 852 Alus (Bennett et al., 2008), and 56 SVAs (Bennett et al., 2004) that are actively transposing. Retrotransposition events of the active RTE subfamilies create insertional polymorphisms within and between populations. As such, an insertion within a defined genomic location can be either present or absent in the genome of two unrelated individuals within a population. Such insertions are not part of the reference genome assembly. These polymorphic RTEs contribute to the genetic diversity of the human genome, and have the potential to influence host susceptibility to disease depending on their genomic location (Bourque et al., 2018; Gardner et al., 2019; Hormozdiari et al., 2019).

# 2.1.1. Early methods of RTE discovery:

Characterising polymorphic RTE insertions in the human genome is troublesome due to their repetitive nature and high sequence homology with ancient subfamilies. PCR display was one of the early methods of polymorphic RTE detection in the human genome (Sheen et al., 2000; Ovchinnikov et al., 2001). It involved two successive PCR experiments: the first experiment being amplified using a set of RTE-specific and non-specific arbitrary primers, and the second reaction amplified with a nested primer characteristic of the active RTE subfamily plus the same non-specific primer of the first experiment. The nested PCR experiment was then followed by southern blot hybridisation using an oligonucleotide probe that is also complementary to the diagnostic sequences of the active subfamily. The chromosomal location of polymorphic insertions were then characterised as

the insertions that are only visible in few of the tested individuals (Sheen et al., 2000; Ovchinnikov et al., 2001). A second example of the early efforts to characterise polymorphic RTE detection involved DNA shredding/fragmentation and PCR amplification with primers complementary to the diagnostic sequences of the active RTE subfamily (Boissinot et al., 2004; Mamedov et al., 2005). The PCR products were then cloned into vectors that were grown in bacterial cultures followed by a number of steps that were designed to identify clones holding polymorphic insertions. Clones that were long enough to contain a polymorphic insertion plus flanking genomic sequences were eventually sequenced via Sanger sequencing and the genomic location of the sequenced insertions were finally identified in the public databases using BLAST and BLAT (Boissinot et al., 2004; Mamedov et al., 2005). Consequently, previous studies characterizing polymorphic RTE insertions using these labour-intensive methods were limited by the number of samples and in the number of insertions they were able to characterise (Sheen et al., 2000; Ovchinnikov et al., 2001; Myers et al., 2002).

## 2.1.2. Current methods of RTE discovery:

Advances in high throughput next-generation sequencing (NGS) technologies and the development of computational detection tools facilitated their genomewide detection. Genome-wide detection of polymorphic RTE insertions via shortread NGS typically involves the use of targeted enrichment of the active RTE elements in the sequencing libraries. PCR-based amplification (David et al., 2015; Streva et al., 2015; Ha et al., 2016) and hybridization-based capture (Baillie et al., 2011; Shukla et al., 2013; Upton et al., 2015) are the most commonly used enrichment techniques. These pre-sequencing enrichment techniques use

specific primers and oligonucleotide probes to target specific DNA sequences that are characteristic of the active RTE subfamilies. The enriched libraries are then sequenced typically using a short-read NGS platform (~150-200bp) such as illumina (Quail et al., 2012; Rishishwar et al., 2016). Reads passing the quality filtering criteria are then mapped to the reference human genome using a sequencing alignment tool such as BWA-MEM (Li and Durbin, 2009) or SOAP2 (Li et al., 2009). Putative insertion sites are then called using various computational tools that are specifically designed for the detection of polymorphic RTE insertions from short-read NGS data (Baillie et al., 2011; David et al., 2015; Streva et al., 2015; Gardner et al., 2017). The many polymorphic RTE detection tools available in the literature typically function using the same fundamental method. Essentially, two main types of sequencing reads that point to the presence of a polymorphic insertion: discordant read pairs and split-reads.

Paired-end sequencing reads are individual reads produced from both ends of the same DNA segment (Paterson et al., 2015). Such reads can be paired together as the distance between them is known, hence the name. The Pairedend sequencing method increases the accuracy of read mapping, especially in repetitive genomic regions, thus facilitates the detection of structural rearrangements. Discordant read pairs (DPs) where only one read aligns at the expected genomic location facilitate the detection of insertions, such as those produced by RTEs (Paterson et al., 2015; Goerner-potvin and Bourque, 2018). In contrast, split reads (SRs) describe sequencing reads where only a part of an individual read aligns with the genome while its other part does not (Goernerpotvin and Bourque, 2018). Polymorphic RTE detection tools use DPs and SRs, usually referred to as unmapped sequencing reads, to identify polymorphic RTE

insertions by aligning those unmapped reads with the consensus sequence of the active RTE subfamilies (Figure 4; Goerner-potvin and Bourque, 2018).

# A



B

# Reference Sequence (No RTE insertion)



Figure 4: Schematic representation of polymorphic retrotransposable elements (RTE) detection using next-generation sequencing data. Paired-end reads are represented as rectangles connected by a solid line representing the unsequenced middle region of the DNA segment. A Genomic region with a polymorphic RTE insertion. Sequencing reads are initially mapped to the reference genome. Unmapped reads that do not partially or fully align with the reference genome as expected are suggestive of an RTE insertion. There are two main types of sequencing reads that are informative for polymorphic RTE identification: 1). Discordant read pairs (DPs) where one read pair aligns with the reference genome while the other align to an RTE sequence, and 2). Split reads (SRs) where only part of one read aligns with the reference genome while the other part aligns to an RTE sequence. B Genomic region without a polymorphic RTE insertion. Both types of sequencing reads align to the reference genome as expected in the absence of an RTE insertion. Figure adapted from "Benchmarking computational tools for polymorphic transposable element detection" by Rishishwar et al, 2016, Briefings in Bioinformatics, (April).

## 2.1.3. Limitations of RTE discovery using NGS data:

Characterising and genotyping genomic variants mediated by RTE insertions using short-read NGS data and RTE detection tools, although convenient, remains a challenging task due to the limited length of sequencing reads that does not span the whole integration site. Consequently, the many computational tools developed for RTE detection that follow the same general method often produce unstandardized findings, with different calls being retrieved from the same sequencing sample due to discrepancies in the algorithmic design and choice of parameters (Ewing, 2015). Recent benchmarking studies have demonstrated the utility of combining multiple RTE detection tools in increasing the accuracy and precision of RTE calling (Rishishwar et al., 2016; Nelson et al., 2017).

## 2.1.4. Online databases for non-reference RTE insertions:

Active RTEs have the potential to implicate human health and disease as their mobilization activity provides a continuous source of structural variations and has the potential to interfere with gene function, epigenetic regulation, and local genomic stability. As such, a comprehensive database of RTE insertions from the active RTE subfamilies is an essential tool for studying RTE-derived SV and for investigating the effects of their continuous activity on genome function. Many studies have been performed for characterising RTE-mediated variants over the last couple of decades. Some of these RTE-derived variants have been collected in online databases, while the majority of them remain scattered in the literature.

Two online databases of polymorphic RTE insertions identified in the human genome exist: the database of retrotransposon insertion polymorphisms (dbRIP;

http://dbrip.brocku.ca/; Wang et al., 2006) and the European database of L1Hs retrotransposon insertions (euL1db; http://eul1db.unice.fr; Mir et al., 2014). At the time of its construction, dbRIP (Wang et al., 2006) queried all the available studies and curated a database of 2,095 unique RTE insertions, including 407 L1s, 1,625 Alus, and 63 SVAs from over 50 studies. At the time of this study, dbRIP (Wang et al., 2006) has not been updated comprehensively since 2009, as only five studies have been added in the second release of dbRIP, bringing the total number of unique insertions up to 2,761, including 598 L1s, 2,086 Alus, and 77 SVAs. Note that the third release of dbRIP, expected in May 2021, was pre-announced on the dbRIP website (https://dbrip.brocku.ca/announcements.html), yet there have been no new file uploads or announcement updates from the date of the pre-announcement up to this date.

The euL1db (Mir et al., 2014) provides a detailed source of recent L1Hs elements, including germline and somatic insertions. It consists of 8,991 non-redundant L1Hs insertions identified in the genomes of 741 individuals that have been curated from 32 studies published up to 2014. The non-redundant list of L1Hs insertions was generated by merging L1 elements located within 200 base pairs (bp) from each other to account for variations in the accuracy of different detection tools and to avoid splitting insertions corresponding to the same retrotransposition event.

# 2.1.5. Study aims:

Existing online RTE databases are not up-to-date, and thus do not include data from the most recent studies, such as RTE variants from phase 3 of the 1000 genome project (1kGP) (Sudmant et al., 2015). This study aims to update and build on data in existing online databases by curating a comprehensive list of

polymorphic RTE insertions from the L1Hs, AluY, and SVA\_E/F subfamilies from peer reviewed journal articles. The updated database of polymorphic RTE insertions will be used for downstream analyses, including inferring the potential impact of RTE activity on genome function and identifying RTE variants that may influence complex traits and predisposition to multifactorial diseases.

## 2.2. Methods:

RTEs were curated from freely available online databases and peer-reviewed publications in the literature.

# 2.2.1. Criteria of RTE database curation:

The inclusion and exclusion criteria of the curated database, as summarized in Table 1, were established to ensure the specific inclusion of polymorphic RTE insertions that segregate within the population. Such RTE insertions have the potential to influence complex traits and predisposition to disease. The effect of recent RTE insertions on the fitness of its host depends on where it lands in the genome, thus only studies that report the exact genomic location of recent RTE insertions were selected for inclusion. Studies reporting engineered RTE insertions in transfected cell lines were excluded as such insertions may not be true representatives of insertions that segregate in the population. Similarly, Somatic RTE insertions does not get passed on to future generations. Germline insertions were included as these are the only type of insertions that segregate in the population, thus contributes towards inter-individual variation and disease risk.

Table 1: Summary of the inclusion and exclusion criteria for curating a comprehensive database of retrotransposable element insertions that contribute to the inter-individual genomic diversity.

| Criteria               | Included   | Excluded                                  |
|------------------------|--|---|
| Genomic<br>coordinates | Exact genomic coordinates<br>reported in any human genome<br>build | Does not report exact genomic coordinates |
| Tissue type            | Fresh samples (e.g. Blood) or non-transfected cell lines.          | Transfected cell lines                    |
| Tissue state           | Healthy or matched non-<br>tumour                                  | Tumour cells                              |
| Insertion type         | Germline   | Somatic                                   |

# 2.2.2. Study selection:

Studies referenced in dbRIP (http://dbrip.brocku.ca/; Wang et al., 2006) and euL1db (http://eul1db.unice.fr; Mir et al., 2014) online databases that were published within the cut-off dates of this study (01/01/2009-11/04/2019) were selected. This cut-off date was decided based on the period all three RTE subtypes were simultaneously updated in dbRIP (http://dbrip.brocku.ca/; Wang et al., 2006). Additional studies were selected via PubMed using the search terms listed in table 2. MeSH terms refer to controlled PubMed vocabulary used for indexing journal articles for easier retrieval of relevant publications via automatic term mapping. The MeSH terms are arranged hierarchically by subject categories with more specific terms beneath the broader term (Ecker and Skelly, 2010). PubMed search results were refined by activating filters to exclude articles published outside the cut-off date. Additional filters were applied to ensure all search results concerned humans and are published in English.

| Search terms                               | Description  |  |  |  |
|--|--|--|--|--|
| Transposable elements                      | Two classes: Retrotransposons and DNA transposons.   |  |  |  |
|  | Narrow MeSH term(s) included in the results:<br>1. Insertions  |  |  |  |
| Retrotransposons                           | Class I transposable elements that mobilise via an RNA intermediate.   |  |  |  |
|  | Narrow MeSH term(s) included in the results:   |  |  |  |
|  | <ol> <li>Endogenous Retroviruses</li> <li>Genes, Intracisternal A-Particle</li> <li>Long Interspersed Nucleotide Elements</li> <li>Short Interspersed Nucleotide Elements</li> <li>Alu Elements</li> </ol> |  |  |  |
| Mobile element<br>polymorphisms/insertions | Synonym of transposable elements and retrotransposons.   |  |  |  |
| Structural Variation                       | Differences in genomic DNA segments between/within individuals of a population.  |  |  |  |
|  | Includes DNA Copy Number Variations (CNVs).  |  |  |  |

Table 2: Search terms used for extract studies identifying retrotransposable element insertions in the human genome from PubMed.

A second PubMed search was performed using the names of principal investigators (PIs) as keywords to avoid missing out on recent articles that may not have been indexed with the MeSH terms found in table 2 at the time of this study. PIs were identified from the transposable elements labs directory of the Mobile DNA journal (<u>https://mobilednajournal.biomedcentral.com/labs</u>).

PIs interested in RTE detection and retrotransposition in humans were selected

(Table 3). Ewing A.D. was selected based on publication record and interest in

RTE detection.

Table 3: Principle investigators queried in PubMed to extract potentially nonindexed recent studies identifying retrotransposable element (RTE) insertions in the human genome.

| Principal Investigator | or Research Interests   |  |  |  |
|------------------------|---|--|--|--|
| Burns K.H.             | <ul> <li>The role of transposable elements in human disease.</li> <li>Characterising human retrotransposon insertion polymorphisms.</li> <li>LINE-1 regulation and RTE insertions in cancer.</li> </ul> |  |  |  |
| Ewing A.D.             | <ul> <li>Development of computational tools for RTE detection.</li> <li>Inferring the functional consequences of mutations caused by RTE insertions.</li> </ul>   |  |  |  |
| Kazazian H.H.          | <ul> <li>Detecting and understanding LINE-1 (L1)<br/>retrotransposons.</li> <li>Better the understanding about RTE role in complex human<br/>disorders.</li> </ul>                                      |  |  |  |
| Moran J.V.             | <ul> <li>Understanding the biology of human L1s.</li> <li>Understanding host defences against the transposition process.</li> </ul>   |  |  |  |
| Jorde L.B.             | • Evolution and effect of RTEs on human genome in health and disease.   |  |  |  |
| Xing J.                | <ul> <li>Understanding the mechanism and consequences of genomic variations caused by RTE insertions in humans health and disease.</li> <li>RTEs in evolutionary genetics.</li> </ul>                   |  |  |  |

Citations retained using the terms listed in Tables 2 and 3 were collated in a text file. Identical citations retained from multiple search terms were removed based on their PubMed ids using an awk command in UNIX. Titles and abstracts of the remaining studies were initially manually scanned to exclude articles unrelated to RTE detection/identification. Studies that did not relate to L1s, Alus, or SVAs were excluded, e.g. those relating to DNA transposons and LTR retrotransposons i.e. human endogenous retroviruses (HERV). Review articles, articles about the origin and evolution of RTEs, and articles assessing the effect of chemical (e.g. drugs) or physical (e.g. radiation) agents on RTEs mobilization/epigenetics were also excluded. Publications that passed this initial scanning step underwent thorough manual survey to investigate whether they meet the inclusion criteria of this study as discussed above (Table 1). Articles that meet the inclusion criteria of this study were retained for the database curation. An overview of the study selection processes is shown in figure 5.



Figure 5: Overview of study selection process for curating a comprehensive database of retrotransposable elements (RTE) insertions.

# 2.2.3. Data curation:

Two types of datasets will be generated for each RTE subtype:

- 1. A general dataset of RTE insertions from all of the included studies.
- A dataset by individual including insertions found with a matching sample id.

Six databases will be created: 2 for L1s, 2 for Alus, and 2 for SVAs. The study intends to use the general database to investigate the genomic landscape of polymorphic RTE insertions, which will provide insight into the effect of recent

RTE activity on genome function and integrity. The intended downstream analysis for the database by individual is to investigate the effect of structural polymorphisms mediated by RTE insertions on the fitness of its host using a more detailed approach as discussed in chapter 4.

The chromosomal locations of RTE insertions were extracted from the selected studies, either directly from the original publication, or from its supplementary files. Somatic RTE insertions, or insertions from subfamilies other than L1Hs, AluY or SVA\_E/F were removed. RTE insertions not reported in GRCh37/hg19 coordinates were converted into hg19 coordinates using the UCSC Genome Browser liftOver tool (available at: <u>https://genome.ucsc.edu/cgi-bin/hgLiftOver</u>; Karolchik et al., 2004). The minimal information recorded from each insertion include:

- 1. Chromosomal location (chromosome name: insertion start-insertion end)
- 2. Study reference.
- 3. Study PubMed id (PMID).

Additional information recorded when available include:

- 1. Strand orientation.
- 2. RTE subtype.
- 3. Allele frequency.

The database by individual (db-individual) which includes non-reference RTE insertions (L1Hs, AluY, or SVA\_E/F) identified in the genome of individuals recognised by a unique sample id will hereinafter be referred to as RTE profile(s). RTE profiles were extracted from studies reporting sample ID information

following the data extraction method described in the general database section. Sample ethnicity was also recorded when available.

### 2.2.4. Quality control:

As there is yet to be a gold-standard method for RTE detection, each of the studies included in the database follows its method of RTE detection consisting of a unique blend of computational parameters and quality control measures. As such, variations in the database are bound to exist, which jeopardize the consistency within the intended database. The following quality control (QC) measures have been applied to maximize the uniformity within the curated database:

- 1. Applying a minimum supporting reads threshold: Evrony et al. (2016) reported that applying a read count threshold of ≥ 3 supporting reads maintains the detection of at least half (53%) of true-positive insertions while excluding >99% of false-positive calls. As such, a minimum read count of ≥ 3 supporting reads was applied to reduce the likelihood of false positives, and insertions identified by less than 3 supporting reads were removed. In case of tumour studies, only the insertions supported by ≥ 3 reads in the matched non-tumour samples were retained.
- 2. PCR validation: Where PCR validation had been performed in a study, putative insertions that failed PCR validations or were located on unplaced/un-localised contigs were also excluded. Data from the offspring of trios were excluded to minimise allele frequency bias that may be introduced from related individuals. To minimise redundancy caused by

variation in breakpoint estimation of the different detection tools, RTEs within 200bp from each other were merged into a single insertion using the merge tool of BEDtools version 2.25.0 (Quinlan, 2014). The merge window was decided based on the analysis conducted by Mir et al. (2014) of the euL1db. Shared strand orientation was not required for the merging as the probability of two independent insertions being on different strands in the same location is extremely low (Sheen et al., 2000).

#### 2.2.5. Addressing duplicate RTE profiles from the database by individual:

Where studies characterised the RTE profile of the same individual, only one RTE profile was selected for inclusion in db-individual to avoid inflation of allele frequencies in the curated database. The RTE profile retained was based on investigating the overlap between the identified RTE profiles in a single individual, as illustrated in figure 6. First, the duplicate RTE profiles were merged by 200bp to account for variability in breakpoint estimation of the different detection tools. A minimum of 50% overlap between both RTE profiles was required for profile selection. Duplicate RTE profiles that failed to meet this requirement suggested that at least one of the studies used a detection method with poor precision or recall therefore all the individual RTE profiles from such a study should be excluded to maintain consistency within the database. Of the 317 duplicate profiles, 293 resulted from a number of studies analysing samples that are part of phase 3 of the 1,000 genomes project (1KGP) dataset (Sudmant et al., 2015). The 1KGP is the biggest and most reliable human genomic variation study. Therefore, for duplicate RTE profiles where one profile is produced by the 1KGP and both profiles overlap by  $\geq$  50%, the 1KGP profile was selected for inclusion in db-individual. Of the remaining 24 duplicate profiles, three resulted from two

studies analysing samples that are part of the pilot phase of the 1KGP (Stewart et al., 2011). In these cases, when the overlap between both profiles was  $\geq$  50%, the profile with the number of insertions closest to the number observed per typical genome was retained (128 L1s, 915 Alus, and 51 SVAs; 1000 Genomes Project Consortium et al., 2015). For the 21 duplicate profiles not part of the pilot phase or phase three of the 1KGP dataset, the profile closest to the average per typical genome was retained in db-individual when both profiles overlapped by  $\geq$  50%. Finally, when the overlap between duplicate profiles was less than 50%, all individual profiles obtained from the study deemed unsatisfactory were excluded from db-individual to maintain consistency within the curated database.



Figure 6: An overview of the procedure applied for selecting one retrotransposable element (RTE) profile for inclusion in the database by individual when duplicate RTE profiles for the same individual (individual x) were produced by two studies (study A and B). Note that an RTE profile refers to non-reference RTE insertions (L1Hs, AluY or SVA\_E/F) identified in the genome of an individual.

# 2.3. Results:

# 2.3.1. Study selection:

Articles reporting non-reference retrotransposable element insertions (RTEs) were selected from PubMed (<u>https://www.ncbi.nlm.nih.gov/pubmed/</u>). Querying PubMed up to the cut-off date (11/04/2019) using the terms listed in tables 1 and 2 produced 14,632 articles in total. Removal of articles returned by multiple search terms (i.e. duplicates) and/or unrelated to RTE detection resulted in 254 publications, of which 45 studies meet the inclusion criteria of this study (table 4). An overview of study selection process is provided in figure 5.

Table 4: Studies included in the curated non-reference retrotransposable element (RTE) databases, including the database by individual (db-individual), along with the total number of samples and RTEs pre- and post- quality control (QC) steps. All 45 studies were included in the general database, of which 28 were included in the database by individual).

| #  | Study ID                   | PMID     | Total<br>samples (S) | Total I        | Total RTEs pre post QC |           |  |
|----|----------------------------|----------|----------------------|----------------|------------------------|-----------|--|
|    |                            |          | S in db-Indv         | l L1           | Alu                    | SVA       |  |
| 1  | Achanta et al., (2016)     | 27843500 | 6                    | 10 10          |                        |           |  |
| 2  | Cardelli et al., (2012)    | 22495107 | 12                   |                | 4   4                  |           |  |
| 3  | Doyle et al., (2017)       | 28585566 | 62                   | 1161   903     |                        |           |  |
| 4  | Ewing et al., (2010) ♦     | 20488934 | 25                   | 367   365      |                        |           |  |
| 5  | Ewing et al., (2011)♦      | 20980553 | 310                  | 67998 0        |                        |           |  |
| 6  | Ewing et al., (2015)•      | 26260970 | 18                   | 1182   1052    |                        |           |  |
| 7  | Feusier et al., (2017)     | 28770012 | 213                  |                | 5288   4890            |           |  |
| 8  | Hehir-Kwa et al., (2016)   | 27708267 | 769                  | 4011   1339    | 8670   5950            | 781   602 |  |
| 9  | Helman et al., (2014)♦     | 24823667 | 200                  | 1103   982     | 6248   6164            | 373   146 |  |
| 10 | Kloosterman et al., (2015) | 25883321 | 769                  |                | 5 5                    |           |  |
| 11 | Konkel et al., (2015)      | 26319576 | 35                   |                | 343   291              |           |  |
| 12 | Kuhn et al., (2014)•       | 24847061 | 20                   | 855   855      |                        |           |  |
| 13 | Kurnosov et al., (2015)•   | 25689626 | 1                    | 19 8           | 9 0                    |           |  |
| 14 | Mir et al., (2014)         | 25352549 | 1023                 | 142,495 S 21 M |                        |           |  |
| 15 | Payer et al., (2017)       | 28465436 | 60 Pooled            |                | 809   579              |           |  |
| 16 | Rouchka et al., (2010)     | 21044359 | 3                    | 22 0           |                        |           |  |
| 17 | Tubio et al., (2014)●      | 25082706 | 244                  | 1478   1478    |                        |           |  |

# (Table 4 continued)

Studies in db-individual

| 18 Arokium et al., (2014)•    | 25289675   | 1   1          | 100   73    |               |           |
|-------------------------------|------------|----------------|-------------|---------------|-----------|
| 19 Baillie et al., (2011)♦    | 22037309   | 3 & Pooled   3 | 9279 96     | 19007   1673  | 2037   21 |
| 20 Beck et al., (2010)♦       | 20602998   | 6   1          | 68   21     |               |           |
| 21 Brandler et al., (2016)    | 27018473   | 235   138      | 1092   1092 | 6402   6402   | 417   417 |
| 22 Carreira et al., (2016)•   | 27843499   | 14 14          | 770 760     |               |           |
| 23 David et al., (2013)       | 23921633   | 7   5          |             | 6057   4521   |           |
| 24 Erwin et al., (2016)●      | 27618310   | 3   3          | 317   279   |               |           |
| 25 Evrony et al., (2012)♦     | 23101622   | 3   3          | 76   43     |               |           |
| 26 Evrony et al., (2015)●     | 25569347   | 1   1          | 24   24     | 48   45       | 8   8     |
| 27 Ha et al., (2016)          | 27478512   | 21   14        |             |               | 409   409 |
| 28 Hormozdiari et al., (2011) | ) 21131385 | 8 7            |             | 4342   3554   |           |
| 29 Iskow et al., (2010)♦      | 20603005   | 30   30        | 2174   299  | 3799   52     |           |
| 30 Lee et al., (2012)♦        | 22745252   | 44   43        | 2639   2277 | 5531   5499   | 225   225 |
| 31 Nguyen et al., (2018)      | 29949758   | 19 19          | 554 186     |               |           |
| 32 Schauer et al., (2018)     | 29643204   | 61   61        | 559 558     | 2462   2459   | 34   27   |
| 33 Scott et al., (2016)●      | 27197217   | 1   1          | 104   104   |               |           |
| 34 Shin et al., (2019)        | 30699287   | 1   1          | 525   494   |               |           |
| 35 Shukla et al., (2013)♦     | 23540693   | 19 19          | 1018   863  | 6283   5301   | 329 316   |
| 36 Solyom et al., (2012)♦     | 22968929   | 21   21        | 7031   124  | 10429   1013  | 8476 18   |
| 37 Stewart et al., (2011)♦    | 21876680   | 156 153        | 998 172     | 4499   4405   | 79 76     |
| 38 Streva et al., (2015)●     | 25887476   | 7 7            | 228   228   |               |           |
| 39 Sudmant et al., (2015)●    | 26432246   | 2504   2504    | 3048   3048 | 12748   12748 | 835   835 |
| 40 Thung et al., (2014)●      | 25348035   | 3   2          | 233   227   | 1541   1488   | 62   54   |
| 41 Upton et al., (2015)●      | 25860606   | 5   5          | 395   385   |               |           |
| 42 Wildschutte et al., (2015) | 26503250   | 53   53        |             | 1614 1599     |           |
| 43 Witherspoon et al., (2013) | ) 23599355 | 169 160        |             | 5799 2674     |           |
| 44 Xing et al., (2009)        | 19439515   | 1   1          | 52   49     | 584 584       | 14 11     |
| 45 Yu Q et al., (2017)        | 28938719   | 90 90          | 2398   2398 | 6483   5975   | 400   367 |

The euL1db publication. The number of insertions retained were from studies that did not require additional QC processing remove

- Studies included in euL1db. Post QC for L1 elements conducted by Roxane Dunbar.
- Studies in L1 database where QC was conducted by Roxane Dunbar.

# 2.3.2. Database structure/content:

Two databases were curated for each RTE type (L1Hs, AluY, and SVA\_E/F): a general database that includes all non-reference RTE insertions, and a database by individual that includes RTE profiles identified within individual genomes. Both databases were curated using the same data extraction method and quality

control procedures as described in the method section. Details about the number of samples and RTE insertions obtained from each selected study, including preand post- the QC steps, are found in table 4. Additional information about each study, including data source, is available in appendix 1.

# 2.3.3. General database:

The general database (db-general) includes RTEs curated from 45 studies (listed in table 4) across 7,285 unrelated samples (including sample redundancy). RTEs within 200bp window were merged to minimise the chance of the same RTE being counted more than once due to varying breakpoint estimation of the detection tools estimations of the breakpoint location. The final database contains 39,798 non-reference RTEs from the L1Hs, AluY and SVA\_E/F subfamilies. A breakdown of the number of RTEs per subtype is shown in table 5.

Table 5: Counts of retrotransposable elements (RTE) curated from 45 studies. RTEs of the same subfamily within a 200bp window were merged to minimise redundancy caused by variation in breakpoint estimation produced by differences in the RTE detection methods of the included studies. The general database (dbgeneral) includes RTEs identified from all the included studies, while the individual database (db-individual) includes RTE profiles of individuals. The average number of RTEs per individual is calculated from db-individual.

| RTE type | db-general                | db-individual               |                           |
|----------|---------------------------|-----------------------------|---------------------------|
|          | RTE counts pre post merge | RTE counts pre   post merge | Average per<br>individual |
| L1Hs     | 20,813   10,211           | 13,800   6,377              | 134                       |
| AluY     | 77,875   27,699           | 59,915   18,698             | 1,064                     |
| SVA_E/F  | 3,532   1,888             | 2,784   1,085               | 51                        |
| Total    | 102,220   39,798          | 76,499 26,160               |                           |

Note that the number of pre-merge AluY elements in db-individual does not add up with the numbers of post-QC for Alu elements in table 4 as 77 Alu insertions from Baillie et al., (2011) were identified in the pooled sample only, thus were only included in db-general.

#### 2.3.4. Databases by individual for L1Hs, AluY, and SVA\_E/F:

The pre-QC databases by individual collectively included 3,360 RTE profiles (including duplicate samples) curated from a total of 28 studies, as indicated in table 4. Any related individuals, including the offspring of trios, were excluded to control allele frequency bias that may be introduced by samples relatedness. Some studies have analysed samples collected from the same individual resulting in duplicate RTE profiles. Duplicate profiles pose the potential issue of overcalling for some of the individual profiles within the curated database, thus affecting the consistency of db-individual. Therefore, when duplicate RTE profiles were identified, a minimum of 50% overlap between both profiles was required before selecting one for inclusion in db-individual (Figure 6). All but three studies of the 13 studies that overlapped by a total of 317 individuals were retained, as summarised in table 6.

The post-QC databases collectively contains the insertional profile of 2,987 nonrelated individuals with an average of 134 L1Hs, 1,064 AluY and 51 SVAs per individual genome (Table 5). The average number of RTEs per individual genome is similar to the numbers reported by the 1000 genome project (128 L1s, 915 Alus, and 51 SVAs; 1000 Genomes Project Consortium et al., 2015). The majority of RTE insertions in db-individual were identified with an allele frequency (AF) below 1% (78% of L1Hs, 65.5% of AluY and 68% of SVA\_E/F). RTEs in the curated database were identified in samples from diverse ethnic groups, including African, Asian, European, and American admixed. About one-third of the RTEs identified in db-individual were singletons, i.e., only present in one of the total samples in the database. (Table 7).

Table 6: Counts of duplicate RTE profiles in the database-by-individual (db-individual). A minimum of 50% overlap between duplicate profiles was required before selecting one of the profiles for inclusion in db-individual. All RTE profiles from the 3 studies that failed to meet this requirement (in bold) were excluded from db-individual.

| Overlapping Studies                                    | Number of<br>overlaping<br>samples | Average<br>frequency of<br>overlaping loci<br>(%) | Included profile<br>reference | Reason   |
|--|------------------------------------|---|-------------------------------|--|
| Sudmant et al. (2015) and<br>Stewart et al. (2011)     | 150                                | 85% (Alu)<br>81% (SVA)                            | Sudmant et al. (2015)         | 1. MELT, the RTE detection<br>tool of the 1kGP (Sudmant et<br>al. 2015) is one of the best |
| Sudmant et al. (2015) and<br>Yu et al. (2017)          | 83                                 | 76% (Alu)<br>70% (SVA)                            | 'n                            | detection tools for RTE calling<br>as shown by its superior<br>performance in benchmarking |
| Sudmant et al. (2015) and<br>Lee et al. (2012)         | 2                                  | 72% (Ahı)<br>65% (SVA)                            | "                             | studies (Rishishwar et al., 2016;<br>Gardner et al., 2017;<br>unpublished in-house         |
| Sudmant et al. (2015) and<br>Witherspoon et al. (2013) | 43                                 | 73% (Alu)   | n                             | benchmarking).   |
| Sudmant et al. (2015) and<br>Hormozdiari et al. (2011) | 3                                  | 85% (Alu)   | 'n                            | 2. All RTEs in Sudmant et al.<br>(2015) are genotyped and<br>phased.                       |
| Sudmant et al. (2015) and<br>David et al. (2013)       | 2                                  | 94% (Alu)   | "                             |  |

# (Table 6 continued)

| Sudmant et al. (2015) and<br><u>Ha et al. (2016)</u> | 10 | 33% (SVA)              | "                    |   |
|--|----|------------------------|----------------------|---|
| Thung et al. (2014) and<br>Stewart et al. (2011)     | 2  | 98% (Alu)<br>71% (SVA) | Thun et al. (2014)   | Thung et al. (2014) reported<br>more RTE insertions,<br>resembling the average number<br>of insertions per individual as<br>reported by the 1kGP and<br>identified in db-individual.  |
| Yu et al. (2017) and<br>Stewart et al. (2011)        | 1  | 81% (Alu)<br>64% (SVA) | Yu et al. (2017)     | Yu et al. (2017) reported more<br>RTE insertions, resembling the<br>average number of insertions<br>per individual as reported by the<br>1kGP and identified in db-<br>individual.    |
| Shukla et al. (2013) and<br>Schauer et al. (2018)    | 19 | 83% (Alu)<br>66% (SVA) | Shukla et al. (2013) | Shukla et al. (2013) reported<br>more RTE insertions,<br>resembling the average number<br>of insertions per individual as<br>reported by the 1kGP and<br>identified in db-individual. |

# (Table 6 continued)

| Wildschutte et al.<br>(2015) and Hormozdiari<br>et al (2011) | 1 | 32.7% (Alu) | Hormozdiari et al. (2011) | Hormozdiari et al. (2011)<br>identified >80% of the<br>insertions called by Sudmant et<br>al. (2015) for the 3 overlapping<br>samples between the two<br>studies, therby increasing the<br>confidence in the sensitivity of<br>its method compared to the<br>method of Wildschutte et al.<br>(2015). |
|--|---|-------------|---------------------------|--|
| <u>Xing et al. (2009)</u> and<br>Witherspoon et al. (2013)   | 1 | 46% (Alu)   | Witherspoon et al. (2013) | Witherspoon et al. (2013)<br>identified >70% of the<br>insertions called by Sudmant et<br>al. (2015) for the 43 overlapping<br>samples between the two<br>studies, therby increasing the<br>confidence in the sensitivity of<br>its method compared to the<br>method of Xing et al. (2009).          |

| Ethnicity  | Singltons/Total insertions per ethnic group (%) |                   |                  |  |  |
|--|---|-------------------|------------------|--|--|
|  | L1  | Alu               | SVA              |  |  |
| African  | 242/1616 (15.0)                                 | 1093/9992 (10.9)  | 39/519 (7.5)     |  |  |
| Ad mixed American                                  | 231/1527 (15.1)                                 | 1231/8890 (13.8)  | 36/496 (7.3)     |  |  |
| American   | 4/188 (2.1)                                     | 11/1419 (0.8)     | 2/60 (3.3)       |  |  |
| European   | 583/2418 (24.1)                                 | 1381/8557 (16.1)  | 91/540 (16.9)    |  |  |
| East Asian   | 1052/2338 (45.0)                                | 1055/7392 (14.3)  | 85/496 (17.1)    |  |  |
| South Asian  | 170/982 (17.3)                                  | 461/5351 (8.6)    | 18/363 (5.0)     |  |  |
| Other  | 796/2166 (36.7)                                 | 941/5880 (16.0)   | 74/381 (19.4)    |  |  |
| Total Singltons/Total<br>RTEs in db-individual (%) | 345/1085 (31.8)                                 | 6173/18698 (33.0) | 3078/6377 (48.3) |  |  |

Table 7: Count and frequency of singleton RTE insertions identified in each of the ethnic groups within the curated database.

Note that the total number of insertions per ethnic group may not add up to the total number of insertions in db-individual as some RTE insertions are identified in more than one ethnic group.

#### 2.4. Discussion:

A comprehensive collection of retrotransposable element insertions in humans have been curated and organised into two databases; a general database and a database by individual (Table 5). The information in this database has been curated from a total of 45 peer-reviewed articles (listed in table 4) published in the last decade up to the 12<sup>th</sup> of April 2019, including data from the final phase of the 1000 genome project (1kGP) (Sudmant et al., 2015) as well as the Genome of the Netherlands (GoNL) project (Hehir-Kwa et al., 2016). The selected articles have been identified via PubMed using the search terms listed in Tables 1 and 2. The general database (db-general) holds 10,211 L1Hs, 27,699 AluY, and 1,888 SVAs from the E and F subfamilies (SVA\_E/F). The database of individual RTE profiles contains 6,377 L1Hs, 18,698 AluY, and 1,085 SVA\_E/F identified in 3,360 non-related individuals from diverse ethnic backgrounds. All RTEs in the curated database are non-reference RTEs, referring to RTEs that are absent from the reference genome.

### 2.4.1. Study database vs. existing online databases

Compared to existing online RTE databases, the curated database holds 10-fold the amount of RTEs in dbRIP (http://dbrip.brocku.ca/; Wang et al., 2006; n=3,106), and an additional 36% germline L1Hs entries compared with the euL1db list (http://eul1db.unice.fr; Mir et al., 2014; n=8,012). In addition, the curated database only includes germline insertions that are polymorphic in the population as the main aim of the database is to provide a resource of RTE variants that potentially contribute towards host susceptibility to disease. This is in contrast to dbRIP and the euL1db databases that also hold insertions

associated with Mendelian disorders (dbRIP) that tend to segregate in specific families, or somatic insertions (euL1db) that do not get passed on to future generations (Wang et al., 2006; Mir et al., 2014).

To our knowledge, the curated database of this study is the first to apply a threshold of  $\geq$ 3 supporting reads. This quality control (QC) measure was suggested by Evrony et al. (2016) to minimize false-positive calls. Applying this threshold may have potentially excluded a few low-frequency true-positive insertions, however, it may have also excluded the majority of false-positive calls as demonstrated in the analysis of Evrony et al. (2016). A recent benchmarking study has also demonstrated the importance of applying a minimum supporting reads threshold. Rishishwar et al. (2016) found that the best performing tools out of the seven tools analysed by their study had applied a minimum supporting reads threshold by default. The best performing tools applying such a threshold included MELT (Gardner et al., 2017) and Mobster (Thung et al., 2014) used by the 1kGP (Sudmant et al., 2015) and the GoNL project (Hehir-Kwa et al., 2016), respectively.

## 2.4.2. Issues with current methods of RTE detection

Accurate RTE detection is essential for understanding the effect of recent RTE activity on genome function. Detecting true-positive RTE insertions in the human genome is challenging, mainly due to the repetitiveness and high sequence homology of these elements in the human genome. Numerous computational tools based on the analysis of NGS data have been developed over the past two decades for genome-wide detection of RTE insertions (Ewing, 2015; Goerner-potvin and Bourque, 2018). However, most RTE detection tools rely on short sequencing reads that do not span the whole integration site. Consequently,

variations in recall sensitivity and positional accuracy do exist between the available RTE detection tools.

The discrepancies in the results of the duplicate RTE profiles curated by this study show the extent of variations in the recalls of different RTE detection tools when analysing the same sample (Figure 6). There has yet to be a standard approach against which the performance of current and future tools operate. Long-read sequencing technologies such as PacBio and MinION (Rhoads and Au, 2015; Lu et al., 2016) have the potential to improve the recall and precision of RTE detection, and eventually become the standard approach for RTE discovery.

# 2.4.3. Correlations between population growth rate and allele frequency spectrum

Most RTE insertions in the curated database have low allele frequencies (AF), including over 65% of the insertions with an AF below 1%. The greater proportion of rare variants (AF < 1%) is largely due to RTEs unique to individuals, i.e., singletons. This is consistent with the well-established effect of the recent explosive growth in population size (Keinan and Clark, 2012; Gao and Keinan, 2016). The increased load of singletons is explained by the growing population shifting the balance between the rate of RTE insertion and elimination from the population (Gazave et al., 2013; Bourgeois and Boissinot, 2019). Therefore populations with a higher growth rate are expected to have a higher load of singletons. Gravel et al. (2011) estimated the growth rate in the East Asian and European populations at 0.48% vs. 0.38% per generation, respectively, starting about 23 thousand years ago (kya) using exon and low-coverage sequencing

data from the 1kGP (n=40 per panel). These results are consistent with the higher fraction of singletons identified in East-Asian compared with European samples. Another recent study inferring population size changes from whole-exome sequencing data of 4,298 European vs. 2,217 African samples reported a higher growth rate in the European population compared to the African population. Chen et al. (2015) estimated the growth rate of the European population at 1.49% per generation starting ~7.26 kya vs. 0.74% per generation starting ~10.01 kya in the African population. These results are also consistent with the higher fraction of singletons identified in the European samples in comparison to the African samples (Table 7).

# 2.4.4. Correlations between population growth rate and efficiency of natural selection

The excess of singleton RTE variants as a consequence of the recent population explosion has the potential to increase the genetic risk of complex disorders within the average individual of the growing populations by impacting purifying selection against deleterious insertions. A simulation-based study by Gazave et al. (2013) suggested that individuals in a growing population show a moderate increase in the fraction of deleterious mutations in comparison to individuals in a non-growing population. This effect was suggested to be due to the increased efficiency of selection at eliminating the most extremely deleterious mutations, resulting in a slight increase in the number of weakly deleterious mutations (Gazave et al., 2013; Gao and Keinan, 2016). In addition, the total number of *de novo* RTE insertions is likely to be much higher in a growing population, which

consequently increases the number of RTE variants that have the potential to contribute towards the susceptibility of complex diseases.

Identifying rare RTE variants in the growing population that are caused by recent insertions requires sequencing of a very large sample size. This is because singletons identified in a small sample of 100 individuals have a frequency of 0.5% and are likely caused by older insertions compared to singletons with a frequency of 0.005%, identified in a sample of 10,000 individuals. However, increasing sample size will also increase type I error which may complicate the analysis and reduce the ability to distinguish between true insertions and false positives. These issues may potentially be tackled via the development of RTE detection tools analysing long sequencing reads. Such tools may increase the sensitivity of RTE detection and reduce the complexity of RTE discovery (Ewing, 2015; Jiang et al., 2019).

# 2.4.5. Study overview

In summary, a comprehensive database of RTE elements has been curated, updating the information reported in existing online databases. The curated database holds an excess of rare insertions, consistent with the well-established effect of the recent population explosion. Capturing such variants is of particular interest for studying the impact of population growth on the genetic architecture of complex disorders. In effect, the curated database is a useful resource for understanding the contribution of RTE variants towards human phenotype and disease.

#### 3. Genomic Distribution of non-LTR RTEs

### 3.1. Introduction

Retrotransposable elements (RTEs) are the most abundant type of repetitive sequences, essentially constituting 45% of the human genome (Lander et al., 2001). The majority of RTEs in the human genome are remnants of ancient insertions, hence they are no longer capable of transposition due to inactivating mutations and internal rearrangements (Lander et al., 2001; Wei et al., 2001; Hancks and Kazazian, 2016). Only the most recently evolved RTE subfamilies retain the ability to transpose within the human genome, creating insertional polymorphisms within and between populations (Wang et al., 2005; Mills et al., 2007; Huang et al., 2010). The ongoing activity of the non-LTRs (Long Terminal Repeats) retrotransposons is driven by a single autonomous family, known as the long interspersed nuclear element-1 (L1 for short).

# 3.1.1. Retrotransposition of L1s, Alus, and SVAs

L1s are the most abundant type of transposable elements (TE) in humans, with over half a million copies of L1s constituting up to 17% of the human genome (Lander et al., 2001). Nevertheless, only about 100 L1s from the evolutionary young human-specific L1 subfamily (L1Hs) in each individual genome are fulllength and capable of transposing, of which a handful have been described as 'hot' L1s, due to them being highly active (Brouha et al., 2003). A full-length L1 element is about 6 kilobases (kb) long and encode two proteins that are essential for its retrotransposition: a small RNA binding protein (ORF1p) and a large protein with endonuclease (EN) and reverse transcriptase (RT) activities (ORF2) (Dombroski et al., 1991; Lander et al., 2001). L1s retrotranspose via a process

termed target-primed reverse transcription (TPRT), whereby the ORF2p reverse transcribes an RNA copy of the parent L1 and integrates the complementary DNA (cDNA) elsewhere in the genome (Cost et al., 2002; Scott and Devine, 2017).

The non-autonomous Alu and SVA elements have evolved to capture the L1 ORF2p, thus L1s mediate the retrotransposition of Alu and SVA elements in *trans* during TPRT (Dewannieux et al., 2003; Raiz et al., 2012). Although the L1 machinery mediates the mobilisation of the non-LTR RTEs, endogenous L1s, Alus, and SVAs, referring to reference insertions that are fixed in the human genome, are known to accumulate in different genomic regions.

#### 3.1.2. Distribution of endogenous RTEs

Endogenous L1 elements accumulate in AT-rich low-activity regions whereas Alus and SVA elements accumulate in GC-rich, high-activity regions (Smit, 1996; Smit, 1999; Lander et al., 2001; Pavlíček et al., 2002; Wang et al., 2005). The accumulation of L1 elements in AT-rich regions have been credited to the specificity of the L1 endonuclease target motif (5'-TTTT/AA-3'), which is significantly denser in AT-rich regions of the genome (Cost and Boeke, 1998; Lander et al., 2001; Graham & Boissinot, 2006). Investigating the surrounding GC content of endogenous RTEs by evolutionary age have shown that the evolutionary young subfamilies of L1s, Alus, and SVAs accumulate in regions of lower GC content in comparison to older subfamilies, a difference that is potentially masked when all the endogenous elements of each type are analysed as one (Lander et al., 2001; Medstrand et al., 2002; Wang et al., 2005; Kvikstad and Makova, 2010; Costantini et al., 2012). As such the observed distribution bias in the genomic distribution of Alus and SVAs, in comparison to L1 elements,

is thought to have been reshaped by differential selection forces acting on each element (Dewannieux et al., 2003; Raiz et al., 2012; Tang et al., 2018).

## 3.1.3. Effects of RTE activity on genome function

RTE insertions are known to affect genome function in a variety of mechanisms, including mediating post-insertional genomic rearrangements. Insertions in genic regions can interfere with gene function or induce loss-of-function mutations through interfering with gene transcription or splicing (Conley and Jordan, 2012; Chénais, 2016; Hancks and Kazazian, 2016; Bourque et al., 2018). In addition, the high copy number and sequence similarity between RTE elements can promote non-allelic homologous recombination (NAHR) events that can cause significant deletions and duplications (Lee et al., 2012; Startek et al., 2015; Nazaryan-petersen et al., 2016). The reader can refer to the following review articles for a more detailed overview of how TE activity can impact genome function both directly and indirectly: Hancks and Kazazian (2016), Bourque et al. (2018), and Saleh et al. (2019).

## 3.1.4. Effects of RTE activity on human health

In terms of causing disease or susceptibility to disease, RTE elements are, on whole, not as well studied as single nucleotide variants (SNVs). However, structural variants (SV) mediated by RTE insertions have been implicated with genetic diseases.

#### 3.1.4.1. RTEs and monogenic diseases

The first reported case of a disease-causing RTE insertion is a *de novo* L1 insertion into exon 14 of the factor VIII (F8), identified in two unrelated

haemophilia A patients (Kazazian et al., 1988). Since then, 124 monogenic diseases mediated by RTE insertions have been reported (Hancks and Kazazian, 2016). Nevertheless, disease-causing RTE insertions are rare events, estimated to be responsible for ~1/1,000 disease-causing mutations (Lutz et al., 2003). Advances in genome sequencing technology, and the development of efficient computational detection tools capable of simultaneously analysing numerous genomic samples to identify RTE insertions on a genome-wide level, have led to a substantial increase in the number of recovered RTE insertions (Ewing, 2015; Rishishwar et al., 2017). Such advances have also improved the recovery of somatic and polymorphic insertions, including insertions implicated in complex disorders.

# 3.1.4.2. RTEs and complex diseases

Somatic L1 retrotranspositions are recognised as mutagenic agents in many epithelial cancers (Chénais, 2016; Burns, 2017; Scott and Devine, 2017). In addition, increased somatic L1 retrotransposition in the brain has been reported in several neurological and neuropsychiatric disorders, including schizophrenia, amyotrophic lateral sclerosis (ALS), and Alzheimer's disease (Guffanti et al., 2016; Savage et al., 2019; Terry et al., 2020). As for germline insertions, a recent study identified a polymorphic SVA element in an intron of the TAF1 gene, associated with an increased risk of X-linked Dystonia-Parkinsonism (XDP) through promoting intron 32 retention, resulting in reduced TAF1 gene expression (Aneichyk et al., 2018). The length of the hexanucleotide repeat domain of the SVA element was found to have a significant inverse correlation with the age of XDP onset (Bragg et al., 2017). Another study identified a polymorphic Alu element in an intron of the CD58 gene, associated with an increased risk of
multiple sclerosis through promoting skipping of exon 3, resulting in reduced CD58 gene expression (Payer et al., 2019).

Deleterious RTE insertions that affect genome function, consequently reducing the fitness of their host, are subject to purifying selection to such a degree that they cannot reach high allele frequencies in the population, and are eventually rendered extinct from the human genome (Loewe, 2008). In contrast, neutral insertions do not affect genome function, and as such, they can reach high frequencies and eventually become fixed in the human genome. Under these assumptions, insertions from the ancient subfamilies are more likely to be neutral than recent insertions from the actively transposing RTE subtypes.

### **3.1.5.** Genomic distribution of recent RTE insertions

The genomic load of RTE activity on genome function can be inferred by comparing the distributions of RTEs from subfamilies of different evolutionary ages. Early studies, including ones from before the initial sequencing and analysis of the draft human genome, comprehensively characterised the genomic landscape of endogenous RTE insertions (Soriano et al., 1983; Smit, 1999; Gu et al., 2000; Lander et al., 2001; Wang et al., 2005). The extent to which the landscape of new insertions resembles that of the endogenous RTE elements which have become fixed in the human genome remains ambiguous. Studies comparing the distribution of fixed RTEs with insertions from the currently amplifying RTE subfamilies (Table 8), have suggested that the majority of new RTEs integrate in neutral or deleterious regions, in contrast to endogenous elements that accumulate in what have been called genomic safe-havens (Boissinot and Furano, 2005; Song and Boissinot, 2007). Nevertheless, the evolutionary fate of a new insertion, including its impact on genome function as

well as its ability to mobilise and generate new insertions, largely depends on where it inserts into the genome.

Some studies adopted an experimental approach for investigating the genomic landscape of RTE insertions in the human genome. In this approach, *de novo* insertions are induced using engineered elements in cell cultures. The induced insertions are then recovered and their pre-insertion loci are characterised and compared with the distribution of endogenous or polymorphic elements (Raiz et al., 2012; Sultana et al., 2019; Flasch et al., 2019; Chen et al., 2020). The main advantage of using this method is that the induced insertions experience minimal selection and thus recapitulate the initial integration site of RTEs. However, the distribution of such insertions may not be representative of natural elements segregating in the human genome, as the influence of cell-line specific factors on the retrotransposition assay cannot be ruled out. In addition, some *de novo* insertions may integrate into genomic locations that may potentially cause embryonic lethality (Boissinot et al., 2004).

The focus of the more recent RTE detection studies seems to have shifted away from characterising the landscape of RTE insertions. Few recent studies reported a partial characterisation of the insertional landscape of polymorphic RTE insertions, mainly reporting its distribution within gene regions (Stewart et al., 2011; David et al., 2013; Witherspoon et al., 2013; Thung et al., 2014; Ha et al., 2016). As such, a comprehensive study analysing the genomic distribution of polymorphic insertions against fixed RTE elements, in order to advance the current understanding regarding the role of germline RTE activity on genome function, has yet to be published.

#### 3.1.6. Aims and objectives

The current study aims to investigate the potential effects of germline RTE activity on genome function and integrity by comparing the genomic distributions of polymorphic RTE insertions with the distribution of endogenous RTEs that are fixed in the human genome. The in-house curated database discussed in chapter 2 is utilised for this analysis. The curated database includes a high fraction of singleton and rare RTE insertions, as a result of its larger sample size, in comparison to previous studies conducting similar analysis (Ovchinnikov et al., 2001 [n=32 L1Hs vs. 30 ancient L1s]; Boissinot et al., 2004 [n=344 L1Hs vs. 300 ancient L1s]; Wang et al., 2005 [106 SVA\_E/F vs. 2,656 SVA\_A-D]; Cordaux et al., 2006 [43 polymorphic vs. 60 fixed AluY]; Ewing and Kazazian, 2010 [367 nonreference vs. 772 reference L1Hs]).

As such, the results of this study are expected to be intermediate between the reported distribution of *de novo* and polymorphic insertions. This study expands on previous studies in the literature by simultaneously comparing the distribution of L1, Alu, and SVA elements in order to understand the effect of each RTE type on genome function and integrity. Knowing the functional impact of recent germline insertions is fundamental for understanding the impact of RTEs, with respect to human health and disease, and the likely contribution of RTE-mediated SV to the missing heritability issue.

Table 8: Summary of the genomic distribution of old RTEs that are fixed in the human genome, in comparison to the distribution of polymorphic RTE elements.

| Genomic feature | Old (fixed)   | Young (polymorphic)   | Supporting references  |
|-----------------|---|---|--|
| Chromosomal dis | tribution   |   |  |
| L1              | Enriched on the X-chromosome as a<br>result of positive selection due to their<br>role in propogating the X silencing<br>signal. Chromosomal distribution<br>correlated positively with<br>chromosome size. | Not enriched or overrepresented on<br>any chromosome. Distribution<br>correlated positively with<br>chromosome size.                  | Smit (1999); Bailey et al., (2000);<br>Lander et al., (2001); Medstrand<br>et al., (2002); Boissinot et al.,<br>(2004); Ewing and Kazazian,<br>(2010); Tang et al., (2018);<br>Sultana et al., (2019); Flasch et al.,<br>(2019); Chen et al., (2020) |
| Alu             | Overrepresented on chromosome 19<br>more than expected for its size. Alu<br>density correlated with chromosome<br>gene density.   | Not enriched or overrepresented on<br>any chromosome. Distribution<br>correlated positively with<br>chromosome size.                  | Lander et al., (2001); Grover et<br>al., (2004); Carter et al., (2004);<br>Otieno et al., (2004); Wagstaff et<br>al., (2012); Tang et al., (2018)  |
| SVA             | Overrepresented on chromosome 19<br>more than expected for its size. SVA<br>density correlated with chromosome<br>gene density.   | Not enriched or overrepresented on<br>any chromosome. Distribution<br>correlated positively with<br>chromosome size and gene density. | Wang et al., (2005); Savage et al.,<br>(2013); Tang et al., (2018);<br>Gianfrancesco et al., (2019)  |

# (Table 8 continues)

# Local GC content

| L1                 | Accumulate in the most AT-rich<br>regions of the genome  | Accumulate in AT-rich regions, but<br>are more evenly distributed in this<br>region in comparision to fixed<br>elements              | Gu et al., (2000); Lander et al.,<br>(2001); Medstrand et al., (2002);<br>Boissinot et al., (2004); Sultana et<br>al., (2019); Flasch et al., (2019);<br>Chen et al., (2020)                                |
|--------------------|--|--|---|
| Alu                | Accumulate in GC-rich regions  | Accumulate in AT-rich regions  | Gu et al., (2000); Lander et al.,<br>(2001); Medstrand et al., (2002):<br>Jurka et al., (2004); Belle et al.,<br>(2005); Costantini et al., (2012);<br>Wagstaff et al., (2012)                              |
| SVA                | Accumulate in GC-rich regions  | Accumulate in regions of higher GC-<br>content in comparision to fixed<br>elements   | Wang et al., (2005); Raiz et al.,<br>(2012); Savage et al., (2013);<br>Gianfrancesco et al., (2019)   |
| Genic distribution | n  |  |   |
| L1                 | Accumulate in intergenic regions.<br>Most intragenic insertions are intronic<br>and significantly more often in the<br>antisense strand. | Accumulate in intergenic regions.<br>Significantly depleated in genic and<br>intronic regions compared with<br>reference insertions. | Lander et al., (2001); Boissinot et<br>al., (2004); Ewing and Kazazian,<br>(2010); Tang et al., (2018);<br>Sultana et al., (2019); Flasch et al.,<br>(2019); Chen et al., (2020);<br>Watkins et al., (2020) |

# (Table 8 continues)

selection

| Alu             | Accumulate in intragenic regions,<br>mostly in introns.   | Significantly depleated in gene regions<br>in comparision to fixed Alu elements.  | Lander et al., (2001); Cordaux et<br>al., (2006); Hormozdiari et al.<br>(2011); Wagstaff et al., (2012);<br>Witherspoon et al., (2013); David<br>et al., (2013); Watkins et al.,<br>(2020) |
|-----------------|---|---|--|
| SVA             | Accumulate in intragenic regions,<br>mostly in introns. The number of<br>fixed SVA elements in gene deserts is<br>lower than expected if the elements<br>inserted randomly. | Accumulate in intergenic and intronic<br>regions. The yonger subfamilies were<br>underrepresented in gene deserts in<br>comparision to the expected<br>distribution, however, they were<br>found in lower frequencies in gene<br>deserts in comparision to the fixed<br>SVA elements. | Wang et al., (2005); Hancks et al.,<br>(2011); Raiz et al., (2012); Savage<br>et al., (2013); Ha et al., (2016);<br>Tang et al., (2018)  |
| Local Recombina | ation rate  |   |  |
| L1              | Studies suggested that fixed L1s<br>accumulate in low and non-<br>recombining regions as a result of  | Accumulate in low recombination regions.  | Lander et al., (2001); Medstrand<br>et al., (2002); Boissinot et al.,<br>(2004); Abrusán et al., (2006);   |

59

Song and Boissinot, (2007);

# (Table 8 continues)

| Alu | Accumulate in regions of higher<br>recombination. Studies suggested that<br>fixed Alu elements contain a motif<br>associated with recombination and<br>genome instability   | No relationship between the<br>distribution of polymorphic elements<br>and local recombination rate  | Lander et al., (2001); Medstrand<br>et al., (2002); Hackenberg et al.,<br>(2005); Myers et al., (2008);<br>Witherspoon et al., (2009) |
|-----|---|--|---|
| SVA | No direct results, however, SVA element<br>recombination-mediated deletions in the<br>occurrence in recombining regions. In ad<br>GC-rich regions, which have a positive co | direct results, however, SVA elements have been reported to cause<br>mbination-mediated deletions in the human genome suggesting their<br>arrence in recombining regions. In addition, SVA elements accumulate in<br>rich regions, which have a positive correlation with recombination rates. |   |

# 3.2. Methods

An overview of the methods workflow is presented in figure 7.

# 3.2.1. RTE Datasets

All datasets are based on the GRCh37/hg19 genome build co-ordinates.

# 3.2.1.1. Non-reference database:

The chromosomal locations of non-reference RTEs were taken from the in-house databases described in chapter 2. The non-reference database consists of 10,211 L1Hs, 27,699 AluYs, and 1,888 SVAs from the E and F human-specific subfamilies.

# 3.2.1.2. Reference database:

In this context, the reference database consists of those RTEs that are fixed in the human genome, such that any two individuals will carry the same insertion. The RepeatMasker Table was downloaded from the UCSC table browser (https://genome.ucsc.edu/cgi-bin/hgTables; Karolchik, 2004) and 38,366 L1PA2-5, 307,612 AluJ, and 1,005 SVAs from the A and B subfamilies were extracted. These elements are thought to be incapable of retrotransposition due to the buildup of random inactivating mutations (Lander et al., 2001; Wei et al., 2001; Hancks and Kazazian, 2016).



Figure 7: Genomic Distribution workflow. Each of the distribution analyses are conducted on the reference and non-reference RTEs input files. The number of RTE insertions per chromosome are counted. Subsequently the local genomic environment is investigated including local GC-content, overlap with gene and enhancer regions, and local chromatin accessibility is investigated by overlapping the location of RTEs with H3K4me3 epigenetic profiles associated with euchromatin domains.

#### 3.2.2. Genomic Distribution analyses

### 3.2.2.1. Chromosomal distribution

The total number of RTEs per chromosome within the reference and nonreference L1Hs, Alu, and SVA databases were counted in UNIX. To investigate if each of the elements were randomly distributed throughout the genome, the chromosomal distribution was investigated based on the size of each chromosome, using linear regression performed in core R (R Core Team, 2012) version 3.4.0. The length of each chromosome was obtained from the human assembly data at the Genome Reference Consortium (GRC) (https://www.ncbi.nlm.nih.gov/grc/human/data?asm=GRCh37).

Given that endogenous L1s are known to accumulate in AT-rich regions, while endogenous Alu and SVA elements accumulate in GC-rich regions, and that genes are known to reside in GC-rich regions of the genome, the chromosomal distribution of RTEs based on gene density was investigated. Understanding the chromosomal distribution of the reference and non-reference RTEs based on gene density, may disentangle the combined influence of both negative selection against the potentially deleterious RTEs within genes, and the insertional bias of the particular RTE. To this end, a second linear regression analysis was performed to investigate the relationship between the chromosomal distribution of reference and non-reference RTEs and gene density across the genomes, defining the density of RTEs and genes as the numbers of each per one million base pairs. Chromosomal locations of RefSeq genes were obtained from the UCSC Genome Browser (University of California Santa Cruz) (https://genome.ucsc.edu/cgi-bin/hgTables) (Karolchik, 2004). R codes for both

regression analyses are provided in GitHub at: https://github.com/RandaAli1/MyPhDproject/tree/master/MyAnalysis.

# 3.2.2.2. Local GC content

The hg19/GRCh37 human genome assembly (chromFa.tar.gz) was downloaded from the UCSC genome browser website ftp (http://hgdownload.cse.ucsc.edu/goldenPath/hg19/bigZips/). Individual fasta files were concatenated in UNIX. The start and end positions of each RTE insertion were extended by 10 kilobases (Kb) to create a 20 Kb window around each insertion using the slop function of BEDTools (Quinlan, 2014) version 2.25.0. This window size was chosen in concordance with previous studies (Lander et al., 2001; Boissinot et al., 2004; Gasior et al., 2007). The GC-content for each window was calculated using the nuc function of BEDTools (Quinlan, 2014) version 2.25.0, and the hg19 human genome assembly. To account for variations in GC content within the human genome, the hg19 genome assembly was divided into 20 Kb adjacent windows from start to end using the makewindows function of BEDTools (Quinlan, 2014) version 2.25.0, and the GC-content of each genomic window was calculated. Windows of different GC-contents were grouped into bins of 2% width using R (R Core Team, 2012) version 3.4.0. The distribution of reference RTEs in genomic regions of different GC-contents was compared with the distribution of non-reference RTEs and with the GC distribution of the genome, using the two-sample Kolmogorov-Smirnov (K-S) test. The K-S test is a nonparametric goodness-of-fit test used to compare the cumulative distribution function of two samples to determine whether the tested samples share the same underlying distribution (Lall, 2015). The K-S test returns a D-statistic, representing the maximum difference between the cumulative distribution

functions of the tested samples and a P-value of significance (Frank and Massey, 1951; Lall, 2015). The GC-content analysis codes are provided in GitHub at: <a href="https://github.com/RandaAli1/MyPhDproject/tree/master/MyAnalysis">https://github.com/RandaAli1/MyPhDproject/tree/master/MyAnalysis</a>.

# 3.2.2.3. Distribution in functional regions

### 3.2.2.3.1. RefSeq genes

The chromosomal locations of genes across the genome were based on the Reference Sequence collection (RefSeq), providing a non-redundant and wellannotated record of sequences submitted to the National Centre for Biotechnology Information (NCBI). The annotated NCBI RefSeq genes were downloaded from the UCSC table browser (https://genome.ucsc.edu/cgibin/hgTables; Karolchik, 2004) (last update 11.09.2017); under the group 'genes and gene predictions' and table 'NCBI RefSeq (refGene)'. Annotations with both the accession prefix NM and NR (mRNA or non-protein-coding RNAs, respectively) were included. The 'output format' was set to 'BED – browser extensible data' allowing additional user choices.

Two files were generated containing the chromosomal locations of:

- I. All genic regions: 'Whole gene' option selected under the heading 'Create one BED record per' to generate a file of the start and stop locations of all genes. The resultant genic regions file contains the transcript start and end of 19,407 coding and 11,173 non-coding genes.
- II. Exonic and intronic regions: To generate a file including the chromosomal start and stop location of all genes exons and introns,

the 'Exons plus' and 'Intron plus' options were selected under the heading 'Create one BED record per'. The two separate files indicating

the exons and introns were combined using the 'cat' command in UNIX. Non-coding genes (prefixed with NR\_\*) such as microRNAs (MiRNAs) were included, as they have been shown to have key regulatory roles within the human genome, and there are numerous cases where mutations in non-coding genes have been shown to cause diseases in humans (Kornienko et al., 2013; Patrushev et al., 2014; Patil et al., 2014; De Almeida et al., 2016; Quinn et al., 2016).

## 3.2.2.3.2. Enhancer file

GeneHancer (Fishilevich et al., 2017) is a database of human enhancers generated by computationally integrating data from the following genome-wide databases while eliminating redundancy:

[1] The Encyclopedia of DNA Elements (ENCODE; Zerbino et al., 2015).

[2] Ensembl regulatory build (The ENCODE Project Consortium, 2012).

[3] The functional annotation of the mammalian genome (FANTOM; Andersson et al., 2014) project.

[4] The VISTA Enhancer Browser (Visel et al., 2017).

The chromosomal locations of the Enhancer elements were obtained from the GeneHancer database (Fishilevich et al., 2017) via the UCSC table browser (https://genome.ucsc.edu/cgi-bin/hgTables; Karolchik, 2004), selecting the 'GH Reg Elems (geneHancerRegElements)' table as part of the 'GeneHancer' track under the 'Regulation' group, including a total of 250,718 entries across the human genome (last updated 2-09-2018). Of these enhancers, approximately

44% (n=110,165) were defined as 'elite' status based on their defined strength of the identification evidence (Fishilevich et al., 2017).

### 3.2.2.3.3. Analysis:

The distribution of RTEs within functional genomic regions was identified by overlapping the genomic position of RTEs, with that of genes and enhancer regions, using the intersect function of bedtools (Quinlan, 2014) version 2.25.0. RTE insertions that did not interrupt a gene region were considered intergenic. Fisher's exact tests were carried out to compare the distribution of reference and non-reference RTEs, in intergenic vs. intragenic regions, and in enhancer vs. enhancer-free regions. The analysis codes for the distribution of reference and non-reference RTEs in genic and enhancer regions are provided in GitHub at: https://github.com/RandaAli1/MyPhDproject/tree/master/MyAnalysis.

# 3.2.2.4. Local recombination rate

The Decode recombination map (https:www.decode.com/; Kong et al., 2010) avoids the limitations of linkage disequilibrium (LD)-based maps, such as biases in recombination rate estimates due to the effect of natural selection on LD, and lack of information about sex differences (Kong et al., 2010). DeCODE produced sex-specific recombination maps using phased haplotypes of 15,257 parent-offspring pairs and a total of 298,069 genome-wide SNPs. Recombination was placed in the region between the two closest flanking markers in the parent within a resolution of 10 Kb. The X-chromosome and 5 Mb (mega base) regions at both ends of autosomal chromosomes were excluded due to reduced reliability in

placing recombination in these regions. The map used in this study is the standardised sex-averaged map, which is essentially the average of the male and female recombination maps.

DeCODE's sex-averaged map was downloaded from the UCSC table browser (https://genome.ucsc.edu/cgi-bin/hgTables; Karolchik, 2004); accessing the 'decodeSexAveraged' table under the group 'All Tables' under the 'hg19' database. The downloaded list consisted of 244,308 non-overlapping bins. Each bin is given a standardised recombination rate (SRR) that indicates the tendency of recombination in a specific 10 Kb genomic region. Bins with an SRR of 0 represent recombination cold-spots while bins with an SRR of 10 or above represent recombination hotspots.

The nearest recombination rate for each RT insertion was identified using the closest function of BEDTools (Quinlan, 2014) version 2.25.0. The expected number of RTEs in each recombination region was determined by calculating the number of elements that would be present in each region in relation to the size of the region. Specifically, if half of the human genome is non-recombining, the expected number of RTEs in non-recombining regions would be 50%. Fisher's exact tests were carried out to compare the distribution of reference and non-reference RTEs in non-recombining and recombination regions of the genome. The distribution of each RTE in regions of different recombination rates was compared with the expected distribution using the chi-squared goodness of fit test. The codes for the local recombination rate analyses are provided in GitHub at: https://github.com/RandaAli1/MyPhDproject/tree/master/MyAnalysis.

# 3.2.2.5. RTEs Enrichment in functional regions and accessible chromatin domains

Roadmap segmented the human genome into various regulatory classes, reflecting different degrees and types of regulatory activity (Roadmap Epigenomics Consortium, 2015). This study took advantage of this classification to define accessible chromatin regions using the H3K4me3 profiles associated with euchromatin domains. Roadmap-annotated BED files for each of the 127 cell types, across 30 types of human tissues, were downloaded (https://egg2.wustl.edu/roadmap/data/byFileType/peaks/consolidated/broadPea k/; last modified: October 2013). One file per cell type was downloaded using the epigenome identifier (EID) (EID-H3K4me3.broadPeak.gz). Each file was decompressed using the gunzip command in UNIX. An additional column was added to each file containing the associated EID identifier. The resulting 127 files were then grouped into one file using the cat command in UNIX. Broad peak calls were used since genomic regions bound with chromatin domains can be very wide.

A control database, known as the Random Database, was generated to test whether the associations observed between the genomic locations of RTEs with functional regions were random or based on the composition of the genomic features. The control database was also used to investigate whether RTEs are enriched in euchromatin domains in any cell type or tissue. The enrichment of non-reference RTEs in the euchromatin domain of any cell type or tissue may potentially affect its function, as active retrotransposition is more likely to occur in accessible chromatin regions. To make the random dataset, the random function of BedTools (Quinlan, 2014) version 2.25.0 was used to generate a random set of intervals in a Bed file format. For each RTE the random dataset

was subsampled based on the non-reference curated database, including 1000 x the size of each database; 10,211 L1Hs; 27,699 AluYs and 1,888 SVAs.



Figure 8: Schematic representation of RTEs enrichment in functional and accessible chromatin domains. A random dataset is generated using BEDtools. First, a samples is extracted based on the size of each of the non-reference curated database. Next, the random sample is overlapped with functional genomic regions including genic and enhancer regions plus accessible chromatin (euchromatin) domains. The dotted line shows a random insertion overlapping with an exon region (green) and is located in euchromatin domain. The process of subsampling and calculating the distribution of random insertions in functional regions and euchromatin domains is reiterated 1000x. Finally, the observed value is compared with the distribution of the 1000 samples using Z-statistics for the enrichment of RTEs in functional regions, or using the empirical P-value for the enrichment of RTEs in euchromatin domains.

The distribution of the random datasets in functional and accessible chromatin regions was determined by overlapping the locations of RTEs with the RefSeq genes, GeneHancer, and Roadmap files using the intersect function of bedtools (Quinlan, 2014) version 2.25.0. The mean overlap with functional regions and standard deviation of the random datasets were identified using the summary () function in R (R Core Team, 2012; V.3.4.0). These statistics were then used to calculate the Z-statistics (McLeod, 2019) for the overrepresentation of RTEs in functional regions including intronic, exonic, and enhancer regions. The enrichment of RTEs in euchromatin domains was calculated using the Empirical P Value (North et al., 2002) calculated as:

$$(r+1) \div (n+1)$$

Where r is the number of replicates that produce a number of overlap greater than or equal to the number of overlaps observed for RTEs in euchromatin regions, and n is 1,000 representing the number of replicate samples that have been created. The enrichment analysis is illustrated in figure 8. The codes for the enrichment analyses are provided in GitHub at: https://github.com/RandaAli1/MyPhDproject/tree/master/MyAnalysis.

# 3.3. Results

# 3.3.1. Chromosomal distribution

The distribution of the three classes of RTEs (L1s, Alus, SVAs) across the chromosomes and genome was studied, comparing number of RTEs, and both chromosome size and the gene density. Both reference and non-reference RTEs were studied separately in order to understand how natural selection forces play a part in the distribution over time.

Table 9: Count of reference and non-Reference LINE 1s, Alus, and SVAs per chromosome, displaying the percentage of the whole genome. Non-reference RTEs were taken from the curated RTE databases. Abbreviation: Chr = Chromosome.

|         | LINEs 1     |               | Alus          |              | SVAs          |              |
|---------|-------------|---------------|---------------|--------------|---------------|--------------|
| <u></u> | Reference   | Non-Reference | Non-Reference | Reference    | Non-Reference | Reference    |
| Chr     | L1s/Chr (%) | L1s/ Chr (%)  | Alus/ Chr (%) | Alus/Chr (%) | SVAs/ Chr (%) | SVAs/Chr (%) |
| 1       | 2641 (6.88) | 751 (7.35)    | 27842 (9.05)  | 2099 (7.58)  | 94 (9.35)     | 204 (10.81)  |
| 2       | 2983 (7.78) | 849 (8.31)    | 21589 (7.02)  | 2320 (8.38)  | 66 (6.57)     | 151 (8.00)   |
| 3       | 2780 (7.25) | 726 (7.11)    | 17233 (5.60)  | 1947 (7.03)  | 61 (6.07)     | 109 (5.77)   |
| 4       | 3035 (7.91) | 808 (7.91)    | 13871 (4.51)  | 1957 (7.07)  | 58 (5.77)     | 81 (4.29)    |
| 5       | 2807 (7.32) | 675 (6.61)    | 14194 (4.61)  | 1773 (6.40)  | 58 (5.77)     | 101 (5.35)   |
| 6       | 2334 (6.08) | 654 (6.40)    | 14775 (4.80)  | 1814 (6.55)  | 62 (6.17)     | 108 (5.72)   |
| 7       | 1915 (4.99) | 590 (5.78)    | 19350 (2.29)  | 1672 (6.04)  | 45 (4.48)     | 88 (4.66)    |
| 8       | 2097 (5.47) | 512 (5.01)    | 13267 (4.31)  | 1406 (5.08)  | 41 (4.08)     | 70 (3.71)    |
| 9       | 1578 (4.11) | 427 (4.18)    | 11827 (3.84)  | 1138 (4.11)  | 44 (4.38)     | 71 (3.76)    |
| 10      | 1500 (3.91) | 456 (4.47)    | 15407 (5.01)  | 1278 (4.61)  | 54 (5.37)     | 98 (5.19)    |
| 11      | 1990 (5.19) | 541 (5.30)    | 12709 (4.13)  | 1261 (4.55)  | 49 (4.88)     | 103 (5.46)   |
| 12      | 1759 (4.58) | 472 (4.62)    | 16451 (5.35)  | 1393 (5.03)  | 51 (5.07)     | 92 (4.87)    |
| 13      | 1214 (3.16) | 374 (3.66)    | 7134 (2.32)   | 1058 (3.82)  | 22 (2.19)     | 53 (2.81)    |
| 14      | 1143 (2.98) | 347 (3.40)    | 9780 (3.18)   | 871 (3.14)   | 36 (3.58)     | 69 (3.65)    |
| 15      | 849 (2.21)  | 264 (2.59)    | 10034 (3.26)  | 825 (2.98)   | 24 (2.39)     | 75 (3.97)    |
| 16      | 650 (1.69)  | 264 (2.59)    | 14686 (4.77)  | 675 (2.44)   | 23 (2.29)     | 63 (3.34)    |
| 17      | 494 (1.29)  | 197 (1.93)    | 14131 (4.59)  | 769 (2.78)   | 36 (3.58)     | 92 (4.87)    |
| 18      | 908 (2.37)  | 265 (2.60)    | 6543 (2.13)   | 802 (2.89)   | 26 (2.59)     | 25 (1.32)    |
| 20      | 535 (1.39)  | 182 (1.78)    | 7859 (2.55)   | 522 (1.88)   | 20 (1.99)     | 68 (3.60)    |
| 19      | 348 (0.91)  | 145 (1.42)    | 15069 (4.90)  | 542 (1.96)   | 40 (3.98)     | 86 (4.56)    |
| 22      | 184 (0.48)  | 51 (0.50)     | 5998 (1.95)   | 310 (1.12)   | 14 (1.39)     | 41 (2.17)    |
| 21      | 395 (1.03)  | 168 (1.65)    | 2960 (1.00)   | 446 (1.61)   | 10 (0.99)     | 13 (0.69)    |
| Х       | 3525 (9.19) | 438 (4.29)    | 12562 (4.08)  | 727 (2.62)   | 62 (6.17)     | 25 (1.32)    |
| Υ       | 702 (1.83)  | 55 (0.54)     | 2341 (0.76)   | 94 (0.34)    | 9 (0.90)      | 2 (0.11)     |
| Total   | 38,366      | 10,211        | 307,612       | 27,699       | 1,005         | 1,888        |

The counts and frequency for each of the three RTEs studied are indicated in table 9 for both the reference and non-reference elements across the human chromosomes. The autosomes are arranged in descending order of size. Based on the frequency of the RTEs for individual chromosomes, table 9 suggests that the frequency is not consistently proportional to the size of the chromosomes. For example, a larger proportion of reference and non-reference LINE elements are located on chromosome 4 than in the larger chromosomes 1, 2, and 3 (reference LINEs only). A larger proportion of reference Alu and SVA elements are located on chromosomes 16, 17 and 18 than found on larger chromosomes; whereas chromosome 17 carries more non-reference Alus and SVAs than the larger chromosome16.

# 3.3.1.1. Linear regression analysis of RTE and chromosome size or gene density

To understand the chromosomal distribution of RTEs, based on the size of the chromosome, and the effect of selection, a linear regression analysis was performed for each RTE, separated into age categories (reference and non-reference). The confident and prediction intervals were also computed. Data points within the confident interval are likely within the range of the true population mean with a 95% certainty, while the prediction interval provides a 95% likelihood estimate that the observed data points are the outcome of the population, as predicted by the regression model.

Overall, the regression analysis shows that L1s, Alus and SVAs are not distributed randomly between chromosomes. Although at the chromosomal level, the number of elements, both the reference (fixed) and non-reference

(polymorphic), is generally related to the chromosome size, with a positive correlation to the physical length of the chromosome. There is a strong linear correlation between the number of insertions and chromosomal size, particularly for the non-reference elements (except for non-reference SVAs), as shown in Figures 1, 2, and 3. When comparing the RTE and gene density, there is a marked difference between the RTE classes, demonstrating either negative correlation, positive correlation, or no correlation at all. In the subsequent sections this will be discussed in more detail.

## 3.3.1.1.1. L1 Chromosomal distribution:

Initial integration of L1s, as shown by the distribution of non-reference L1s, do tend to show a greater correlation with chromosome size in comparison to reference L1s, evidenced by a greater correlation coefficient (r<sup>2</sup> =0.81 & 0.93 respectively for reference and non-reference L1s). There are some exceptions, for example, chromosome 4 for which there is an overrepresentation of nonreference L1 elements made evident by its position just below the upper limit of the prediction interval. In addition, there is an enrichment of reference L1s on chromosome X (Figure 9.A). The weaker correlation of reference L1s with chromosome size compared to non-reference L1s is mainly due of the enrichment of reference L1s on the X-chromosome, which has been previously linked to their role in propagating the X-silencing signal. Conducting the regression analysis for reference L1s without the X-chromosome data point increases the correlation coefficient (r<sup>2</sup>) and statistical significance (r<sup>2</sup> from 0.81 to 0.90 and the P-value from 1.76x10<sup>-9</sup> to 4.97x10<sup>-12</sup>, respectively for reference and reference minus the X chromosome). Extending the analysis to include gene and L1 density across each chromosome revealed a weak inverse correlation for reference L1s

( $r^2$ =0.27, P-value = 9.38E-3). (Figure 9.B). However, no such correlation was observed between the non-reference L1s and the gene density.



Figure 9: Scatter plots of the distribution of L1 elements across chromosomes and gene density. Elements counts as percentages of overall counts per chromosome are plotted against chromosomes size for reference and non-reference plots (left and right plots respectively) are shown in plots A. Plots B represent percentage of elements counts against gene density per chromosome. The fitted regression line is shown (blue line), along with 95% confidence intervals (grey cloud) and 95% prediction interval (red dotted line) for each scatter plot. Correlation between the count of elements and chromosome size, and element count and gene density are indicated within the plot, R<sup>2</sup> and P-value are given.

### 3.3.1.1.2. Alu Chromosomal distribution

Non-reference Alu elements appear to be distributed somewhat differently to the reference Alu elements. The initial integration of Alus, as shown by the distribution of non-reference Alus, resembles the initial integration of L1 elements. Non-reference Alus also tend to show a greater correlation with chromosome size (Figure 10.A) in comparison to reference Alus ( $r^2 = 0.64 \& 0.89$ respectively for reference and non-reference Alus). There are some exceptions, for example the X chromosome is depleted of non-reference Alus, evidenced by its position below the lower limit of the prediction interval (Figure 10.A). In addition, the correlation between the density of non-reference Alus and gene density is not significant. By contrast, there is a positive correlation between reference Alus density and gene density, suggesting that reference Alus are enriched in gene regions (Figure 10. B). These results reflect the enrichment of reference Alus on chromosome 19 more than expected for its physical length, as the density of reference Alus on chromosome 19 is proportional to its gene density. Reference Alus tend to show a greater correlation with gene density than chromosome size ( $r^2$ = 0.64 & 0.88 respectively for chromosome size and gene density). Chromosome 16 is an exception, where reference Alus are better correlated with its physical length than its gene density.



Figure 10: Scatter plots of the distribution of Alu elements across chromosomes and gene density. Elements counts as percentages of overall counts per chromosome are plotted against chromosomes size for reference and nonreference plots (left and right plots respectively) are shown in plots A. Plots B represent percentage of elements counts against gene density per chromosome. The fitted regression line is shown (blue line), along with 95% confidence intervals (grey cloud) and 95% prediction interval (red dotted line) for each scatter plot. Correlation between the count of elements and chromosome size, and element count and gene density are indicated within the plot, R<sup>2</sup> and P-value are given.

## 3.3.1.1.3. SVA Chromosomal Distribution

Unlike L1 and Alu elements, reference SVAs tend to show a stronger correlation with chromosome size in comparison to non-reference SVAs ( $r^2 = 0.82 \& 0.58$ respectively for reference and non-reference SVAs). There are some exceptions, for example chromosome 19, for which there is an enrichment of reference SVA elements evidenced by its position above the upper limit of the prediction interval (Figure 11.A). In addition, non-reference SVAs are depleted on chromosome X. There also tends to be a positive correlation with SVA density and gene density, suggesting that SVAs are enriched in gene regions (Figure 11.B). The initial integration of SVAs, as shown by the distribution of non-reference SVAs, does tend to show a greater correlation with gene density in comparison to reference SVAs ( $r^2 = 0.63 \& 0.77$  respectively for reference and non-reference SVAs). Chromosome X is an exception, as it is depleted of non-reference SVAs, evidenced by its position below the lower limit of the prediction interval (Figure 11.B). Nevertheless, non-reference SVAs tend to show a greater correlation with gene density than chromosome size  $(r^2 = 0.58 \& 0.77$  respectively for chromosome size and gene density), while the opposite trend is observed for reference SVAs. These results suggest that SVAs do integrate preferentially in gene-rich regions and reflect the combined role of chromosome size and gene density in shaping the chromosomal distribution of reference SVAs. As such, recent SVA insertions are likely to have the most negative impact on gene function and regulation, in contrast to L1s and Alus, which tend to avoid integrating into gene-rich regions.



Figure 11: Scatter plots of the distribution of SVA elements across chromosomes and gene density. Elements counts as percentages of overall counts per chromosome are plotted against chromosomes size for reference and nonreference plots (left and right plots respectively) are shown in plots A. Plots B represent percentage of elements counts against gene density per chromosome. The fitted regression line is shown (blue line), along with 95% confidence intervals (grey cloud) and 95% prediction interval (red dotted line) for each scatter plot. Correlation between the count of elements and chromosome size, and element count and gene density are indicated within the plot, R<sup>2</sup> and P-value are given.

### 3.3.2. Local GC content

To understand the local base-composition of RTEs, the GC content for each RTE separated into age categories (reference and non-reference) was studied, alongside the genome GC content in 20 Kb windows. Genomic regions of higher GC content tend to have a higher gene density and recombination rate (Fullerton et al., 2001; Lander et al., 2001). The GC content was calculated to determine if the integration of RTEs is random within the chromosomes, or have been shaped by factors such as selection and/or preferential integration, that may have been driven by genomic regions of specific base-composition.

L1s, Alus and SVAs are not distributed randomly within different GC regions. Non-reference RTEs do show a tendency to accumulate in higher GC regions than reference elements, except for Alus. The distribution of L1s and SVA elements generally shifts towards lower GC bins with time, whilst the distribution of Alu elements shows the opposite trend and shift towards higher GC bins.

# 3.3.2.1. L1 GC content

Reference and non-reference L1 elements, at the genome level, appear to cluster in low GC regions, with maximum densities in the bin corresponding to 36-38% GC content. The overall accumulation of L1s in low GC regions is supported by the position of their frequency distribution curves being to the left of the genome curve, and their average GC content being below the genome-wide average of 41% (average GC content of 38% & 39% respectively for reference and nonreference L1s). Although L1s generally accumulate in low GC regions, nonreference L1s do tend to accumulate in higher GC regions than reference L1s, made evident by the position of its frequency distribution curve to the right of the

distribution curve of reference L1s. In addition, the non-reference distribution peak is below the peak of reference L1 elements (Figure 12). The statistical significance of the reported observations was confirmed using the two-sample K-S test, as shown in figure 12.

The K-S test returns a D-statistic that varies between 0 and 1 (Lall, 2015). The closer the D-statistic of the K-S test is to 0, the more similar the underlying distributions of the two samples are to each other. That is because a D value of 0 occurs when there is no difference between the cumulative distribution functions of the two samples. The D-statistic for the distribution of reference L1 elements vs. the genome is greater in comparison to the distribution of non-reference L1s. These results suggest that the initial integration of L1s, as shown by the distribution of non-reference L1s. In addition, the lowest D-statistic is observed for the K-S test between the distributions of reference vs. non-reference L1 elements, supporting the comparable accumulation of L1 elements in GC-poor regions.

# 3.3.2.2. Alu GC content

Non-reference Alu elements appear to accumulate in different GC regions to the reference Alus. The initial integration of Alu elements with respect to local basecomposition, as shown by the distribution of non-reference Alus (Figure 13), is similar to the distribution of L1 elements. Although the frequency curve of nonreference Alus resembles the distribution curve of the genome, non-reference Alus appear to cluster in low GC regions with maximum density in the 36-38% GC bin. This observation is supported by the position of the frequency distribution curve of non-reference Alus being slightly to the left of the genome curve, and

their average GC content being below the genome-wide average of 41% (average GC content of non-reference Alus is 40%). In addition, the D-statistic of the K-S test is lowest for the K-S test between the distributions of non-reference Alus and the genome.

In contrast, reference Alus appear to cluster in genomic regions of higher GC content, with maximum density in the 40-42% GC bin. The frequency distribution curve of reference Alus is skewed to the right and is positioned to the right of the genome curve. In addition, the average GC content of reference Alus is above the genome-wide average (average GC content of reference Alus is 43%). These results indicate a tendency of Alu elements to shift towards regions of higher GC content over time. The D-statistic is highest for the K-S test between the distributions of reference vs. non-reference Alus, supporting the marked difference in the local base-composition of Alu elements of different evolutionary age.

## 3.3.2.3. SVA GC content

Reference and non-reference SVA elements, at the genome level, appear to cluster in higher GC regions with maximum densities in the 40-42% GC bin (Figure 14). The overall accumulation of SVA elements in higher GC regions is supported by the position of their frequency distribution curves being to the right of the genome curve, and their average GC content being above the genome-wide average (average GC content of 42% & 43% respectively for reference and non-reference SVAs). In addition, the lowest D-statistic is observed for the K-S test between the distributions of reference vs. non-reference SVA elements, supporting their comparable accumulation in GC-rich regions. Although SVAs are generally found in higher GC regions, non-reference SVAs do tend to accumulate

in higher GC regions, more so than reference SVAs, made evident by the frequency distribution curve of non-reference SVAs being positioned to the right of the curve of reference SVAs. In addition, the D-statistic is greatest for the K-S test between the distributions of non-reference SVAs vs. the genome. These results suggest that the initial integration of SVA elements, as shown by the distribution of non-reference SVAs, do tend to prefer higher GC regions of the genome.



Figure 12: Frequency distribution of L1 elements in different GC fractions of the human genome. The GC content around each element is calculated over 20 Kb window (10 Kb on each side of the insertion). The x-axis from left to right correspond to increasing 2% GC content, and the frequency of L1s is show on the y-axis. The genome GC content was calculated by dividing the genome into 20 Kb windows from start to end. The dotted vertical line represents the position of the average genome-wide GC content of 41%. K-S test statistics are indicated within the plot, D statistics and P-value are given.



Figure 13: Frequency distribution of Alu elements in different GC fractions of the human genome. The GC content around each element is calculated over 20 Kb window (10 Kb on each side of the insertion). The x-axis from left to right correspond to increasing 2% GC content, and the frequency of L1s is show on the y-axis. The genome GC content was calculated by dividing the genome into 20 Kb windows from start to end. The dotted vertical line represents the position of the average genome-wide GC content of 41%. K-S test statistics are indicated within the plot, D statistics and P-value are given.



Figure 14: Frequency distribution of SVA elements in different GC fractions of the human genome. The GC content around each element is calculated over 20 Kb window (10 Kb on each side of the insertion). The x-axis from left to right correspond to increasing 2% GC content, and the frequency of L1s is show on the y-axis. The genome GC content was calculated by dividing the genome into 20 Kb windows from start to end. The dotted vertical line represents the position of the average genome-wide GC content of 41%. K-S test statistics are indicated within the plot, D statistics and P-value are given.

# 3.3.3. Distribution in functional regions

RTE integration in functional regions has the potential to alter gene expression, splicing, or dosage. The distribution of each RTE in gene and enhancer regions was studied to determine whether the integration of RTEs is random, or if it is biased by factors that favour or restrict its integration, such as selection and/or preferential integration.

L1s, Alus, and SVAs are not randomly distributed in functional genomic regions.

All RTE classes show a significant difference in the distribution of their reference vs. non-reference elements across the functional genomic regions analysed, as confirmed by Fisher's exact test (Tables 10 & 11). Although RTEs are generally

less frequent in functional regions, non-reference RTEs do show a greater tendency to accumulate in intragenic (within genes) and enhancer regions than reference elements, with the exception of Alu elements (Figures 15 & 16). Overall, the distribution of L1 and SVA elements generally shifts away from functional regions over time, while the opposite trend is observed for the distribution of Alu elements.

### 3.3.3.1. L1 distribution in functional regions

L1 elements, from both age categories, are more frequent in intergenic regions than expected by chance alone, made evident by their positive Z-statistics in intergenic regions (Table 12). The initial integration of L1s, as shown by the distribution of non-reference L1s, do tend to accumulate more frequently in functional genomic regions in comparison to reference L1s. Non-reference L1s are 1.19 and 2.83 times more frequent in intragenic and enhancer regions, respectively, than reference L1s (Tables 10 & 11; Figures 15 & 16). The distribution of L1 elements within gene regions (from transcription, start to end, including the 5' and 3' untranslated regions) show a greater accumulation of L1s in intronic regions, although it should be noted, more non-reference L1s, in terms of frequencies, are found within intronic and exonic regions in comparison to reference L1 elements (Figure 15). Still, L1 elements (in both age categories) are depleted in functional regions in comparison to the random insertion model, evidenced by their negative Z-score values in intronic, exonic, and enhancer regions (Table 12). These results suggest that, although L1 elements in general tend to be depleted in functional genomic regions, the initial integration of L1 elements in functional regions is more uniform in comparison to reference (fixed)

L1s. The distribution of L1 elements in functional regions is in line with their accumulation in low GC regions that tend to be less functional than GC-rich regions.

Table 10: Counts and percentages of RTEs located within intergenic and intragenic regions. Intragenic regions include the gene region from transcription start to end including the 5' and 3' untranslated regions of the NCBI RefSeq genes. Reference RTEs are fixed elements in the reference genome obtained from the RepeatMasker table of repeats. Non-reference elements are polymorphic insertions curated in-house from published studies. P-value and OR for Fisher's exact test statistics are included. Abbreviations: OR, Odds Ratio; CI, Confident interval.

|             | L1             |           | Alu              |           | SVA              |           |
|-------------|----------------|-----------|------------------|-----------|------------------|-----------|
|             | Reference Non- |           | Reference        | Non-      | Reference        | Non-      |
|             | (%)            | Reference | (%)              | Reference | (%)              | Reference |
|             |                | (%)       |                  | (%)       |                  | (%)       |
| Interessie  | 24,476         | 6,104     | 142,735          | 15,045    | 575              | 962       |
| Intergenic  | (63.80)        | (59.78)   | (46.40)          | (54.32)   | (57.21)          | (50.95)   |
| <b>T</b>    | 13,890         | 4,107     | 164,877          | 12,654    | 430              | 926       |
| Intragenic  | (36.20)        | (40.22)   | (53.60)          | (45.68)   | (42.79)          | (49.05)   |
| P-value     | 1.02E-13       |           | 1.06E-140        |           | 0.00             | 013       |
| OR (95% CI) | 1.19 (1.1      | 3-1.24)   | 0.73 (0.71-0.75) |           | 1.29 (1.10-1.51) |           |

Table 11: Counts and percentages of RTEs located within enhancer regions of the GeneHancer database. Reference RTEs are fixed elements in the reference genome obtained from the RepeatMasker table of repeats. Non-reference elements are polymorphic insertions curated in-house from published studies. P-value and OR for Fisher's exact test statistics are included. Abbreviations: OR, Odds Ratio; CI, Confident interval.

|              | L1             |           | Α         | lu        |           | SVA           |  |
|--------------|----------------|-----------|-----------|-----------|-----------|---------------|--|
|              | Reference Non- |           | Reference | Non-      | Reference | Non-Reference |  |
|              | (%)            | Reference | (%)       | Reference | (%)       | (%)           |  |
|              |                | (%)       |           | (%)       |           |               |  |
| Enhancer     | 1,266          | 900       | 47,305    | 3,356     | 65        | 300           |  |
|              | (3.30)         | (8.81)    | (15.38)   | (12.12)   | (6.47)    | (15.89)       |  |
| Non-enhancer | 37,100         | 9,311     | 260,307   | 24,343    | 940       | 1,588         |  |
|              | (96.70)        | (91.19)   | (84.62)   | (87.88)   | (93.53)   | (84.11)       |  |
| P-value      | 1.42E-108      |           | 3.05E-50  |           | 4.25E-14  |               |  |
| OR (95% CI)  | 2.83 (2.       | 59-3.10)  | 0.76 (0.  | 73-0.79)  | 2.73      | (2.10-3.67)   |  |

Table 12: Z-test statistics for the distribution of RTEs located within intergenic and intragenic regions of the NCBI RefSeq genes in comparison with a random database including 1,000x iterations. Z-test statistics for the distribution of RTEs in comparison with the random database in enhancer regions of the GeneHancer database are also given. Reference RTEs are fixed elements in the reference genome obtained from the RepeatMasker table of repeats. Non-reference elements are polymorphic insertions curated in-house from published studies.

| -          |                | L1             | 1              | Alu            | S              | SVA            |  |
|------------|----------------|----------------|----------------|----------------|----------------|----------------|--|
|            | Reference      | Non-Reference  | Reference      | Non-Reference  | Reference      | Non-Reference  |  |
|            | Z-score (Pval) |  |
| Intergenic | 16.35          | 7.60           | -40.74         | -8.01          | 0.79           | -4.54          |  |
|            | (4.10E-60)     | (2.91E-14)     | (< 2.2E-16)    | (1.17E-15)     | (0.43)         | (5.73E-6)      |  |
| Intronic   | -9.71          | -3.91          | 50.77          | 12.64          | 1.81           | 5.95           |  |
|            | (2.63E-22)     | (9.31E-5)      | (< 2.2E-16)    | (1.22E-36)     | (0.07)         | (2.74E-9)      |  |
| Exonic     | -18.44         | -10.24         | -26.34         | -12.12         | -7.39          | -3.53          |  |
|            | (6.05E-76)     | (1.27E-24)     | (6.15E-153)    | (8.17E-34)     | (1.47E-13)     | (4.17E-4)      |  |
| Enhancer   | -29.51         | -12.71         | 14.38          | -4.44          | -8.47          | 3.48           |  |
|            | (1.09E-191)    | (5.53E-37)     | (6.55E-47)     | (9.04E-6)      | (2.56E-17)     | (5.03E-4)      |  |

# 3.3.3.2. Alu distribution in functional regions

Non-reference Alu elements are distributed differently in functional regions in comparison to the distribution reference Alus. This result was expected, since Alu elements from both age categories are also distributed differently in different GC regions. Alu elements, from both age categories, are less frequent in intergenic regions than expected by chance alone, made evident by their negative Z-statistics in intergenic regions (Table 12). In addition, the initial integration of Alus do tend to be less frequent in functional regions in comparison to reference Alus. Non-reference Alus are 0.73 and 0.76 times less common in intragenic and enhancer regions, respectively, than reference Alus (Tables 10 & 11; Figures 15 & 16). Although Alu elements, both reference and non-reference, overall do show a tendency to be overrepresented in intronic regions in comparison to the random distribution model, the significance level of accumulation is greater for reference Alus. In addition, reference Alus are significantly more frequent in enhancer

regions in comparison to random insertions, while non-reference Alus are significantly less frequent, evidenced by the positive and negative Z-score values for reference and non-reference Alus, respectively (Table 12). Alu elements are generally depleted in exon regions in comparison to random insertions, although it should be noted, more non-reference Alus, in terms of frequency, are found in exon regions. These results suggest that the initial integration of Alu elements, as shown by the distribution of non-reference Alus, tend to avoid functional genomic regions. However, post-integration factors such as selection can alter the relative distribution of Alus among genic and enhancer regions, increasing the frequency of Alus within functional regions with age.

### 3.3.3.3. SVA distribution in functional regions

Although SVA elements, from both age categories, are more frequent in intergenic regions than genic regions (Table 10), non-reference SVAs appear to be depleted in intergenic regions when compared with the distribution of the random dataset. In addition, the accumulation of reference SVAs in intergenic regions is not significantly different from the distribution of random insertions (Table 12). The initial integration of SVAs, as shown by the distribution of non-reference SVAs, do tend to accumulate more frequently in functional genomic regions in comparison to reference SVAs. Non-reference SVAs are 1.29 and 2.73 times more frequent in intragenic and enhancer regions in comparison to reference, overall do show a tendency to accumulate more frequently in intronic regions in comparison with the random insertion model, the significance level of accumulation is greater for non-reference SVAs. In addition,
non-reference SVAs are significantly more frequent in enhancer regions than reference SVAs, when compared with the distribution of the random dataset (Table 12). SVA elements are generally depleted in exon regions in comparison to the random database, although it should be noted, more non-reference SVAs, in terms of frequency, are found in exon regions. These results suggest that SVA elements tend to integrate preferentially in functional genomic regions, as shown by significant accumulation of non-reference SVAs in intronic and enhancer regions, in comparison to the distribution of random insertions. However, postintegration processes such as selection can alter the relative distribution of SVAs within functional genomic regions, reducing the frequency of SVAs frequency within functional regions with age. The distribution of SVA elements in functional regions is in line with their accumulation in GC-rich regions that tend to be more functional than GC-poor regions. The distribution of all RTEs in functional regions, overall, suggests that non-reference SVA elements may have the strongest potential to affect functional genomic regions, due to its significant overrepresentation in both genes and enhancer regions in comparison to the other RTE types.



Figure 15: Frequency distribution (%) of RTEs located within intergenic and intragenic regions. Intragenic regions include intronic and exonic gene region from transcription start to end including the 5' and 3' untranslated regions of the NCBI RefSeq genes. Reference RTEs are fixed elements in the reference genome obtained from the RepeatMasker table of repeats. Non-reference elements are polymorphic insertions curated in-house from published studies.



Figure 16: Frequency distribution (%) of RTEs located within enhancer regions of the GeneHancer database. Reference RTEs are fixed elements in the reference genome obtained from the RepeatMasker table of repeats. Non-reference elements are polymorphic insertions curated in-house from published studies.

### 3.3.4. Local recombination rate

The standardised sex-averaged (female and male) recombination map, described by Kong et al., (2010), was used to study the distribution of RTEs in regions of different recombination capacity. This recombination map provides a total of 244,308 bins, which were divided into three groups based on their standardised recombination rate (SRR): 104,488 bins (42.77%) are cold, 135,814 (55.59%) are intermediate, and 4006 (1.64%) are hot. Previous studies have reported that recombination rates tend to be highest in genomic regions surrounding genes. Owing to the high copy number and sequence homology between RTE elements, RTE integration in higher recombination regions has the potential to mediate significant deletions and duplications resulting from nonallelic homologous recombination events. Such deletions/duplications can result in the loss of function of many genes or an upset of the gene dosage balance. The distribution of each RTE, separated into age categories, in different recombination regions was studied to determine whether the integration of RTEs, with respect to local recombination rate, is random or whether it is biased by factors such as selection and/or preferential integration.



Figure 17: Frequency distribution (%) of RTEs located within different recombination regions using the standardised sex-averaged (female and male) recombination map described by Kong et al., (2010). Reference RTEs are fixed elements in the reference genome obtained from the RepeatMasker table of repeats. Non-reference elements are polymorphic insertions curated in-house from published studies.

Table 13: Counts and percentages of RTEs located within recombination regions using the standardised sex-averaged (female and male) recombination map described by Kong et al., (2010). Reference RTEs are fixed elements in the reference genome obtained from the RepeatMasker table of repeats. Non-reference elements are polymorphic insertions curated in-house from published studies. P-value and OR for Fisher's exact test statistics are included. Abbreviations: OR, Odds Ratio; CI, Confident interval.

|                 | L1               |               | Alu              |               | SVA              |               |
|-----------------|------------------|---------------|------------------|---------------|------------------|---------------|
|                 | Reference        | Non-Reference | Reference        | Non-Reference | Reference        | Non-Reference |
|                 | (%)              | (%)           | (%)              | (%)           | (%)              | (%)           |
| Nee meeticine   | 16,517           | 4,354         | 115,431          | 11,496        | 454              | 747           |
| Non-recombining | (48.38)          | (44.80)       | (39.44)          | (42.77)       | (48.61)          | (40.14)       |
| Description     | 17,622           | 5,364         | 177,278          | 15,382        | 480              | 1,114         |
| Recombining     | (51.62)          | (55.20)       | (60.56)          | (57.23)       | (51.39)          | (59.86)       |
| Total           | 34,139           | 9,718         | 292,709          | 26,878        | 934              | 1,861         |
| P-value         | 4.71E-10         |               | 1.71E-26         |               | 2.11E-05         |               |
| OR (95% CI)     | 1.15 (1.10-1.21) |               | 0.87 (0.85-0.89) |               | 1.41 (1.20-1.66) |               |

Table 14: Counts and percentages of RTEs located within recombination regions using the standardised sex-averaged (female and male) recombination map described by Kong et al., (2010). Recombining regions are divided into intermediate and hot regions, defined by a standardized recombination rate (SRR) > 0 & <10 for intermediate regions, and SSR of 10 and above for hot recombination regions. Reference RTEs are fixed elements in the reference genome obtained from the RepeatMasker table of repeats. Non-reference elements are polymorphic insertions curated in-house from published studies. The random insertion model assumes that the fraction of insertions is proportional to the fractional size of each of the recombination regions. P-value for Chi-squared goodness of fit test statistics are given.

|                  | L1                |                  | Alu                |                   | SVA            |                  |
|------------------|-------------------|------------------|--------------------|-------------------|----------------|------------------|
|                  | Reference         | Non-             | Reference          | Non-              | Reference      | Non-             |
|                  | (%)               | Reference (%)    | (%)                | Reference (%)     | (%)            | Reference (%)    |
| Cold             | 16,517<br>(48.38) | 4,354<br>(44.80) | 115,431<br>(39.44) | 11,496<br>(42.77) | 454<br>(48.61) | 747<br>(40.14)   |
| Intermediate     | 17,219<br>(50.44) | 5,224<br>(53.76) | 171,626<br>(58.63) | 14,907<br>(55.46) | 469<br>(50.21) | 1,088<br>(58.46) |
| Hot              | 403<br>(1.18)     | 140<br>(1.44)    | 5,652<br>(1.93)    | 475<br>(1.77)     | 11<br>(1.18)   | 26<br>(1.40)     |
| P-value compared |                   |                  |                    |                   |                |                  |
| with random      | 2.99E-100         | 1.48E-04         | 1.06E-304          | 0.26              | 1.16E-03       | 0.040            |
| insertion model  |                   |                  |                    |                   |                |                  |

The initial integration of RTE elements, with the exception of Alu elements, is not random with respect to local recombination rates. RTEs are found in all recombination regions, with the highest fraction observed in intermediate regions for all RTEs (Figure 17). In addition, all RTE classes show a significant difference in the distribution of their reference vs. non-reference elements, across the various recombination regions analysed, as confirmed by Fisher's exact test (Table 13). Although RTEs are generally more frequent in intermediate regions, non-reference RTEs do show a greater tendency to accumulate in recombining regions than reference elements, with the exception of Alus (Figure 17; Table 14). Overall, the distribution of L1 and SVA elements generally shifts away from recombining regions with time, while the opposite trend is observed for the distribution of Alu elements.

### 3.3.4.1. L1 local recombination rate

The initial integration of L1s, as shown by the distribution of non-reference L1s, tends to be more frequent in recombining regions. Non-reference L1s are 1.15 times more frequent in recombining regions in comparison to reference L1s (Table 13). The distribution of L1s within recombining regions shows a greater accumulation of L1s, both reference and non-reference, in intermediate regions in comparison to hot recombination regions (Figure 17; Table 14). Overall, L1 elements from both age categories are not randomly distributed within the different recombination regions analysed, as confirmed by the Chi-square goodness-of-fit test (Table 14). Although it should be noted, more L1 elements, in terms of frequencies, are found within non-recombining regions, in comparison to the fractional size of non-recombining bins in the genome (48.38% & 44.80% respectively for reference and non-reference L1s vs. 42.77% of non-recombining bins in the genome), suggesting the preferential integration of L1 elements in non-recombining regions. Overall, the initial integration of L1s in recombining regions is more uniform in comparison to reference (fixed) L1s. The distribution of L1 elements in recombination regions is in line with their preferential accumulation in GC-poor, non-functional genomic regions that tend to have a low recombination rate.

### 3.3.4.2. Alu local recombination rate

Non-reference Alu elements appear to be distributed differently to the reference Alu elements. This result was expected, since Alu elements from both age categories are also distributed differently in different GC and functional regions. The initial integration of Alus, as shown by the distribution of non-reference Alus, appears to be random. In comparison, the distribution of reference Alus is significantly different from the distribution expected by chance, as confirmed by the Chi-square goodness-of-fit test (Table 14). Although the distribution of Alus, both reference and non-reference, show a greater accumulation in recombining regions, non-reference Alus are 0.87 times less frequent in recombining regions than reference Alus (Table 13). The distribution of Alu elements within recombining regions shows a greater accumulation of Alus in regions of intermediate recombination rates, although it should be noted, more reference Alus, in terms of frequencies, are found within intermediate and hot regions in comparison to non-reference Alu elements (Table 14). In addition, the frequency of non-reference Alu elements in non-recombining regions (referred to as cold regions in the table) is higher in comparison to the frequency of reference Alus (Table 14). The increased accumulation of reference Alus in recombining regions is in line with their significant accumulation in GC-rich, gene-rich regions of the genome. These results suggest that the initial integration of Alus, as shown by the distribution of non-reference Alus, in regions of different recombination rates, tends to resemble a random integration pattern. It appears that post-integration factors, such as selection, can alter the relative distribution of Alus in different recombination regions, increasing their frequency within recombining regions with age.

### 3.3.4.3. SVA local recombination rate

Although SVA elements, from both age categories, are more abundant in recombining regions, non-reference SVAs are 1.41 times more frequent in recombining regions in comparison to reference SVAs (Table 13). The distribution of SVAs, both reference and non-reference, within recombining regions shows a greater accumulation in intermediate regions in comparison to hot recombination regions (Figure 17; Table 14). The distribution of SVA elements from both age categories, overall do appear to be significantly different from the distribution expected by chance, as confirmed by the Chi-square goodness-of-fit test (Table 14). Although it should be noted, more reference SVA elements, in terms of frequencies, are found within non-recombining regions in comparison to non-reference SVAs (48.61% & 40.14% respectively for reference and non-reference SVAs). In addition, reference SVA elements are more frequent in non-recombining regions in comparison to the fractional size of nonrecombining bins in the genome. The increased frequency of reference SVA elements in non-recombining regions, in comparison to non-reference SVAs, suggests the role of post-integration processes in re-shaping the fractional distribution of SVA elements in different recombination regions. Overall, the initial integration of SVA elements in recombining regions, as shown by the distribution of non-reference SVAs, is more uniform in comparison to reference (fixed) SVAs. These results are in line with the reduced frequency of reference SVA elements in functional genomic regions, and accumulation in lower GC regions, in comparison to non-reference SVAs.

### 3.3.5. Local chromatin accessibility

This section analyses the enrichment of non-reference RTEs in accessible chromatin regions marked with the epigenetic modification H3K4me3, using 127 epigenomes divided into 30 anatomical regions, characterised by the Roadmap epigenomics project (Roadmap Epigenomics Consortium, 2015). The nonreference RTEs are the younger, potentially active RTEs that will have more of an effect in disrupting genome function in comparison to reference (fixed) RTEs that are no longer active. The observed density of non-reference RTEs in each of the 127 epigenomes was compared with the densities produced by 1,000 datasets that have been randomly generated. RTE elements overall appear to be enriched in the accessible chromatin domains of a wide variety of cell types and anatomical regions. Non-reference RTEs were significantly enriched (empirical P-values > 0.05) in a total of 103/127 cell types belonging to 27/30 unique anatomical groups (Table 15: Figure 18). L1s, Alus, and SVAs tend to show a greater enrichment in cell types belonging to the blood anatomical group. In addition, RTEs are enriched in the accessible domains of many types of epithelium cell groups, such as skin, heart, breast, and gastrointestinal. L1 elements are enriched in a narrower variety of cell types and anatomical groups (36 &16, respectively for cell types and anatomical groups) in comparison with Alu and SVA elements (Alu=65 & 22, SVA=68 & 25, respectively for cell types and anatomical groups). These results suggest that non-reference RTEs that remain active in the genome have the potential to negatively affect the function of a wide variety of cell types and organs. Alu and SVA elements have a greater potential to influence genome function in comparison to L1 elements.



Figure 18: Count of non-reference (polymorphic) RTEs enriched in the euchromatin domains of at least one epigenome reported in the Roadmap project. Axes show anatomical groups (x-axis) against the count of cell types with an enrichment of RTEs in its euchromatin domains (y-axis). Abbreviations: ESC, Embryonic stem cells; IPSC, Induced pluripotent stem cells; GI, Gastrointestinal.

| EID  |         | P-value |         | Anatomy     | Standardized Epigenome Name                            |
|------|---------|---------|---------|-------------|--|
|      | L1      | Alu     | SVA     |             |  |
| E001 | 1.0E-03 | 1.0E-03 | 1.0E-03 | ESC         | ESnaI3 Cells   |
| E002 | 1.0E-03 | 1.0E-03 | -       | ESC         | ESnaWA7 Cells  |
| E003 | -       | 2.7E-02 | 1.0E-03 | ESC         | H1 Cells   |
| E004 | -       | 1.0E-03 | -       | ESC_DERIVED | H1 BMP4 Derived Mesendoderm Cultured Cells             |
| E005 | -       | -       | 1.0E-03 | ESC_DERIVED | H1 BMP4 Derived Trophoblast Cultured Cells             |
| E006 | -       | -       | 3.4E-02 | ESC_DERIVED | H1 Derived Mesenchymal Stem Cells                      |
| E007 | -       | -       | 1.3E-02 | ESC_DERIVED | H1 Derived Neuronal Progenitor Cultured Cells          |
| E008 | -       | -       | 1.0E-03 | ESC         | H9 Cells   |
| E009 | -       | -       | 2.9E-02 | ESC_DERIVED | H9 Derived Neuronal Progenitor Cultured Cells          |
| E010 | -       | -       | 2.8E-02 | ESC_DERIVED | H9 Derived Neuron Cultured Cells                       |
| E011 | 1.0E-03 | 1.0E-03 | 1.0E-03 | ESC_DERIVED | hESC Derived CD184+ Endoderm Cultured Cells            |
| E012 | 1.0E-03 | 2.0E-03 | -       | ESC_DERIVED | hESC Derived CD56+ Ectoderm Cultured Cells             |
| E013 | -       | -       | 2.0E-03 | ESC_DERIVED | hESC Derived CD56+ Mesoderm Cultured Cells             |
| E014 | 1.0E-03 | 1.0E-03 | 1.0E-03 | ESC         | HUES48 Cells   |
| E015 | 1.0E-03 | 1.0E-03 | 1.0E-03 | ESC         | HUES6 Cells  |
| E016 | 1.0E-03 | 1.0E-03 | 1.0E-03 | ESC         | HUES64 Cells   |
| E017 | -       | -       | 1.0E-03 | LUNG        | IMR90 fetal lung fibroblasts Cell Line                 |
| E018 | 5.0E-03 | -       | 1.0E-03 | IPSC        | iPSna15b Cells   |
| E019 | 1.0E-03 | 1.6E-02 | 4.0E-03 | IPSC        | iPSna18 Cells  |
| E020 | 1.0E-03 | 1.0E-03 | 2.0E-03 | IPSC        | iPSna20b Cells   |
| E023 | 1.0E-03 | 1.0E-03 | 1.0E-03 | FAT         | Mesenchymal Stem Cell Derived Adipocyte Cultured Cells |

Table 15: Empirical P values for the enrichment of RTEs located within euchromatin domains using the H3K4me3 profiles of the Roadmap project. RTEs are polymorphic insertions curated in-house from published studies.

# (Table 15 continues)

| E024 | -       | 1.0E-03 | -       | ESC                | ESnaUCSF4 Cells  |
|------|---------|---------|---------|--------------------|--|
| E025 | 1.0E-03 | 1.0E-03 | 2.2E-02 | FAT                | Adipose Derived Mesenchymal Stem Cell Cultured Cells           |
| E026 | -       | 1.3E-02 | 3.0E-03 | STROMAL_CONNECTIVE | Bone Marrow Derived Cultured Mesenchymal Stem Cells            |
| E027 | -       | 2.2E-02 | 1.0E-03 | BREAST             | Breast Myoepithelial Primary Cells                             |
| E028 | 5.0E-03 | 1.0E-03 | 1.0E-03 | BREAST             | Breast variant Human Mammary Epithelial Cells (vHMEC)          |
| E030 | -       | -       | 3.0E-03 | BLOOD              | Primary neutrophils from peripheral blood                      |
| E031 | -       | -       | 1.4E-02 | BLOOD              | Primary B cells from cord blood                                |
| E032 | -       | 1.2E-02 | -       | BLOOD              | Primary B cells from peripheral blood                          |
| E033 | -       | 1.0E-03 | -       | BLOOD              | Primary T cells from cord blood                                |
| E035 | -       | 3.0E-02 | 1.0E-03 | BLOOD              | Primary hematopoietic stem cells                               |
| E036 | -       | -       | 6.0E-03 | BLOOD              | Primary hematopoietic stem cells short term culture            |
| E037 | 1.0E-03 | 1.0E-03 | -       | BLOOD              | Primary T helper memory cells from peripheral blood 2          |
| E038 | 1.0E-03 | 1.0E-03 | -       | BLOOD              | Primary T helper naive cells from peripheral blood             |
| E039 | -       | 4.0E-03 | 1.0E-03 | BLOOD              | Primary T helper naive cells from peripheral blood             |
| E040 | 1.0E-03 | 1.0E-03 | -       | BLOOD              | Primary T helper memory cells from peripheral blood 1          |
| E041 | 1.0E-03 | 1.0E-03 | 9.0E-03 | BLOOD              | Primary T helper cells PMAnaI stimulated                       |
| E042 | 5.0E-02 | 1.0E-03 | -       | BLOOD              | Primary T helper 17 cells PMAnaI stimulated                    |
| E043 | -       | -       | 1.0E-03 | BLOOD              | Primary T helper cells from peripheral blood                   |
| E044 | -       | -       | 1.0E-03 | BLOOD              | Primary T regulatory cells from peripheral blood               |
| E045 | 1.0E-03 | 1.0E-03 | -       | BLOOD              | Primary T cells effector/memory enriched from peripheral blood |
| E046 | -       | 1.0E-03 | -       | BLOOD              | Primary natural Killer cells from peripheral blood             |
| E047 | -       | 1.0E-03 | -       | BLOOD              | Primary T CD8+ naive cells from peripheral blood               |
| E048 | 2.0E-03 | 1.0E-03 | -       | BLOOD              | Primary T CD8+ memory cells from peripheral blood              |
| E049 | -       | 1.7E-02 | 6.0E-03 | STROMAL_CONNECTIVE | Mesenchymal Stem Cell Derived Chondrocyte Cultured Cells       |
| E051 | -       | -       | 2.0E-03 | BLOOD              | Primary hematopoietic stem cells GnaCSFnamobilized Male        |
| E052 | -       | 1.1E-02 | 3.7E-02 | MUSCLE             | Muscle Satellite Cultured Cells                                |
| E055 | -       | -       | 1.0E-03 | SKIN               | Foreskin Fibroblast Primary Cells skin01                       |

## (Table 15 continues)

| E056 | -       | -       | 1.0E-03 | SKIN         |
|------|---------|---------|---------|--------------|
| E057 | -       | -       | 8.0E-03 | SKIN         |
| E058 | -       | -       | 1.0E-03 | SKIN         |
| E059 | -       | -       | 1.0E-03 | SKIN         |
| E061 | -       | -       | 1.0E-03 | SKIN         |
| E062 | -       | 1.0E-03 | -       | BLOOD        |
| E063 | 1.0E-03 | -       | -       | FAT          |
| E065 | 1.0E-03 | 1.0E-03 | -       | VASCULAR     |
| E066 | 1.0E-03 | 1.0E-03 | -       | LIVER        |
| E067 | -       | 1.0E-03 | -       | BRAIN        |
| E070 | -       | -       | 4.6E-02 | BRAIN        |
| E074 | -       | 2.0E-03 | -       | BRAIN        |
| E075 | -       | -       | 6.0E-03 | GI_COLON     |
| E076 | -       | 1.0E-03 | -       | GI_COLON     |
| E077 | 1.7E-02 | 1.0E-02 | 3.0E-03 | GI_DUODENUM  |
| E078 | 1.0E-03 | 1.0E-03 | 3.0E-03 | GI_DUODENUM  |
| E081 | 8.0E-03 | 1.0E-03 | -       | BRAIN        |
| E082 | -       | -       | 1.1E-02 | BRAIN        |
| E083 | 1.0E-03 | 1.0E-03 | -       | HEART        |
| E084 | -       | 4.0E-03 | -       | GI_INTESTINE |
| E086 | -       | -       | 7.0E-03 | KIDNEY       |
| E087 | -       | -       | 4.0E-03 | PANCREAS     |
| E088 | 1.0E-03 | 1.0E-03 | -       | LUNG         |
| E093 | -       | 6.0E-03 | -       | THYMUS       |
| E095 | 1.0E-03 | 1.0E-03 | -       | HEART        |
| E097 | 1.0E-03 | 1.0E-03 | -       | OVARY        |
| E099 | -       | 1.0E-03 | 1.0E-03 | PLACENTA     |
| E100 | 1.0E-03 | 1.0E-03 | -       | MUSCLE       |

Foreskin Fibroblast Primary Cells skin02 Foreskin Keratinocyte Primary Cells skin02 Foreskin Keratinocyte Primary Cells skin03 Foreskin Melanocyte Primary Cells skin01 Foreskin Melanocyte Primary Cells skin03 Primary mononuclear cells from peripheral blood Adipose Nuclei Aorta Liver Brain Angular Gyrus Brain Germinal Matrix Brain Substantia Nigra Colonic Mucosa Colon Smooth Muscle Duodenum Mucosa Duodenum Smooth Muscle Fetal Brain Male Fetal Brain Female Fetal Heart Fetal Intestine Large Fetal Kidney Pancreatic Islets Fetal Lung Fetal Thymus Left Ventricle Ovary Placenta Amnion Psoas Muscle

# (Table 15 continues)

| E101 | -       | 1.0E-03 | 1.0E-03 | GI_RECTUM    | Rectal Mucosa Donor 29                           |
|------|---------|---------|---------|--------------|--|
| E102 | 1.0E-03 | 1.0E-03 | -       | GI_RECTUM    | Rectal Mucosa Donor 31                           |
| E103 | -       | -       | 1.9E-02 | GI_RECTUM    | Rectal Smooth Muscle                             |
| E104 | 1.0E-03 | 1.0E-03 | 2.2E-02 | HEART        | Right Atrium                                     |
| E105 | -       | 2.0E-03 | 4.7E-02 | HEART        | Right Ventricle                                  |
| E106 | 1.1E-02 | 1.0E-03 | -       | GI_COLON     | Sigmoid Colon                                    |
| E109 | -       | 1.0E-03 | -       | GI_INTESTINE | Small Intestine                                  |
| E110 | -       | 1.0E-03 | -       | GI_STOMACH   | Stomach Mucosa                                   |
| E111 | -       | -       | 4.9E-02 | GI_STOMACH   | Stomach Smooth Muscle                            |
| E112 | -       | -       | 6.0E-03 | THYMUS       | Thymus   |
| E113 | -       | -       | 4.0E-03 | SPLEEN       | Spleen   |
| E114 | -       | 1.0E-03 | 2.0E-03 | LUNG         | A549 EtOH 0.02pct Lung Carcinoma Cell Line       |
| E115 | -       | -       | 1.0E-03 | BLOOD        | Dnd41 TCell Leukemia Cell Line                   |
| E116 | -       | 1.1E-02 | 2.0E-03 | BLOOD        | GM12878 Lymphoblastoid Cells                     |
| E117 | -       | -       | 1.0E-03 | CERVIX       | HeLanaS3 Cervical Carcinoma Cell Line            |
| E118 | -       | -       | 2.0E-03 | LIVER        | HepG2 Hepatocellular Carcinoma Cell Line         |
| E119 | -       | 1.0E-03 | 9.0E-03 | BREAST       | HMEC Mammary Epithelial Primary Cells            |
| E120 | -       | -       | 1.0E-03 | MUSCLE       | HSMM Skeletal Muscle Myoblasts Cells             |
| E121 | -       | 1.0E-03 | 1.0E-03 | MUSCLE       | HSMM cell derived Skeletal Muscle Myotubes Cells |
| E122 | -       | 4.0E-02 | 1.2E-02 | VASCULAR     | HUVEC Umbilical Vein Endothelial Primary Cells   |
| E123 | -       | 1.0E-03 | 1.0E-03 | BLOOD        | K562 Leukemia Cells                              |
| E124 | 1.0E-03 | 1.0E-03 | 1.0E-03 | BLOOD        | MonocytesnaCD14+ RO01746 Primary Cells           |
| E125 | 1.0E-03 | 1.0E-03 | -       | BRAIN        | NHnaA Astrocytes Primary Cells                   |
| E126 | -       | 1.5E-02 | -       | SKIN         | NHDFnaAd Adult Dermal Fibroblast Primary Cells   |
| E127 | -       | -       | 1.0E-03 | SKIN         | NHEKnaEpidermal Keratinocyte Primary Cells       |
| E128 | -       | -       | 1.4E-02 | LUNG         | NHLF Lung Fibroblast Primary Cells               |
| E129 | -       | -       | 3.0E-03 | BONE         | Osteoblast Primary Cells                         |

#### 3.4. Discussion

A comparison between the genomic distributions of reference RTEs (fixed) and non-reference RTEs (polymorphic) was conducted. Polymorphic RTEs, specifically rare insertions (MAF  $\geq$  1%), experience selection to a lesser extent than ancient RTE insertions that are now fixed in the human genome. As such, the genomic landscape of non-reference RTEs was expected to be in-between that observed for fixed endogenous elements and *de novo* insertions that potentially reflect integration site preference. To this end, a database of polymorphic non-reference RTEs was curated. The in-house curated database is, to the best of our knowledge, the most comprehensive list of non-reference RTEs in the human genome, encompassing 39,798 RTE insertions identified in over 7,000 individuals. The landscape of L1, Alu, and SVA elements in the human genome was investigated by studying the distribution of RTEs within the following genomic features:

- I. Chromosomal distribution; investigated to determine whether the properties of any chromosome allow it to harbour more RTE insertions.
- II. Local base composition and functionality; investigated to understand the potential effect of RTE insertions on genome function and stability.
- III. Local recombination rate; investigated as there is a strong positive correlation between selection and recombination, and also because of the risk NAHR between homologous RTEs can pose on genome integrity and rearrangement.

IV. Chromatin accessibility; investigated to understand whether RTEs integrate preferentially into regions that allow them to propagate and create new insertions.

Overall, the distribution of non-reference RTEs do display aspects of the interplay between integration preference and differential selection. Reference and nonreference RTEs are characterised by unique genomic distributions, with polymorphic non-reference RTEs displaying a closer genomic landscape to *de novo* insertions than reference RTEs. On average, and in agreement with previous studies, non-reference L1 and Alu elements were similarly distributed in GC-poor, low activity regions, while non-reference SVAs accumulated in GC-rich, high activity regions of the human genome. Below is a discussion of the distribution results for each of the studied RTE elements in each of the studied genomic features.

# 3.4.1. Chromosomal distribution

The distribution of L1 elements is in line with previous studies. The strong linear correlation between the number of non-reference L1s and chromosome size is consistent with the chromosome-wide distribution of *de novo* L1s (Flasch et al., 2019; Sultana et al., 2019; Chen et al., 2020). The chromosomal distribution analysis shows an over-representation of reference L1 elements on the X-chromosome, which have been associated with its role in propagating the X-inactivation signal (Lyon, 1988; Bailey, et al., 2000). In contrast, non-reference L1s are not significantly enriched on the X-chromosome (Figure 9). The lack of obvious enrichment of non-reference L1s on the X-chromosome is consistent with the reported distribution of *de novo* L1 insertions (Sultana et al., 2019; Chen

et al., 2020), confirming that the accumulation of reference L1s in the Xchromosome results from post-integration selection processes. Non-reference L1s are slightly over-represented in chromosome 4, consistent with a previous study analysing the distribution of 344 non-ref L1s (Boissinot et al., 2004). Boissinot et al. (2004) suggested that the observed bias of L1Hs elements on chromosome 4 is not likely due to preferential integration on this chromosome, but rather a reflection of the amplification of active L1 elements. The chromosomal distribution of *de novo* insertions obtained using engineered L1s supports this suggestion. Two recent studies reported an over-representation of de novo L1s in chromosome 1 and chromosome 5 (Sultana et al., 2019 and Flasch et al., 2019, respectively), suggesting that the integration of L1 elements is not perfectly random. The accumulation of non-reference L1s in low GC regions of the genome is consistent with the non-random distribution reported for *de novo* L1 elements. The study by Sultana et al. (2019) attributed the biased integration of L1s in GC-poor regions to pre-existing biases in the distribution of the L1 ORF1 target motif. Nevertheless, it was found that new L1s integrate into higher GC regions and broadly target all genomic regions in comparison to endogenous L1s, a difference that was predominantly attributed to evolutionary selection (Flasch et al., 2019; Sultana et al., 2019; Chen et al., 2020).

Sultana *et al.* (2019) reported that *de novo* L1s are not significantly enriched or depleted in gene regions. In contrast, non-reference L1Hs elements, endogenous in HeLa-S3 cells and reference L1s, are significantly depleted in genic regions and enriched in low activity regions. In addition, Chen et al. (2020) reported that the distribution of polymorphic L1s in both gene and active regions is closer to the distribution of reference L1Hs elements than *de novo* L1s. The reported significant depletion of polymorphic L1s in active regions is consistent with the

results of this study, yet their comparison with the control dataset suggests less significant depletion in contrast to the depletion of reference L1s. As such, the results of this study do show that selection pressures acting on polymorphic L1s are in-between those of *de novo* and fixed L1 elements.

Previous studies investigating the genomic distribution of Alu elements have suggested the occurrence of differences between the density of Alus from different evolutionary families across different chromosomes (Grover et al., 2004; Kim et al., 2004). Grover et al. (2004) when examining Alu elements from repeat masker (AluS, AluJ, and Alu Y) reported that, in terms of Alu elements density, chromosome 19 is the densest and chromosome Y is the least dense chromosome. When examining the reference Alu density across chromosomes in this study and others, the same trend is observed, and chromosome 19 appears to hold an increased Alu density in comparison to its size (Figure 10). Reference SVAs are also overrepresented on chromosome 19 (Figure 11). In line with previous studies, the higher density of fixed Alu and SVA elements on chromosome 19 is proportional to the high gene density of this chromosome, as shown by the strong correlation between Alu and SVA density with gene density (Lander et al., 2001; Grover et al., 2004; Wagstaff et al., 2012; Tang et al., 2018; Gianfrancesco et al., 2019).

In contrast to previous studies, non-reference Alu and SVA elements appear to be underrepresented on the X-chromosome (Figures 10 & 11). Wang et al. (2006) and Cotton et al. (2014) both reported a positive correlation between the Alu content of genes on the X-chromosome and their ability to escape the inactivation signal. These observations may explain the under-representation of nonreference Alu and SVA elements on the X-chromosome, given that SVA elements

contain an Alu-like segment in their sequence. Another possibility for the underrepresentation of non-reference Alu and SVA elements on the X-chromosome may be due to sampling bias caused by the heterozygosity of the X-chromosome in males, however, this is unlikely since this phenomenon was not observed for the distribution of non-reference L1 elements.

#### 3.4.2. Local GC content

Alu and SVA elements are both non-autonomous RTEs that use the L1 machinery for transposition, yet SVAs and reference Alu elements (Figures 13 and 14) accumulated in GC-rich regions while L1s (Figure 12) and non-reference Alus accumulated into AT-rich regions. L1 and Alu elements initially integrate into AT-rich regions as the target site of the L1 ORF2 (5'-TTTT/AA-3') are more frequent in these genomic regions (Costantini et al., 2012). In contrast, SVA elements preferentially integrate into GC-rich regions, even though their target site resembles the L1 consensus sequence (Raiz et al., 2012). The reasons behind the preferential integration of SVA elements in GC-rich regions are yet to be understood. Nevertheless, the shift in the GC distribution pattern observed between reference and non-reference RTEs has been associated with natural selection. Alu elements in GC-rich regions were subject to positive selection, due to their role in regulating gene expression and increasing gene stability (Costantini et al., 2012). This explains the shift in GC distribution patterns observed between reference and non-reference Alu elements (Figure 13). Another explanation is that negative selection mostly acts on Alu elements in ATrich regions, as their removal from these regions is less likely to be harmful to the genome function than the removal of Alu elements in GC-rich/gene-rich regions (Abrusán & Krambeck, 2006). Either explanation would have resulted in shifting

the distribution pattern of Alu elements over time to higher GC regions and would explain the over-representation of reference Alu elements in intron regions (Figures 13 & 15). The removal of deleterious L1 and SVA elements by unequal crossover is thought to contribute to the shifting of the GC distribution pattern of these elements (Wang et al., 2005; Song & Boissinot, 2007). Nevertheless, the preferential integration of SVA elements in GC-rich regions, together with their low density in the human genome (Figure 11.B), gives them a better chance of becoming fixed in GC-rich gene-rich regions. This may explain the overrepresentation of SVA elements in intron regions, more so than expected by chance (Figure 15, Table 12).

### **3.4.3.** Distribution in genomic regions of functional relevance

The functional impact of RTEs on genome function was examined by analysing their location in relation to known genes and enhancer regions. Non-reference L1 and SVA elements are more frequent in functional regions than their reference counterparts (Figures 15 and 16). The shift in the distribution of L1 and SVA elements in functional genomic regions with time has been attributed to the role of purifying selection in removing deleterious insertions from the genome (Boissinot et al., 2001; Belle et al., 2005; Wang et al., 2005). The over-representation of L1 elements in gene-free regions has been suggested to be due to its retrotransposition mechanism, that may have evolved to target what was called "genomic safe havens" (Levin and Moran, 2014), to minimise the damage of its transposition on the genome function of its host (Cost & Boeke, 1998; Levin & Moran, 2014). A more recent study analysing the target sites of 1,565 L1 insertions that had been experimentally induced suggested that pre-

existing biases in the distribution of the L1 ORF2 motif in the human genome may have impacted the observed distribution of recent L1 insertions (Sultana et al., 2019).

Reference Alu elements are also over-represented in intronic and enhancer regions. The over-representation of reference Alus in intron and enhancer regions suggests their preferential retention in functional regions, possibly due to their positive effect on genome function. This observation is in line with previous studies that suggested the contribution of ancient Alu elements in gene regulation, by providing genes with promoters and enhancers (Cordaux & Batzer, 2009; Su et al., 2014; Trizzino, Kapusta, & Brown, 2018). New Alu insertions do not necessarily offer "ready-to-use" regulatory elements (Warnefors et al., 2010), but their potential ability to gain functional advantages may explain the overrepresentation of non-reference Alu elements in intron regions compared to the control distribution. Non-reference SVA elements are over-represented in intron and enhancer regions, compared with the control distribution and the distribution of reference SVAs (Figures 15 & 16, Table 12). These results suggest that SVA elements in functional regions are subject to purifying selection due to their negative impact on genome function. The preferential integration of SVA elements in gene regions has been previously reported in the literature (Raiz et al., 2012; Savage et al., 2013; Gianfrancesco et al., 2019).

SVA elements have the potential to influence genome function and regulation through a variety of mechanisms (Kwon et al., 2013; Savage et al., 2013; Bragg et al., 2017; Gianfrancesco et al., 2017; Pontis et al., 2019). The GC-rich sequence of SVAs gives them the potential to create G-quadruplexes (G4) structures (Savage et al., 2013; Bragg et al., 2017). These secondary DNA

structures are strongly associated with their negative impact on genomic and epigenomic stability (Bragg et al., 2017; Spiegel, et al., 2020). Evidence of the ongoing co-evolution of SVA retrotransposons and zinc finger genes that are known to suppress SVA mobilisation, supporting the harmful effect of SVA insertions on genome function and integrity (Jacobs et al., 2014; Gianfrancesco et al., 2019).

### 3.4.4. Local recombination rate

The distribution of RTEs in regions of different recombination rates may be associated with their local GC content, due to the significant correlation between recombination rate and local base composition. Local GC content is positively correlated with recombination rate, while local AT content correlates negatively with recombination rate (Kong et al., 2002; Mugal et al., 2015). Consistent with previous studies, L1 and SVA elements shift to regions associated with lower recombination rate, while Alu elements shift to regions of higher recombination rate with age (Lander et al., 2001; Medstrand et al., 2002; Wang et al., 2005; Myers et al., 2008). In contrast, Alu elements shift to genomic regions of higher recombination rate with age (Figure 17). This observed shift may be associated with the reduced strength of selection in genomic regions of low recombination rates (Boissinot et al., 2001; Abrusán & Krambeck, 2006; Dolgin & Charlesworth, 2008) and complements the observed shift in the GC distribution pattern of L1 and SVA elements with time to regions of lower GC-content (Figures 12 and 14). In comparison, the observed shift in local recombination rate of Alus from cold to intermediate with age reflects their preferential retention in gene regions, as mentioned above. Interestingly, Abrusán & Krambeck (2006) reported the lack of

difference in the distribution of L1 and Alu elements over time in gene-poor regions on chromosomes 4 and X, suggesting the importance of genes in shaping the genomic distribution of RTEs in the genome. In addition, a recent review article has reported the growing number of studies supporting the co-evolution between RTEs integration and local recombination rate, implicating the importance of transposons in the evolution of the genome structure and recombination rates (Kent et al., 2017).

## 3.4.5. Local chromatin accessibility

The distribution of RTEs within active (euchromatin) and repressed (heterochromatin) chromatin states were investigated. Reference SVAs are the highest of the RTEs in heterochromatin regions, followed by non-reference L1s. In contrast, non-reference SVAs are the most predominant RTEs in euchromatin regions followed by reference Alus and non-reference L1s (Figure 18). The differential distribution of reference and non-reference SVAs in genomic regions of different chromatin accessibility, suggests the negative effect of SVA transposition on the fitness of its host. These observations are consistent with the continuous co-evolution of zinc finger genes with SVA elements to suppress SVA activity. The high fraction of reference Alus in euchromatin domains is consistent with its accumulation in intron regions. Non-reference L1 elements are more frequent in both euchromatin and heterochromatin domains compared to the reference L1s, however, they are more frequent in heterochromatin domains. These results are inconsistent with that of a recent study reporting that new L1 insertions are not affected by chromatin states (Sultana et al., 2019). The discrepancy between both studies may be due to this study using an average

percentage of L1s from different cell types that belong to the same group of tissue, while Sultana et al. (2019) investigated the insertion of *de novo* L1 insertions in HeLa S3 cells. Sultana et al. (2019) have also suggested that L1 integration is influenced by replication timing of the target region. Chromatin states of different cell types may potentially have a different effect in shaping the integration pattern of L1 insertions.

# 3.4.6. Study overview and concluding remarks

This chapter demonstrates the differential genomic distribution of reference RTEs that are fixed in the human genome, and non-reference RTEs that are polymorphic in the population. The current study builds on previous reports, supporting the role of selection in shaping the genomic distribution of endogenous elements, while revealing aspects of the interplay between integration preference and selection forces in shaping the distribution of polymorphic RTEs. Nevertheless, the genomic distribution of non-reference elements suggests that RTE activity has the potential to cause detrimental effects on genome function and increase susceptibility to multifactorial disorders, made evident by their ready occurrence in regions of functional relevance. In theory, RTE activity has the potential to affect all human diseases. Indeed, RTE activity has already been associated with several complex disorders such as cancer (Burns, 2017), ALS (Savage et al., 2019), schizophrenia and Alzheimer's disease (Guffanti et al., 2014; Terry et al., 2020). We hypothesise that SVA transposons in particular pose the largest detrimental effect on the human genome, based on the increased accumulation of non-reference SVAs in active regions in comparison to non-

reference L1 and Alu elements. This finding is significant since it demonstrates the importance of co-analysing the distribution of all active RTE elements simultaneously, in order to achieve a comprehensive understanding about the effect of all RTE activity on genome function as a whole.

Although this study analysed a larger sample size than any previous study, potentially analysing more of the most recent insertions of low and rare allelic frequencies, the heterogeneity of allele frequency may have masked some variations in the genomic distribution of RTE elements. Future in-depth analysis of the genomic distribution of RTEs separated into groups of similar allele frequencies is required to gain a deeper understanding regarding the interplay between selection and integration preference of the currently amplifying RTE families. In addition, a recent analysis of *de novo* SVA insertions in culture, similar to the recent analyses of *de novo* engineered L1s (Flasch et al., 2019; Sultana et al., 2019; Chen et al., 2020), is required to gain a better understanding about the integration preference of SVA elements in gene-rich regions.

### 4. RTEs as potential variants of disease

#### 4.1. Introduction

Structural variants (SVs), defined as sequence variations (> 50bp) between individual genomes (Sudmant et al., 2015), are an important class of genomic variations that account for most base pair (bp) differences between the genomes of individuals within a population. SVs include, amongst other types, deletions, duplications, copy-number variations (CNVs), and insertions (Feuk et al., 2006; Stankiewicz and Lupski, 2010; Weischenfeldt et al., 2013; Escaramís et al., 2015). These types of genomic variations are known to influence gene expression and pathological traits in humans (Feuk et al., 2006; Weischenfeldt et al., 2013; Chiang et al., 2017). As such, SVs have been proposed as a potential source of genomic variants accountable for part of the missing heritability problem of complex traits.

# 4.1.1. The missing heritability of complex traits:

Complex traits are traits determined by multiple genetic and environmental factors. Such traits are more common than monogenic traits (i.e., traits influenced by a single allele/gene) and show a continuous range of phenotypic characteristics, influenced by the interplay between the genetic and environmental factors (Rowe and Tenesa, 2012; Barton et al., 2017). Examples of complex traits include natural hair colour, height, body mass index (BMI), and many diseases, including Autism spectrum disorders (ASDs), Parkinson's disease, and Alzheimer's disease. Genome-wide association studies (GWAS)

aim to identify associations between genetic variants, typically single-nucleotide polymorphisms (SNPs), and the observed phenotypic variation. However, for many complex traits, the cumulative effect size of all genome-wide significant SNPs ( $P < 5x10^{-8}$ ) can only explain a small portion of the trait heritability as inferred from family-based studies, thus raising the missing heritability issue (Maher, 2008; Manolio et al., 2009; Rowe and Tenesa, 2012).

Two distinct models have been proposed for explaining the missing heritability of complex traits. The first model suggests that complex traits are controlled by many common variants, each contributing an infinitely small additive effect on the observed phenotype (Gibson, 2012; Hu et al., 2012; Weiner et al., 2017). This model proposes that variants with an effect size too small to be significant are usually missed from association studies, thus, heritability is not so much missing but rather hidden beneath the stringent significant level required by GWAS. Recent studies have indeed demonstrated that the majority of the missing heritability for several complex traits is recoverable from many variants of small effect sizes (Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014; Wood et al., 2014; Abraham et al., 2016). The second model suggests that the missing heritability is largely caused by a smaller number of large-effect rare variants that are neither well tagged by local SNPs nor covered by commercial SNP arrays that are typically used in GWAS (Dickson et al., 2010; Gibson, 2012; Yang et al., 2015). It has been suggested that both models are likely to contribute by different degrees to the heritability of complex traits and disorders (Gibson, 2012; Agarwala et al., 2013). Recent studies have confirmed that integrating both common and rare variants in the heritability analysis does recover a larger proportion of the expected heritability for several traits (Weiner et al., 2017; Wainschtein et al., 2019). However, heritability estimates derived

from GWAS can be further enhanced by incorporating other types of genomic variations that continue to segregate in humans.

### 4.1.2. Structural variants and complex traits:

SVs are likely to have a greater impact on genome function than SNPs because of their larger genomic size, spanning hundreds and thousands of base pairs (bp). In addition to their large genomic size, SVs account for the majority of bp genetic variations in humans, therefore, integrating these variants in association studies could improve estimating the genetic variance of complex traits (Manolio et al., 2009). Indeed, numerous studies have implicated SV with complex human traits and diseases including obesity, cancer, cognitive ability, and psychiatric disorders plus many others (Stankiewicz and Lupski, 2010; Kawamura et al., 2011; Malhotra and Sebat, 2012; Lacaria et al., 2013; Weischenfeldt et al., 2013; Waddell et al., 2015; Carvalho et al., 2016; Cuccaro et al., 2016; Smoller, 2016; Shorter, 2017; Weiner et al., 2017). However, association studies of this sort have mainly focused on few SV types, such as copy number variants (CNVs) and megabase-scale deletions and duplications. As such, associations of other SV types, such as polymorphic RTE insertions, with complex human traits and diseases are not well described.

## 4.1.3. RTE insertions as SV:

Active RTE subfamilies provide an ongoing source of SVs in the human genome. Germline RTE insertions are capable of creating inter-individual insertional polymorphisms, defined as insertions showing variations in their presence or absence state at specific genomic loci across the genome of individuals within a

population (Wang et al., 2005; Mills et al., 2007; Huang et al., 2010; Rishishwar et al., 2015). Active RTEs are also capable of mediating other types of SV, including deletions and duplications. (Xing et al., 2009; Startek et al., 2015; Bourque et al., 2018). The repetitive nature of RTE elements in the human genome plus their high sequence homology with ancient RTE subfamilies that are no longer active makes it difficult to detect polymorphic insertions that contribute to human genetic diversity (Ewing, 2015; Rishishwar et al., 2017; Bourque et al., 2018). RTE detection studies post the development of computational detection tools enabled the genome-wide discovery of polymorphic RTEs. Such studies were able to show that RTE variants are a natural component of the human genome and can be present at both common (minor allele frequency (MAF)  $\geq$  0.01) and rare (MAF < 0.01) allele frequencies within a population (Rishishwar et al., 2017). A recent analysis of human genetic variations from phase 3 of the 1,000 genome project (1kGP) proposed that RTE insertions account for a large proportion of inter-individual genetic diversity, estimating that about 691 kilobases per individual genome are composed of polymorphic RTEs (Sudmant et al., 2015). Still, SVs mediated by RTE insertions have been frequently overlooked by previous association studies possible due to the complexity of their discovery within the human genome (Ewing, 2015; Goerner-potvin and Bourgue, 2018). As such, the clinical significance of many RTE variants remains unknown.

### 4.1.4. RTE-mediated SVs and Complex traits:

Trait-associated SNPs (TAS) rarely have a direct causal effect on trait phenotype. Instead, TAS act as genomic markers that are co-inherited with the causing variant in the same haplotype (Frayling, 2014). This provides the opportunity for associating polymorphic RTE insertions with complex traits and diseases. Recent studies have shown that RTE insertions can be found in genomic regions that have been associated with complex traits. Sudmant et al. (2015) reported that GWAS loci are enriched for common SVs by up to threefold, however, the enrichment analysis combined many SV types including RTE-mediated SVs, and the enrichment was most pronounced for large deletions (>20 Kb). Alu elements are the most active and abundant class of RTEs by copy number in the human genome. A recent study investigating the association of these elements with complex traits reported a significant enrichment of Alus in GWAS risk loci (Pvalue = 0.013) (Payer et al., 2017). The previously mentioned studies plus others found that some polymorphic RTE insertions in GWAS loci are in linkage disequilibrium (LD) with the TASs (Sudmant et al., 2015; Hehir-Kwa et al., 2016; Payer et al., 2016; Wang et al., 2017). In addition, Wang et al. (2017) and Spirito et al., (2019) have shown that some RTEs in LD with TAS are associated with altered gene expression in a tissue-specific manner. These results suggest the RTE variants can potentially be the causative variant within some GWAS loci. Characterizing the association between RTE variants with complex human traits and diseases will improve as additional GWAS and RTE detection studies identify more TAS and RTE variants, respectively.

#### 4.1.5. Study overview:

This study conducts an enrichment analysis of L1s, Alus, and SVAs in GWAS risk loci using an updated list of TAS from the NHGRI-EBI Catalog of published GWAS (www.ebi.ac.uk/gwas; Buniello et al., 2019), and a comprehensive inhouse curated database of polymorphic RTE insertions reported in the literature up to April 2019. The total number of RTEs in the in-house curated database is 2-fold higher than the number reported in phase 3 of the 1kGP (Sudmant et al., 2015) and includes an additional 750, 718, and 35 common L1s, Alus, and SVAs, respectively. Although L1 and SVA elements are not as active or abundant as Alu elements, their larger size and genomic distribution are suggestive of their potentially harmful effect on genome function. The genomic distribution analysis of this study identified several L1 and SVA variants within gene regions, including genes critical for cellular maintenance, proper development, and neurophysiological processes. This study will also conduct a genome-wide screen for additional RTE polymorphisms in LD with TAS.

### 4.2. Methods

#### 4.2.1. Overview of methods:

The in-house curated database of polymorphic RTE elements is used to identify RTE elements in linkage disequilibrium (LD) with SNPs that have been associated with the risk of various complex disorders through GWAS. As LD is population specific, this study focuses on variants identified in individuals of European descent, to maximize the use of GWAS data since the majority of the association studies have been conducted on cohorts of European descent (Evans and Cardon, 2005; Medina-Gomez et al., 2015). Note that European descent is defined here as Caucasian individuals of European ancestry. Polymorphic RTEs that overlap with the LD-blocks of genome-wide significant (GWS) ( $P \le 5x10^{-8}$ ) trait-associated SNPs (TAS) were identified. The enrichment of RTE in the LD-blocks of TAS was calculated by comparing the fraction of RTEs contained within a TAS LD-block with the fraction expected by chance using 1,000 sets of random LD-blocks that match the genomic features of the TAS. The non-random association between the occurrence of the RTE and the TAS, i.e., the likelihood of the two alleles being co-inherited in the same individual, was calculated using genotype data from the European population samples in phase 3 of the 1,000 genome project (1kGP) (Sudmant et al., 2015). The distribution of RTEs that are in LD with TAS within functional genomic regions was compared with the distribution of all polymorphic RTEs of the in-house curated database.

Note that RTE elements and LD-blocks located on the sex chromosomes or within the human leukocyte antigen (HLA) region were excluded from the analysis. RTEs and LD-blocks in these genomic regions were eliminated to reduce biases in the results that may arise due to the unequal effect of evolutionary processes on the sex chromosomes (Johnson and Lachance, 2012) and the haplotype diversity of the HLA loci (Shiina et al., 2009).

#### 4.2.2. Datasets:

### 4.2.2.1. Polymorphic retrotransposable element (RTE) insertions:

A comprehensive database of non-reference L1Hs, AluY, and SVA\_E/F was curated in-house (Chapter 2: Database Curation). The database by individual contains the insertional profile of 2,987 nonrelated individuals and consists of 6,377 L1Hs, 18,698 AluYs, and 1,085 SVAs from the E and F human-specific subfamilies. RTEs overlapping with HLA regions were removed using the subtract tool of BEDtools version 2.25.0 (Quinlan, 2014). The HLA region coordinates were obtained from the genome reference consortium website (GRC; https://www.ncbi.nlm.nih.gov/grc/human/regions/MHC?asm=GRCh37).

Insertions on the sex chromosomes were removed using a conditional awk statement in UNIX based on the chromosome name column.

Low frequency and common RTEs (MAF  $\geq$  0.01) identified in samples of European descents were extracted using a conditional awk statement in UNIX based on the allele frequency column. In the case of missing allele frequency information, insertions identified in two or more unrelated individuals by more than one study were retained. This is because the chance of identifying a rare allele in the same location by more than one RTE detection method in two or more unrelated individuals is very slim considering that different methods produce different results as discussed in the database curation chapter. Alternatively, the AF for insertions identified in two or more unrelated individuals by the same study was inferred assuming heterozygosity and the total number of samples analysed

by the study. For example, if the study sample size was 10 and the insertion was identified in 2 individuals, the AF was inferred to be 0.1 and the insertion was retained.

### 4.2.2.2. Trait associated SNPs:

The trait associated SNPs (TAS) of the NHGRI-EBI Catalog of published genome-wide association studies (www.ebi.ac.uk/gwas) (Buniello et al., 2019) was downloaded from the UCSC genome browser tables (last updated: 2019-08-07) (https://genome.ucsc.edu/cgi-bin/hgTables) (Karolchik, 2004) using the hg19 genome assembly coordinates. Genome-wide significant (GWS) SNPs (P-value  $\leq 5x10^{-8}$ ) identified in European cohorts were extracted using a conditional awk statement in UNIX.

# 4.2.2.3. SNP and RTE genotype files from the 1000 genome project:

Genotypes of SNPs from phase 3 (version 5a) release of the 1kGP (Sudmant et al., 2015) were obtained from the 1kGP ftb website (<u>ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20130502/</u>). Two files in .vcf and .tbi format were obtained for each autosome (chr1-chr22). Sample names from the European super population were extracted into a text file from the 1kGP sample panel file

(ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20130502/integrated\_call\_sam ples\_v3.20130502.ALL.panel) using a conditional awk statement in UNIX. Vcftools version 0.1.11 ((C) Adam Auton 2009) was then used to extract SNP genotypes identified in the 503 European samples and convert the .vcf files to transposed ped (tped) and fam (tfam) files. The transposed files were converted into plink PED/MAP files using PLINK version 1.07 (Purcell et al., 2007). A new dataset was created using the --maf plink filter which extracted all rare variants with a MAF below 0.01 (MAF < 0.01). The new dataset was then converted into plink binary format (.bed, .bim, .fam) using the --make-bed option. Duplicate markers were identified using the awk command and .bed file. Unique SNPs were saved into a text file and were filtered out using the --extract option. The process of downloading and formatting the vcf file was then repeated for each chromosome. The individual binary files for each autosome were then merged into one binary file using --merge-list option in PLINK version 1.07 (Purcell et al., 2007). All the commands used in the steps above from downloading the vcf file to creating the binary PLINK files for all autosomes were uploaded to github (https://github.com/RandaAli1/MyPhDproject/blob/master/RTE\_enrichment\_in\_GWAS\_loci/1kGPEuropeanGenotypes.txt). The merged binary files for all autosomes were then used to identify tagging SNPs for creating the LD-blocks.

Genotypes of genomic structural variations from phase 3 (volume 1) release of the 1kGP (Sudmant et al., 2015) were obtained from the 1kGP ftb website (ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/phase3/integrated\_sv\_map) as .vcf and .tbi files. The vcf file contained 12 different structural variation types including 3,048 L1s, 12,748 Alus, and 835 SVAs (Sudmant et al., 2015). L1, Alu and SVA elements were extracted from the structural variations .vcf file using the grep command in UNIX. The new vcf file containing genotypes of the RTE elements was converted into a binary PLINK file format using the same steps mentioned above up to the removal of duplicate variants. The individual binary files for each autosome plus the binary file of the RTE variants were merged into one binary file using the --merge-list option in PLINK version 1.07 (Purcell et al., 2007). The new merged file was used for calculating LD between RTEs and TAS.

# 4.2.2.4. Functional regions file:

The Reference Sequence (RefSeq) genes (O'Leary et al., 2016) and GeneHancer (Fishilevich et al., 2017) enhancer files described in the genomic distribution chapter were used for the analysis of this chapter as well.

#### 4.2.3. Method of data analyses

### 4.2.3.1. Overlapping RTEs with TAS LD-blocks

Linkage disequilibrium (LD) blocks for each TAS were defined using the left and right-most (5' and 3') tagging SNPs ( $r^2 \ge 0.8$ ) (Figure 19). The tagging SNPs were identified using the --show-tags option and --tag-r2 filters of PLINK version 1.90b6.21 (Purcell et al., 2007). LD-blocks of TAS that lacked a 5' or a 3' tagging SNP were arbitrarily extended by half the median of the LD-blocks defined by 5' and 3' tagging SNPs using the slope tool and -I and -r options of BEDtools version 2.25.0 (Quinlan, 2014). Arbitrary LD blocks for untagged TAS were created using the slope tool and -d option of BEDtools version 2.25.0 (Quinlan, 2014). The list of LD-blocks were reduced using the merge tool of BEDtools version 2.25.0 (Quinlan, 2014) to create non-overlapping LD-blocks. LD-blocks overlapping the HLA https://www.ncbi.nlm.nih.gov/grc/human/regions region (GRC; /MHC?asm=GRCh37) were removed using the subtract tool of BEDtools version 2.25.0 (Quinlan, 2014). LD-blocks on the sex chromosomes were removed using a conditional awk statement in UNIX. The final list of LD-blocks were overlapped with the list of polymorphic RTEs using the intersect tool of BEDtools version 2.25.0 (Quinlan, 2014).


Figure 19: Creating LD-blocks around each trait associated SNP (TAS) using tagging SNPs with an  $r2 \ge 0.8$ 

#### 4.2.3.2. Enrichment of RTE variants in GWAS risk loci

The enrichment of overlap between RTEs and TAS LD-blocks was investigated by creating a thousand set of random SNPs that match the genomic features of the TAS such as allele frequency, number of SNPs in LD, distance to nearest gene and gene density, were generated using SNPsnap default settings (https://data.broadinstitute.org/mpg/snpsnap/) (Pers et al., 2015). The TAS were matched in this way to control for the biased distribution of TAS in the genome, which are reportedly enriched in gene regions (Hindorff et al., 2009).

Non-overlapping LD-blocks for each matching SNPs set were generated as previously described using an integrated R script (https://github.com/RandaAli1/MyPhDproject/tree/master/RTE\_enrichment\_in\_GWAS\_loci). The script loops through each set of the 1,000 random SNPs sets and create a merged list of LD-blocks for it, which it then exports into a file using the write.table() function in R version 3.4.0 (R Core Team, 2012). The overlap between each of the 1,000 sets of random LD-blocks and polymorphic RTEs was identified using the intersect tool of BEDtools version 2.25.0 (Quinlan, 2014) via a loop function in R version 3.4.0 (R Core Team, 2012). The loop function

intersects each set of random LD blocks with the list of polymorphic RTE elements (L1, Alu, or SVA) and calculates the number of LD blocks containing a polymorphic RTE

(https://github.com/RandaAli1/MyPhDproject/tree/master/RTE\_enrichment\_in\_ <u>GWAS\_loci</u>). A density plot representing the percentages of LD blocks overlapped by a polymorphic RTE were created in R version 3.4.0 (R Core Team, 2012) for each RTE type. The empirical P-value was then calculated to compare the percentage of TAS LD-blocks overlapping with each RTE type against the percentage distribution of random LD-blocks (North et al., 2002).

# 4.2.3.3. LD between RTEs and TAS:

An RTE in the genomic region of a TAS that is potentially the causative variant within the TAS haplotype is expected to be in LD with the TAS. LD analysis was only possible for RTEs identified by the 1kGP (Sudmant et al., 2015) as it is the only study within the in-house curated database that provides an accessible source of SNP and RTE genotypes for each sample. LD analysis between RTEs in risk regions and the corresponding TAS was conducted using genotype data of European samples (n=503) from phase 3 of the 1kGP (Sudmant et al., 2015) using PLINK version 1.90b6.21 (Purcell et al., 2007). RTE elements from the 1kGP that overlapped with a TAS LD-block were extracted using a conditional awk statement. LD between the set of 1kGP RTEs and TASs were calculated using the --Id-snp-list command and the --Id-window-r2 filter using PLINK version 1.90b6.21 (Purcell et al., 2007). A moderate r<sup>2</sup> threshold of 0.6 (Tian et al., 2017) was set in order to capture as many associations between RTEs and TAS as possible. RTEs in LD with TAS were matched with the trait information using the merge by SNP function in R version 3.4.0 (R Core Team, 2012). RTEs in LD with

a TAS ( $r^2 > 0.6$ ) were overlapped with gene and enhancer regions using the intersect tool of BEDtools version 2.25.0 (Quinlan, 2014). The difference between the distributions of RTEs in LD with TAS in gene regions compared to all non-reference RTEs was compared using the chi-squared goodness of fit test.

# 4.3. Results

#### 4.3.1. TAS Linkage disequilibrium blocks (LD-blocks):

A total of 158,654 trait associated SNPs (TASs) were downloaded from the NHGRI-EBI Catalog of published genome-wide association studies (<u>www.ebi.ac.uk/gwas</u>) (August 2019 & earlier). From this set, 50,171 SNPs were extracted that met the following criteria:

- 1. Significantly association with a trait at a P-value level  $\leq 5 \times 10^{-8}$  and,
- 2. Identified in a European population.

Linkage disequilibrium blocks were identified for 64.24% of the 50,171 TASs (n=32,229). The generated LD blocks ranged from 3 bp to 499.964 kilobases (Kb) in size, with a median of 54.096 Kb. The remaining 17,942 SNPs lacked a 5' or 3' tagging SNP ( $r^{2}\ge0.8$ ). As such, LD blocks were created for these untagged TASs by extending the region either side of the TAS by half of the median (n=27.048) of the generated LD blocks.

A total of 48,911 LD-blocks located on autosomes and not interrupting the HLA region were extracted. The 48,911 LD blocks were reduced to 10,905 non-overlapping LD-blocks using BEDtools intersect. The 48,911 non-reduced LD blocks generated are available in github

(https://github.com/RandaAli1/MyPhDproject/blob/master/RTE\_enrichment\_in\_ GWAS loci/allEurGWS TAS LDblocks nosexchrNoHLA 22082019.bed).

# 4.3.2. Overlapping RTEs with TAS LD-blocks:

A total of 5,240 RTEs (1,160 L1s, 3,825 Alus, and 255 SVAs) were extracted from the in-house curated database by individual that met the following criteria:

- 1. Identified in samples of European descents.
- 2. Low frequency and common RTEs identified with a MAF  $\geq$  0.01.
- 3. Are autosomal RTE insertions.
- 4. Do not overlap with the HLA region.

The extracted RTEs were overlapped with the 10,905 TAS LD-blocks using BEDtools intersect. Of the 5,240 RTEs, a total of 2,063 (425 L1s, 1,523 Alus, and 115 SVAs) overlapped the genomic regions of 19,296 TAS contained within the reduced TAS LD-blocks, of which 16,212 were unique TAS (Table 16). More than one-third of polymorphic L1s and Alus and half of the polymorphic SVAs were found within a TAS LD-block. The proportion of class-specific RTEs in a TAS LD-block is significantly higher for SVA elements compared to both L1 and Alu variants (P-value = 0.024, Fisher exact test).

Table 16: The overlap between polymorphic RTEs and the LD-blocks of genomewide significance ( $P \le 5x10^{-8}$ ) TASs. LD blocks were generated using tagging SNPs ( $r^2 \ge 0.8$ ) in PLINK. Polymorphic RTEs were curated in-house. Abbreviations: RTE: Retrotransposable elements; TAS: Trait associated SNP; LD: Linkage disequilibrium.

|  | L1Hs            | AluY             | SVA_E/F        |
|--|-----------------|------------------|----------------|
| Total RTEs in in-house curated database by individual                                  | 6,377           | 18,698           | 1,085          |
| Common autosomal RTEs identified in European samples, excluding RTEs in the HLA region | 1160            | 3825             | 255            |
| Common RTEs intersecting a TAS LD-block  | 425<br>(36.64%) | 1523<br>(39.82%) | 115<br>(45.1%) |
| Number of TAS with an RTE within its LD-block<br>(TAS n= 48,911)                       | 4,189           | 13,407           | 1,700          |

#### 4.3.3. Enrichment of RTEs in TAS LD-blocks:

The enrichment of RTEs in TAS LD-blocks was investigated by comparing the observed number of overlaps with the values expected by chance using 1,000 sets of random LD-blocks using SNPs that mirror the genomic properties of the TAS. A total of 42,766 were matched by SNPsnap (Pers et al., 2015) from the 48,911 autosomal TAS list. Similar to the TAS LD-blocks, the random LD-blocks were also reduced to non-overlapping LD-blocks using BEDtools intersect. The generated LD blocks for the 1,000 random sets ranged from 1536 to 19,746 non-overlapping LD-blocks, with an average of 17,388 LD-blocks. As such, the percentage of overlap was calculated to standardize the varying numbers of LD-blocks from each of the random sets.

On average, 3% of the random LD-blocks were interrupted by L1s, 10% were interrupted by Alus, and 0.7% were interrupted by SVAs. In comparison, 4% of the 10,905 TAS LD-blocks were interrupted by L1s, 14% were interrupted by Alus, and 1% were interrupted by SVA elements. The percentage of TAS LD-blocks interrupted by RTE elements is significantly more than that observed for random LD-blocks (Empirical P-values =  $1 \times 10^{-3}$  for L1s and Alus, and  $3 \times 10^{-3}$  for SVAs) (Figure 20).



B: AluY



Percentage of random LD-blocks interrupted by AluY elements (%)



Figure 20: Density plot for the enrichment of polymorphic RTEs at GWAS risk loci. The frequency distribution of random LD-blocks intersected by polymorphic RTEs (black curve) was compared with the frequency observed for TAS LD-blocks intersected by L1Hs (3.90%; A), AluY (13.97%; B), and SVA\_E/F (1.05%; C) (red vertical line). The 1,000 sets of random LD-blocks matched the genomic properties of risk SNPs LD-blocks. The empirical P-value was used to calculate the statistical significance of polymorphic RTE enrichment at GWAS risk loci.

#### 4.3.4. LD between RTEs and TAS:

LD analysis between genomic variants is calculated using genotype information of the variants within a specified population. The 1kGP study is the only study within the in-house curated database with accessible genotype information of SNPs and RTEs within the same sample. In addition, about 80% of the Alus and SVAs and a third of the L1s interrupting a TAS LD-blocks (Table 16) were also identified by the 1kGP (Sudmant et al., 2015). As such, the 1kGP genotype data was utilised for calculating LD between RTEs and TASs using a moderate r<sup>2</sup> threshold of 0.6 (Tian et al., 2017). A total of 137 RTEs (16 L1, 113 Alus, and 7 SVAs) are in LD ( $r^2 > 0.6$ ) with 429 TAS, including redundant TAS associated with the same phenotype or trait (Appendix 2). Forty-nine RTEs (8 L1s, 38 Alus, and 3 SVAs) of the 136 total are in strong LD ( $r^2 \ge 0.8$ ) with 157 TAS that have been associated with a variety of traits, including brain-related disorders such as Parkinson's disease. Progressive supranuclear palsy, Schizophrenia, Depression, and anxiety (Table 17). In cases of redundant TAS, the TAS with the highest r<sup>2</sup> of association was included in the table. Where both TAS had the same r<sup>2</sup> value, the TAS reported with the most significant P-value of association with the trait is retained in table 17.

Table 17: Polymorphic RTEs in LD ( $r^2 \ge 0.8$ ) with GWAS TAS. The  $r^2$  values are to the nearest decimal place. Abbreviations: RTE: Retrotransposable element; TAS: Trait associated SNP; LD: Linkage disequilibrium; GWAS: Genome-wide association studies. Note: Table includes strongest LD/GWAS signal when there are multiple RTE-TAS associations of the same phenotype.

| Cl       | DTEC      |            |             | <b>т</b> і.                           | P-value of | 2   |
|----------|-----------|------------|-------------|---------------------------------------|------------|-----|
| Chr      | KIE Start | KIE Name   | 1AS (rs#)   | l rait                                | TAS        | r   |
| 6        | 141414904 | ALLI 5647  | rs113803678 | Body mass index                       | 4.00E-08   | 0.9 |
| 12       | 24868717  | LINE1 2249 | rs61914312  | Hair color                            | 3.00E-10   | 0.9 |
| 9        | 11329329  | ALU 7283   | rs2152261   | Menarche (age at onset)               | 2.00E-13   | 0.9 |
| 12       | 56753252  | ALU 9228   | rs2066819   | Inflammatory skin disease             | 5.00E-17   | 0.9 |
| 1        | 174484646 | ALU 604    | rs140581634 | Feeling miserable                     | 2.00E-08   | 0.9 |
| 12       | 120130849 | ALU 9540   | rs17442937  | Red cell distribution width           | 4.00E-08   | 0.9 |
| 17       | 44153977  | SVA 706    | rs62055546  | Alcohol consumption (drinks per week) | 8.00E-25   | 0.8 |
| 17       | 44153977  | SVA_706    | rs17563986  | Cognitive ability                     | 5.00E-12   | 0.8 |
| 17       | 44153977  | SVA_706    | rs62057061  | Depressed affect                      | 2.00E-22   | 0.8 |
| 17       | 44153977  | SVA_706    | rs12150229  | Ease of getting up in the morning     | 4.00E-09   | 0.8 |
| 17       | 44153977  | SVA_706    | rs62057107  | Educational attainment                | 5.00E-38   | 0.8 |
| 17       | 44153977  | SVA_706    | rs55657917  | Experiencing mood swings              | 3.00E-20   | 0.8 |
| 17       | 44153977  | SVA_706    | rs56303031  | Heel hone mineral density             | 6.00E-20   | 0.8 |
| 17       | 44153977  | SVA_706    | rs17563683  | Hemoglobin concentration              | 2.00E-24   | 0.8 |
| 17       | 44153977  | SVA_706    | rs62055701  | Irritable mood                        | 6.00E-20   | 0.0 |
| 17       | 44153977  | SVA_706    | rs1864325   | Lumbar spine hone mineral density     | 5.00E-15   | 0.8 |
| 17       | 44153077  | SVA_706    | rc70412431  | Lung function                         | 3.00E-11   | 0.0 |
| 17       | 44153077  | SVA_706    | ro12373124  | Male pattern baldness                 | 5.00E-49   | 0.0 |
| 17       | 44153977  | SVA_706    | rs241036    | Mana-pattern baldness                 | 7.00E-10   | 0.0 |
| 17       | 44153977  | SVA_706    | rs55657017  | Negative Feelings                     | 7.00E-13   | 0.0 |
| 17       | 44153977  | SVA_706    | rs76761706  | Neuroticism                           | 7.00E-29   | 0.0 |
| 17       | 44153977  | SVA_706    | 18/0/01/00  | Derkinson's disease                   | 1.00E-32   | 0.0 |
| 17       | 44153977  | SVA_700    | 182942100   | Parkinson's disease                   | 1.00E-20   | 0.0 |
| 17       | 44153977  | SVA_706    | 1855657917  | Physical activity measurement         | 5.00E-12   | 0.0 |
| 17       | 44153977  | SVA_706    | 194000752   | Subsectional brain region reduction   | 1.00E-17   | 0.0 |
| 17       | 44153977  | SVA_706    | 1560/2451   | Subcortical brain region volumes      | 1.00E-08   | 0.0 |
| 1/       | 44153977  | SVA_/06    | rs/5022332  | worry                                 | 2.00E-08   | 0.8 |
| 9<br>1 F | 16682313  | ALU_/311   | rs12335424  | Height                                | 2.00E-21   | 0.8 |
| 15       | /6826019  | ALU_10819  | 15506000    | Estimated glomerular filtration rate  | 2.00E-15   | 0.8 |
| 1/       | 44153977  | SVA_/06    | rs11/124984 | Daytime nap                           | 3.00E-13   | 0.8 |
| 1/       | 44153977  | SVA_/06    | rs1981997   | Interstitial lung disease             | 9.00E-14   | 0.8 |
| 17       | 44153977  | SVA_/06    | 1\$80/0/23  | Progressive supranuclear palsy        | 2.00E-118  | 0.8 |
| 1/       | 44153977  | SVA_/06    | rs2106/86   | Red blood cell count                  | 3.00E-36   | 0.8 |
| 1/       | 44153977  | SVA_/06    | rs62061/33  | Eosinophil counts                     | 3.00E-29   | 0.8 |
| 12       | 56/53252  | ALU_9228   | rs5991/308  | Height                                | 3.00E-32   | 0.8 |
| 1 /      | 44153977  | SVA_/06    | rs112010353 | Self-reported math ability            | 2.00E-08   | 0.8 |
| 2        | 210260754 | ALU_1947   | rs1080278   | Lung function                         | 1.00E-19   | 0.8 |
| 17       | 44153977  | SVA_706    | rs1991556   | Sleep duration                        | 3.00E-09   | 0.8 |
| 16       | 75655176  | ALU_11116  | rs61537885  | Smoking Status                        | 8.00E-09   | 0.8 |
| 17       | 44153977  | SVA_706    | rs80103986  | Hand grip strength                    | 1.00E-09   | 0.8 |
| 4        | 134596423 | LINE1_967  | rs12507927  | Educational attainment                | 3.00E-11   | 0.8 |
| 17       | 44153977  | SVA_706    | rs17652520  | Medication use (anilides)             | 8.00E-13   | 0.8 |
| 1        | 169524859 | LINE1_164  | rs6128      | Blood protein levels                  | 2.00E-26   | 0.8 |
| 17       | 44153977  | SVA_706    | rs62063281  | Number of sexual partners             | 4.00E-15   | 0.8 |
| 17       | 44153977  | SVA_706    | rs62063281  | Osteoarthritis (hip)                  | 5.00E-12   | 0.8 |
| 1        | 163639693 | ALU_559    | rs12564153  | Lung function                         | 1.00E-09   | 0.8 |
| 5        | 109051004 | ALU_4562   | rs4388249   | Schizophrenia                         | 2.00E-08   | 0.8 |
| 17       | 44153977  | SVA_706    | rs62064364  | Macular thickness                     | 4.00E-35   | 0.8 |
| 10       | 106566893 | ALU_8208   | rs61867293  | Depression                            | 7.00E-10   | 0.8 |

# (Table 17 continues)

| 21 | 33050849  | ALU_12379  | rs17660708  | LDL cholesterol                       | 1.00E-10 | 0.8 |
|----|-----------|------------|-------------|---------------------------------------|----------|-----|
| 17 | 44153977  | SVA_706    | rs9303525   | Intracranial volume                   | 8.00E-15 | 0.8 |
| 20 | 26190974  | ALU_12132  | rs6051320   | Lung function                         | 2.00E-08 | 0.8 |
| 11 | 54958589  | ALU_8580   | rs77584654  | Height                                | 5.00E-17 | 0.8 |
| 7  | 18273084  | ALU_5868   | rs1528683   | Lung function                         | 2.00E-17 | 0.8 |
| 12 | 77965056  | ALU_9355   | rs17788937  | Pathological Myopia                   | 2.00E-12 | 0.8 |
| 11 | 43877448  | ALU_8559   | rs1061810   | Type 2 diabetes                       | 4.00E-10 | 0.8 |
| 8  | 110101605 | ALU_7037   | rs28499085  | Pulse pressure                        | 3.00E-13 | 0.8 |
| 14 | 92619420  | SVA_615    | rs34016308  | Myopia                                | 4.00E-14 | 0.8 |
| 5  | 40041345  | LINE1_1097 | rs10053502  | Pathological Myopia                   | 1.00E-16 | 0.8 |
| 1  | 174484646 | ALU_604    | rs75650221  | Chronotype                            | 4.00E-18 | 0.8 |
| 5  | 25233926  | ALU_4154   | rs111257433 | General risk tolerance                | 5.00E-10 | 0.8 |
| 17 | 44153977  | SVA_706    | rs62062288  | Risk-taking tendency                  | 1.00E-29 | 0.8 |
| 6  | 56387576  | ALU_5205   | rs4288197   | Heel bone mineral density             | 5.00E-17 | 0.8 |
| 11 | 49282683  | ALU_8572   | rs7103270   | HDL cholesterol and physical activity | 7.00E-12 | 0.8 |
|    |           |            |             | interaction                           |          |     |
| 4  | 76993824  | ALU_3412   | rs7693693   | Blood protein levels                  | 2.00E-17 | 0.8 |
| 1  | 219558910 | ALU_810    | rs75128958  | Heel bone mineral density             | 1.00E-08 | 0.8 |
| 1  | 219558910 | ALU_810    | rs75128958  | Lung function                         | 2.00E-23 | 0.8 |
| 2  | 30669993  | ALU_1087   | rs28538173  | Eosinophil counts                     | 3.00E-09 | 0.8 |
| 6  | 96009421  | ALU_5389   | rs80268500  | Blood protein levels                  | 2.00E-12 | 0.8 |
| 16 | 80848077  | ALU_11145  | rs34018670  | Monocyte count                        | 5.00E-09 | 0.8 |
| 1  | 119553366 | LINE1_122  | rs3790553   | Male-pattern baldness                 | 4.00E-19 | 0.8 |
| 17 | 44153977  | SVA_706    | rs76640332  | Lymphocyte percentage of white cells  | 5.00E-13 | 0.8 |
| 3  | 193354185 | LINE1_769  | rs11925699  | Educational attainment                | 3.00E-08 | 0.8 |
| 1  | 180857564 | ALU_629    | rs1043069   | Systolic blood pressure               | 5.00E-15 | 0.8 |
| 9  | 4237141   | ALU_7235   | rs2224492   | Intraocular pressure                  | 4.00E-16 | 0.8 |
| 15 | 47507342  | LINE1_2640 | rs6493265   | Educational attainment                | 2.00E-17 | 0.8 |
| 15 | 47507342  | LINE1_2640 | rs12914084  | Neuroticism                           | 3.00E-08 | 0.8 |
| 2  | 652672    | ALU_958    | rs13021737  | Body mass index                       | 8.00E-40 | 0.8 |
| 2  | 652672    | ALU_958    | rs12995480  | C-reactive protein levels             | 1.00E-10 | 0.8 |
| 2  | 652672    | ALU_958    | rs12714415  | Heel bone mineral density             | 4.00E-09 | 0.8 |
| 2  | 652672    | ALU_958    | rs6752706   | Lung function                         | 2.00E-13 | 0.8 |
| 2  | 652672    | ALU_958    | rs5017302   | Menarche (age at onset)               | 5.00E-38 | 0.8 |
| 2  | 652672    | ALU_958    | rs13396935  | Smoking status                        | 4.00E-13 | 0.8 |
| 8  | 109135936 | SVA_389    | rs617117    | Macular thickness                     | 2.00E-09 | 0.8 |
| 12 | 28163331  | ALU_9104   | rs1838564   | Breast size/Breast Cancer             | 1.00E-12 | 0.8 |
| 4  | 22043212  | ALU_3139   | rs62301574  | Insomnia                              | 1.00E-08 | 0.8 |
| 14 | 39875097  | LINE1_2544 | rs34983854  | Systolic blood pressure               | 2.00E-11 | 0.8 |
| 6  | 140417842 | ALU_5637   | rs62429521  | Insomnia                              | 2.00E-09 | 0.8 |
| 14 | 55795871  | ALU_10325  | rs10146637  | White blood cell count                | 4.00E-11 | 0.8 |
| 6  | 97017683  | ALU_5395   | rs11153071  | Systolic blood pressure               | 3.00E-15 | 0.8 |
| 8  | 109135936 | SVA_389    | rs392783    | Hair color                            | 2.00E-23 | 0.8 |
| 15 | 49609604  | ALU_10695  | rs11632038  | Lung adenocarcinoma                   | 5.00E-10 | 0.8 |
| 11 | 49282683  | ALU_8572   | rs77828979  | Intraocular pressure                  | 6.00E-12 | 0.8 |
| 11 | 49282683  | ALU_8572   | rs11040595  | Systolic blood pressure               | 1.00E-11 | 0.8 |
| 2  | 30669993  | ALU_1087   | rs829636    | Eczema                                | 6.00E-09 | 0.8 |
| 10 | 34571038  | ALU_/901   | rs610493    | Height                                | 2.00E-10 | 0.8 |
| 8  | /1914591  | ALU_6806   | rs2639935   | Lung function                         | 3.00E-08 | 0.8 |

# 4.3.5. The distribution of RTEs in LD with TAS in functional genomic regions:

The distribution of RTEs in LD ( $r^2 > 0.6$ ) with TAS in functional genomic regions was compared with the distribution of all non-reference RTE elements to investigate the potential effect of RTEs in LD with TAS on gene function and regulation. About two-thirds (59.9%) of the RTEs in LD with TAS were found in gene regions (Table 18). A total of 10 L1s overlapped with intronic regions of genes, of which 4 were on the sense strand of the gene. Note that RTE insertions on the sense strand of genes have a greater impact on gene function and regulation as RTEs contain internal promoters and 3'-poly(A) tails that can interfere with gene transcription and post-transcriptional regulation (Guffanti et al., 2014; Elbarbary et al., 2016). Of the 113 Alus in LD with TAS, 64 were found in the intron regions of genes, 3 interrupted the 5' or 3' untranslated regions (UTR), and 2 Alus were less than 10 Kb upstream of gene regions. Twenty-nine of the 67 Alu elements in gene regions were on the sense strand of the gene. Five SVA elements interrupted intronic genomic regions, one of which was on the sense strand of the gene. Nevertheless, the distribution of L1 and SVA elements in LD with TAS in gene regions is not significantly different from the distribution of all non-reference RTEs in these genomic regions (P-value = 0.135 and 0.426, chi-squared test). However, Alu elements are significantly more frequent in gene regions compared with the distribution of all non-reference AluY elements (Pvalue = 0.0143, chi-squared test).

Table 18: A list of the overlap between gene regions and RTEs in LD ( $r^2 > 0.6$ ) with TAS. The highlighted RTEs are on the sense strand of the gene. \*Long non-coding RNA. Abbreviations: RTE: Retrotransposable element; TAS: Trait associated SNP; LD: Linkage disequilibrium.

| Chr | Start_RTE | End_RTE   | RTE<br>Strand | RTE        | Gene name     | Gene<br>Strand | Gene region |
|-----|-----------|-----------|---------------|------------|---------------|----------------|-------------|
| 1   | 169524859 | 169524860 | +             | LINE1_164  | F5            | -              | Intron      |
| 2   | 144010793 | 144010794 | +             | LINE1_410  | ARHGAP15      | +              | Intron      |
| 3   | 55788580  | 55788581  | +             | LINE1_590  | ERC2          | -              | Intron      |
| 3   | 85576571  | 85576572  | -             | LINE1_629  | CADM2         | +              | Intron      |
| 3   | 193354185 | 193354186 | -             | LINE1_769  | OPA1          | +              | Intron      |
| 6   | 46310306  | 46310307  | +             | LINE1_1293 | RCAN2         | -              | Intron      |
| 6   | 46310306  | 46310307  | +             | LINE1_1293 | LOC101926915* | +              | Intron      |
| 7   | 8019027   | 8019028   | +             | LINE1_1448 | GLCCI1        | +              | Intron      |
| 9   | 94058487  | 94058488  | -             | LINE1_1863 | AUH           | -              | Intron      |
| 14  | 39875097  | 39875098  | +             | LINE1_2544 | FBXO33        | -              | Intron      |
| 15  | 47507342  | 47507343  | -             | LINE1_2640 | SEMA6D        | +              | Intron      |
| 1   | 174484646 | 174484647 | -             | ALU_604    | RABGAP1L      | +              | Intron      |
| 1   | 180857564 | 180857565 | +             | ALU_629    | XPR1          | +              | UTR         |
| 1   | 198243300 | 198243301 | -             | ALU_726    | NEK7          | +              | Intron      |
| 1   | 227502452 | 227502453 | +             | ALU_841    | CDC42BPA      | -              | Intron      |
| 1   | 232587774 | 232587775 | +             | ALU_865    | SIPA1L2       | -              | Intron      |
| 2   | 11353711  | 11353712  | +             | ALU_1002   | ROCK2         | -              | Intron      |
| 2   | 98582157  | 98582158  | +             | ALU_1385   | TMEM131       | -              | Intron      |
| 2   | 141534074 | 141534075 | -             | ALU_1585   | LRP1B         | -              | Intron      |
| 2   | 181880746 | 181880747 | -             | ALU_1805   | UBE2E3        | +              | Intron      |
| 2   | 198763462 | 198763463 | -             | ALU_1894   | PLCL1         | +              | Intron      |
| 3   | 42898420  | 42898421  | -             | ALU_2319   | ACKR2         | +              | Intron      |
| 3   | 152053972 | 152053973 | +             | ALU_2814   | MBNL1         | +              | Intron      |
| 3   | 157962934 | 157962935 | -             | ALU_2845   | RSRC1         | +              | Intron      |
| 3   | 158089835 | 158089836 | -             | ALU_2846   | RSRC1         | +              | Intron      |
| 3   | 168885760 | 168885761 | +             | ALU_2909   | MECOM         | -              | Intron      |
| 4   | 76993824  | 76993825  | +             | ALU_3412   | ART3          | +              | Intron      |
| 5   | 25233926  | 25233927  | +             | ALU_4154   | LINC02211     | +              | Intron      |
| 5   | 109051004 | 109051005 | -             | ALU_4562   | MAN2A1        | +              | Intron      |
| 6   | 45260479  | 45260480  | +             | ALU_5132   | SUPT3H        | -              | Intron      |
| 6   | 53167475  | 53167476  | +             | ALU_5181   | ELOVL5        | -              | Intron      |
| 6   | 56387576  | 56387577  | -             | ALU_5205   | DST           | -              | Intron      |
| 6   | 66163982  | 66163983  | -             | ALU_5227   | EYS           | -              | Intron      |
| 6   | 74504855  | 74504856  | +             | ALU_5280   | CD109         | +              | Intron      |
| 6   | 96009421  | 96009422  | -             | ALU_5389   | MANEA-AS1     | -              | Intron      |
| 6   | 97017683  | 97017684  | -             | ALU_5395   | FHL5          | +              | Intron      |
| 6   | 139294734 | 139294735 | -             | ALU_5628   | REPS1         | -              | Intron      |
| 6   | 163013855 | 163013856 | -             | ALU_5742   | PRKN          | -              | Intron      |

# (Table 18 continues)

| 7     | 18273084     | 18273085  | - | ALU_5868  | HDAC9        | + | Intron       |
|-------|--------------|-----------|---|-----------|--------------|---|--------------|
| 7     | 33195329     | 33195330  | - | ALU_5942  | BBS9         | + | Intron       |
| 7     | 78146522     | 78146523  | - | ALU_6127  | MAGI2        | - | Intron       |
| 7     | 91751552     | 91751553  | + | ALU_6200  | CYP51A1      | - | Intron       |
| 7     | 119259819    | 119259820 | - | ALU_6325  | LINC02476    | - | UTR          |
| 8     | 8920127      | 8920128   | + | ALU_6560  | ERI1         | + | Intron       |
| 8     | 13975433     | 13975434  | - | ALU_6584  | SGCZ         | - | Intron       |
| 8     | 63344481     | 63344482  | + | ALU_6774  | NKAIN3       | + | Intron       |
| 8     | 100782579    | 100782580 | + | ALU_6981  | VPS13B       | + | Intron       |
| 8     | 110101605    | 110101606 | - | ALU_7037  | TRHR         | + | Intron       |
| 9     | 4237141      | 4237142   | + | ALU_7235  | GLIS3        | - | Intron       |
| 9     | 16682313     | 16682314  | - | ALU_7311  | BNC2         | - | Intron       |
| 9     | 117928281    | 117928282 | + | ALU_7672  | DEC1         | + | Intron       |
| 10    | 3569025      | 3569026   | + | ALU_7750  | LOC105376360 | + | Intron       |
| 10    | 11984965     | 11984966  | + | ALU_7788  | UPF2         | - | Intron       |
| 10    | 34571038     | 34571039  | + | ALU_7901  | PARD3        | - | Intron       |
| 10    | 46074893     | 46074894  | - | ALU_7934  | MARCH8       | - | Intron       |
| 10    | 65356114     | 65356115  | - | ALU_8023  | REEP3        | + | Intron       |
| 10    | 106566893    | 106566894 | - | ALU_8208  | SORCS3       | + | Intron       |
| 11    | 43877448     | 43877449  | - | ALU_8559  | HSD17B12     | + | UTR          |
| 11    | 65984338     | 65984339  | - | ALU_8622  | PACS1        | + | Intron       |
| 12    | 26697612     | 26697613  | - | ALU_9091  | ITPR2        | - | Intron       |
| 12    | 28417298     | 28417299  | - | ALU_9107  | CCDC91       | + | Intron       |
| 12    | 28438612     | 28438613  | - | ALU_9108  | CCDC91       | + | Intron       |
| 12    | 41847723     | 41847724  | + | ALU_9169  | PDZRN4       | + | Intron       |
| 12    | 56753252     | 56753253  | - | ALU_9228  | STAT2        | - | Intron       |
| 12    | 71525479     | 71525480  | + | ALU_9320  | TSPAN8       | - | Intron       |
| 12    | 120130849    | 120130850 | + | ALU_9540  | CIT          | - | Intron       |
| 13    | 46647748     | 46647749  | - | ALU_9748  | CPB2         | - | Intron       |
| 13    | 46647748     | 46647749  | - | ALU_9748  | CPB2-AS1     | + | Intron       |
| 13    | 62588972     | 62588973  | - | ALU_9847  | LINC00358    | - | Intron       |
| 14    | 55795871     | 55795872  | - | ALU_10325 | FBXO34       | + | Intron       |
| 14    | 60741400     | 60741401  | + | ALU_10351 | PPM1A        | + | Intron       |
| 15    | 49609604     | 49609605  | + | ALU_10695 | GALK2        | + | Intron       |
| 15    | 73983319     | 73983320  | - | ALU_10812 | CD276        | + | Intron       |
| 15    | 76826019     | 76826020  | + | ALU_10819 | SCAPER       | - | Intron       |
| 16    | 75655176     | 75655177  | - | ALU_11116 | ADAT1        | - | Intron       |
| 17    | 46505002     | 46505003  | + | ALU_11333 | SKAP1        | - | Intron       |
| 18    | 53146075     | 53146076  | - | ALU_11714 | TCF4-AS1     | + | Intron       |
| 18    | 53146075     | 53146076  | - | ALU_11714 | TCF4         | - | Intron       |
| 20    | 1546228      | 1546229   | + | ALU_12014 | SIRPB1       | - | Intron       |
| 21    | 33050849     | 33050850  | + | ALU_12379 | SCAF4        | - | Intron       |
| 2     | 174952231    | 174952232 | - | SVA_134   | OLA1         | - | Intron       |
| 6     | 153429856    | 153429857 | + | SVA_315   | RGS17        | - | Intron       |
| 9     | 33130564     | 33130565  | + | SVA_401   | B4GALT1      | - | Intron       |
| 14    | 92619420     | 92619421  | - | SVA_615   | CPSF2        | + | Intron       |
| 17    | 44153977     | 44153978  | + | SVA_706   | KANSL1       | - | Intron       |
| Upstı | ream of Gene |           |   |           |              |   |              |
| 6     | 140417842    | 140417843 | + | ALU_5637  | LOC100507477 | + | 3 kb Upstrea |
| 16    | 80848077     | 80848078  | - | ALU_11145 | CDYL2        | - | 10 kb Upstre |

Twenty Alu elements and 1 SVA element interrupted enhancer regions (Table 19), however, the distribution of RTEs in LD with TAS in enhancer regions is not significantly different from the distribution of all non-reference RTEs (P-value = 0.069 and 0.908, respectively; chi-squared test).

Table 19: List of RTEs in LD with TAS that overlap with enhancer regions. Enhancer regions and names are based on data from the GeneHancer database of enhancers (Fishilevich et al., 2017). Abbreviations: RTE: Retrotransposable element; TAS: Trait associated SNP.

| Chr | RTE start | RTE end   | RTE name  | Enhancer Start | Enhancer End | GeneHancer name |
|-----|-----------|-----------|-----------|----------------|--------------|-----------------|
| 1   | 78607067  | 78607068  | ALU_276   | 78606737       | 78609541     | GH01J078141     |
| 1   | 198243300 | 198243301 | ALU_726   | 198241174      | 198243363    | GH01J198272     |
| 1   | 227502452 | 227502453 | ALU_841   | 227501737      | 227507587    | GH01J227314     |
| 1   | 232587774 | 232587775 | ALU_865   | 232586521      | 232589442    | GH01J232450     |
| 2   | 30669993  | 30669994  | ALU_1087  | 30669326       | 30671855     | GH02J030446     |
| 4   | 76993824  | 76993825  | ALU_3412  | 76993459       | 76994847     | GH04J076072     |
| 5   | 56109723  | 56109724  | ALU_4294  | 56109413       | 56115758     | GH05J056814     |
| 6   | 53167475  | 53167476  | ALU_5181  | 53164103       | 53169223     | GH06J053299     |
| 6   | 139294734 | 139294735 | ALU_5628  | 139291022      | 139295452    | GH06J138969     |
| 7   | 38209213  | 38209214  | ALU_5970  | 38208802       | 38210018     | GH07J038169     |
| 7   | 50473286  | 50473287  | ALU_6027  | 50472233       | 50475870     | GH07J050404     |
| 7   | 120538086 | 120538087 | ALU_6336  | 120536766      | 120540791    | GH07J120896     |
| 9   | 16682313  | 16682314  | ALU_7311  | 16682312       | 16684265     | GH09J016682     |
| 10  | 3569025   | 3569026   | ALU_7750  | 3567620        | 3571242      | GH10J003525     |
| 10  | 34571038  | 34571039  | ALU_7901  | 34568588       | 34571868     | GH10J034279     |
| 10  | 106566893 | 106566894 | ALU_8208  | 106565146      | 106570717    | GH10J104805     |
| 12  | 56753252  | 56753253  | ALU_9228  | 56752000       | 56755336     | GH12J056358     |
| 12  | 120130849 | 120130850 | ALU_9540  | 120128986      | 120132955    | GH12J119691     |
| 16  | 75655176  | 75655177  | ALU_11116 | 75653160       | 75658011     | GH16J075619     |
| 17  | 46505002  | 46505003  | ALU_11333 | 46503573       | 46508375     | GH17J048426     |
| 9   | 33130564  | 33130565  | SVA_401   | 33127963       | 33132882     | GH09J033127     |
|     |           |           |           |                |              |                 |

#### 4.4. Discussion

#### 4.4.1. RTEs overlap and enrichment in GWAS risk loci

This study adopted an approach for identifying polymorphic RTEs that have the potential to implicate human health and influence individual predisposition to disease by screening for RTEs in risk regions previously identified by GWAS. Over one-third of the common L1s and Alus (36.64% and 39.82%, respectively) and more than half of the SVAs (57.27%) analysed in this study overlapped with TAS LD-blocks (Table 16). These RTEs were significantly enriched in risk loci compared with random genomic regions (Figure 20). The enrichment of structural variants (SVs) mediated by RTE insertions in risk loci is in line with previous reports in the literature. Sudmant et al. (2015) reported a 1.5-fold enrichment of TAS in the genomic region surrounding SVs, of which some were RTEs. However, the majority of the enrichment signal seemed to be attributed to large SV (>20 Kb) (Sudmant et al., 2015). A more recent study reported a significant enrichment of polymorphic Alu elements in GWAS risk regions (P-value = 0.013) using a set of 13,572 polymorphic Alus and 3,242 TAS LD-blocks ( $P < 10^{-9}$ ) (Payer et al., 2017). These results are in line with the enrichment of Alus in TAS LD-blocks observed in this study. The significant enrichment of L1 and SVA elements in the genomic regions of TAS reported in this study (Figure 20) adds to previous reports in the literature and suggests the RTEs in risk loci are candidate causative variants with the potential to impact functional genomic regions.

#### 4.4.2. LD analysis in comparison to previous reports in the literature

Polymorphic RTEs with a potential functional impact in risk regions are likely in LD with the TAS of that region. RTEs that are not in LD with the TAS are potentially not on the risk haplotype and are unlikely candidates of causation. The association analysis identified 429 RTE-TAS LD associations ( $r^2 > 0.6$ ) using GWS TAS that have been identified with a P-value  $\leq 5 \times 10^{-8}$ , and RTE variants of low and common AF (MAF  $\geq$  0.01) that have been identified in European populations. Of these, 157 TAS are in strong LD ( $r^2 \ge 0.8$ ) with 49 RTEs (Table 17). Previous studies conducting similar analysis report a total of 164 RTE-TAS LD pairs ( $r^2 > 0.6$ ) of which 41 RTE-TAS associations were replicated by this study (Table 20; Appendix 3). Some previously reported RTE-TAS associations not replicated by this study were either identified in non-European cohorts, were not GWS, or were within the HLA region. Other RTE-TAS associations may have been missed because of different studies using genotype data of different samples, thus affecting the r<sup>2</sup> of the LD calculation (Wray, 2005; Medina-Gomez et al., 2015). Another reason for missing some of the previously identified RTE-TAS associations might be because some of the LD-blocks of this study were arbitrarily extended using the median of the LD-blocks defined by tagging SNPs. This may have under-estimated the size of the LD-block of some TASs which may have resulted in missing some RTEs from the association analysis, especially since the LD analysis in this study was mainly calculated for RTEs interrupting a TAS LD-block. Nevertheless, this study adds a list of 354 new RTE-TAS associations to previous reports in the literature.

Table 20: Comparing the list of polymorphic RTEs in LD ( $r^2 > 0.6$ ) with GWAS TAS identified by previous similar studies with the list of RTE-TAS associations identified by the current study. Abbreviations: RTE: Retrotransposable element; TAS: Trait associated SNP; LD: Linkage disequilibrium. GWS: Genome-wide significant, defined as TAS with a P-value  $\leq 5x10^{-8}$ .

| Study reference<br>[PMID]                | Total number of<br>TAS in LD with<br>at least one RTE<br>identified by the<br>referenced study | Number of<br>TAS in LD<br>with RTEs that<br>overlap with<br>the current<br>study | Number of discrepancies (reason)  |
|--|--|--|---|
| Sudmant et al.<br>(2015) [26432246]      | 6  | 5  | 1 (TAS not GWS)   |
| Hehir-Kwa et al.<br>(2016)<br>[27708267] | 43   | 13   | <ul><li>16 (TAS not GWS)</li><li>10 (TAS not identified in European cohort)</li><li>2 (TAS in HLA region)</li><li>2 (other)</li></ul> |
| Payer et al. (2017)<br>[28465436]        | 64   | 16   | 3 (TAS not GWS)<br>5 (TAS not identified in European cohort)<br>40 (other)  |
| Wang et al. (2017)<br>[28824558]         | 51   | 7  | 23 (TAS not GWS)<br>8 (TAS not identified in European cohort)<br>13 (other)   |

## 4.4.3. Distribution of RTEs in LD with TAS:

Of the RTEs in LD with TAS, 84 are in or near gene regions, including 36 RTEs that are on the sense strand of the gene (Table 18). In addition, 21 of the RTEs in LD with TAS are in enhancer regions (Table 19). The distribution of L1 and SVA elements in LD with TAS in functional genomic regions is not significantly different relative to all polymorphic L1s and SVAs in the curated database (P-value > 0.05). In contrast, polymorphic Alu elements in LD with TAS are significantly enriched in gene regions (P-value = 0.0143) in line with the results

of Payer et al. (2017). The relative enrichment of Alu elements in LD with TAS within genes relative to all polymorphic Alus is expected due to the enrichment of TAS in genes (Hindorff et al., 2009; Payer et al., 2017). The lack of enrichment of L1s and SVAs in LD with TAS within genes relative to all polymorphic L1 and SVA elements may have been missed due to their small sample size of L1s (n=16) and SVAs (n =7) in LD with TAS, which is likely to increase type II error (Banerjee et al., 2009). Nevertheless, given that RTE elements have been known to interfere with human gene expression through a variety of mechanisms (Chuong et al., 2017; Bourque et al., 2018), RTEs in LD with TAS that also interrupt gene regions are likely candidates of causation with the potential to interfere with gene function and expression.

# 4.4.4. RTEs as causative variants affecting gene expression:

A study by Wang et al. (2017) confirmed the potential of RTEs in LD with TAS as candidate causative variant. Wang et al. (2017) identified 437 RTEs identified in European samples and associated with disease. These RTEs were also located within tissue-specific enhancers. Expression quantitative trait loci (eQTL) analysis was then performed using human B-cells and the set of RTE-TAS associations within enhancers of blood and immune tissue. By using this method, the Wang et al. (2017) research group were able to identify seven RTEs in LD with TAS and associated with the expression of genes of importance to the trait phenotype.

An example of an RTE from the list of RTE-TAS associations reported in this study with the potential to act as a causative variant is SVA\_706, located on chromosome 17q21.31 on the opposite strand of the KANSL1 gene. This SVA is in LD with 90 TAS linked with a variety of traits including Parkinson's disease,

progressive supranuclear palsy (PSP), cognitive ability, depression, and anxiety (Table 17).

A recent study by Spirito et al., (2019) reported the significant association between SVA\_706 and the expression of a number of genes including KANSL1 gene and its antisense transcript KANSL1-AS1, Corticotropin Releasing Hormone Receptor 1 (CRHR1) gene, and Leucine-Rich Repeat Containing 37A2 (LRRC37A2) gene. These genes have been previously associated with a number of physiological processes including PSP, depression, and anxiety (Liu et al., 2013; Allen et al., 2016; Ferrari et al., 2017). These findings confirm that RTE variants do have the potential to impact human health and can influence individual predisposition to disease.

#### 4.4.5. Study overview and concluding remarks

This chapter discusses the candidacy of polymorphic RTE insertions as potential causative variants in GWAS risk loci. Polymorphic L1s, Alus, and SVAs with common allele frequencies in populations of European descents were found to be overrepresented at GWAS risk loci, more than expected by chance. In addition, hundreds of RTEs located within risk loci were found to be in LD with TASs. Thus the findings of the study at hand build on previous reports in the literature, supporting the potential contribution of RTEs as risk variants associated with complex diseases. It is noteworthy that association does not necessarily equate to causation, therefore the RTE-TAS associations identified in this study are merely candidate causative variants requiring future investigations to uncover whether their existence within risk haplotypes does have an observed effect on genome function that can be related to the trait phenotype.

#### 5. General discussion and future directions

Transposable elements (TEs) make up a huge percentage of the human genome (~45%) and have been a component of our DNA throughout the history of human evolution (Lander et al., 2001). TEs were first discovered in the genome of maize by Barbara McClintock in the 1950s (Ravindran, 2012). However, the effect of TE activity on genome function in humans was not realised until the late 1980s. following the first reported case of a genetic disease, namely Haemophilia, caused by an L1 insertion into exon 14 of the factor VIII gene in two unrelated individuals (Kazazian, 1988). Since then, over 124 monogenic diseases caused by recent TE activity have been reported in the literature (Hancks and Kazazian, 2016). Despite this, the general effect of TE activity on genome function and its potential contribution towards multifactorial traits and disorders remains an open question. This thesis set out to investigate the effect of the ongoing transposition activity from the active L1, Alu, and SVA subfamilies on genome function, including investigating the candidacy of RTE-mediated genomic variants as potential causative variants that can influence individual predisposition to complex traits and diseases. To this end, a comprehensive database of known non-reference RTEs that are polymorphic in the human genome was curated from peer-reviewed journal articles scattered through the literature. The database was utilised to investigate the genomic distribution of non-reference RTEs in comparison to ancient RTE insertions that are fixed in the genome of all humans. The results of the distribution analysis show that polymorphic RTE variants are found in active genomic regions more frequently than ancient RTEs that are fixed in the human genome. These results suggest that the activity of RTE elements do harm genome function and thus are subjects of negative selection. As such,

RTE variants that are potentially deleterious and disease-causing were sought after in the next step of the analysis.

Firstly, the enrichment of RTEs in close proximity to risk regions was investigated. It was found that L1s, Alus, and SVAs were significantly enriched in GWAS risk loci, compared with random genomic regions of similar properties. We next tried to identify RTE variants that have the potential to be the causative variant within the risk haplotype, by calculating LD between the RTE variant and the TAS. This analysis resulted in a list of 354 RTE-TAS associations, each of which has the potential to be the causative variant within the haplotype of the TAS. This thesis employed a constructed framework for identifying RTE variants of relevance to disease risk by utilising public data that is available in the literature. The next sections will discuss each component of this thesis in more detail, including study limitations and proposed future studies.

#### 5.1. Database curation

Identifying RTE insertions from the recently evolved and active subfamilies of L1s, Alus, and SVAs has been a difficult task, due to their repetitive nature and high sequence homology with endogenous RTEs that have been fixed in the human genome throughout human evolution. The development of short-read NGS technology and numerous RTE detection tools have simplified and replaced early labour-intensive methods and drastically increased the scalability of RTE detection. Since then, more and more research groups have shown a great interest in RTE discovery as numerous studies characterising polymorphic RTE insertions have been published. These studies have collectively reported thousands of RTE variants, of which only a fraction have been systematically

organised into online databases, while the majority remain scattered in the literature. As such, there was a need for a comprehensive database of RTE variants, to serve as a resource that could be used to facilitate large-scale genomic studies, including population genetics and association studies. This study reports a comprehensive list of L1, Alu, and SVA variants that have been reported in the literature up to April 2019. The current version of the curated database includes the insertional profiles of 3,360 samples and 39,798 RTEs, obtained from a total of 45 studies.

In contrast to previous online databases, namely dbRIP (<u>http://dbrip.brocku.ca/;</u> Wang et al., 2006) and the euL1db (<u>http://eul1db.unice.fr;</u> Mir et al., 2014), the curated database applied quality control measures to ensure the removal of potential false positives. In addition, the database of this study only includes germline variants that have been identified in healthy human samples, which is in contrast to the dbRIP and the euL1db databases (Wang et al., 2006; Mir et al., 2014), that include somatic insertions or insertions identified in pathological human samples. Nevertheless, 52% of dbRIP records and 46% of the germline L1Hs reported in the euL1Hs database overlapped with or were within 200bp of the RTE data included in the curated database of this study.

Overall, the curated database provides a comprehensive resource of known germline polymorphic RTE insertions that can be a vital resource in the study of the physical and pathological impact of recent RTE activity on the human genome.

# 5.1.1. Reflections and limitations

It was noted during the database curation process that different studies use various nomenclature to describe RTE insertions. Examples of terms (other than RTEs) that have been used by some studies to describe L1, Alu, and SVA insertions include: mobile element insertions, retrotransposons, and retroelements. Although the scientific community recognises that all these terms are synonyms for one another, PubMed searches for the different terms produce a different number of results. There are ways of getting around this, for example, by using MeSH terms or advanced information retrieval functions in PubMed to formulate a query. However, a recent study analysing PubMed user sessions has reported that over 94% of information queries were performed by inexperienced users, defined as users who do not utilise PubMed advanced information retrieval functions (Yoo and Mosa, 2015). As such, many scientists conducting a PubMed search of non-reference RTE insertions may misidentify several known nonreference elements. This could result in future RTE detection studies misidentifying known non-reference insertions as novel insertions, and further illustrating the importance and the need for a comprehensive and accessible database of RTE elements.

Variations within the RTE database of this study are bound to exist owing to differences within the methods applied by each study, including variations within the algorithmic design of the different RTE detection tools, and the applied quality control measures for RTE calling. Such variations have likely had different effects on the accuracy, precision, and false discovery rate of the included studies, thus limiting the consistency of the curated database. Nevertheless, every effort was made to minimise the potential effects of this shortfall, for example, by applying

a minimum supporting reads threshold to eliminate false positives, and by merging insertions located within 200bp of each other, to accommodate for variations within the precision of the different RTE detection tools.

# 5.2. Genomic distribution of RTEs

The genomic location of an RTE insertion can determine its potential impact on genome function and its ability to be expressed and mobilised. RTEs are capable of introducing insertional mutagens that can affect genome function in a variety of mechanisms, including interfering with gene expression, alternative splicing, and post-transcriptional regulation (Guffanti et al., 2014; Bourgue et al., 2018; Savage et al., 2019). In addition, RTEs can impact genomic stability, by inducing DNA breakage during their retrotransposition or by causing post-transposition deletions and duplications via NAHR, which can occur due to the repetitive nature and high sequence homology between the different subfamilies of RTEs (Startek et al., 2015; Nazaryan-petersen et al., 2016; Bourque et al., 2018). RTEs can also induce epigenetic modifications by attracting chromatin modification complexes as part of the host defence mechanisms to suppress RTE activity (Jacobs et al., 2014; Garcia-Perez et al., 2016). Therefore, characterising the integration site of RTEs is essential for understanding the potential impact of their activity on genome function and integrity, including the extent of their contribution to human health and disease.

Previous studies investigating the genomic distribution of endogenous RTEs have reported the accumulation of L1 elements in AT-rich, low activity genomic regions, while Alu and SVA elements accumulate in GC-rich, high-activity regions (Smit, 1999; Lander et al., 2001; Wang et al., 2005). Nevertheless, endogenous

RTEs are mostly fixed in the human genome and are thought to have a neutral effect on genome function. The differential distribution of Alu and SVA elements, in comparison to the distribution of L1s despite their transposition via the L1 machinery, has been attributed to post-integrational processes that have differentially reshaped the genomic landscape of each element, mainly by purifying selection and ectopic recombination (Medstrand et al., 2002; Wang et al., 2005; Kvikstad and Makova, 2010; Costantini et al., 2012). Polymorphic RTE insertions that are not part of the human reference genome have not been subjects of selection pressures to the same extent as the fixed endogenous elements. Accordingly, analysing the genomic distribution of polymorphic insertions, in comparison with the landscape of fixed RTEs, is one of the methods that can be used to gain insight into the interplay between RTE activity and its potential impact on genome function and integrity. Previous studies conducting similar analysis have provided some insight into the potential effects of the continuous RTE activity on genome function, but provided limited information about integration site preference, due to the low number of polymorphic insertions recovered from an even lower number of samples (Ovchinnikov et al., 2001; Boissinot et al., 2004; Wang et al., 2005; Cordaux et al., 2006; Ewing and Kazazian, 2010). The small number of samples analysed by previous studies means that the majority of the recovered insertions were likely common, with an allele frequency >1%. In short, retrotransposition is induced in vitro using an engineered RTE construct, and the distribution of the recovered de novo insertions is then compared with that of endogenous elements (Flasch et al., 2019; Sultana et al., 2019; Chen et al., 2020). At the moment, this method has only been applied for investigating the integration preference of L1 elements.

This study compared the genomic distribution of endogenous RTEs with the distribution of polymorphic non-reference insertions that were curated in-house. Near one-third of the in-house curated database (32%) is composed of singleton insertions, that are more likely to provide information about the integration site preference of active RTEs, due to their younger evolutionary age compared with common polymorphic insertions. As expected, the results for the genomic distribution of L1 elements from this study were intermediate between those reported by previous studies using non-reference insertions and the more recent studies using engineered L1 constructs. Thus, it was deduced that the distribution results of non-reference insertions from this study represent aspects of the integration site preference of L1, Alu, and SVA elements.

The initial integration of non-reference RTEs is not completely random. Nonreference L1 and Alu elements are similarly distributed in AT-rich low-activity regions, suggesting that both of these elements share similar integration site preferences. A recent study has reported that the most influential factors in determining the integration site preference of active L1s include the specificity of the L1 machinery and pre-existing biases within the human genome (Sultana et al., 2019). These influential factors are also likely to be true for determining the initial integration site of Alus, especially since the retrotransposition of mobile Alu elements is reliant on the L1 machinery. In contrast, SVA elements accumulate in GC-rich high-activity regions, suggesting the role of different influential factors in determining the integration site preference of SVAs, which are yet to be determined.

Overall, the differential distribution of reference vs. non-reference RTEs displays aspects of the interplay between the integration site preference and the effect of

post-integrational processes in modulating the genomic landscape of RTE insertions. In addition, the more frequent occurrence of non-reference RTE insertions in functional genomic regions, in comparison with reference insertions, suggests the potential negative impact of RTE activity on genome function and integrity. This study provides the most recent analysis for the genomic distribution of Alu and SVA elements that have not been studied as extensively as L1 elements.

#### 5.2.1. Study limitations

The non-reference SVA elements analysed by this study may not be representative of the true integration site preference of SVA elements. A recent pedigree-based study investigating the rate of new RTE elements has estimated the occurrence of 1 new L1 and SVA element per 63 births (Feusier et al., 2019). However, the number of non-reference SVA insertions recovered so far is a fraction of the number of known non-reference L1 elements, suggesting shortfalls of SVA discovery within the human genome. In addition, recent germline SVA insertions that have been identified in the population may have already been exposed to strong and rapid post-insertional selection via compositional matching. The compositional matching hypothesis suggests the removal of DNA elements, particularly repetitive elements with a sequence composition that does not match the isochore in which they are found (Pavlíček et al., 2001; Hackenberg et al., 2005). These possibilities limit the reliability of conclusions drawn by this study for the integration site preference of SVA elements.

Finally, the distribution analysis of this study provided some great insight into the potential impact of RTE activity on genome function. However, aspects of the integration site preference may have been masked by the grouping of

polymorphic RTEs of different allelic frequencies, thereby limiting the scope of the conclusions drawn.

# 5.3. Correlation between RTEs and TASs

RTEs that remain capable of transposing within the human genome are an important source of genomic diversity within human populations, yet their contribution to complex traits and diseases remains an open question. RTEs are often masked in genomic and association studies, despite their continuous contribution towards creating SV in humans, and their various effects on genome function and regulation. Previous studies may have neglected RTE insertions, due to their repetitive nature and high sequence homology, which makes them difficult to characterise and study. Many studies filter out repetitive regions including TEs from WGS data before conducting downstream analyses (Goernerpotvin and Bourgue, 2018). As such, previous association studies have mainly relied on SNPs, as they are ubiquitous in the human genome, occurring on average once every 300 base pairs (Nelson et al., 2004). However, the collective effect size of GWS SNPs could only explain a fraction of the trait heritability for many complex traits, thus the missing heritability issue was raised (Manolio et al., 2009; Rowe and Tenesa, 2012). Soon after the missing heritability issue was raised, more and more studies started to incorporate other types of SVs, however, these studies were mainly focused on CNVs or mega base deletions and duplications (Stankiewicz and Lupski, 2010; Lacaria et al., 2013; Waddell et al., 2015). Studies have only recently begun investigating the contribution of RTEs to complex traits and diseases, thus the impact of RTE variants as potential causative candidates that can influence individual predisposition to disease, remains largely uncharacterised.

A recent study investigating the potential implications of polymorphic RTE insertions on human health has reported a significant enrichment of polymorphic Alu elements in GWAS risk loci (Payer et al., 2017). Also, recent studies have reported that polymorphic RTE insertions can be in strong LD with TAS, suggesting their potential candidacy as causative variants within the risk haplotype (Sudmant et al., 2015; Hehir-Kwa et al., 2016; Payer et al., 2016; Wang et al., 2017). In addition, some RTE variants in LD with TAS were also shown to be associated with altered gene expression of nearby genes in a tissue-specific manner (Wang et al., 2017; Spirito et al., 2019). This study aimed to build upon previous findings by investigating the proximity and enrichment of polymorphic RTEs in GWAS risk loci, and by identifying additional RTEs in LD with TAS that could be potential candidates of causation within the risk haplotype. The analysis of this study is focussed on exploring the effect of common variants from the three active classes of non-LTR RTEs, namely L1s, Alus, and SVAs, and their potentially uncharacterised contribution as underlying causative variants of complex traits.

L1 and SVA elements were found to be significantly enriched in GWAS risk loci, suggesting the detection of the potential functional impact of polymorphic RTE insertions at multiple GWAS risk regions. The significant enrichment of Alu elements in GWAS risk loci is in line with the results of Payer et al., 2016. RTE elements were readily identified in GWAS risk loci. This study also identified 354 new RTE-TAS associations, of which 157 are in strong LD (r2 > 0.8; Table 17). Most significantly, a non-reference SVA element (SVA\_706) was found to be in strong LD with multiple TAS over a large genomic region. Upon further investigation, it was found that this SVA is located within a large haplotype in European populations that have been extensively studied in neurological

diseases, yet its contribution to disease risk has not yet been fully elucidated upon (Boettger et al., 2012; Li et al., 2014; Koolen et al., 2016). Interestingly, Spirito et al. (2019) reported strong associations between this SVA element and the expression of several genes that have been implicated with neurological conditions such as depression and anxiety. Altogether, these results suggest that SVA\_706 is likely the missing variant that could potentially explain the contribution of this large haplotype to the risk of developing various neurological diseases, thus its contribution should be validated with follow-up wet-lab studies.

Overall, the results of our study and previous studies show RTEs can be causative variants in potentially all complex traits and disorders, and should be routinely incorporated in association studies to address aspects of the missing heritability issue.

#### 5.3.1. Study limitations

Estimating the LD-block size for TAS that lacked tagging SNPs, may have introduced type II error during the LD-analysis, resulting in the misidentification of some RTE-TAS associations that were reported in previous studies. The LDanalysis was limited to RTEs identified by the 1kGP (Sudmant et al., 2015) as it is the only study within the curated database that included accessible genotype information of SNPs and RTE elements. The LD-analysis was also limited to variants identified in individuals of European descent, as most GWAS have been conducted predominantly on European cohorts. Finally, some of the RTEs in LD with TAS reported in this study may not be associated with disease risk. Nevertheless, the list of RTE-TAS associations reported in this study identifies some RTEs that are potential candidates of causation. The contribution of the

RTE variant as a potential risk variant from the reported list can only be confirmed by wet-lab experiments.

# 5.4. Summary of key findings

This study investigated the genomic landscape of recent RTE insertions and the potential contribution of polymorphic RTEs as causative variants of disease in GWAS risk loci, in an effort to understand the impact of RTE insertions and their role in complex human disorders. To this end, a comprehensive database of polymorphic RTE insertions was curated using online databases and peer-reviewed journal articles. The curated database is a handy resource for future studies in various fields, including population genetics and cancer genomics, made available at GitHub

# (https://github.com/RandaAli1/MyPhDproject/tree/master/MyAnalysis/RTE\_files)

Through investigating the genomic distribution of RTEs, we have found that transposable elements are readily located in active genomic regions, and thus have the potential to influence gene function and regulation in a variety of mechanisms. Of the three RTE types investigated in this study, SVA elements accumulated the most in active regions, suggesting that SVAs are likely to have the most negative impact on genome function. This finding is significant as it highlights the importance of conducting more research on SVA elements, since they are the least favoured RTEs to study due to their complex structure, which makes them difficult to detect in the human genome.

Finally, we investigated the potential association of RTEV with disease susceptibility and found a significant enrichment of RTEs in GWAS risk loci, plus over 400 RTEs in LD (r2 > 0.6) with various TAS. This finding suggests that SV mediated by RTE insertions do have the potential to impact complex human traits

and are likely causative variants in some GWAS risk loci. Although the RTE-TAS associations identified in this study are purely candidate variants of causation requiring future validation studies, the result of this analysis highlights the importance of including RTEV in future association studies to better the understanding of complex human traits and disorders.

# 5.5. Future directions

RTEs provide a continuous source of genetic variation in humans, including some variants that can be involved with the aetiology of complex traits. Following the results of this study, it was concluded that SVA elements have the highest potential impact on the function of the human genome relative to other classes of active RTEs, namely L1 and Alu elements. This conclusion was based on the accumulation of non-reference SVA elements in highly active genomic regions, and the significantly higher proportion of their occurrence in risk loci, compared to both L1 and Alu variants. Nevertheless, the integration site preference analysis in this study was limited by the reliance on polymorphic germline insertions of various allele frequencies that may not be representative of the actual integration site preferences of SVAs. As such, future studies characterising the integration sites of experimentally induced de novo SVA elements in cultured cells are required to confirm the conclusions drawn by the current study, and better understand the contribution of various genomic features in favouring or restricting the mobilisation of SVA elements. In addition, this study identified a list of RTE variants that are potential candidates of causation at GWAS risk loci. These RTE-TAS associations require future experimental validation studies, to confirm the causal relationship between RTE variants and numerous multifactorial traits in humans. An example of this would be investigating the association between

candidate RTE variants and the expression of nearby genes with functional effects that can be linked to the trait phenotype. Lastly, the inclusion of ethnic cohorts other than European in future GWAS could allow upcoming studies to expand the RTE-TAS associations, which could lead to a better understanding of disease etiology.

# References

- Abraham, G. *et al.* (2016) 'Genomic prediction of coronary heart disease', *European Heart Journal*, 37(43), pp. 3267–3278. doi: 10.1093/eurheartj/ehw450.
- Abrusán, G. and Krambeck, H. J. (2006) 'The distribution of L1 and Alu retroelements in relation to GC content on human sex chromosomes is consistent with the ectopic recombination model', *Journal of Molecular Evolution*, 63(4), pp. 484–492. doi: 10.1007/s00239-005-0275-0.
- Achanta, P. *et al.* (2016) 'Somatic retrotransposition is infrequent in glioblastomas', *Mobile DNA*, 7(1), pp. 1–9. doi: 10.1186/s13100-016-0077-5.
- Agarwala, V. *et al.* (2013) 'Evaluating empirical bounds on complex disease genetic architecture', *Nature Genetics*. Nature Publishing Group, 45(12), pp. 1418–1427. doi: 10.1038/ng.2804.
- Akagi, K., Li, J. and Symer, D. E. (2013) 'How do mammalian transposons induce genetic variation? A conceptual framework: The age, structure, allele frequency, and genome context of transposable elements may define their wide-ranging biological impacts', *BioEssays*, 35(4), pp. 397–407. doi: 10.1002/bies.201200133.
- Allen, M. *et al.* (2016) 'Data Descriptor : Human whole genome genotype and transcriptome data for Alzheimer's and other neurodegenerative diseases', pp. 1–10.
- Andersson, R. *et al.* (2014) 'Shiori Maeda 5, 6 , Yutaka Negishi 5,6 , Christopher J. Mungall 11', *Nature*, 507(7493), pp. 455–461. doi: 10.1038/nature12787.
- Aneichyk, T. et al. (2018) 'Dissecting the Causal Mechanism of X-Linked Dystonia-Parkinsonism by Integrating Genome and Transcriptome Assembly Article Dissecting the Causal Mechanism of X-Linked Dystonia-Parkinsonism by Integrating Genome and Transcriptome Assembly', Cell, 172(5), pp. 897–909. doi: 10.1016/j.cell.2018.02.011.
- Arokium, H. *et al.* (2014) 'Deep sequencing reveals low incidence of endogenous LINE-1 retrotransposition in human induced pluripotent stem cells', *PLoS ONE*, 9(10), p. e108682. doi: 10.1371/journal.pone.0108682.
- Auton, A. (2009) 'VCFtools'. Available at [http://vcftools.sourceforge.net/man\_latest.html]
- Bailey, J. A. et al. (2000) 'Molecular evidence for a relationship between LINE-1 elements and X chromosome inactivation: the Lyon repeat hypothesis', Proceedings of the National Academy of Sciences of the United States of America, 97(12), pp. 6634–9. doi: 10.1073/pnas.97.12.6634.
- Baillie, J. K. *et al.* (2011) 'Somatic retrotransposition alters the genetic landscape of the human brain', Nature, 479(7374), pp. 534–537. doi: 10.1038/nature10531.

- Banerjee A, Chitnis UB, Jadhav SL, Bhawalkar JS, Chaudhury S. (2009) 'Hypothesis testing, type I and type II errors', *Ind Psychiatry J*, 18(2), pp. 127– 131. Available at: <u>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2996198/</u>.
- Barton, N. H., Etheridge, A. M. and Véber, A. (2017) 'The infinitesimal model: Definition, derivation, and implications', *Theoretical Population Biology*. Elsevier Inc., 118, pp. 50–73. doi: 10.1016/j.tpb.2017.06.001.
- Batzer, M. A. *et al.* (1996) 'Standardized nomenclature for Alu repeats', *Journal of Molecular Evolution*, 42(1), pp. 3–6. doi: 10.1007/BF00163204.
- Beck, C. R. *et al.* (2010) 'LINE-1 Retrotransposition Activity in Human Genomes', *Cell*, 141(7), pp. 1159–1170. doi: 10.1016/j.cell.2010.05.021.LINE-1.
- Beck, C. R. *et al.* (2011) 'LINE-1 Elements in Structural Variation and Disease', *Annual Review of Genomics and Human Genetics*, 12(1), pp. 187–215. doi: 10.1146/annurev-genom-082509-141802.
- Belle, E. M. S., Webster, M. T., & Eyre-Walker, A. (2005). Why are young and old repetitive elements distributed differently in the human genome? Journal of Molecular Evolution, 60(3), 290–296. <u>https://doi.org/10.1007/s00239-004-0020-0</u>
- Bennett, E. A. *et al.* (2004) 'Natural Genetic Variation Caused by Transposable Elements in Humans', 951(October), pp. 933–951. doi: 10.1534/genetics.104.031757.
- Bennett, E. A. *et al.* (2008) 'Active Alu retrotransposons in the human genome', *Genome Research*, 18, pp. 1875–1883. doi: 10.1101/gr.081737.108.7.
- Bestor, T. H. and Bourc'his, D. (2004) 'Transposon silencing and imprint establishment in mammalian germ cells', *Cold Spring Harbor Symposia on Quantitative Biology*, 69, pp. 381–387. doi: 10.1101/sqb.2004.69.381.
- Bire, S. and Rouleux-bonnin, F. (2012) 'Transposable Elements as Tools for Reshaping the Genome: It Is a Huge World After All!'. *Methods in Molecular Biology*, 859. doi: 10.1007/978-1-61779-603-6\_1.
- Boeke JD, Garfinkel DJ, Styles CA, Fink GR. (1985) 'Ty elements transpose through an RNA intermediate', *Cell*, 40(3), pp. 491–500. doi: 10.1016/0092-8674(85)90197-7.
- Boettger LM, Handsaker RE, Zody MC, M. S. (2012) 'Structural haplotypes and recent evolution of the human 17q21.31 region', *Nature Genetics*, 44(8), pp. 881–885. doi: 10.1038/ng.2334.
- Boissinot, S., Entezam, a, & Furano, a V. (2001). Selection against deleterious LINE-1-containing loci in the human lineage. Mol. Biol. Evol., 18(6), 926–935. https://doi.org/10.1093/oxfordjournals.molbev.a003893

- Boissinot, S. *et al.* (2004) 'The insertional history of an active family of L1 retrotransposons in humans', *Genome Research*, 14(7), pp. 1221–1231. doi: 10.1101/gr.2326704.
- Boissinot, S. and Furano, A. (2005) 'The recent evolution of human L1 retrotransposons', *Cytogenetic and Genome Research*, 110, pp. 402–406. doi: 10.1159/000084972.
- Bourgeois, Y. and Boissinot, S. (2019) 'On the population dynamics of junk: A review on the population genomics of transposable elements', *Genes*, 10(6). doi: 10.3390/genes10060419.
- Bourque, G. *et al.* (2018) 'Ten things you should know about transposable elements', *Genome biology*. Genome Biology, 19(199), pp. 1–12. doi: <u>https://doi.org/10.1186/s13059-018-1577-z</u>.
- Bowen NJ. Jordan IK. (2002) 'Transposable Elements and the Evolution of Eukaryotic Complexity', *Curr. Issues Mol. Biol*, 4(3), pp. 65–76. doi: 10.1016/0168-9525(89)90039-5.
- Bragg, D. C., Mangkalaphiban, K., Vaine, C. A., Kulkarni, N. J., Shin, D., Yadav, R., Ozelius, L. J. (2017). Disease onset in X-linked dystonia-parkinsonism correlates with expansion of a hexameric repeat within an SVA retrotransposon in TAF1. Proceedings of the National Academy of Sciences, 114(51), E11020– E11028. <u>https://doi.org/10.1073/pnas.1712526114</u>
- Brandler, W. M. *et al.* (2016) 'Frequency and Complexity of *De Novo* Structural Mutation in Autism', *The American Journal of Human Genetics*. The American Society of Human Genetics, 98(4), pp. 667–679. doi: 10.1016/j.ajhg.2016.02.018.
- Brouha, B. et al. (2003) 'Hot L1s account for the bulk of retrotransposition in the human population', Proceedings of the National Academy of Sciences, 100(9), pp. 5280–5285. doi: 10.1073/pnas.0831042100.
- Buniello, A. *et al.* (2019) 'The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019', *Nucleic Acids Research*. Oxford University Press, 47(D1), pp. D1005–D1012. doi: 10.1093/nar/gky1120.
- Burns, K. H. (2017) 'Transposable elements in cancer', *Nature Reviews Cancer*. Nature Publishing Group, 17(7), pp. 415–424. doi: 10.1038/nrc.2017.35.
- Callinan, P. A. *et al.* (2005) 'Alu retrotransposition-mediated deletion', *Journal of Molecular Biology*, 348(4), pp. 791–800. doi: 10.1016/j.jmb.2005.02.043.
- Cardelli, M., Marchegiani, F. and Provinciali, M. (2012) 'Alu insertion profiling: Arraybased methods to detect Alu insertions in the human genome', *Genomics*. Elsevier Inc., 99(6), pp. 340–346. doi: 10.1016/j.ygeno.2012.03.005.
- Carreira, P. E. *et al.* (2016) 'Evidence for L1-associated DNA rearrangements and negligible L1 retrotransposition in glioblastoma multiforme', *Mobile DNA*, 7(1), p. 21. doi: 10.1186/s13100-016-0076-6.
- Carter, A. B. *et al.* (2004) 'Genome-wide analysis of the human Alu Yb-lineage', Human Genomics, 1(3), pp. 167–178.
- Carvalho, C. M. B. and Lupski, J. R. (2016) 'Mechanisms underlying structural variant formation in genomic disorders.', *Nature reviews. Genetics.* Nature Publishing Group, 17(4), pp. 224–38. doi: 10.1038/nrg.2015.25.
- Chen, C., Ara, T. and Gautheret, D. (2009) 'Using Alu elements as polyadenylation sites: A case of retroposon exaptation', *Molecular Biology and Evolution*, 26(2), pp. 327–334. doi: 10.1093/molbev/msn249.
- Chen, H., Hey, J. and Chen, K. (2015) 'Inferring very recent population growth rate from population-scale sequencing data: Using a large-sample coalescent estimator', *Molecular Biology and Evolution*, 32(11), pp. 2996–3011. doi: 10.1093/molbev/msv158.
- Chen, D. *et al.* (2020) 'Human L1 transposition dynamics unraveled with functional data analysis', Molecular Biology and Evolution, 37(12), pp. 3576–3600. doi: 10.1093/molbev/msaa194.
- Chénais, B. (2016) 'Transposable Elements in Cancer and Other Human Diseases Transposable Elements in Cancer and Other Human Diseases', (April). doi: 10.2174/1568009615666150317122506.
- Chiang, C. *et al.* (2017) 'The impact of structural variation on human gene expression', *Nature Publishing Group*. Nature Publishing Group, 49(5), pp. 692–699. doi: 10.1038/ng.3834.
- Chuong, E. B., Elde, N. C. and Feschotte, C. (2017) 'Regulatory activities of transposable elements: from conflicts to benefits', *Nat Rev Genet*, 18(2), pp. 71–86. doi: 10.1038/nrg.2016.139.
- Conley, A. B. and Jordan, I. K. (2012) 'Cell type-specific termination of transcription by transposable element sequences', Mobile DNA, 3(1), pp. 1–13. doi: 10.1186/1759-8753-3-15.
- Cordaux, R. *et al.* (2006) 'Recently integrated Alu retrotransposons are essentially neutral residents of the human genome', *Gene*, 373(1–2), pp. 138–144. doi: 10.1016/j.gene.2006.01.020.
- Cordaux, R., & Batzer, M. A. (2009). The impact of retrotransposons on human genome evolution. Nature Reviews Genetics, 10(10), 691–703. https://doi.org/10.1038/nrg2640
- Cost, G. J. *et al.* (2002) 'Human L1 element target-primed reverse transcription in vitro', *EMBO Journal*, 21(21), pp. 5899–5910. doi: 10.1093/emboj/cdf592.

- Cost, G. J., & Boeke, J. D. (1998). Targeting of human retrotransposon integration is directed by the specificity of the L1 endonuclease for regions of unusual DNA structure. Biochemistry, 37(51), 18081–18093. https://doi.org/10.1021/bi981858s
- Costantini, M., Auletta, F., & Bernardi, G. (2012). The Distributions of "" New " and " Old " Alu Sequences in the Human Genome : The Solution of a " Mystery " Research article. 29(2001), 421–427. <u>https://doi.org/10.1093/molbev/msr242</u>
- Coufal, N. G. et al. (2011) 'Ataxia telangiectasia mutated (ATM) modulates long interspersed element-1 (L1) retrotransposition in human neural stem cells', *Proceedings of the National Academy of Sciences of the United States of America*, 108(51), pp. 20382–20387. doi: 10.1073/pnas.1100273108.
- Cuccaro, D. *et al.* (2016) 'Copy number variants in Alzheimer's disease', *Journal of Alzheimer's Disease*, 55(1), pp. 37–52. doi: 10.3233/JAD-160469.
- David, M., Mustafa, H. and Brudno, M. (2013) 'Detecting Alu insertions from highthroughput sequencing data', *Nucleic Acids Research*, 41(17), pp. 1–13. doi: 10.1093/nar/gkt612.
- De Almeida, R. A. *et al.* (2016) 'Non-coding RNAs and disease: The classical ncRNAs make a comeback', Biochemical Society Transactions, 44(4), pp. 1073–1078. doi: 10.1042/bst20160089.
- De Fazio, S. *et al.* (2011) 'The endonuclease activity of Mili fuels piRNA amplification that silences LINE1 elements', *Nature*, 480(7376), pp. 259–263. doi: 10.1038/nature10547.
- Dewannieux, M., Esnault, C. and Heidmann, T. (2003) 'LINE-mediated retrotransposition of marked Alu sequences', *Nature Genetics*, 35(1), pp. 41– 48. doi: 10.1038/ng1223.
- Dickson, S. P. *et al.* (2010) 'Rare Variants Create Synthetic Genome-Wide Associations', *PLoS Biology*, 8(1). doi: 10.1371/journal.pbio.1000294.
- Diehl, A. G., Ouyang, N. and Boyle, A. P. (2020) 'Transposable elements contribute to cell and species-specific chromatin looping and gene regulation in mammalian genomes', *Nature Communications*. Springer US, 11(1), pp. 1–18. doi: 10.1038/s41467-020-15520-5.
- Dolgin, E. S., & Charlesworth, B. (2008). The effects of recombination rate on the distribution and abundance of transposable elements. Genetics, 178(4), 2169– 2177. <u>https://doi.org/10.1534/genetics.107.082743</u>
- Dombroski, B. A. *et al.* (1991) 'Isolation of an active human transposable element', Science, 254(5039), pp. 1805–1808. doi: 10.1126/science.1662412.
- Doolittle WF, Sapienza C. (1980) 'Selfish genes, the phenotype paradigm and genome evolution', *Nature*, 284(5757), pp. 601–3. doi: 10.1038/284601a0.

- Doyle, G. A. *et al.* (2017) 'Analysis of LINE-1 elements in DNA from postmortem brains of individuals with schizophrenia', *Neuropsychopharmacology*. Nature Publishing Group, 42(13), pp. 2602–2611. doi: 10.1038/npp.2017.115.
- Ecker, E. D. and Skelly, A. C. (2010) 'Conducting a winning literature search', *Evid Based Spine Care J*, 1(1), pp. 9–14. doi: 10.1055/s-0028-1100887.
- Elbarbary, R. A., Lucas, B. A. and Maquat, L. E. (2016) 'Retrotransposons as regulators of gene expression', *Science*, 351(6274). doi: 10.1126/science.aac7247.
- Erwin, J. A., Marchetto, M. C., & Gage, F. H. (2014). Mobile DNA elements in the generation of diversity and complexity in the brain. Nature Reviews. Neuroscience, 15(8), 497–506. <u>https://doi.org/10.1038/nrn3730</u>
- Erwin, J. A. *et al.* (2016) 'L1-associated genomic regions are deleted in somatic cells of the healthy human brain', *Nature Neuroscience*, 19(12), pp. 1583–1591. doi: 10.1038/nn.4388.
- Escaramís, G., Docampo, E. and Rabionet, R. (2015) 'A decade of structural variants: Description, history and methods to detect structural variation', *Briefings in Functional Genomics*, 14(5), pp. 305–314. doi: 10.1093/bfgp/elv014.
- Evans, D. M. and Cardon, L. R. (2005) 'A comparison of linkage disequilibrium patterns and estimated population recombination rates across multiple populations', *American Journal of Human Genetics*, 76(4), pp. 681–687. doi: 10.1086/429274.
- Evrony, G. D. *et al.* (2012) 'Single-neuron sequencing analysis of I1 retrotransposition and somatic mutation in the human brain', *Cell.* Elsevier, 151(3), pp. 483–496. doi: 10.1016/j.cell.2012.09.035.
- Evrony, G. D. *et al.* (2015) 'Cell Lineage Analysis in Human Brain Using Endogenous Retroelements', *Neuron*, 85(1), pp. 49–59. doi: 10.1016/j.neuron.2014.12.028.
- Evrony, G. D. *et al.* (2016) 'Resolving rates of mutation in the brain using singleneuron genomics', eLife, 5(FEBRUARY2016), pp. 1–32. doi: 10.7554/eLife.12966.
- Ewing, A. D. and Kazazian, H. H. (2010) 'High-throughput sequencing reveals extensive variation in human-specific L1 content in individual human genomes High-throughput sequencing reveals extensive variation in human-specific L1 content in individual human genomes', *Genome Research*, 20(215), pp. 1262– 1270. doi: 10.1101/gr.106419.110.
- Ewing, A. D. and Kazazian, H. H. (2011) 'Whole-genome resequencing allows detection of many rare LINE-1 insertion alleles in humans', *Genome Research*, 21(6), pp. 985–990. doi: 10.1101/gr.114777.110.
- Ewing, A. D. (2015) 'Transposable element detection from whole genome sequence data', *Mobile DNA*. Mobile DNA, 6(1), p. 24. doi: 10.1186/s13100-015-0055-3.

- Faulkner, G. J. and Billon, V. (2018) 'L1 retrotransposition in the soma: A field jumping ahead', *Mobile DNA*. Mobile DNA, 9(1), pp. 1–18. doi: 10.1186/s13100-018-0128-1.
- Ferrari, R. *et al.* (2017) 'Genetic architecture of sporadic frontotemporal dementia and overlap with Alzheimer's and Parkinson's diseases', *Neurol Neurosurg Psychiatry*, 88(2), pp. 152–164. doi: 10.1136/jnnp-2016-314411.Genetic.
- Feschotte, C. (2008) 'The contribution of transposable elements of the evolution of regulatory networks', *Nature Reviews Genetics*, 9(5), pp. 397–405. doi: 10.1038/nrg2337.
- Feuk, L. *et al.* (2006) 'Structural variants: changing the landscape of chromosomes and design of disease studies.', *Human molecular genetics*, 15(1), pp. 57–66. doi: 10.1093/hmg/ddl057.
- Feusier, J. *et al.* (2017) 'Discovery of rare, diagnostic AluYb8/9 elements in diverse human populations', Mobile DNA. Mobile DNA, 8(1), pp. 21–23. doi: 10.1186/s13100-017-0093-0.
- Feusier, J. *et al.* (2019) 'Pedigree-based estimation of human mobile element retrotransposition rates', *Genome Research*, 29(10), pp. 1567–1577. doi: 10.1101/gr.247965.118.
- Fishilevich, S. *et al.* (2017) 'GeneHancer: genome-wide integration of enhancers and target genes in GeneCards', *Database : the journal of biological databases and curation*, 2017, pp. 1–17. doi: 10.1093/database/bax028.
- Flasch, D. A. *et al.* (2019) 'Genome-wide *de novo* L1 Retrotransposition Connects Endonuclease Activity with Replication', Cell, 177(4), pp. 837-851.e28. doi: 10.1016/j.cell.2019.02.050.
- Frank J. Massey, J. (1951) 'The Kolmogorov-Smirnov Test for Goodness of Fit', Journal of the American Statistical Association, 46(253), pp. 68–78. doi: https://doi.org/10.2307/2280095.
- Frayling, T. (2014) 'Genome-wide association studies: the good, the bad and the ugly', 14(4), pp. 428–431. Available at: <u>www.ebi.ac.uk/fgpt/gwas</u>.
- Fuhrman, S. A. *et al.* (1981) 'Analysis of transcription of the human alu family ubiquitous repeating element by eukaryotic RNA polymerase III', *Nucleic Acids Research*, 9(23), pp. 6439–6456. doi: 10.1093/nar/9.23.6439.
- Fullerton, S. M., Carvalho, A. B. and Clark, A. G. (2001) 'Local rates of recombination are positively correlated with GC content in the human genome [4]', Molecular Biology and Evolution, 18(6), pp. 1139–1142. doi: 10.1093/oxfordjournals.molbev.a003886.
- Gao, F. and Keinan, A. (2016) 'Explosive genetic evidence for explosive human population growth', *Current Opinion in Genetics and Development*. Elsevier Ltd, 41, pp. 130–139. doi: 10.1016/j.gde.2016.09.002.

- Garcia-Perez, J. L. *et al.* (2010) 'Epigenetic silencing of engineered L1 retrotransposition events in human embryonic carcinoma cells', *Nature*. Nature Publishing Group, 466(7307), pp. 769–773. doi: 10.1038/nature09209.
- Garcia-Perez, J. L., Widmann, T. J. and Adams, I. R. (2016) 'The impact of transposable elements on mammalian development', *Development*, 143(22), pp. 4101–4114. doi: 10.1242/dev.132639.
- Gardner, E. J. *et al.* (2017) 'The Mobile Element Locator Tool (MELT): populationscale mobile element discovery and biology', *Genome Research*, 27, pp. 1916– 1929. doi: 10.1101/gr.218032.116.Freely.
- Gardner EJ, Prigmore E, Gallone G, Danecek P, Samocha KE, Handsaker J, Gerety SS, Ironfield H, Short PJ, Sifrim A, Singh T, Chandler KE, Clement E, Lachlan KL, Prescott K, Rosser E, FitzPatrick DR, Firth HV, H. M. (2019) 'Contribution of Retrotransposition to Developmental Disorders', Nature Communications, 10(1). doi: 10.1038/s41467-019-12520-y.
- Gasior, S. L. *et al.* (2006) 'The human LINE-1 retrotransposon creates DNA doublestrand breaks', *Journal of Molecular Biology*, 357(5), pp. 1383–1393. doi: 10.1016/j.jmb.2006.01.089.
- Gasior, S. L. *et al.* (2007) 'Characterization of pre-insertion loci of *de novo* L1 insertions', *Gene*, 390(1–2), pp. 190–198. doi: 10.1016/j.gene.2006.08.024.
- Gazave, E. *et al.* (2013) 'Population growth inflates the per-individual number of deleterious mutations and reduces their mean effect', *Genetics*, 195(3), pp. 969–978. doi: 10.1534/genetics.113.153973.
- Gianfrancesco, O., Bubb, V. J., & Quinn, J. P. (2017). SVA retrotransposons as potential modulators of neuropeptide gene expression. Neuropeptides, 64, 3–7. https://doi.org/10.1016/j.npep.2016.09.006
- Gianfrancesco, O., Geary, B., Savage, A. L., Billingsley, K. J., Bubb, V. J., & Quinn, J. P. (2019). The role of SINE-VNTR-Alu (SVA) retrotransposons in shaping the human genome. International Journal of Molecular Sciences, 20(23), 1–17. <u>https://doi.org/10.3390/ijms20235977</u>
- Gibson, G. (2012) 'Rare and common variants: Twenty arguments', *Nature Reviews Genetics*. Nature Publishing Group, 13(2), pp. 135–145. doi: 10.1038/nrg3118.
- Goerner-potvin, P. and Bourque, G. (2018) 'Computational tools to unmask transposable elements', *Nature Reviews Genetics*. Springer US, 19(November), pp. 688–704. doi: 10.1038/s41576-018-0050-x.
- Goodier, J. L. (2016) 'Restricting retrotransposons: A review', *Mobile DNA*. Mobile DNA, 7(1). doi: 10.1186/s13100-016-0070-z.
- Graham, T. and Boissinot, S. (2006) 'The genomic distribution of L1 elements: The role of insertion bias and natural selection', Journal of Biomedicine and Biotechnology, 2006, pp. 1–5. doi: 10.1155/JBB/2006/75327.

- Gravel, S. *et al.* (2011) 'Demographic history and rare allele sharing among human populations', *Proceedings of the National Academy of Sciences of the United States of America*, 108(29), pp. 11983–11988. doi: 10.1073/pnas.1019276108.
- Gregory, T. R. (2005) 'Synergy between sequence and size in Large-scale genomics', Nature Reviews Genetics. Nature Publishing Group, 6, p. 699. Available at: <u>http://dx.doi.org/10.1038/nrg1674</u>.
- Grover, D. *et al.* (2004) 'Alu repeat analysis in the complete human genome: Trends and variations with respect to genomic composition', Bioinformatics, 20(6), pp. 813–817. doi: 10.1093/bioinformatics/bth005.
- Gu, Z. *et al.* (2000) 'Densities, length proportions, and other distributional features of repetitive sequences in the human genome estimated from 430 megabases of genomic sequence', Gene, 259(1–2), pp. 81–88. doi: 10.1016/S0378-1119(00)00434-0.
- Guffanti, G. *et al.* (2014) 'Transposable elements and psychiatric disorders', *American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics*, 165B(3). doi: 10.1002/ajmg.b.32225.
- Guffanti, G. et al. (2016) 'LINE1 insertions as a genomic risk factor for schizophrenia: Preliminary evidence from an affected family', American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics, 171(4), pp. 534–545. doi: 10.1002/ajmg.b.32437.
- Ha, H., Loh, J. W. and Xing, J. (2016) 'Identification of polymorphic SVA retrotransposons using a mobile element scanning method for SVA (ME-Scan-SVA)', *Mobile DNA*. Mobile DNA, 7(1), pp. 15–17. doi: 10.1186/s13100-016-0072-x.
- Hackenberg, M. *et al.* (2005) 'The biased distribution of Alus in human isochores might be driven by recombination', Journal of Molecular Evolution, 60(3), pp. 365–377. doi: 10.1007/s00239-004-0197-2.
- Han, K. *et al.* (2005) 'Genomic rearrangements by LINE-1 insertion-mediated deletion in the human and chimpanzee lineages', *Nucleic Acids Research*, 33(13), pp. 4040–4052. doi: 10.1093/nar/gki718.
- Hancks, D. C. *et al.* (2011) 'Retrotransposition of marked SVA elements by human L1s in cultured cells', *Human Molecular Genetics*, 20(17), pp. 3386–3400. doi: 10.1093/hmg/ddr245.
- Hancks, D. C., Kazazian, H. H. and Jr. (2016) 'Roles for retrotransposon insertions in human disease.', *Mobile DNA*. Mobile DNA, 7, p. 9. doi: 10.1186/s13100-016-0065-9.
- Hehir-Kwa, J. Y. *et al.* (2016) 'A high-quality human reference panel reveals the complexity and distribution of genomic structural variants', *Nature Communications*, 7, pp. 1–10. doi: 10.1038/ncomms12989.

- Helman, E. *et al.* (2014) 'Somatic retrotransposition in human cancer revealed by whole-genome and exome sequencing', *Genome Research*, 24(7), pp. 1053–1063. doi: 10.1101/gr.163659.113.
- Henry L. Levin, John V. Moran. (2014). Dynamic interactions between transposable elements and their hosts. (August 2011). <u>https://doi.org/10.1038/nrg3030</u>
- Higashino, S. *et al.* (2014) 'Polymorphic L1 retrotransposons are frequently in strong linkage disequilibrium with neighboring SNPs', *Gene.* Elsevier B.V., 541(1), pp. 55–59. doi: 10.1016/j.gene.2014.03.008.
- Hindorff, L. A. *et al.* (2009) 'Potential etiologic and functional implications of genomewide association loci for human diseases and traits', *PNAS*, 106(23), pp. 9362– 7. doi: 10.1073/pnas.0903103106.
- Hormozdiari, F. *et al.* (2011) 'Alu repeat discovery and characterization within human genomes', Genome Research, 21(6), pp. 840–849. doi: 10.1101/gr.115956.110.
- Hormozdiari, Farhad *et al.* (2019) 'Functional disease architectures reveal unique biological role of transposable elements', *Nature Communications*. Springer US, 10(1). doi: 10.1038/s41467-019-11957-5.
- Hu, Z., Wang, Z. and Xu, S. (2012) 'An infinitesimal model for quantitative trait genomic value prediction', *PLoS ONE*, 7(7), pp. 1–14. doi: 10.1371/journal.pone.0041336.
- Huang, C. R. L. et al. (2010) 'Mobile interspersed repeats are major structural variants in the human genome', Cell. Elsevier Ltd, 141(7), pp. 1171–1182. doi: 10.1016/j.cell.2010.05.026.
- Iskow, R. C. *et al.* (2010) 'Natural mutagenesis of human genomes by endogenous retrotransposons', *Cell.* Elsevier Ltd, 141(7), pp. 1253–1261. doi: 10.1016/j.cell.2010.05.020.
- Jacobs, F. M. J., Greenberg, D., Nguyen, N., Haeussler, M., Ewing, A. D., Katzman, S., Haussler, D. (2014). An evolutionary arms race between KRAB zinc-finger genes ZNF91/93 and SVA/L1 retrotransposons. Nature, 516(7530), 242–245. <u>https://doi.org/10.1038/nature13760</u>
- Jacques, P.-E., Jeyakani, J. and Bourque, G. (2013) 'The Majority of Primate-Specific Regulatory Sequences Are Derived from Transposable Elements', *PLoS Genetics*, 9(5). doi: 10.1371/journal.pgen.1003504.
- Jiang, T. *et al.* (2019) 'RMETL: Sensitive mobile element insertion detection with long read realignment', *Bioinformatics*, 35(18), pp. 3484–3486. doi: 10.1093/bioinformatics/btz106.
- Jeggo, P. A. and Löbrich, M. (2007) 'DNA double-strand breaks: Their cellular and clinical impact?', *Oncogene*, 26(56), pp. 7717–7719. doi: 10.1038/sj.onc.1210868.

- Johnson, N. and Joseph, L. (2012) 'The genetics of sex chromosomes: evolution and implications for hybrid incompatibility', *Bone*, 1256(1), pp. E1-22. doi: 10.1111/j.1749-6632.2012.06748.x.
- Johnson, R. and Guigó, R. (2014) 'The RIDL hypothesis: Transposable elements as functional domains of long noncoding RNAs', *Rna*, 20(7), pp. 959–976. doi: 10.1261/rna.044560.114.
- Jordan, I. K. *et al.* (2003) 'Origin of a substantial fraction of human regulatory sequences from transposable elements', *Trends in Genetics*, 19(2), pp. 68–72. doi: 10.1016/S0168-9525(02)00006-9.
- Jung, I. (2017) 'Some facts that you might be unaware of about the P-value', Archives of Plastic Surgery, 44(2), pp. 93–94. doi: 10.5999/aps.2017.44.2.93.
- Jurka, J. and Smith, T. (1988) 'A fundamental division in the Alu family of repeated sequences', *Proceedings of the National Academy of Sciences of the United States of America*, 85(13), pp. 4775–4778. doi: 10.1073/pnas.85.13.4775.
- Jurka, J. *et al.* (2004) 'Duplication, coclustering, and selection of human Alu retrotransposons', Proceedings of the National Academy of Sciences of the United States of America, 101(5), pp. 1268–1272. doi: 10.1073/pnas.0308084100.
- Karolchik, D. (2004) 'The UCSC Table Browser data retrieval tool', *Nucleic Acids Research*, 32(90001), pp. 493D 496. doi: 10.1093/nar/gkh103.
- Kawamura, Y. *et al.* (2011) 'A genome-wide CNV association study on panic disorder in a Japanese population', *Journal of Human Genetics*. Nature Publishing Group, 56(12), pp. 852–856. doi: 10.1038/jhg.2011.117.
- Kazazian HH Jr, Wong C, Youssoufian H, Scott AF, Phillips DG, A. S. (1988) 'Haemophilia A resulting from *de novo* insertion of L1 sequences represents a novel mechanism for mutation in man', *Nature*, 332(6160), pp. 164–6.
- Kazazian, H. H. (2004) 'Mobile elements: drivers of genome evolution.' *Science*, 303(5664), pp. 1626–32. doi: 10.1126/science.1089670.
- Keinan, A. and Clark, A. G. (2012) 'Recent explosive human population growth has resulted in an excess of rare genetic variants.' *Science*, 336(6082), pp. 740–3. doi: 10.1126/science.1217283.
- Kelley, D. and Rinn, J. (2012) 'Transposable elements reveal a stem cell-specific class of long noncoding RNAs', *Genome biology*, 13(11), p. R107. doi: 10.1186/gb-2012-13-11-r107.
- Kent, T. V., Uzunović, J. and Wright, S. I. (2017) 'Coevolution between transposable elements and recombination', Philosophical Transactions of the Royal Society B: Biological Sciences, 372(1736). doi: 10.1098/rstb.2016.0458.

- Kidwell MG, Lisch DR (2001) 'Perspective: transposable elements, parasitic dna, and genome evolution', *Evolution*, 55(1), pp. 1–24. doi: 10.1111/j.0014-3820.2001.tb01268.x.
- Kleckner, N. (1981) 'Transposable elements in prokaryotes.' *Annu Rev Genet*, 15, pp. 341–404. doi: 10.1146/annurev.ge.15.120181.002013.
- Kloosterman, W. P. *et al.* (2015) 'Characteristics of *de novo* structural changes in the human genome', *Genome Research*, 25(6), pp. 792–801. doi: 10.1101/gr.185041.114.
- Kong, A. *et al.* (2010) 'Fine-scale recombination rate differences between sexes, populations and individuals', *Nature*. Nature Publishing Group, 467(7319), pp. 1099–1103. doi: nature09525 [pii]\r10.1038/nature09525.
- Kong, A., Gudbjartsson, D. F., Sainz, J., Jonsdottir, G. M., Gudjonsson, S. A., Richardsson, B., Stefansson, K. (2002). A high-resolution recombination map of the human genome. Nature Genetics, 31(3), 241–247. <u>https://doi.org/10.1038/ng917</u>
- Konkel, M. K. *et al.* (2015) 'Sequence analysis and characterization of active human alu subfamilies based on the 1000 genomes pilot project', *Genome Biology and Evolution*, 7(9), pp. 2608–2622. doi: 10.1093/gbe/evv167.
- Koolen, D. A. *et al.* (2016) 'The Koolen-de Vries syndrome: A phenotypic comparison of patients with a 17q21.31 microdeletion versus a KANSL1 sequence variant', *European Journal of Human Genetics*, 24(5), pp. 652–659. doi: 10.1038/ejhg.2015.178.
- Kornienko, A. E. et al. (2013) 'Gene regulation by the act of long non-coding', BMC Biology, 11(59), pp. 1–14.
- Kuhn, A. et al. (2014) 'Linkage disequilibrium and signatures of positive selection around LINE-1 retrotransposons in the human genome', Proceedings of the National Academy of Sciences of the United States of America, 111(22), pp. 8131–6. doi: 10.1073/pnas.1401532111.
- Kurnosov, A. A., Ustyugova, S. V and Nazarov, V. I. (2015) 'The Evidence for Increased L1 Activity in the Site of Human Adult Brain Neurogenesis', *PLoS ONE*, 10(2), p. e0117854. doi: 10.1371/journal.pone.0117854.
- Kvikstad, E. M. and Makova, K. D. (2010) 'The (r) evolution of SINE versus LINE distributions in primate genomes : Sex chromosomes are important', *Genome Research*, 20, pp. 600–613. doi: 10.1101/gr.099044.109.1.
- Kwon, Y., Choi, Y., Eo, J., Noh, Y., Gim, J., Jung, Y., Kim, H. (2013). Structure and Expression Analyses of SVA Elements in Relation to Functional Genes. 11(3), 142–148.
- Lacaria, M., Gu, W. and Lupski, J. R. (2013) 'A functional role for structural variation in metabolism', *Adipocyte*, 2(1), pp. 55–57. doi: 10.4161/adip.22031.

- Lall, A. (2015) 'Data streaming algorithms for the Kolmogorov-Smirnov test', *Proceedings - 2015 IEEE International Conference on Big Data, IEEE Big Data* 2015, pp. 95–104. doi: 10.1109/BigData.2015.7363746.
- Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J., International Human Genome Sequencing, C. (2001). Initial sequencing and analysis of the human genome. Nature, 409(6822), 860–921. https://doi.org/10.1038/35057062
- Lee, J. *et al.* (2012) 'Human Genomic Deletions Generated by SVA-Associated Events', *Comparative and Functional Genomics*, 2012. doi: 10.1155/2012/807270.
- Lev-Maor, G. *et al.* (2008) 'Intronic Alus influence alternative splicing', *PLoS Genetics*, 4(9), pp. 1–12. doi: 10.1371/journal.pgen.1000204.
- Li, H. and Durbin, R. (2009) 'Fast and accurate short read alignment with Burrows-Wheeler transform', *Bioinformatics*, 25(14), pp. 1754–1760. doi: 10.1093/bioinformatics/btp324.
- Li, R. *et al.* (2009) 'SOAP2: An improved ultrafast tool for short read alignment', Bioinformatics, 25(15), pp. 1966–1967. doi: 10.1093/bioinformatics/btp336.
- Li, Y. *et al.* (2014) 'An Epigenetic Signature in Peripheral Blood Associated with the Haplotype on 17q21.31, a Risk Factor for Neurodegenerative Tauopathy', *PLoS Genetics*, 10(3). doi: 10.1371/journal.pgen.1004211.
- Liu, Z. *et al.* (2013) 'Negative life events and corticotropin-releasing-hormone receptor1 gene in recurrent major depressive disorder', *Scientific Reports*, 3, pp. 1–5. doi: 10.1038/srep01548.
- Loewe, L. (2008) Negative selection. Nature Education 1(1):59. Available at: [https://www.nature.com/scitable/topicpage/negative-selection-1136/] (Accessed: 22 June 2019).
- Lowe, C. B. and Haussler, D. (2012) '29 Mammalian Genomes Reveal Novel Exaptations of Mobile Elements for Likely Regulatory Functions in the Human Genome', *PLoS ONE*, 7(8). doi: 10.1371/journal.pone.0043128.
- Lu, H., Giordano, F. and Ning, Z. (2016) 'Oxford Nanopore MinION Sequencing and Genome Assembly', Genomics, Proteomics and Bioinformatics. Beijing Institute of Genomics, Chinese Academy of Sciences and Genetics Society of China, 14(5), pp. 265–279. doi: 10.1016/j.gpb.2016.05.004.
- Lutz, S. M. *et al.* (2003) 'Allelic Heterogeneity in LINE-1 Retrotransposition Activity', *The American Journal of Human Genetics*, 73(6), pp. 1431–1437. doi: 10.1086/379744.
- Lynch, V. J. *et al.* (2011) 'Transposon-mediated rewiring of gene regulatory networks contributed to the evolution of pregnancy in mammals', *Nature Genetics.* Nature Publishing Group, 43(11), pp. 1154–1159. doi: 10.1038/ng.917.

- Lynch, V. J. *et al.* (2015) 'Ancient transposable elements transformed the uterine regulatory landscape and transcriptome during the evolution of mammalian pregnancy', *Cell Reports*, 10(4), pp. 551–561. doi: 10.1016/j.celrep.2014.12.052.
- Maher, B. (2008) 'Personal genomes: The case of the missing heritability', *Nature*, 456(7218), pp. 18–21. doi: 10.1038/456018a.
- Malhotra, D. and Sebat, J. (2012) 'CNVs: Harbingers of a rare variant revolution in psychiatric genetics', *Cell*. Elsevier Inc., 148(6), pp. 1223–1241. doi: 10.1016/j.cell.2012.02.039.
- Mamedov, I. Z. *et al.* (2005) 'Whole-genome experimental identification of insertion/deletion polymorphisms of interspersed repeats by a new general approach.', Nucleic acids research, 33(2). doi: 10.1093/nar/gni018.
- Manolio TA, Collins FS, Cox NJ, Goldstein DB, *et al.* (2009) 'Finding the missing heritability of complex diseases', *Nature*, 461(7265), pp. 747–753. doi: 10.1038/nature08494.
- McClintock, B. (1956) 'Intranuclear systems controlling gene action and mutation.' *Brookhaven Symp Biol*, 8, pp. 58–74.
- McLeod, S. A. (2019, May 17). Z-score: definition, calculation and interpretation. Simply Psychology. <u>https://www.simplypsychology.org/z-score.html</u>
- Medina-Gomez, C. *et al.* (2015) 'Challenges in conducting genome-wide association studies in highly admixed multi-ethnic populations: the Generation R Study', *European Journal of Epidemiology*, 30(4), pp. 317–330. doi: 10.1007/s10654-015-9998-4.
- Medstrand, P., Lagemaat, L. N. Van De and Mager, D. L. (2002) 'Retroelement Distributions in the Human Genome : Variations Associated With Age and Proximity to Genes Distributions of Retroelements in Different', *Cold Spring Harbor Press*, 12, pp. 1483–1495. doi: 10.1101/gr.388902.5.
- Mills, R. E. *et al.* (2007) 'Which transposable elements are active in the human genome?', Trends in Genetics, 23(4), pp. 183–191. doi: 10.1016/j.tig.2007.02.006.
- Mir, A. A., Philippe, C. and Cristofari, G. (2014) 'euL1db: The European database of L1HS retrotransposon insertions in humans', Nucleic Acids Research. doi: 10.1093/nar/gku1043.
- Moran, J. V. *et al.* (1996) 'High frequency retrotransposition in cultured mammalian cells', *Cell*, 87(5), pp. 917–927. doi: 10.1016/S0092-8674(00)81998-4.
- Mugal, C. F., Weber, C. C., & Ellegren, H. (2015). GC-biased gene conversion links the recombination landscape and demography to genomic base composition: GC-biased gene conversion drives genomic base composition across a wide range of species. BioEssays, 37(12), 1317–1326. https://doi.org/10.1002/bies.201500058

- Munoz-Lopez, M. and Garcia-Perez, J. (2010) 'DNA Transposons: Nature and Applications in Genomics', *Current Genomics*, 11(2), pp. 115–128. doi: 10.2174/138920210790886871.
- Myers, J. S. *et al.* (2002) 'A Comprehensive Analysis of Recently Integrated Human Ta L1 Elements', *The American Journal of Human Genetics*, 71(2), pp. 312– 326. doi: 10.1086/341718.
- Myers, S. *et al.* (2008) 'A common sequence motif associated with recombination hot spots and genome instability in humans', Nature Genetics, 40(9), pp. 1124–1129. doi: 10.1038/ng.213.
- Nazaryan-Petersen, L. *et al.* (2016) 'Germline Chromothripsis Driven by L1-Mediated Retrotransposition and Alu/Alu Homologous Recombination', *Human Mutation*, 37(4), pp. 385–395. doi: 10.1002/humu.22953.
- Nelson, M. R. *et al.* (2004) 'Large-scale validation of single nucleotide polymorphisms in gene regions', *Genome Research*, 14(8), pp. 1664–1668. doi: 10.1101/gr.2421604.
- Nelson, M. G., Linheiro, R. S. and Bergman, C. M. (2017) 'McClintock: An integrated pipeline for detecting transposable element insertions in whole-genome shotgun sequencing data', *G3: Genes, Genomes, Genetics*, 7(8), pp. 2763–2778. doi: 10.1534/g3.117.043893.
- Nigumann, P. *et al.* (2002) 'Many human genes are transcribed from the antisense promoter of L1 retrotransposon', *Genomics*, 79(5), pp. 628–634. doi: 10.1006/geno.2002.6758.
- Ngamphiw, C., Tongsima, S. and Mutirangura, A. (2014) 'Roles of intragenic and intergenic L1s in mouse and human', PLoS ONE, 9(11), pp. 1–8. doi: 10.1371/journal.pone.0113434.
- Nguyen, T. H. M. *et al.* (2018) 'L1 Retrotransposon Heterogeneity in Ovarian Tumor Cell Evolution', Cell Reports. ElsevierCompany., 23(13), pp. 3730–3740. doi: 10.1016/j.celrep.2018.05.090.
- North, B. V., Curtis, D., & Sham, P. C. (2002). A note on the calculation of empirical P values from Monte Carlo procedures. *American journal of human genetics*, 71(2), 439–441. https://doi.org/10.1086/341527.
- O'Leary, N. A. *et al.* (2016) 'Reference sequence (RefSeq) database at NCBI: Current status, taxonomic expansion, and functional annotation', Nucleic Acids Research, 44(D1), pp. D733–D745. doi: 10.1093/nar/gkv1189.
- Orgel LE. Crick FH. (1980) 'Selfish DNA: the ultimate parasite', *Nature*, 284(5757), pp. 604–7. doi: 10.1038/284604a0.
- Ostertag, E. M. *et al.* (2003) 'SVA Elements Are Nonautonomous Retrotransposons that Cause Disease in Humans', The American Journal of Human Genetics, 73(6), pp. 1444–1451. doi: 10.1086/380207.

- Otieno, A. C. *et al.* (2004) 'Analysis of the human Alu Ya-lineage', Journal of Molecular Biology, 342(1), pp. 109–118. doi: 10.1016/j.jmb.2004.07.016.
- Ovchinnikov, I. *et al.* (2001) 'Genomic Characterization of Recent Human LINE-1 Insertions : Evidence Supporting Random Insertion Genomic Characterization of Recent Human LINE-1 Insertions : Evidence Supporting Random Insertion', *Genome Research*, pp. 2050–2058. doi: 10.1101/gr.194701.
- Paterson, A. L. *et al.* (2015) 'Mobile element insertions are frequent in oesophageal adenocarcinomas and can mislead paired-end sequencing analysis', *BMC Genomics*. BMC Genomics, 16(1), p. 473. doi: 10.1186/s12864-015-1685-z.
- Patil, V. S., Zhou, R. and Rana, T. M. (2014) 'Gene regulation by noncoding RNAs Veena', Crit Rev Biochem Mol Biol, 25(3), pp. 289–313. doi: 10.3109/10409238.2013.844092.Gene.
- Patrushev, L. I. and Kovalenko, T. F. (2014) 'Functions of noncoding sequences in mammalian genomes', Biochemistry (Moscow), 79(13), pp. 1442–1469. doi: 10.1134/S0006297914130021.
- Pavlíček, A. *et al.* (2001) 'Similar integration but different stability of Alus and LINEs in the human genome', Gene, 276(1–2), pp. 39–45. doi: 10.1016/S0378-1119(01)00645-X.
- Payer, L. M. et al. (2017) 'Structural variants caused by Alu insertions are associated with risks for many human diseases', *Proceedings of the National Academy of Sciences*, 114(20), pp. E3984–E3992. doi: 10.1073/pnas.1704117114.
- Payer, L. M. *et al.* (2019) 'Alu insertion variants alter mRNA splicing', *Nucleic Acids Research*. Oxford University Press, 47(1), pp. 1–11. doi: 10.1093/nar/gky1086.
- Perepelitsa-Belancio, V. and Deininger, P. (2003) 'RNA truncation by premature polyadenylation attenuates human mobile element activity', *Nature Genetics*, 35(4), pp. 363–366. doi: 10.1038/ng1269.
- Pers, T. H., Timshel, P. and Hirschhorn, J. N. (2015) 'SNPsnap: A Web-based tool for identification and annotation of matched SNPs', *Bioinformatics*, 31(3), pp. 418–420. doi: 10.1093/bioinformatics/btu655.
- Platt, R. N., Vandewege, M. W. and Ray, D. A. (2018) 'Mammalian transposable elements and their impacts on genome evolution', *Chromosome Research*. Chromosome Research, 26(1–2), pp. 25–43. doi: 10.1007/s10577-017-9570-z.
- Pontis, J., Planet, E., Offner, S., Turelli, P., Duc, J., Coudray, A., Trono, D. (2019). Hominoid-Specific Transposable Elements and KZFPs Facilitate Human Embryonic Genome Activation and Control Transcription in Naive Human ESCs. Cell Stem Cell, 24(5), 724-735.e5. https://doi.org/10.1016/j.stem.2019.03.012

- Price, A. L., Eskin, E. and Pevzner, P. A. (2004) 'Whole-genome analysis of Alu repeat elements reveals complex evolutionary history', Genome Research, 14(11), pp. 2245–2252. doi: 10.1101/gr.2693004.
- Purcell, S. *et al.* (2007) 'PLINK : A Tool Set for Whole-Genome Association and Population-Based Linkage Analyses', *The American Journal of Human Genetics*, 81(September), pp. 559–575. doi: 10.1086/519795.
- Qin, S. *et al.* (2015) 'The role of transposable elements in the origin and evolution of microRNAs in human', *PLoS ONE*, 10(6), pp. 1–10. doi: 10.1371/journal.pone.0131365.
- Quail, M. A. et al. (2012) 'A tale of three next generation sequencing platforms: comparison of Ion Torrent, Pacific Biosciences and Illumina MiSeq sequencers', BMC Genomics, 13(341), p. 13.
- Quinlan, A. R. (2014) BEDTools: The Swiss-Army tool for genome feature analysis, Current Protocols in Bioinformatics. doi: 10.1002/0471250953.bi1112s47.
- Quinn, J. P. and Bubb, V. J. (2014) 'SVA retrotransposons as modulators of gene expression', Mobile Genetic Elements, 4, p. e32102. doi: 10.4161/mge.32102.
- Quinn, J. J. and Chang, H. Y. (2016) 'Unique features of long non-coding RNA biogenesis and function', Nature Reviews Genetics. Nature Publishing Group, 17(1), pp. 47–62. doi: 10.1038/nrg.2015.10.
- R Core Team (2017). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https://www.Rproject.org/.
- Raiz, J. *et al.* (2012) 'The non-autonomous retrotransposon SVA is trans -mobilized by the human LINE-1 protein machinery', Nucleic Acids Research, 40(4), pp. 1666–1683. doi: 10.1093/nar/gkr863.
- Ravindran, S. (2012) 'Barbara McClintock and the discovery of jumping genes.' Proceedings of the National Academy of Sciences of the United States of America, 109(50), pp. 20198–20199. doi: 10.1073/pnas.1219372109.
- Reilly, M. T. et al. (2013) 'The role of transposable elements in health and diseases of the central nervous system.', *The Journal of neuroscience : the official journal* of the Society for Neuroscience, 33(45), pp. 17577–86. doi: 10.1523/JNEUROSCI.3369-13.2013.
- Rhoads, A. and Au, K. F. (2015) 'PacBio Sequencing and Its Applications', Genomics, Proteomics and Bioinformatics. Beijing Institute of Genomics, Chinese Academy of Sciences and Genetics Society of China, 13(5), pp. 278– 289. doi: 10.1016/j.gpb.2015.08.002.
- Rishishwar, L., Tellez Villa, C. E. and Jordan, I. K. (2015) 'Transposable element polymorphisms recapitulate human evolution.', *Mobile DNA*. Mobile DNA, 6, p. 21. doi: 10.1186/s13100-015-0052-6.

- Rishishwar, L., Mariño-Ramírez, L. and Jordan, I. K. (2016) 'Benchmarking computational tools for polymorphic transposable element detection', Briefings in Bioinformatics, (April), p. bbw072. doi: 10.1093/bib/bbw072.
- Roadmap Epigenomics Consortium *et al.* (2015) 'Integrative analysis of 111 reference human epigenomes', *Nature*, 518, pp. 317–330. doi: 10.1038/nature14248.
- Rouchka, E. *et al.* (2010) 'Assessment of genetic variation for the LINE-1 retrotransposon from next generation sequence data', *BMC Bioinformatics*, 11(SUPPL. 9), p. S12. doi: 10.1186/1471-2105-11-S9-S12.
- Rowe, S.J. and Tenesa, A. (2012) 'Human Complex Trait Genetics: Lifting the Lid of the Genomics Toolbox - from Pathways to Prediction', *Current Genomics*, 13(3), pp. 213–224. doi: 10.2174/138920212800543101.
- Saleh, A., Macia, A. and Muotri, A. R. (2019) 'Transposable elements, inflammation, and neurological disease', Frontiers in Neurology, 10. doi: 10.3389/fneur.2019.00894.
- Salvatore Mangiafico (2021). rcompanion: Functions to Support Extension Education Program Evaluation. R package version <u>https://CRAN.R-project.org/package=rcompanion</u>.
- Savage, A. L., Bubb, V. J., Breen, G., & Quinn, J. P. (2013). Characterisation of the potential function of SVA retrotransposons to modulate gene expression patterns. BMC Evolutionary Biology, 13(1). <u>https://doi.org/10.1186/1471-2148-13-101</u>
- Savage, A. L. *et al.* (2019) 'Retrotransposons in the development and progression of amyotrophic lateral sclerosis', *Journal of Neurology, Neurosurgery and Psychiatry*, 90(3), pp. 284–293. doi: 10.1136/jnnp-2018-319210.
- Schauer, S. N. *et al.* (2018) 'L1 retrotransposition is a common feature of mammalian hepatocarcinogenesis', *Genome Research*, 28(5), pp. 639–653. doi: 10.1101/gr.226993.117.
- Schizophrenia Working Group of the Psychiatric Genomics Consortium (2014) 'Biological insights from 108 schizophrenia-associated genetic loci', *Nature*, 511. doi: 10.1038/nature13595.
- Scott, E. C. and Devine, S. E. (2017) 'The role of somatic L1 retrotransposition in human cancers', Viruses, 9(6), pp. 1–19. doi: 10.3390/v9060131.
- Sheen, F. *et al.* (2000) 'Reading between the LINEs : Human Genomic Variation Induced by LINE-1 Retrotransposition', *Genome Research*, 10, pp. 1496–1508. doi: 10.1101/gr.149400.
- Shen, L. et al. (1994) 'Structure and genetics of the partially duplicated gene RP located immediately upstream of the complement C4A and the C4B genes in the HLA class III region', *Journal of Biological Chemistry*, 269(11), pp. 8466– 8476. doi: 10.1016/s0021-9258(17)37217-4.

- Shiina, T. *et al.* (2009) 'The HLA genomic loci map: Expression, interaction, diversity and disease', *Journal of Human Genetics*, 54(1), pp. 15–39. doi: 10.1038/jhg.2008.5.
- Shin, W. *et al.* (2019) 'Novel discovery of line-1 in a korean individual by a target enrichment method', *Molecules and Cells*, 42(1), pp. 87–95. doi: 10.14348/molcells.2018.0351.
- Shorter, E. (2017) 'Current research into the association between DNA copy number variation (CNV) and obesity', *Bioscience Horizons: The International Journal of Student Research*, 10, pp. 1–8. doi: 10.1093/biohorizons/hzx014.
- Shukla, R. et al. (2013) 'Endogenous retrotransposition activates oncogenic pathways in hepatocellular carcinoma', Cell, 153(1), pp. 101–111. doi: 10.1016/j.cell.2013.02.032.
- Smalheiser, NR. Torvik, VI. (2005) 'Mammalian microRNAs derived from genomic repeats', *Trends in Genetics*, 21(6), pp. 322–326. doi: 10.1016/j.tig.2005.04.008.
- Smit, A. F. A. (1996) 'The origin of interspersed repeats in the human genome', Current Opinion in Genetics and Development, 6(6), pp. 743–748. doi: 10.1016/S0959-437X(96)80030-X.
- Smit, A. F. (1999) 'Interspersed repeats and other mementos of transposable elements in mammalian genomes', Current Opinion in Genetics and Development, 9(6), pp. 657–663. doi: 10.1016/S0959-437X(99)00031-3.
- Smoller, J. W. (2016) 'The Genetics of Stress-Related Disorders: PTSD, Depression, and Anxiety Disorders', *Neuropsychopharmacology*. Nature Publishing Group, 41(1), pp. 297–319. doi: 10.1038/npp.2015.266.
- Song, M. and Boissinot, S. (2007) 'Selection against LINE-1 retrotransposons results principally from their ability to mediate ectopic recombination', *Gene*, 390(1–2), pp. 206–213. doi: 10.1016/j.gene.2006.09.033.
- Soriano, P., Meunier-Rotival, M. and Bernardi, G. (1983) 'The distribution of interspersed repeats is nonuniform and conserved in the mouse and human genomes.', *Proceedings of the National Academy of Sciences of the United States of America*, 80(7), pp. 1816–20. doi: 10.1073/pnas.80.7.1816.
- Spiegel, J., Adhikari, S., & Balasubramanian, S. (2020). The Structure and Function of DNA G-Quadruplexes. Trends in Chemistry, 2(2), 123–136. https://doi.org/10.1016/j.trechm.2019.07.002
- Spirito, G. *et al.* (2019) 'Impact of polymorphic transposable elements on transcription in lymphoblastoid cell lines from public data', *BMC Bioinformatics*. BMC Bioinformatics, 20(Suppl 9), pp. 1–13. doi: 10.1186/s12859-019-3113-x.
- Stankiewicz, P. Lupski, J. (2010) 'Structural variation in the human genome and its role in disease', *Annu Rev Med*, 61, pp. 437–455. doi: 10.1146/annurev-med-100708-204735.

- Startek, M. *et al.* (2015) 'Genome-wide analyses of LINE-LINE-mediated nonallelic homologous recombination', Nucleic Acids Research, 43(4), pp. 2188–2198. doi: 10.1093/nar/gku1394.
- Stewart, C. *et al.* (2011) 'A comprehensive map of mobile element insertion polymorphisms in humans', *PLoS Genetics*, 7(8). doi: 10.1371/journal.pgen.1002236.
- Streva, V. A. *et al.* (2015) 'Sequencing, identification and mapping of primed L1 elements (SIMPLE) reveals significant variation in full length L1 elements between individuals', BMC Genomics, 16. doi: 10.1186/s12864-015-1374-y.
- Su, M., Han, D., Boyd-kirkup, J., Yu, X., & Han, J. J. (2014). Report Evolution of Alu Elements toward Enhancers. CellReports, 7(2), 376–385. https://doi.org/10.1016/j.celrep.2014.03.011
- Sudmant, P. H. *et al.* (2015) 'An integrated map of structural variation in 2,504 human genomes', *Nature*, 526(7571), pp. 75–81. doi: 10.1038/nature15394.
- Sultana, T., van Essen, D., Siol, O., Bailly-Bechet, M., Philippe, C., Zine El Aabidine, A., Cristofari, G. (2019). The Landscape of L1 Retrotransposons in the Human Genome Is Shaped by Pre-insertion Sequence Biases and Post-insertion Selection. Molecular Cell, 74(3), 555-570.e7. <u>https://doi.org/10.1016/j.molcel.2019.02.036</u>
- Sundaram, V. *et al.* (2014) 'innovation of gene regulatory networks Widespread contribution of transposable elements to the innovation of gene regulatory networks', *Genome Research*, 24, pp. 1963–1976. doi: 10.1101/gr.168872.113.
- Tang, W., Mun, S., Joshi, A., & Han, K. (2018). Mobile elements contribute to the uniqueness of human genome with 15, 000 human-specific insertions and 14 Mbp sequence increase. 25(July), 521–533. <u>https://doi.org/10.1093/dnares/dsy022</u>
- Terry, D. M. and Devine, S. E. (2020) 'Aberrantly High Levels of Somatic LINE-1 Expression and Retrotransposition in Human Neurological Disorders', *Frontiers in Genetics*, 10(January), pp. 1–14. doi: 10.3389/fgene.2019.01244.
- Tian, C. *et al.* (2017) 'Genome-wide association and HLA region fine-mapping studies identify susceptibility loci for multiple common infections', *Nature Communications*. Springer US, 8(1). doi: 10.1038/s41467-017-00257-5.
- The 1000 Genomes Project Consortium. (2015) 'A global reference for human genetic variation', *Nature*, 526(7571), pp. 68–74. doi: 10.1038/nature15393.
- The ENCODE Project Consortium (2012) 'An Integrated Encyclopedia of DNA Elements in the Human Genome', *Nature*, 489(7414), pp. 57–74. doi: 10.1038/nature11247.An.
- Thung, D. T. *et al.* (2014) 'Mobster: accurate detection of mobile element insertions in next generation sequencing data', *Genome biology*, 15(488). doi: 10.1186/s13059-014-0488-x.

- Touchon, M. and Rocha, E. P. C. (2007) 'Causes of insertion sequences abundance in prokaryotic genomes', *Molecular Biology and Evolution*, 24(4), pp. 969–981. doi: 10.1093/molbev/msm014.
- Trizzino, M., Kapusta, A., & Brown, C. D. (2018). Transposable elements generate regulatory novelty in a tissue-specific fashion. BMC Genomics, 19(1), 1–12. https://doi.org/10.1186/s12864-018-4850-3
- Tubio, J. M. C. *et al.* (2014) 'Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes', *Science*, 345(6196), p. 1251343. doi: 10.1126/science.1251343.
- Ullu E, Tschudi C, .(1984) 'Alu sequences are processed 7SL RNA genes', *Nature*, 312(5990), pp. 171–172. doi: doi: 10.1038/312171a0.
- Upton, K. R. *et al.* (2015) 'Ubiquitous L1 mosaicism in hippocampal neurons', *Cell*, 161(2), pp. 228–239. doi: 10.1016/j.cell.2015.03.026.
- Viollet, S., Monot, C. and Cristofari, G. (2014) 'L1 retrotransposition: The snapvelcro model and its consequences', *Mobile genetic elements*, 4(1), pp. e28907–e28907. doi: 10.4161/mge.28907.
- Visel, A. *et al.* (2007) 'VISTA Enhancer Browser A database of tissue-specific human enhancers', *Nucleic Acids Research*, 35(SUPPL. 1), pp. 88–92. doi: 10.1093/nar/gkl822.
- Waddell N, Pajic M, Patch AM, Chang DK. *et al.* (2015) 'Whole genomes redefine the mutational landscape of pancreatic cancer', *Nature*, 518(7540), pp. 125– 131. doi: 10.1038/nature14169.Whole.
- Wagstaff, B. J. *et al.* (2012) 'Rescuing Alu: Recovery of New Inserts Shows LINE-1 Preserves Alu Activity through A-Tail Expansion', PLoS Genetics, 8(8). doi: 10.1371/journal.pgen.1002842.
- Wainschtein, P. *et al.* (2021) 'Recovery of trait heritability from whole genome sequence data', *bioRxiv*, p. 588020. doi: 10.1101/588020.
- Wang, H., Xing, J., Grover, D., Hedges Kyudong Han, D. J., Walker, J. A., & Batzer, M. A. (2005). SVA elements: A hominid-specific retroposon family. Journal of Molecular Biology, 354(4), 994–1007. <u>https://doi.org/10.1016/j.jmb.2005.09.085</u>
- Wang, J. Song, L. Grover, D. Azrak, S. Batzer, MA. Liang, P. (2006) 'db RIP: A Highly Integrated Databadse of Retrotransposon Insertion Polymorphisms in Humans', *Human Mutation*, 27(4), pp. 323–329. doi: 10.1002/humu.20307.
- Wang, T. et al. (2007) 'Species-specific endogenous retroviruses shape the transcriptional network of the human tumor suppressor protein p53', Proceedings of the National Academy of Sciences of the United States of America, 104(47), pp. 18613–18618. doi: 10.1073/pnas.0703637104.
- Warnefors, M., Pereira, V., & Eyre-Walker, A. (2010). Transposable elements: Insertion pattern and impact on gene expression evolution in hominids.

Molecular Biology and Evolution, 27(8), 1955–1962. https://doi.org/10.1093/molbev/msq084

- Watkins, W. S. *et al.* (2020) 'The Simons Genome Diversity Project: A Global Analysis of Mobile Element Diversity', Genome Biology and Evolution, 12(6), pp. 779–794. doi: 10.1093/gbe/evaa086.
- Wei, W. E. I. *et al.* (2001) 'Human L1 Retrotransposition: cis Preference versus trans Complementation', *Molecular and cellular Biology*, 21(4), pp. 1429–1439. doi: 10.1128/MCB.21.4.1429.
- Weiner, DJ. Wigdor, EM. Ripke, S. *et al.* (2017) 'Polygenic transmission disequilibrium confirms that common and rare variation act additively to create risk for autism spectrum disorders', *Nature Genetics*, 49(7), pp. 978–985. doi: 10.1038/ng.3863.
- Weischenfeldt, J. *et al.* (2013) 'Phenotypic impact of genomic structural variation: Insights from and for human disease', *Nature Reviews Genetics*. Nature Publishing Group, 14(2), pp. 125–138. doi: 10.1038/nrg3373.
- Wickham, H. (2016) ggplot2: Elegant Graphics for Data Analysis. Springer-Verlag New York.
- Witherspoon, D. J. *et al.* (2009) 'Alu repeats increase local recombination rates', BMC Genomics, 10(530). doi: 10.1186/1471-2164-10-530.
- Witherspoon, D. J. *et al.* (2013) 'Mobile element scanning (ME-Scan) identifies thousands of novel Alu insertions in diverse human populations', *Genome Research*, 23(7), pp. 1170–1181. doi: 10.1101/gr.148973.112.
- Wildschutte, J. H. *et al.* (2015) 'Discovery and characterization of Alu repeat sequences via precise local read assembly', *Nucleic Acids Research*, 43(21), pp. 10292–10307. doi: 10.1093/nar/gkv1089.
- Wood, AR. Esko, T. Yang, J. Vedantam, S. *et al.* (2014) 'Defining the role of common variation in the genomic and biological architecture of adult human height', *Nature Genetics*, 46(11), pp. 1173–1186. doi: 10.1038/ng.3097.
- Wray, G. A. *et al.* (2003) 'The evolution of transcriptional regulation in eukaryotes', *Molecular Biology and Evolution*, 20(9), pp. 1377–1419. doi: 10.1093/molbev/msg140.
- Xing, J. *et al.* (2009) 'Mobile elements create structural variation : Analysis of a complete human genome', (801), pp. 1516–1526. doi: 10.1101/gr.091827.109.1516.
- Yang, J. Bakshi, A. Zhu, Z. Hemani, G. *et al.* (2015) 'Genetic variance estimation with imputed variants finds negligible missing heritability for human height and body mass index', *Nature Genetics*, 47(10), pp. 1114–1120. doi: 10.1038/ng.3390.

- Yang, F. and Wang, P. J. (2016) 'Multiple LINEs of retrotransposon silencing mechanisms in the mammalian germline', Seminars in Cell and Developmental Biology. Elsevier Ltd, 59, pp. 118–125. doi: 10.1016/j.semcdb.2016.03.001.
- Yoo, I., & Mosa, A. S. (2015). Analysis of PubMed User Sessions Using a Full-Day PubMed Query Log: A Comparison of Experienced and Nonexperienced PubMed Users. *JMIR medical informatics*, *3*(3), e25. https://doi.org/10.2196/medinform.3740.
- Yu, Q. *et al.* (2017) 'Population-wide sampling of retrotransposon insertion polymorphisms using deep sequencing and efficient detection', *Gigascience*, 6(9), pp. 1–11. doi: 10.1093/gigascience/gix066.
- Zampella, J. G. *et al.* (2016) 'A map of mobile DNA insertions in the NCI-60 human cancer cell panel', *Mobile DNA*, 7(1), p. 20. doi: 10.1186/s13100-016-0078-4.
- Zeng, L. *et al.* (2018) 'Genome-Wide Analysis of the Association of Transposable Elements with Gene Regulation Suggests that Alu Elements Have the Largest Overall Regulatory Impact', *Journal of Computational Biology*, 25(6), pp. 551– 562. doi: 10.1089/cmb.2017.0228.
- Zerbino, D. R. *et al.* (2015) 'The Ensembl Regulatory Build', *Genome Biology*, 16(1), pp. 1–8. doi: 10.1186/s13059-015-0621-5.
- Zhang, W. *et al.* (2011) 'Alu distribution and mutation types of cancer genes', *BMC Genomics*, 12(157). doi: 10.1186/1471-2164-12-157
- Zhang, L., Chen, J. and Zhao, Q. (2015) 'Regulatory roles of Alu transcript on gene expression', *Experimental Cell Research*. Elsevier, 338(1), pp. 113–118. doi: 10.1016/j.yexcr.2015.07.019.
- Zhang, H. H. *et al.* (2020) 'Horizontal transfer and evolution of transposable elements in vertebrates', *Nature Communications*. Springer US, 11(1), pp. 1– 10. doi: 10.1038/s41467-020-15149-4.

**Appendix 1:** Additional information about the 45 studies included in the curated database of this study

This supplementary table is an extension of table 4 (p. 36-37) and it includes a record of the following:

- 1. RTE Detection tool applied by the study
- 2. Information regarding the detection sensitivity/validation as reported by each respective study
- 3. Source of insertions data

Detection Sensitivity/Validation Key:

- ¶ | PCR verification
- P | Precision
- R | Recall
- S | Sensitivity
- δ | Specificity False discovery
- ‡ | rate
- .avg | Average

Table 21: Studies included in the curated non-reference retrotransposable element (RTE) databases, including name of the detection tool used by each study, information about sensitivity/validation, and source file from which the insertions in the database got extracted from

|    |                            |            |                   | Reported Detection  |                   |
|----|----------------------------|------------|-------------------|---|-------------------|
| #  | Study ID                   | PMID       | Detection tool    | sensitivity   | Data source       |
| 1  | David at al (2012)         | 22021(22   | Alu dotost        | 070/P 050/ R (00/ ¶   | Eile S1           |
| 1  | David et al., (2013)       | 23921033 1 | Alu-delect        | 9/%0,85%0 00%0 "  | File 51           |
| 2  | Sudmant et al., (2015)♦    | 26432246 N | MELT              | 83-96 <sup>%</sup> <sup>\$</sup> ,4 <sup>%</sup> <sup>‡</sup> | 1KGP ftp.<br>web  |
| 3  | Witherspoon et al., (2013) | 23599355 N | ME-Scan           | 95% <sup>\$</sup> ,44% <sup>¶</sup> ,4.6% <sup>‡</sup>        | Sup .txt file     |
| 4  | Thurse at al. $(2014)$     | 25240025   | Mahatar           | 00,000/5,010/9,00/1   | File              |
| 4  | 1 nung et al., (2014)♦     | 25548055 1 | MODSter           | 90-99% , 91%,9%   | S2,S3,S4          |
| 5  | Brandler et al., (2016)    | 27018473 N | Mobster           | 70% KNR (Fig. S7)   | Tbl. S2           |
| 6  | Baillie et al., (2011)♦⋮   | 22037309 I | RC-seq            | 100% <sup>¶</sup> (Tbl. S6)                                   | Tbl. S4 and       |
| 7  | Shuld at al. $(2012)$      | 23540602 1 |                   | 0.0 50/ 1/11 55   | Th \$2.54         |
| /  | Shukia et al., (2013)♥:    | 23340093 1 | AC-seq            | 96.5% (101. 55)   | 101. 55, 54       |
| 8  | Solyom et al., (2012)♦∃    | 22968929 I | L1- & RC-seq      | 67.3% <sup>¶</sup> (Tbl. S3)                                  | Tbl. S1a.b,<br>S2 |
| 9  | Wildschutte et al., (2015) | 26503250 I | RetroSeq          | 5% <sup>‡</sup> , 100% <sup>¶</sup> (Tbl. S3)                 | Tbl S1a, S6       |
| 10 | Evrony et al., (2015)♦     | 25569347 s | scTea             | 86-96 <sup>%</sup> , 96 <sup>%</sup>                          | Tbl. S3           |
| 11 | Lee et al., (2012)♦⋮       | 22745252   | Геа               | 100% <sup>¶</sup> (Tbl. S7)                                   | Tbl. S6, S8       |
| 12 | Hormozdiari et al., (2011) | 21131385   | VariationHunter-2 | 98% <sup>¶</sup> (Tbl. S4, S5)                                | Tbl. S1           |

| 13             | Ha et al., (2016)   | 27478512                         | ME-Scan-SVA   | 89% <sup>S</sup> , 55% <sup>¶</sup> (Tbl.S2)   | File S3                      |
|----------------|---|----------------------------------|---|--|------------------------------|
| 14             | Stewart et al., (2011)♦⋮  | 21876680                         | SPANNER   | 95% <sup>¶</sup> , 4.5±0.8 <sup>‡</sup>  | Tbl. S1                      |
| 15             | Yu Q et al., (2017)   | 28938719                         | SID   | 86.7% <sup>S.avg</sup> ,96.9% <sup>¶</sup> (Tbl.<br>S7,S8)   | Tbl. S11                     |
| 16             | Xing et al., (2009)   | 19439515                         | Computational   | 100% <sup>¶</sup> (Tbl. S1)  | Tbl. S3                      |
| 17             | Upton et al., (2015)♦   | 25860606                         | RC-seq  | 97.5% <sup>s</sup> , 100% <sup>¶</sup> (Tbl.<br>S2)  | Tbl. S2                      |
| 18             | Tubio et al., (2014)♦   | 25082706                         | TraFiC  | 73-83.9% <sup>S</sup> , >99% <sup>δ</sup><br>(Tbl. S4)   | Tbl. S7                      |
| 19             | Shin et al., (2019)   | 30699287                         | Custom pipeline                                       | 92.5% <sup>¶</sup> (Tbl.S4)  | Tbl. S3                      |
| 20             | Schauer et al., (2018)  | 29643204                         | RC-seq  | 100% <sup>¶*</sup> (Tbl. S2)   | Tbl. S2                      |
| 21             | Rouchka et al., (2010)  | 21044359                         | Computational   | 100% <sup>¶</sup> (Tbl. 1)   | Tbl. 1                       |
| 22             | Payer et al., (2017)  | 28465436                         | PCR of KNR (S3)                                       | 100% <sup>¶</sup> (Dataset S3)   | Dataset S3                   |
| 23             | Mir et al., (2014)♦ ∃   | 25352549                         | euL1db  |  | euL1db web                   |
| 24             | Kurnosov et al., (2015)♦  | 25689626                         | Computational   | 53% <sup>¶.avg*</sup> (Tbl. S1)  | Tbl. S1                      |
| 25             | Kuhn et al., (2014)♦  | 24847061                         | L1-seq  | 78% <sup>S</sup> , 94% <sup>δ</sup> (Fig. S2)  | Dataset S2                   |
| 26             | Konkel et al., (2015)   | 26319576                         | Sanger sequencing of 343 Alu<br>by 1kGP (pilot phase) | MEIs PCR validated   | Tbl. S1,S2                   |
| 27             | Kloosterman et al., (2015)  | 25883321                         | Mobster   | 77.6% <sup>s</sup> , 100% <sup>¶</sup> (Tbl.<br>S2)  | Tbl. S2                      |
| 28             | Iskow et al., (2010)♦!  | 20603005                         | L1-seq  | 89-97% <sup>¶*</sup> (Tbl.1)   | ТЫ.<br>S1,S2,S3              |
| 29             | Helman et al., (2014)♦⋮   | 24823667                         | TranspoSeq  | 99% <sup>S</sup> , 83% <sup>¶*</sup> (Tbl. S1)   | Tbl.S2                       |
| 30             | Hehir-Kwa et al., (2016)  | 27708267                         | Mobster   | 96% <sup>¶</sup> (Data S1)   | Nlgenome<br>web              |
| 31             | Feusier et al., (2017)  | 28770012                         | ME-Scan   | 58% <sup>¶</sup> (Tbl. S2,S3,S6)   | Tbl. S11                     |
| 32             | Ewing et al., (2015)♦   | 26260970                         | L1-seq  | >93% <sup>S</sup> (Tbl. S1)  | Tbl. S3a-d                   |
| 33             | Ewing et al., (2011)♦!  | 20980553                         | Custom pipeline (Fig.3)                               | 80.5% (Tbl. S1)  | Tbl. S2                      |
| 34             | Ewing et al., (2010)♦!  | 20488934                         | Perl script   | >80% <sup>8</sup> , 93±4% <sup>S</sup> , ~7% <sup>‡</sup><br>(S.pdf)   | Tbl. S1                      |
| 35             | Evrony et al., (2012)♦∃   | 23101622                         | Custom pipeline                                       | 81±6% <sup>s</sup> , 94% <sup>¶</sup>  | Tbl. S3                      |
| 36             | Erwin et al., (2016)♦   | 27618310                         | Machine learning-based                                | 80% <sup>¶</sup> (Tbl. S3)   | Tbl. S3                      |
| 37             | Doyle et al., (2017)  | 28585566                         | L1-seq  | 50% <sup>¶</sup> (Tbl.S2)  | Tbl. S5                      |
| 38             | Cardelli et al., (2012)   | 22495107                         | 2 AIP methods   | 67-90% <sup>s</sup> (Tbl.1),<br>100% <sup>¶</sup> (Tbl.2)  | Tbl. 2                       |
| 39             | Beck et al., (2010)♦  | 20602998                         | Experimental Strategy                                 | Confirmed 18/68 <sup>¶</sup> in ABC13  | Tbl. S2                      |
| 40             | Arokium et al., (2014)♦   | 25289675                         | Adapted L1-Seq  | 94% <sup>¶</sup> (Tbl. S3)   | Tbl. S2                      |
| 11             | Nonvon et al. $(2019)$  | 29949758                         | RC-seq  | 93.5% <sup>¶*</sup> (Tbl.S2)   | Tbl. S2                      |
| 71             | Nguyen et al., (2016)   |                                  |   |  |                              |
| 42             | Carreira et al., (2016)♦  | 27843499                         | RC-seq  | >82% <sup>S</sup> (Tbl. S1)  | Tbl. S2                      |
| 42<br>43       | Carreira et al., (2016) ◆<br>Achanta et al., (2016)                         | 27843499<br>27843500             | RC-seq<br>TIPseq                                      | >82% <sup>S</sup> (Tbl. S1)<br>100% <sup>¶</sup> (Tbl.2)   | Tbl. S2<br>Tbl. 2            |
| 42<br>43<br>44 | Carreira et al., (2016)<br>Achanta et al., (2016)<br>Streva et al., (2015)♦ | 27843499<br>27843500<br>25887476 | RC-seq<br>TIPseq<br>SIMPLE                            | >82% <sup>\$</sup> (Tbl. S1)<br>100% <sup>¶</sup> (Tbl.2)<br>94% <sup>\$</sup> , 100% <sup>¶</sup> (Tbl. S4) | Tbl. S2<br>Tbl. 2<br>Tbl. S2 |

Table 22: Full list of RTEs in LD with TAS. This supplementary table is an expansion of table 17 (p.132-133) and it includes all RTEs in LD ( $r^2 > 0.6$ ) with GWS TAS identified in cohorts of European descents. Note: When there are RTEs in LD with a TAS that have been identified by multiple GWAS, the table includes the strongest GWAS signal. Table ordered by  $r^2$  value.

| Chr | Start     | RTE<br>(1kGP name) | TAS         | Trait  | P-val | $r^2$ | Trait_PMID |
|-----|-----------|--------------------|-------------|--|-------|-------|------------|
| 6   | 141414904 | ALU_5647           | rs113803678 | Body mass index  | 4E-08 | 0.92  | 30595370   |
| 3   | 85576571  | LINE1_629          | rs62250759  | Self-reported risk-taking behaviour                      | 5E-12 | 0.92  | 29391395   |
| 12  | 24868717  | LINE1_2249         | rs61914312  | Hair color   | 3E-10 | 0.91  | 30595370   |
| 1   | 174484646 | ALU_604            | rs140588606 | Feeling miserable  | 6E-10 | 0.91  | 29500382   |
| 1   | 174484646 | ALU_604            | rs77417259  | Feeling miserable  | 3E-10 | 0.91  | 29500382   |
| 9   | 11329329  | ALU_7283           | rs2152261   | Menarche (age at onset)                                  | 2E-13 | 0.91  | 30595370   |
| 12  | 56753252  | ALU_9228           | rs2066819   | Psoriasis  | 5E-17 | 0.88  | 23143594   |
| 1   | 174484646 | ALU_604            | rs140581634 | Feeling miserable  | 2E-08 | 0.87  | 29500382   |
| 12  | 120130849 | ALU_9540           | rs17442937  | Red cell distribution width                              | 4E-08 | 0.85  | 30595370   |
| 17  | 44153977  | SVA_706            | rs12150229  | Ease of getting up in the morning                        | 4E-09 | 0.84  | 30804565   |
| 17  | 44153977  | SVA_706            | rs12150672  | Red blood cell count                                     | 4E-09 | 0.84  | 28017375   |
| 17  | 44153977  | SVA_706            | rs12185268  | Parkinson's disease                                      | 3E-14 | 0.84  | 21738487   |
| 17  | 44153977  | SVA_706            | rs12373124  | Male-pattern baldness                                    | 5E-10 | 0.84  | 22693459   |
| 17  | 44153977  | SVA_706            | rs17563683  | Hemoglobin concentration                                 | 2E-28 | 0.84  | 27863252   |
| 17  | 44153977  | SVA 706            | rs17563986  | Cognitive ability  | 5E-12 | 0.84  | 29186694   |
| 17  | 44153977  | SVA_706            | rs17650842  | Irritable mood   | 2E-12 | 0.84  | 29500382   |
| 17  | 44153977  | SVA_706            | rs1864325   | Lumbar spine bone mineral density                        | 5E-11 | 0.84  | 22504420   |
| 17  | 44153977  | SVA_706            | rs2214258   | Neuroticism  | 2E-25 | 0.84  | 29255261   |
| 17  | 44153977  | SVA 706            | rs241036    | Experiencing mood swings                                 | 8E-20 | 0.84  | 29500382   |
| 17  | 44153977  | SVA_706            | rs241036    | Menarche (age at onset)                                  | 7E-13 | 0.84  | 30595370   |
| 17  | 44153977  | SVA 706            | rs2942168   | Parkinson's disease                                      | 1E-28 | 0.84  | 21292315   |
| 17  | 44153977  | SVA_706            | rs4606752   | Reticulocyte count                                       | 1E-17 | 0.84  | 27863252   |
| 17  | 44153977  | SVA_706            | rs55657917  | Feeling hurt/Mood swings<br>Accelerometer-based physical | 7E-29 | 0.84  | 29500382   |
| 17  | 44153977  | SVA_706            | rs55657917  | activity measurement (average acceleration)              | 5E-12 | 0.84  | 29899525   |
| 17  | 44153977  | SVA_706            | rs56303031  | Heel bone mineral density                                | 6E-24 | 0.84  | 30595370   |
| 17  | 44153977  | SVA_706            | rs56319902  | Educational attainment (years of education)              | 6E-33 | 0.84  | 30038396   |
| 17  | 44153977  | SVA_706            | rs62055546  | Alcohol consumption (drinks per week)                    | 8E-25 | 0.84  | 30643258   |
| 17  | 44153977  | SVA_706            | rs62055701  | Irritable mood   | 6E-13 | 0.84  | 29500382   |
| 17  | 44153977  | SVA_706            | rs62055935  | Feeling nervous  | 2E-15 | 0.84  | 29500382   |
| 17  | 44153977  | SVA_706            | rs62057061  | Depressed affect   | 2E-22 | 0.84  | 29942085   |
| 17  | 44153977  | SVA_706            | rs62057107  | Educational attainment                                   | 5E-38 | 0.84  | 30038396   |

| 17  | 44153977  | SVA_706    | rs75022332         | Worry too long after an                               | 2E-08           | 0.84 | 29500382  |
|-----|-----------|------------|--------------------|---|-----------------|------|-----------|
| 17  | 44153977  | SVA 706    | <b>r</b> s76761706 | Neurociticism   | 7E-32           | 0.84 | 29500382  |
| 17  | 44153977  | SVA_706    | rs79412431         | Lung function   | 3E-49           | 0.84 | 30804560  |
| 17  | 44153977  | SVA_706    | rs79857651         | Experiencing mood swings                              | 9E-20           | 0.84 | 29500382  |
| 17  | +155777   | 511_700    | 1377037031         | Subcortical brain region                              | 711-20          | 0.04 | 27500502  |
| 17  | 44153977  | SVA_706    | rs8072451          | volumes   | 1E-08           | 0.84 | 25607358  |
| 9   | 16682313  | ALU_7311   | rs12335424         | Height  | 2E-21           | 0.84 | 30595370  |
| 1 5 | 7/02/010  | ATLL 10010 | 1((00)             | Estimated glomerular filtration                       | FT 12           | 0.02 | 21150172  |
| 15  | /6826019  | ALU_10819  | rs166906           | rate  | 5E-13           | 0.83 | 31152163  |
| 15  | 76826019  | ALU_10819  | rs506000           | Estimated glomerular filtration rate                  | 2E-15           | 0.83 | 31152163  |
| 17  | 44153977  | SVA_706    | rs112333322        | Experiencing mood swings                              | 4E-19           | 0.83 | 29500382  |
| 17  | 44153977  | SVA_706    | rs117124984        | Daytime nap   | 3E-13           | 0.83 | 30804565  |
| 17  | 44153977  | SVA_706    | rs17577369         | Feeling miserable                                     | 4E-12           | 0.83 | 29500382  |
| 17  | 44153977  | SVA_706    | rs17649553         | Parkinson's disease                                   | 1E-68           | 0.83 | 28892059  |
| 17  | 44153977  | SVA_706    | rs17661015         | Irritable mood  | 4E-12           | 0.83 | 29500382  |
| 17  | 44153977  | SVA_706    | rs17661015         | Feeling hurt  | 3E-28           | 0.83 | 29500382  |
| 17  | 44153977  | SVA_706    | rs1981997          | Interstitial lung disease                             | 9E-14           | 0.83 | 23583980  |
| 17  | 44153977  | SVA_706    | rs35524223         | Lung function (FEV1)                                  | 1E-13           | 0.83 | 28166213  |
| 17  | 44153977  | SVA_706    | rs56280951         | Feeling miserable                                     | 8E-13           | 0.83 | 29500382  |
| 17  | 44153977  | SVA_706    | rs62055544         | Feeling fed-up  | 5E-16           | 0.83 | 29500382  |
| 17  | 44153977  | SVA_706    | rs79301522         | Neurociticism   | 1E-30           | 0.83 | 29500382  |
| 4 7 |           |            | 0050500            | Progressive supranuclear                              | <b>21</b> 1 1 0 | 0.02 | 01 (05010 |
| 1/  | 44153977  | SVA_/06    | rs80/0/23          | palsy/Parkinson's disease                             | 2E-118          | 0.83 | 21685912  |
| 17  | 44153977  | SVA_706    | rs919462           | Male-pattern baldness                                 | 1E-26           | 0.83 | 29146897  |
| 17  | 44153977  | SVA_706    | rs111433752        | Neuroticism   | 9E-12           | 0.83 | 27067015  |
| 17  | 44153977  | SVA_706    | rs17689882         | Subcortical brain region volumes                      | 8E-09           | 0.83 | 25607358  |
| 17  | 44153977  | SVA_706    | rs2106785          | Irritable mood  | 3E-13           | 0.83 | 29500382  |
| 17  | 44153977  | SVA_706    | rs2106786          | Red blood cell count                                  | 3E-36           | 0.83 | 27863252  |
| 17  | 44153977  | SVA_706    | rs365825           | Parkinson's disease                                   | 4E-32           | 0.83 | 27182965  |
| 17  | 44153977  | SVA 706    | rs393152           | Parkinson's disease                                   | 2E-16           | 0.83 | 19915575  |
| 17  | 44153977  | SVA 706    | rs62061733         | Eosinophil counts                                     | 3E-29           | 0.83 | 30595370  |
| 17  | 44153977  | SVA 706    | rs62061733         | Feeling hurt  | 2E-28           | 0.83 | 29500382  |
| 12  | 56753252  | ALU 9228   | rs59917308         | Height  | 3E-32           | 0.83 | 30595370  |
| 17  | 44153977  | SVA 706    | rs112010353        | Self-reported math ability                            | 2E-08           | 0.83 | 30038396  |
| 2   | 210260754 | ALU 1947   | rs1080278          | Lung function (FVC)                                   | 1E-19           | 0.83 | 30595370  |
| 17  | 44153977  | SVA_706    | rs1991556          | Lung function (FVC)                                   | 1E-53           | 0.83 | 30595370  |
| 17  | 44153977  | SVA_706    | rs1991556          | Sleep duration  | 3E-09           | 0.83 | 30531941  |
| 16  | 75655176  | ALU_11116  | rs61537885         | Smoking initiation (ever regular<br>vs never regular) | 8E-09           | 0.82 | 30643251  |
| 17  | 44153977  | SVA 706    | rs80103986         | Hand grip strength                                    | 1E-09           | 0.82 | 29313844  |
| 4   | 134596423 | LINE1 967  | rs12507927         | Highest math class taken                              | 3E-11           | 0.82 | 30038396  |
| 17  | 44153977  | SVA 706    | rs17652520         | Medication use (anilides)                             | 8E-13           | 0.82 | 31015401  |
| 17  | 44153977  | SVA_706    | rs17652520         | Neuroticism   | 2E-27           | 0.82 | 30595370  |
| 1   | 174484646 | ALU 604    | rs75035127         | Feeling miserable                                     | 7E-09           | 0.82 | 29500382  |
| 1   | 169524859 | LINE1_164  | rs6128             | Blood protein levels                                  | 2E-26           | 0.82 | 29875488  |
| 12  | 56753252  | ALU_9228   | rs11575234         | Inflammatory skin disease                             | 2E-12           | 0.82 | 25574825  |
| 17  | 44153977  | SVA_706    | rs62063281         | Number of sexual partners                             | 4E-15           | 0.82 | 30643258  |
| 17  | 44153977  | SVA_706    | rs62063281         | Osteoarthritis (hip)                                  | 5E-12           | 0.82 | 30664745  |
| 17  | 44153977  | SVA_706    | rs17665188         | Experiencing mood swings                              | 1E-18           | 0.82 | 29500382  |
| 17  | 44153977  | SVA_706    | rs62065453         | Neuroticism   | 2E-24           | 0.82 | 29255261  |
| 17  | 44153977  | SVA_706    | rs62065453         | Feeling nervous/Irritable mood                        | 6E-15           | 0.82 | 29500382  |
|     |           | _          |                    | . ·   |                 |      |           |

| 1   | 163639693 | ALU_559         | rs12564153  | Lung function (FEV1/FVC)       | 1E-09        | 0.82 | 30595370 |
|-----|-----------|-----------------|-------------|--------------------------------|--------------|------|----------|
| 12  | 56753252  | ALU_9228        | rs2066807   | Psoriasis                      | 5E-12        | 0.81 | 25903422 |
| 12  | 56753252  | ALU_9228        | rs2066807   | Height                         | 1E-13        | 0.81 | 20881960 |
| 5   | 109051004 | ALU_4562        | rs4388249   | Schizophrenia                  | 8E-09        | 0.81 | 28991256 |
| 17  | 44153977  | SVA_706         | rs62064364  | Macular thickness              | 4E-35        | 0.81 | 30535121 |
| 10  | 106566893 | ALU_8208        | rs61867293  | Depression                     | 7E-10        | 0.81 | 29700475 |
| 21  | 33050849  | ALU_12379       | rs17660708  | LDL cholesterol                | 1E-10        | 0.81 | 30275531 |
| 17  | 44153977  | SVA_706         | rs2732631   | Macular thickness              | 3E-35        | 0.81 | 30535121 |
| 17  | 44153977  | SVA_706         | rs4471723   | Feeling guilty                 | 5E-09        | 0.81 | 29500382 |
| 17  | 44153977  | SVA_706         | rs8080583   | Cognitive ability              | 1E-08        | 0.81 | 29186694 |
| 17  | 44153977  | SVA_706         | rs9303525   | Intracranial volume            | 8E-15        | 0.81 | 22504418 |
| 20  | 26190974  | ALU_12132       | rs6051320   | Lung function (FEV1/FVC)       | 2E-08        | 0.81 | 30595370 |
|     |           |                 |             | Heel bone mineral density/     |              |      |          |
| 11  | 54958589  | ALU_8580        | rs77584654  | Height                         | 5E-17        | 0.81 | 30595370 |
| 17  | 44153977  | SVA 706         | rs2732708   | Feeling miserable              | 3E-11        | 0.80 | 29500382 |
| 17  | 44153977  | SVA 706         | rs2732708   | Neuroticism                    | 2E-23        | 0.80 | 29255261 |
| 17  | 44153977  | SVA 706         | rs62057151  | Feeling worry                  | 1E-09        | 0.80 | 29500382 |
| 7   | 18273084  | ALU 5868        | rs1528683   | Lung function (FVC)            | 2E-17        | 0.80 | 30595370 |
| 12  | 77965056  | ALU 9355        | rs17788937  | Myopia (pathological)          | 4E-15        | 0.80 | 23049088 |
| 17  | 44153977  | SVA 706         | rs2696532   | Feeling guilty                 | 4E-08        | 0.80 | 29500382 |
| 17  | 44153977  | SVA_706         | rs242559    | General cognitive ability      | 1E-13        | 0.80 | 29844566 |
| 11  | 43877448  | ALU 8559        | rs1061810   | Type 2 diabetes                | 4E-10        | 0.80 | 28566273 |
| 8   | 110101605 | ALU 7037        | rs28499085  | Pulse pressure                 | 3E-13        | 0.79 | 30224653 |
| 14  | 92619420  | SVA 615         | rs34016308  | Myonia                         | 4E-14        | 0.79 | 27182965 |
| 5   | 40041345  | LINE1 1097      | rs10053502  | Myopia (pathological)          | 1E-16        | 0.79 | 23049088 |
| 17  | 44153977  | SVA 706         | rs58879558  | Red blood cell count           | 3E-98        | 0.79 | 30595370 |
| 17  | 44153977  | SVA_706         | rs77804065  | Feeling guilty                 | 6E-10        | 0.79 | 29500382 |
| 17  | 44153977  | SVA_706         | rs77804065  | Neuroticism                    | 1E 31        | 0.79 | 20042085 |
| 1   | 174484646 | ALU 604         | rs75650221  | Negative Feelings              | 3E-10        | 0.79 | 29500382 |
| 1   | 174404040 | <u>11L0_004</u> | 1375050221  | Fase of getting up in the      | 511-10       | 0.79 | 27500502 |
| 1   | 174484646 | ALU_604         | rs75650221  | marching                       | 4E-18        | 0.79 | 30804565 |
| 5   | 25233926  | ALU 4154        | re111257433 | General risk tolerance         | 5F 10        | 0.79 | 30643258 |
| 17  | 44153077  | SVA 706         | rs62062288  | Neurociticism                  | 6E 32        | 0.79 | 20500382 |
| 1 / | 44133977  | 3V11_/00        | 1802002200  | Alcohol use disorder (total    | 012-52       | 0.79 | 29300382 |
| 17  | 44153977  | SVA_706         | rs62062288  |                                | 5E-10        | 0.79 | 30336701 |
| 17  | 44152077  | SVA 706         | mac2062288  | Negative Feelinge              | 7E 10        | 0.70 | 20500282 |
| 17  | 44153977  | SVA_706         | 1802002288  | Rick taking tondoney           | 1E-10        | 0.79 | 29500562 |
| 6   | 56297576  | ALL 5205        | 1502002200  | Heal hone mineral density      | 5E 17        | 0.79 | 20505270 |
| 0   | 30387370  | ALU_3203        | 184200197   | Seborical equivalent or muonia | JE-17        | 0.78 | 30393370 |
| 14  | 92619420  | SVA_615         | rs11160044  | (and of diagnosis)             | 7E-11        | 0.78 | 29808027 |
|     |           |                 |             | (age of diagnosis)             |              |      |          |
| 11  | 49282683  | ALU_8572        | rs7103270   | HDL cholesterol x physical     | 7E-12        | 0.78 | 30670697 |
| 4   | 76002024  | ATTI 2410       |             | Read and the level             | <b>2E 17</b> | 0.79 | 20075400 |
| 4   | 76995824  | ALU_3412        | rs/693693   | blood protein levels           | 2E-17        | 0.78 | 298/3488 |
| 1   | 219558910 | ALU_810         | rs/5128958  | Lung function (FEV1/FVC)       | 2E-23        | 0.78 | 20505270 |
| 1   | 219558910 | ALU_810         | rs/5128958  |                                | 1E-08        | 0.78 | 20595570 |
| 2   | 30669993  | ALU_108/        | rs285381/3  | Eosinophil counts              | 3E-09        | 0.78 | 30595370 |
| 0   | 96009421  | ALU_5389        | rs80268500  | Blood protein levels           | 0E+00        | 0.78 | 298/5488 |
| 16  | 80848077  | ALU_11145       | rs34018670  | Monocyte count                 | 5E-09        | 0.78 | 2/863252 |
| 1   | 1/4484646 | ALU_604         | rs1150/3088 | Chronotype                     | 4E-12        | 0.78 | 30696823 |
| 1   | 119553366 | LINE1_122       | rs3/90553   | Male-pattern baldness          | 4E-19        | 0.78 | 305/3740 |
| 12  | 56753252  | ALU_9228        | rs2066808   | Psoriasis                      | 6E-10        | 0.77 | 25574825 |
| 12  | 56/53252  | ALU_9228        | rs36207871  | Inflammatory skin disease      | 3E-12        | 0.77 | 255/4825 |
| 3   | 193354185 | LINE1_769       | rs34023161  | Highest math class taken       | 3E-08        | 0.77 | 30038396 |
| 17  | 44153977  | SVA_706         | rs76640332  | Lymphocyte percentage of white | 5E-13        | 0.77 | 27863252 |
|     |           | _               |             | cells                          |              |      |          |

| 12     | 56753252             | ALU_9228   | rs59626664  | General risk tolerance  | 2E-09 | 0.77 | 30643258 |
|--------|----------------------|------------|-------------|---|-------|------|----------|
| 3      | 193354185            | LINE1_769  | rs11925699  | Educational attainment  | 3E-08 | 0.77 | 30038396 |
| 1      | 180857564            | ALU_629    | rs1043069   | Systolic blood pressure   | 5E-15 | 0.77 | 30224653 |
| 9      | 4237141              | ALU 7235   | rs2224492   | Intraocular pressure  | 4E-16 | 0.77 | 29235454 |
| 17     | 44153977             | SVA 706    | rs1378358   | Negative Feelings   | 2E-11 | 0.76 | 29500382 |
| 17     | 44153977             | SVA 706    | rs1378358   | Neurociticism   | 2E-27 | 0.76 | 29500382 |
| 17     | 44153977             | SVA 706    | rs199456    | Macular thickness   | 3E-28 | 0.76 | 30535121 |
| 17     | 44153977             | SVA 706    | rs538628    | Feeling nervous   | 9E-13 | 0.76 | 29500382 |
| 15     | 47507342             | LINE1_2640 | rs12914084  | Neuroticism   | 3E-08 | 0.76 | 30643256 |
| 15     | 47507342             | LINE1_2640 | rs6493265   | Educational attainment (years of education)   | 2E-17 | 0.76 | 30038396 |
| 2      | 652672               | ALU_958    | rs10189761  | Obesity   | 6E-24 | 0.76 | 23563607 |
| 2      | 652672               | ALU_958    | rs12714415  | Heel bone mineral density   | 4E-09 | 0.76 | 28869591 |
| 2      | 652672               | ALU_958    | rs12995480  | C-reactive protein levels   | 1E-10 | 0.76 | 30388399 |
| 2      | 652672               | ALU_958    | rs13021737  | Body mass index   | 4E-69 | 0.76 | 30108127 |
| 2      | 652672               | ALU_958    | rs13396935  | Smoking status (ever vs never smokers)  | 4E-13 | 0.76 | 30643258 |
| 2      | 652672               | ALU_958    | rs4854344   | Body mass index (joint analysis<br>main effects and physical activity<br>internation) | 9E-23 | 0.76 | 28448500 |
| 2      | 652672               | ATTI 058   | rc5017302   | Monarcha (aga at opsat)   | 5E 38 | 0.76 | 30505370 |
| 2      | 652672               | ALU_958    | 185017502   | Reder mean index  | 3E-30 | 0.76 | 10070261 |
| 2      | 652672               | ALU_958    | rs0548238   | Body mass index   | 1E-18 | 0.76 | 190/9261 |
| 2      | 652672               | ALU_958    | rs6/25549   | Body mass index   | 1E-/4 | 0.76 | 264269/1 |
| 2      | 652672               | ALU_958    | rs6/48821   | Obese vs. thin  | 8E-21 | 0.76 | 30677029 |
| 2      | 652672               | ALU_958    | rs6/52/06   | Lung function (FEV I/FVC)   | 2E-13 | 0.76 | 30595370 |
| 2      | 6526/2               | ALU_958    | rs6/55502   | Waist/Hip circumference   | 2E-30 | 0.76 | 256/3412 |
| 17     | 44153977             | SVA_706    | rs199443    | Feeling fed-up  | 4E-13 | 0.76 | 29500382 |
| 17     | 44153977             | SVA_706    | rs199447    | Neuroticism   | 2E-26 | 0.76 | 29942085 |
| 17     | 44153977             | SVA_706    | rs199533    | Parkinson's disease   | 1E-14 | 0.76 | 19915575 |
| 8      | 109135936            | SVA_389    | rs617117    | Macular thickness   | 2E-09 | 0.76 | 30535121 |
| 12     | 28163331             | ALU_9104   | rs1838564   | Breast size   | 1E-12 | 0.76 | 27182965 |
| 4      | 22043212             | ALU_3139   | rs62301574  | Insomnia  | 1E-08 | 0.76 | 30804565 |
| 14     | 39875097             | LINE1_2544 | rs34983854  | Systolic blood pressure   | 2E-11 | 0.76 | 30224653 |
| 6      | 140417842            | ALU_5637   | rs62429521  | Insomnia<br>HDL cholesterol levels v  | 2E-09 | 0.76 | 30804565 |
|        |                      |            |             | alcohol consumption (drinkers   |       |      |          |
| 11     | 49282683             | ALU_8572   | rs658118    | vs non-drinkers) interaction  | 1E-49 | 0.76 | 30698716 |
|        |                      |            |             | (2df)   |       |      |          |
| 14     | 55795871             | ALU_10325  | rs10146637  | White blood cell count  | 4E-11 | 0.76 | 30595370 |
| 6      | 97017683             | ALU 5395   | rs11153071  | Systolic blood pressure   | 3E-15 | 0.76 | 30595370 |
| 2      | 652672               | ALU 958    | rs4854349   | Childhood body mass index   | 5E-22 | 0.76 | 26604143 |
| 8      | 109135936            | SVA 389    | rs392783    | Hair color  | 2E-23 | 0.76 | 30595370 |
| 6      | 97017683             | ALU 5395   | rs11153018  | Systolic blood pressure   | 1E-11 | 0.76 | 30578418 |
| 15     | 49609604             | ALU 10695  | rs11632038  | Lung adenocarcinoma   | 5E-10 | 0.76 | 28604730 |
| 6      | 56387576             | ALU 5205   | rs112462597 | Heel bone mineral density   | 6E-16 | 0.76 | 30048462 |
| 2      | 652672               | ALU 958    | rs62105306  | Body mass index (adult)   | 3E-28 | 0.75 | 28430825 |
| - 11   | 49282683             | ALU 8572   | rs11040595  | Systolic blood pressure   | 1E-11 | 0.75 | 30578418 |
| 11     | 49282683             | ALU 8572   | rs77828979  | Intraocular pressure  | 6E-12 | 0.75 | 29617998 |
| 2      | 30669993             | ALU 1087   | rs829636    | Eczema  | 6E-09 | 0.75 | 30595370 |
| -4     | 134596423            | LINE1 967  | rs1157684   | Self-reported math ability  | 3E-14 | 0.75 | 30038396 |
| 4      | 134596423            | LINE1 967  | rs981033    | Self-reported math ability  | 1E-14 | 0.75 | 30038396 |
| 10     | 34571038             | ALU 7901   | rs610493    | Height  | 2E-10 | 0.75 | 30595370 |
| Q      | 7101/501             |            | ro2620025   | Lung function (FEV1/EVC)  | 2E 10 | 0.75 | 30505270 |
| 0      | 07017692             | ALU_0000   | 182039933   | Stratelia blood areastrat   | 5E-08 | 0.75 | 07041070 |
| 0<br>5 | 9/01/083<br>56100722 | ALU_3393   | 1833410524  | Systone blood pressure  | 5E-10 | 0.75 | 2/8418/8 |
| Э      | 50109/23             | alu_4294   | 1810880364  | preast cancer (early onset)   | 5E-12 | 0.75 | 24493630 |

| 15      | 47507342                    | LINE1_2640         | rs11853760  | Educational attainment (years of  | 5E-13          | 0.75 | 30038396 |
|---------|-----------------------------|--------------------|-------------|-----------------------------------|----------------|------|----------|
| 15      | 47507242                    | INE1 2640          | #2860040    | Educational attainment            | 2E 15          | 0.75 | 20029206 |
| 15      | 47307342                    | LINE1_2040         | 182800049   | Pada massindar                    | 2E-13<br>1E-10 | 0.75 | 20505270 |
| 2       | 144010793                   | $LINE1_410$        | 18021/1096  | Body mass index                   | 1E-10<br>2E 10 | 0.75 | 20109127 |
| 6       | 45260479                    | $\Delta I II 5132$ | rs1/0/8222  | Hoight                            | 1E 20          | 0.75 | 25282103 |
| 1       | 43200479                    | ALU_5152           | 1810946222  | Facing misserble                  | 4E-20          | 0.75 | 20500292 |
| 1       | 174404040                   | ALU_604            | 1841304330  | Feeling miserable                 | 4E-09          | 0.75 | 29500562 |
| 1       | 1/4464040                   | ALU_004            | 18/0/055/9  |                                   | 2E-09          | 0.75 | 29500562 |
| 2       | 652672                      | ALU_958            | rs/50151/   | weight                            | 2E-18          | 0.75 | 19079260 |
| 2       | 052672                      | ALU_958            | rs/56151/   | Body mass index                   | 4E-1/          | 0.75 | 190/9260 |
| 12      | 28163331                    | ALU_9104           | rs123/1//8  | Breast size                       | 1E-08          | 0.75 | 22/4/683 |
| 2       | 6526/2                      | ALU_958            | rs62105303  | Breast size                       | 3E-08          | 0.74 | 2/182965 |
| 3       | 42898420                    | ALU_2319           | rs4683346   | myeloid white cells               | 5E-19          | 0.74 | 27863252 |
| 17      | 44153977                    | SVA_706            | rs9896243   | Worry                             | 2E-11          | 0.74 | 29942085 |
| 2       | 652672                      | ALU_958            | rs12463617  | Body mass index                   | 3E-17          | 0.74 | 23669352 |
| 1       | 174484646                   | ALU_604            | rs77560793  | Body mass index                   | 7E-13          | 0.74 | 30595370 |
| 6       | 46310306                    | LINE1_1293         | rs10498767  | Body mass index                   | 2E-10          | 0.74 | 30595370 |
| 16      | 75655176                    | ALU_11116          | rs4888444   | Age of smoking initiation         | 9E-09          | 0.74 | 30643251 |
| 8       | 63344481                    | ALU_6774           | rs16928927  | Rapid automised naming of letters | 2E-08          | 0.74 | 30741946 |
| 17      | 44153977                    | SVA 706            | rs17688916  | Sleep duration (long sleep)       | 1E-11          | 0.74 | 30846698 |
| 17      | 44153977                    | SVA 706            | rs17688916  | Feeling worry                     | 3E-11          | 0.74 | 29500382 |
| 17      | 46505002                    | ALU 11333          | rs7207826   | Ovarian cancer                    | 2E-17          | 0.74 | 28346442 |
| 2       | 198763462                   | ALU 1894           | rs700655    | Red blood cell count              | 3E-10          | 0.74 | 30595370 |
| 17      | 44153977                    | SVA 706            | rs57222984  | Snoring                           | 3E-11          | 0.73 | 30804565 |
| 7       | 8019027                     | LINE1 1448         | rs56195338  | Eosinophil counts                 | 7E-10          | 0.73 | 30595370 |
| 2       | 198763462                   | –<br>ALU_1894      | rs700641    | Morning vs. evening chronotype    | 5E-10          | 0.73 | 26835600 |
| 11      | 43877448                    | ALLI 8559          | rs11555762  | Body mass index                   | 5E-14          | 0.73 | 29273807 |
| 17      | 44153977                    | SVA 706            | rs199441    | Male-pattern baldness             | 1E-181         | 0.73 | 30573740 |
| 17      | 44153977                    | SVA_706            | rs199441    | Neuroticism                       | 3E-20          | 0.73 | 29255261 |
| 17      | 44153977                    | SVA_706            | rs199441    | Feeling hurt/Mood swings          | 4E-24          | 0.73 | 29500382 |
| 2       | 198763462                   | ALU 1894           | rs12472359  | Morning person                    | $1E_{-27}$     | 0.73 | 30696823 |
| 1       | 232587774                   | ALU 865            | rs4649269   | Hair color                        | 2E-08          | 0.75 | 30595370 |
| 17      | 44153977                    | NLO_000            | rs109525    | Intracranial volume               | 2E-00<br>2E 20 | 0.73 | 30818088 |
| 17      | 44153977                    | SVA_706            | rs199525    | Feeling guilty                    | 4E-20          | 0.73 | 20500382 |
| 17      | 44153077                    | SVA_706            | rs100525    | Lung function (EEV1)              | 1E-00          | 0.73 | 20061600 |
| 2       | 44133977                    | ALU 2014           | 18199323    | Prostate concer                   | 1E-09<br>4E-11 | 0.73 | 20802016 |
| 3       | 192000012                   | ALU 2086           | 18182314334 | Chronotype                        | 7E 10          | 0.73 | 20606822 |
| 2       | 182299013                   | ALU_2980           | 184404214   | Moningnose                        | 7E-10<br>2E 10 | 0.75 | 20004565 |
| 5<br>7  | 162299015                   | ALU_2960           | 180443610   | Pland Call source                 | 2E-10<br>2E-00 | 0.75 | 27862252 |
| 17      | 6019027<br>4650500 <b>2</b> | LINE1_1440         | 18/804300   | Diood Cell counts                 | 2E-09<br>5E-15 | 0.75 | 2/003232 |
| 1/<br>5 | 46505002                    | ALU_11555          | rs9303542   | Uvarian cancer                    | 3E-13          | 0.75 | 20505270 |
| 2       | 438/0854                    | ALU_4250           | rs/9904209  | Lung function (FEV1/FVC)          | 3E-17          | 0.73 | 30595370 |
| 2       | 652672                      | ALU_958            | rs6/44646   | Body mass index                   | 4E-111         | 0.73 | 30595370 |
| 6       | 45260479                    | ALU_5132           | rs2396502   | Osteoarthritis (hip)              | 2E-12          | 0.73 | 30664/45 |
| 9       | 118509752                   | ALU_/6/6           | rs12344818  | Height                            | 5E-33          | 0.72 | 30595370 |
| 15      | 4/50/342                    | LINE1_2640         | rs12903078  | Neurociticism                     | 4E-08          | 0.72 | 29500382 |
| I       | /860/067                    | ALU_2/6            | rs540/42    | Body mass index                   | /E-09          | 0.72 | 292/3807 |
| 6       | 9/01/683                    | ALU_5395           | rs9486719   | Migraine                          | 6E-21          | 0.72 | 2/182965 |
| 5       | 87399827                    | ALU_4449           | rs2217250   | Feeling tense                     | 1E-08          | 0.72 | 29500382 |
| 6       | 153429856                   | SVA_315            | rs9479509   | Diastolic blood pressure          | 1E-09          | 0.72 | 30224653 |
| 12      | 56753252                    | ALU_9228           | rs808919    | Blood protein levels              | 7E-16          | 0.72 | 30072576 |
| 2       | 652672                      | ALU_958            | rs2867125   | Body mass index                   | 5E-75          | 0.72 | 26426971 |
| 2       | 652672                      | ALU_958            | rs2867125   | Type 2 diabetes                   | 4E-10          | 0.72 | 30054458 |
| 2       | 652672                      | ALU_958            | rs2903492   | Body mass index                   | 6E-15          | 0.72 | 23563607 |

| 2       | 652672    | ALU_958      | rs6711012   | Obesity   | 3E-40          | 0.72 | 23563607 |
|---------|-----------|--------------|-------------|---|----------------|------|----------|
| 2       | 652672    | ALU_958      | rs6711254   | Age of smoking initiation   | 1E-16          | 0.72 | 30643251 |
| 2       | 652672    | ALU_958      | rs6731872   | Smoking initiation (ever regular vs never regular)                | 4E-31          | 0.72 | 30643251 |
| 2       | 652672    | ALU_958      | rs6731872   | Alcohol consumption (drinks per week)                             | 4E-09          | 0.72 | 30643251 |
| 2       | 652672    | ALU_958      | rs7567570   | Smoking status  | 7E-12          | 0.72 | 30595370 |
| 2       | 652672    | ALU_958      | rs939584    | Body mass index   | 6E-23          | 0.72 | 28892062 |
| 7       | 50473286  | ALU_6027     | rs80271829  | Monocyte count  | 4E-15          | 0.72 | 27863252 |
| 6       | 97017683  | ALU_5395     | rs3798293   | Pulse pressure  | 6E-09          | 0.72 | 30578418 |
| 17      | 44153977  | SVA_706      | rs199505    | Depressed affect  | 1E-18          | 0.71 | 29942085 |
| 17      | 44153977  | SVA 706      | rs199515    | Parkinson's disease   | 3E-17          | 0.71 | 22451204 |
| 17      | 44153977  | SVA 706      | rs70600     | Irritable mood  | 3E-11          | 0.71 | 29500382 |
| 5       | 56109723  | ALU 4294     | rs1017226   | Breast cancer (early onset)                                       | 6E-11          | 0.71 | 24493630 |
| 5       | 56109723  | ALU 4294     | rs16886397  | Breast cancer (early onset)                                       | 4E-12          | 0.71 | 24493630 |
| 5       | 56109723  | ALU 4294     | rs16886448  | Breast cancer (early onset)                                       | 2E-12          | 0.71 | 24493630 |
| 9       | 17062597  | ALU 7312     | rs112488223 | Heel bone mineral density   | 5E-16          | 0.71 | 30595370 |
| 9       | 17062597  | ALU 7312     | rs79439080  | Height  | 7E-24          | 0.71 | 30595370 |
| 11      | 65984338  | ALU 8622     | rs10896090  | Bipolar disorder  | 2E-08          | 0.71 | 31043756 |
| 15      | 47507342  | LINE1 2640   | rs1563245   | Neuroticism   | 2E 00          | 0.71 | 29255261 |
| 15      | 47507542  | LII (L1_20+0 | 131303245   | Well-being spectrum   | 512-11         | 0.71 | 27255201 |
| 15      | 47507342  | LINE1_2640   | rs1563245   | (multivariate analysis)   | 1E-08          | 0.71 | 30643256 |
| 8       | 76080146  | ATTI 6846    | rs72656102  | Height  | 5F 10          | 0.71 | 30595370 |
| 2       | 652672    | ALU_058      | rs66006321  | Obesity (extreme)   | 1E 34          | 0.71 | 30677020 |
| 2       | 652672    | ALU 058      | rs2047411   | Smoking initiation  | 5E 10          | 0.71 | 30617029 |
| 2       | 652672    | ALU_958      | 182947411   | Monarcha (and at angot)   | 2E 10          | 0.70 | 25221970 |
| 2<br>17 | 44152077  | ALU_936      | 18294/411   | Idiopathia pulmonary fibrosia                                     | ZE-19          | 0.70 | 23231070 |
| 5       | 56100723  | ALL 4204     | 1517090705  | Broast capeer (early open)  | 5E 12          | 0.70 | 24429130 |
| 10      | 65356114  | ALU_4294     | 183622023   | Poticulo cute count   | JE-12<br>4E-16 | 0.70 | 24493030 |
| 0       | 24702600  | ALU_6025     | 18412/40/2  | Reference count   | 4E-10<br>2E 15 | 0.70 | 2/003232 |
| 9<br>10 | 34703099  | SVA_402      | 18113/4914  | Recurratoria artificias   | ZE-13          | 0.70 | 24390342 |
| 12      | 28103331  | ALU_9104     | rs10771399  | Breast cancer   | 3E-34          | 0.70 | 20029206 |
| З       | 105419456 | ALU_25//     | rs5//14592  | Educational attainment (many of                                   | TE-08          | 0.70 | 30038396 |
| 3       | 175673943 | ALU_2951     | rs57939424  | educational attainment (years of                                  | 2E-13          | 0.70 | 30038396 |
| 1       | 227502452 | ALU_841      | rs112779011 | Hair color  | 7E-11          | 0.70 | 30595370 |
|         |           |              |             | Chronic inflammatory diseases                                     |                |      |          |
|         |           |              |             | (ankylosing spondylitis, Crohn's                                  |                |      |          |
| 9       | 34703699  | SVA_402      | rs2812378   | disease, psoriasis, primary<br>sclerosing cholangitis, ulcerative | 6E-09          | 0.70 | 26974007 |
|         |           |              |             | colitis) (pleiotropy)   |                |      |          |
| 9       | 34703699  | SVA_402      | rs2812378   | Rheumatoid arthritis (ACPA-<br>positive)                          | 5E-11          | 0.70 | 24532676 |
| 3       | 182299013 | ALU_2986     | rs7652216   | Body mass index   | 3E-08          | 0.69 | 30595370 |
| 17      | 44153977  | SVA_706      | rs417968    | education)  | 6E-16          | 0.69 | 30595370 |
| 4       | 145395308 | ALU_3782     | rs13142879  | Post bronchodilator FEV1  | 1E-11          | 0.69 | 26634245 |
| 4       | 145395308 | ALU_3782     | rs35440220  | Post bronchodilator FEV1  | 2E-11          | 0.69 | 26634245 |
| 4       | 145395308 | ALU_3782     | rs7656246   | Post bronchodilator FEV1  | 1E-11          | 0.69 | 26634245 |
| 4       | 145395308 | ALU_3782     | rs1813337   | Post bronchodilator FEV1  | 2E-11          | 0.69 | 26634245 |
| 4       | 145395308 | ALU_3782     | rs1961266   | Post bronchodilator FEV1  | 2E-11          | 0.69 | 26634245 |
| 4       | 145395308 | ALU_3782     | rs56304346  | Post bronchodilator FEV1  | 6E-11          | 0.69 | 26634245 |
| 4       | 145395308 | ALU_3782     | rs7666298   | Post bronchodilator FEV1  | 2E-11          | 0.69 | 26634245 |
| 7       | 91751552  | ALU_6200     | rs10644111  | Breast cancer   | 3E-11          | 0.69 | 29059683 |
| 7       | 91751552  | ALU_6200     | rs6964587   | Breast cancer   | 9E-11          | 0.69 | 29059683 |
| 17      | 44153977  | SVA_706      | rs4630591   | Feeling fed-up  | 1E-17          | 0.69 | 29500382 |
|         |           |              |             |   |                |      |          |

| 13           | 46647748             | ALU_9748            | rs9526137   | Blood protein levels  | 2E-15           | 0.69 | 29875488 |
|--------------|----------------------|---------------------|-------------|---|-----------------|------|----------|
| 13           | 46647748             | ALU_9748            | rs9526138   | Blood protein levels  | 1E-109          | 0.69 | 29875488 |
| 6            | 70327733             | ALU_5250            | rs7761673   | Body mass index   | 5E-11           | 0.69 | 30595370 |
| 13           | 46647748             | ALU_9748            | rs3742264   | Blood protein levels  | 3E-83           | 0.69 | 28240269 |
|              |                      |                     |             | Waist circumference adjusted                                      |                 |      |          |
|              |                      |                     |             | for BMI (joint analysis main                                      |                 |      |          |
| 12           | 28417298             | ALU_9107            | rs10843151  | effects and physical activity                                     | 1E-09           | 0.69 | 28448500 |
|              |                      |                     |             | interaction)  |                 |      |          |
| 13           | 46647748             | ALU 9748            | rs9567617   | Blood protein levels  | 5E-109          | 0.69 | 29875488 |
| 21           | 28221359             | ALU 12341           | rs162531    | Lung function (FEV1/FVC)  | 8E-11           | 0.69 | 30595370 |
| 4            | 145395308            | ALU 3782            | rs1505770   | Post bronchodilator FEV1  | 2E-11           | 0.68 | 26634245 |
| 4            | 145395308            | ALU 3782            | rs2130499   | Post bronchodilator FEV1  | 2E-11           | 0.68 | 26634245 |
| 1            | 145395308            | ALU 3782            | rs55694701  | Post bronchodilator FEV1  | 2E 11<br>1E 11  | 0.68 | 26634245 |
| т<br>Л       | 145395308            | ALU 3782            | rs56268708  | Post bronchodilator FEV1  | 2E 11           | 0.00 | 26634245 |
| т<br>1       | 145305308            | ALU 3782            | rs62334742  | Post bronchodilator FEV1  | 2E-11<br>2E-11  | 0.00 | 26634245 |
| +<br>12      | 145595500            | ALU_9782            | 1802334742  | Placed protein levels   | 212-11          | 0.00 | 20034243 |
| 15           | 40047740             | ALU_9740            | 184942471   | Broast as peop  | 9E-115<br>9E-11 | 0.00 | 20050692 |
| 7            | 91751552             | ALU_6200            | 185541/51/  | Breast cancer   | 0E-11<br>1E-00  | 0.08 | 29059065 |
| /            | 91/51552             | ALU_6200            | r\$35522438 | Breast cancer   | 1E-09           | 0.68 | 29059685 |
| 7            | 91751552             | ALU_6200            | rs6465353   | Educational attainment (years of                                  | 3E-08           | 0.68 | 30038396 |
|              | 111015001            |                     |             | education)  | <b>2 1 1 1</b>  | 0.40 | 00505050 |
| 3            | 114915094            | ALU_2641            | rs/64361/   | Menarche (age at onset)   | 3E-11           | 0.68 | 30595370 |
| 11           | 49282683             | ALU_8572            | rs11040204  | Intraocular pressure  | 4E-14           | 0.68 | 29617998 |
| 11           | 49282683             | ALU_8572            | rs2202454   | Medication use (diuretics)  | 8E-11           | 0.68 | 31015401 |
| 16           | 75655176             | ALU 11116           | rs117657830 | Smoking initiation (ever regular                                  | 3E-09           | 0.68 | 30643251 |
|              |                      | _                   |             | vs never regular)   |                 |      |          |
| 8            | 8920127              | ALU_6560            | rs2953805   | Neuroticism   | 2E-29           | 0.68 | 29255261 |
| 6            | 97017683             | ALU_5395            | rs11759769  | Migraine  | 2E-12           | 0.68 | 23793025 |
| 17           | 44153977             | SVA_706             | rs4327090   | Highest math class taken  | 1E-10           | 0.68 | 30038396 |
| 2            | 11353711             | ALU_1002            | rs56211149  | Height  | 2E-13           | 0.68 | 30595370 |
| 7            | 120538086            | ALU_6336            | rs201852005 | Heel bone mineral density   | 4E-14           | 0.68 | 30048462 |
| 7            | 120538086            | ALU_6336            | rs73427834  | Heel bone mineral density   | 1E-47           | 0.68 | 30595370 |
| 8            | 8920127              | ALU_6560            | rs2921378   | Neuroticism   | 1E-27           | 0.68 | 30643256 |
| 3            | 110271029            | ALU_2610            | rs1398346   | Chronotype  | 4E-08           | 0.68 | 30696823 |
| 17           | 44153977             | SVA_706             | rs199529    | Intraocular pressure  | 4E-08           | 0.68 | 30054594 |
| 18           | 53146075             | ALU_11714           | rs4801157   | Depressed affect  | 2E-10           | 0.68 | 29942085 |
| 3            | 175673943            | ALU_2951            | rs72622559  | Educational attainment  | 6E-13           | 0.68 | 30038396 |
| 6            | 66163982             | ALU_5227            | rs7449561   | Educational attainment  | 1E-11           | 0.67 | 30038396 |
| 12           | 28417298             | ALU_9107            | rs11049611  | Height  | 3E-32           | 0.67 | 25282103 |
| 7            | 38209213             | ALU_5970            | rs9801416   | Height  | 2E-09           | 0.67 | 30595370 |
| 1            | 191477465            | ALU_689             | rs677325    | Subjective well-being   | 1E-08           | 0.67 | 29292387 |
| 17           | 32629274             | ALU_11283           | rs9906695   | Monocyte percentage of white                                      | 3E-11           | 0.67 | 27863252 |
| 17           | 32629274             | ALU_11283           | rs9909465   | Granulocyte percentage of<br>myeloid white cells                  | 1E-09           | 0.67 | 27863252 |
| 11           | 49282683             | ALU_8572            | rs10839204  | Medication use (agents acting on<br>the renin-angiotensin system) | 2E-09           | 0.67 | 31015401 |
| 9            | 4237141              | ALU 7235            | rs6476827   | Intraocular pressure  | 5E-33           | 0.67 | 29617998 |
| 8            | 71914591             | ALU 6806            | rs7007887   | Snoring   | 1E-13           | 0.67 | 30804565 |
| 14           | 60741400             | ALU 10351           | rs1887103   | Hair color  | 3E-16           | 0.67 | 30595370 |
| 1 <b>-</b> † | 04059497             | I NE1 1062          | rs7048045   | Male pattern haldnoss   | 7E 10           | 0.67 | 30572740 |
| プ<br>10      | 2403040/<br>46074002 | $\Delta I I = 7024$ | 15/040243   | I umphocute counts  | 7E-10<br>2E 00  | 0.07 | 2706225  |
| 10           | 400/4093             | MLU_/934            | 151/13/030  | Lymphocyte counts   | ZE-09           | 0.07 | 21003232 |
| 10           | 46074893             | ALU_7934            | rs34731408  | cells   | 7E-10           | 0.67 | 27863252 |
| 10           | 46074893             | ALU_7934            | rs34897497  | Mean corpuscular volume   | 1E-52           | 0.67 | 27863252 |
| 10           | 46074893             | ALU_7934            | rs35993099  | Red blood cell count  | 2E-44           | 0.67 | 27863252 |

| 10      | 46074893  | ALU_7934  | rs76493570     | Immature fraction of                       | 4E-52           | 0.67 | 27863252             |
|---------|-----------|-----------|----------------|--|-----------------|------|----------------------|
| 10      | 46074893  | ALU 7934  | rs901683       | Red blood cell traits                      | 2E-16           | 0.67 | 23222517             |
| 3       | 36839159  | ALU 2289  | rs75968099     | Schizophrenia                              | 1E-13           | 0.67 | 25056061             |
| 12      | 28417298  | ALU 9107  | rs10843164     | Height                                     | 6E-12           | 0.00 | 23563607             |
| 2       | 198763462 | ALU 1894  | rs57862683     | Morning person                             | 1E-12           | 0.00 | 30696823             |
| 2       | 174952231 | SVA 134   | rs77345174     | Blood protein levels                       | 0E 15           | 0.00 | 30072576             |
| 2<br>17 | 1/4/32231 | SVA_706   | rs7207400      | Height                                     | 2E-15           | 0.00 | 30595370             |
| 17      | 44153977  | SVA_706   | rs7207400      | Worry                                      | 2E-30<br>2E-15  | 0.00 | 20042085             |
| 15      | 49609604  | ALU 10695 | rs10519227     | Thuroid hormone levels                     | 1E 11           | 0.00 | 23/08006             |
| 3       | 157962934 | ALU 2845  | rs73030851     | Blood protein levels                       | 1E-11<br>1E 300 | 0.00 | 30072576             |
| 15      | 107902904 | ALU 10605 | 1575050651     | Lung function (EEV1 /EVC)                  | 1E-300<br>4E-12 | 0.00 | 20505270             |
| 15<br>2 | 49009004  | ALU_10095 | 15/10/032      | Mean corpuscular homoglobin                | 4E-13           | 0.00 | 30595370             |
| 2       | 101000/40 | ALU_1605  | 184303162      | Rich taking tondongy (4 domain             | JE-11           | 0.00 | 30393370             |
| 2       | 181880746 | ALU_1805  | rs79719017     | Risk-taking tendency (4-domain             | 4E-08           | 0.66 | 30643258             |
|         |           |           |                | Suminal in colonatel concer                |                 |      |                      |
| 6       | 53167475  | ALU_5181  | rs209489       | (distant motostatio)                       | 8E-10           | 0.66 | 26586795             |
| 1       | 210559010 | ATTI 010  | -17525022      | (distant metastatic)                       | 217 27          | 0.65 | 20505270             |
| 1       | 219558910 | ALU_810   | rs1/525055     | Character (a single and b)                 | 2E-2/           | 0.65 | 30393370             |
| 9       | 4237141   | ALU_7235  | rs736893       | Glaucoma (primary angle                    | 1E-14           | 0.65 | 27064256             |
|         |           |           |                | closure)                                   |                 |      |                      |
| 17      | 44153977  | SVA_706   | rs56214516     | Medication use (antithrombotic             | 1E-08           | 0.65 | 31015401             |
| 17      | 44452077  | STA 704   | E ( 01 4 E 1 ( | agents)                                    | 11 17           | 0.65 | 20500202             |
| 1/      | 44153977  | SVA_/06   | rs56214516     | Feeling ted-up                             | 1E-16<br>2E-10  | 0.65 | 29500382             |
| 2       | 198/63462 | ALU_1894  | rs1025549      | Eczema                                     | 3E-19           | 0.65 | 30595370             |
| 2       | 198/63462 | ALU_1894  | rs6/38825      | Cronn's disease                            | 4E-09           | 0.65 | 21102463             |
| 9       | 11/928281 | ALU_/6/2  | rs3833490      | Blood protein levels                       | 6E-224          | 0.65 | 298/5488             |
| 10      | 460/4893  | ALU_7934  | rs34285816     | Red blood cell count                       | 6E-49           | 0.65 | 30595370             |
| 10      | 460/4893  | ALU_/934  | rs/1494/99     | Mean corpuscular hemoglobin                | 9E-138          | 0.65 | 30595370             |
| 3       | 85576571  | LINE1_629 | rs1375561      | Cognitive performance                      | 2E-15           | 0.65 | 30038396             |
| 3       | 85576571  | LINE1_629 | rs/314154/     | Highest math class taken                   | 1E-16           | 0.65 | 30038396             |
| 3       | 55/88580  | LINE1_590 | rs6801405      | Lung function (FEV1/FVC)                   | 6E-12           | 0.65 | 30595370             |
| 1       | 194595960 | ALU_707   | rs13376197     | Cerebrospinal fluid t-tau:AB1-<br>42 ratio | 3E-10           | 0.65 | 28641921             |
| 12      | 28438612  | ALU_9108  | rs1581630      | Heel bone mineral density                  | 7E-30           | 0.65 | 30048462             |
| 6       | 74504855  | ALU_5280  | rs10943130     | Heel bone mineral density                  | 1E-40           | 0.65 | 30048462             |
| 15      | 49609604  | ALU_10695 | rs17400427     | Lung adenocarcinoma                        | 6E-10           | 0.65 | 28604730             |
| 11      | 49282683  | ALU_8572  | rs113221947    | Heel bone mineral density                  | 2E-09           | 0.64 | 30595370             |
| 2       | 181880746 | ALU_1805  | rs10184839     | Diastolic blood pressure                   | 2E-13           | 0.64 | 30224653             |
| 10      | 106566893 | ALU_8208  | rs2864034      | Self-reported math ability                 | 2E-16           | 0.64 | 30038396             |
| 10      | 54466942  | ALU_7961  | rs12218358     | Heel bone mineral                          | 7E-58           | 0.64 | 30595370             |
| 7       | 33195329  | ALU 5942  | rs10232036     | density/Height<br>Height                   | 5E-11           | 0.64 | 30595370             |
| 12      | 20473893  | ALU 9052  | rs11045171     | HDL cholesterol                            | 2E-18           | 0.64 | 30275531             |
| 10      | 11984965  | ALU 7788  | rs11819344     | Mean corpuscular hemoglobin                | 4E-09           | 0.64 | 30595370             |
| 20      | 1546228   | ALU 12014 | rs3848788      | Blood protein levels                       | 1E-213          | 0.64 | 29875488             |
| 6       | 74504855  | ALU 5280  | rs6903575      | Blood protein levels                       | 7E-69           | 0.64 | 29875488             |
| 5       | 148096780 | ALU 4747  | rs58862611     | Systolic blood pressure                    | 4E-08           | 0.64 | 30595370             |
| 6       | 74504855  | ALU 5280  | rs10455097     | Blood protein levels                       | 3E-46           | 0.64 | 28240269             |
| 7       | 78146522  | ALU 6127  | rs62468583     | Menarche (age at onset)                    | 3E-08           | 0.64 | 30595370             |
| 8       | 13975433  | ALU 6584  | rs12675921     | Intelligence                               | 2E-08           | 0.64 | 20042086             |
| 8       | 100782570 | ATT 6021  | re021212       | Mean corpuscular hemoglobin                | 2E-00<br>3E 12  | 0.04 | 30505270             |
| 6       | 163013855 | ALU_0901  | rs36007625     | Body mass index                            | 7E 14           | 0.04 | 30595570             |
| 2       | 08582157  | ALU_3742  | re4851167      | Diastolic blood pressure                   | 7 E-14<br>6日 12 | 0.04 | 30333370             |
| 2       | 181880746 | ATT 1805  | re10101550     | Heel hone mineral density                  | 0E 22           | 0.04 | 30505270             |
| 2<br>2  | 101000/40 | ATT 1805  | rs10191339     | Red blood cell count                       | 7E-32<br>AE 10  | 0.04 | 20222270<br>27862250 |
| ∠<br>11 | 101000/40 |           | ro(1110760     | Systelic blood processes                   | 4E-10<br>4E-00  | 0.04 | 27011070             |
| 11      | 47707093  | MLU_00/2  | 1501440/02     | Systone blood pressure                     | 412-09          | 0.04 | 2/0410/8             |

| 3  | 103419436 | ALU_2577       | rs6776198   | Highest math class taken                                       | 1E-12     | 0.64      | 30038396 |
|----|-----------|----------------|-------------|--|-----------|-----------|----------|
| 2  | 174952231 | SVA_134        | rs77998199  | Reaction time  | 2E-10     | 0.64      | 29844566 |
| 6  | 74504855  | ALU_5280       | rs6909201   | Blood protein levels   | 1E-115    | 0.63      | 30072576 |
| 10 | 3569025   | ALU_7750       | rs10795055  | Waist-hip ratio  | 6E-10     | 0.63      | 30595370 |
| 9  | 4237141   | ALU_7235       | rs1570204   | Intraocular pressure   | 7E-31     | 0.63      | 29617998 |
| 13 | 62588972  | ALU_9847       | rs17208030  | Educational attainment (years of education)                    | 4E-10     | 0.63      | 30595370 |
| 7  | 119259819 | ALU_6325       | rs73719951  | Heel bone mineral density                                      | 7E-09     | 0.63      | 30595370 |
| 2  | 198763462 | ALU_1894       | rs10497813  | Self-reported allergy  | 6E-10     | 0.63      | 23817569 |
| 11 | 55408899  | ALU_8584       | rs7104561   | Medication use (agents acting on the renin-angiotensin system) | 5E-08     | 0.63      | 31015401 |
| 4  | 145395308 | ALU_3782       | rs13142776  | Post bronchodilator FEV1                                       | 2E-12     | 0.63      | 26634245 |
| 4  | 145395308 | ALU_3782       | rs1512283   | Post bronchodilator FEV1                                       | 1E-10     | 0.63      | 26634245 |
| 4  | 145395308 | ALU_3782       | rs1960493   | Post bronchodilator FEV1                                       | 1E-10     | 0.63      | 26634245 |
| 4  | 145395308 | ALU_3782       | rs34265962  | Post bronchodilator FEV1                                       | 1E-12     | 0.63      | 26634245 |
| 4  | 145395308 | ALU_3782       | rs35937742  | Post bronchodilator FEV1                                       | 1E-10     | 0.63      | 26634245 |
| 4  | 145395308 | ALU_3782       | rs7678427   | Post bronchodilator FEV1                                       | 1E-12     | 0.63      | 26634245 |
| 4  | 145395308 | ALU_3782       | rs973796    | Post bronchodilator FEV1                                       | 3E-12     | 0.63      | 26634245 |
| 1  | 198243300 | ALU 726        | rs1938376   | Height   | 2E-08     | 0.63      | 30595370 |
| 4  | 145395308 | ALU 3782       | rs1512282   | Post bronchodilator FEV1                                       | 4E-11     | 0.63      | 26634245 |
| 17 | 44153977  | SVA 706        | rs113322852 | Neuroticism  | 3E-19     | 0.63      | 30643256 |
| 11 | 49282683  | ALU 8572       | rs7929717   | Intraocular pressure   | 1E-15     | 0.63      | 29617998 |
| 17 | 44153977  | SVA 706        | rs183211    | Ovarian cancer   | 2E-13     | 0.63      | 25581431 |
| 15 | 47507342  | LINE1 2640     | rs12442330  | Neuroticism  | 2E-10     | 0.63      | 29942085 |
| 3  | 168885760 | ALU 2909       | rs9290361   | Plateletcrit   | 1E-22     | 0.63      | 27863252 |
| 3  | 158089835 | ALU 2846       | rs1714510   | Neuroticism  | 2E-08     | 0.62      | 29942085 |
| 9  | 33130564  | SVA 401        | rs10971420  | In Galycosylation patterns                                     | 2E-00     | 0.62      | 29535710 |
| ,  | 55150504  | 5 • 11_+01     | 13107/1420  | Thrombin activatable   | 211-12    | 0.02      | 27555710 |
| 13 | 46647748  | ALU_9748       | rs1087      | fibrinolysis inhibitor levels                                  | 3E-29     | 0.62      | 29378355 |
| 10 | 54466942  | ALU 7961       | rs7088220   | Heel bone mineral density                                      | 2E-54     | 0.62      | 30048462 |
| 11 | 49366217  | ALU 8573       | rs7929543   | Type 2 diabetes  | 2E-09     | 0.62      | 30054458 |
| 10 | 106566893 | ALU 8208       | rs10400054  | Highest math class taken                                       | 2E-11     | 0.62      | 30038396 |
| 10 | 106566893 | ALU 8208       | rs17118088  | Highest math class taken                                       | 5E-18     | 0.62      | 30038396 |
| 11 | 65503489  | _<br>ALU_8620  | rs478304    | Spherical equivalent or myopia<br>(age of diagnosis)           | 1E-09     | 0.62      | 29808027 |
| 11 | 65503489  | ALU_8620       | rs478304    | Acne (severe)  | 3E-11     | 0.62      | 24927181 |
| 17 | 44153977  | SVA_706        | rs56192752  | Educational attainment (years of education)                    | 9E-31     | 0.62      | 30038396 |
| 9  | 117928281 | ALU_7672       | rs35157100  | Blood protein levels   | 3E-96     | 0.62      | 29875488 |
| 4  | 112628973 | LINE1 928      | rs9991259   | Body mass index  | 1E-10     | 0.62      | 30595370 |
| 15 | 73983319  | _<br>ALU_10812 | rs8038465   | Liver enzyme levels (gamma-<br>glutamyl transferase)           | 1E-09     | 0.62      | 22001757 |
| 3  | 85576571  | LINE1 629      | rs55686445  | Educational attainment   | 5E-12     | 0.62      | 27046643 |
| 3  | 85576571  | LINE1 629      | rs66568921  | Educational attainment   | 6E-39     | 0.62      | 30038396 |
| 12 | 41847723  | ALU 9169       | rs1458156   | Body mass index  | 3E-15     | 0.62      | 30595370 |
| 17 | 44153977  | SVA 706        | rs1879586   | Serous invasive ovarian cancer                                 | 3E-12     | 0.62      | 28346442 |
| 17 | 44153977  | SVA_706        | rs1879586   | Ovarian cancer   | 2E-19     | 0.62      | 28346442 |
| 17 | 44153977  | SVA_706        | rs916888    | Lung function (EEV1)   | 4E-09     | 0.62      | 30061609 |
| 9  | 94058487  | LINE1 1863     | rs112679102 | Balding type 1   | 1E-10     | 0.02      | 30595370 |
| 6  | 74504855  | ALU 5280       | rs9447004   | Blood protein levels   | 2E-44     | 0.02      | 28240269 |
| 12 | 71525470  | ALU 9320       | rs7138300   | Type 2 diabetes  | 6E-10     | 0.62      | 30054459 |
| 5  | 87300827  | ALU 4449       | rs55940342  | Systolic blood pressure  | 1E_12     | 0.62      | 30595370 |
| 8  | 8920127   | ALU 6560       | rs4537305   | Medication use (diuretics)                                     | 1E-14     | 0.61      | 31015401 |
| 12 | 28417298  | ALU 9107       | rs1511550   | Height   | 3E-114    | 0.61      | 30595370 |
|    |           |                |             |  | ~ ~ ~ ~ 1 | ~ • • • • | 2.270010 |

| 12 | 71525479  | ALU_9320   | rs11178649 | Respiratory diseases                                  | 3E-09 | 0.61 | 30595370 |
|----|-----------|------------|------------|---|-------|------|----------|
| 12 | 71525479  | ALU_9320   | rs7955901  | Type 2 diabetes                                       | 7E-09 | 0.61 | 22885922 |
| 6  | 139294734 | ALU_5628   | rs62441842 | Height  | 3E-13 | 0.61 | 30595370 |
| 3  | 175673943 | ALU_2951   | rs66481714 | Smoking initiation (ever regular<br>vs never regular) | 3E-10 | 0.61 | 30643251 |
| 9  | 17062597  | ALU_7312   | rs78817479 | Heel bone mineral density                             | 1E-12 | 0.61 | 30048462 |
| 12 | 26697612  | ALU_9091   | rs11613431 | Educational attainment (years of education)           | 7E-09 | 0.61 | 30038396 |
| 5  | 87399827  | ALU_4449   | rs17286052 | Blood pressure  | 7E-11 | 0.61 | 27841878 |
| 10 | 27929928  | ALU_7862   | rs1494204  | Waist-hip ratio                                       | 4E-12 | 0.61 | 30595370 |
| 13 | 61734497  | LINE1_2424 | rs9563886  | Insomnia  | 2E-08 | 0.61 | 30804565 |
| 3  | 36839159  | ALU_2289   | rs6550435  | Bipolar disorder                                      | 2E-08 | 0.61 | 24618891 |
| 3  | 16796099  | ALU_2173   | rs7625399  | Smoking cessation                                     | 9E-10 | 0.60 | 30643251 |
| 3  | 175673943 | ALU_2951   | rs9841807  | Smoking initiation (ever regular vs never regular)    | 1E-08 | 0.60 | 30643251 |
| 3  | 36839159  | ALU_2289   | rs3732386  | Schizophrenia   | 3E-11 | 0.60 | 28991256 |
| 2  | 141534074 | ALU_1585   | rs17515225 | Motion sickness                                       | 3E-09 | 0.60 | 25628336 |
|    |           |            |            |   |       |      |          |

**Appendix 3:** RTE-TAS associations in the literature compared to the results of this study.

Table 23: List of RTEs in LD ( $r^2 > 0.6$ ) with TAS identified by previous studies in the literature and how it compares to RTE-TAS associations identified by this study. Y = Yes. N = No

| TAS        | RTE type | r2   | Study   | PMID     | Data source            | Replicated? |  |
|------------|----------|------|---------|----------|------------------------|-------------|--|
| rs2679073  | ALU      | 0.80 | Sudmant | 26432246 | Supplementary Table 10 | Ν           |  |
| rs2942168  | SVA      | 0.84 | Sudmant | 26432246 | Supplementary Table 10 | Υ           |  |
| rs12185268 | SVA      | 0.84 | Sudmant | 26432246 | Supplementary Table 10 | Υ           |  |
| rs1864325  | SVA      | 0.84 | Sudmant | 26432246 | Supplementary Table 10 | Υ           |  |
| rs12373124 | SVA      | 0.84 | Sudmant | 26432246 | Supplementary Table 10 | Υ           |  |
| rs1981997  | SVA      | 0.83 | Sudmant | 26432246 | Supplementary Table 10 | Υ           |  |
| rs7534016  | ALU      | 0.75 | Wang    | 28824558 | Supplementary Table S1 | Ν           |  |
| rs28588043 | ALU      | 0.74 | Wang    | 28824558 | Supplementary Table S1 | Ν           |  |
| rs2820037  | ALU      | 0.84 | Wang    | 28824558 | Supplementary Table S1 | Ν           |  |
| rs10189761 | ALU      | 0.77 | Wang    | 28824558 | Supplementary Table S1 | Ν           |  |
| rs2681019  | L1       | 0.75 | Wang    | 28824558 | Supplementary Table S1 | Ν           |  |
| rs10496262 | ALU      | 0.72 | Wang    | 28824558 | Supplementary Table S1 | Ν           |  |
| rs2163349  | ALU      | 0.77 | Wang    | 28824558 | Supplementary Table S1 | Ν           |  |
| rs7594648  | L1       | 0.70 | Wang    | 28824558 | Supplementary Table S1 | Ν           |  |
| rs10865924 | ALU      | 0.78 | Wang    | 28824558 | Supplementary Table S1 | Ν           |  |
| rs9841504  | ALU      | 0.75 | Wang    | 28824558 | Supplementary Table S1 | Ν           |  |
| rs13077101 | ALU      | 0.71 | Wang    | 28824558 | Supplementary Table S1 | Ν           |  |
| rs345013   | ALU      | 0.82 | Wang    | 28824558 | Supplementary Table S1 | Ν           |  |
| rs7442317  | ALU      | 0.75 | Wang    | 28824558 | Supplementary Table S1 | Ν           |  |
| rs10034228 | L1       | 0.87 | Wang    | 28824558 | Supplementary Table S1 | Ν           |  |
| rs16886364 | ALU      | 0.76 | Wang    | 28824558 | Supplementary Table S1 | Y           |  |
| rs4388249  | ALU      | 0.80 | Wang    | 28824558 | Supplementary Table S1 | Y           |  |
| rs2523822  | ALU      | 0.77 | Wang    | 28824558 | Supplementary Table S1 | Ν           |  |
| rs4530903  | ALU      | 0.78 | Wang    | 28824558 | Supplementary Table S1 | Ν           |  |
| rs3077     | SVA      | 0.81 | Wang    | 28824558 | Supplementary Table S1 | Ν           |  |
| rs10948222 | ALU      | 0.75 | Wang    | 28824558 | Supplementary Table S1 | Y           |  |
| rs9357506  | L1       | 0.76 | Wang    | 28824558 | Supplementary Table S1 | Ν           |  |
| rs11757063 | ALU      | 0.72 | Wang    | 28824558 | Supplementary Table S1 | Ν           |  |
| rs12666612 | ALU      | 0.79 | Wang    | 28824558 | Supplementary Table S1 | Ν           |  |
| rs1404697  | ALU      | 0.82 | Wang    | 28824558 | Supplementary Table S1 | Ν           |  |
| rs16939046 | ALU      | 0.72 | Wang    | 28824558 | Supplementary Table S1 | Ν           |  |
| rs11574914 | SVA      | 0.70 | Wang    | 28824558 | Supplementary Table S1 | Υ           |  |
| rs7028939  | ALU      | 0.78 | Wang    | 28824558 | Supplementary Table S1 | Ν           |  |
| rs10768747 | L1       | 0.88 | Wang    | 28824558 | Supplementary Table S1 | Ν           |  |
| rs11246602 | ALU      | 0.70 | Wang    | 28824558 | Supplementary Table S1 | Ν           |  |
| rs12371778 | ALU      | 0.81 | Wang    | 28824558 | Supplementary Table S1 | Ν           |  |
| rs11049611 | ALU      | 0.71 | Wang    | 28824558 | Supplementary Table S1 | Y           |  |
| rs1979679  | ALU      | 0.74 | Wang    | 28824558 | Supplementary Table S1 | Ν           |  |
| rs11575234 | ALU      | 0.84 | Wang    | 28824558 | Supplementary Table S1 | Ν           |  |
| rs17788937 | ALU      | 0.79 | Wang    | 28824558 | Supplementary Table S1 | Y           |  |
| rs8023445  | ALU      | 0.78 | Wang    | 28824558 | Supplementary Table S1 | Ν           |  |
| rs1436958  | ALU      | 0.71 | Wang    | 28824558 | Supplementary Table S1 | Ν           |  |

| rs12373124              | SVA            | 0.85 | Wang          | 28824558 | Supplementary Table S1 | Y        |
|-------------------------|----------------|------|---------------|----------|------------------------|----------|
| rs9303542               | ALU            | 0.73 | Wang          | 28824558 | Supplementary Table S1 | Ν        |
| rs816535                | ALU            | 0.81 | Wang          | 28824558 | Supplementary Table S1 | Ν        |
| rs12530                 | ALU            | 0.75 | Wang          | 28824558 | Supplementary Table S1 | Ν        |
| rs426736                | ALU            | 0.77 | Wang          | 28824558 | Supplementary Table S1 | Ν        |
| rs426736                | ALU            | 0.79 | Wang          | 28824558 | Supplementary Table S1 | Ν        |
| rs1585471               | L1             | 0.79 | Wang          | 28824558 | Supplementary Table S1 | Ν        |
| rs2523822               | ALU            | 0.84 | Wang          | 28824558 | Supplementary Table S1 | Ν        |
| rs225675                | L1             | 0.71 | Wang          | 28824558 | Supplementary Table S1 | Ν        |
| rs12554999              | L1             | 0.76 | Wang          | 28824558 | Supplementary Table S1 | Ν        |
| rs7947821               | ALU            | 0.78 | Wang          | 28824558 | Supplementary Table S1 | Ν        |
| rs2250417               | L1             | 0.72 | Wang          | 28824558 | Supplementary Table S1 | Ν        |
| rs1340490               | ALU            | 0.70 | Wang          | 28824558 | Supplementary Table S1 | Ν        |
| rs6117615               | ALU            | 0.80 | Wang          | 28824558 | Supplementary Table S1 | Ν        |
| rs816535                | ALU            | 0.75 | Wang          | 28824558 | Supplementary Table S1 | Ν        |
| rs7534016               | ALU            | 0.90 | Hehir-Kwa     | 27708267 | Supplementary Data 7   | Ν        |
| rs4085613               | L1             | 0.93 | Hehir-Kwa     | 27708267 | Supplementary Data 7   | Ν        |
| rs4112788               | L1             | 0.92 | Hehir-Kwa     | 27708267 | Supplementary Data 7   | Ν        |
| rs12185268              | SVA            | 0.92 | Hehir-Kwa     | 27708267 | Supplementary Data 7   | Y        |
| rs12027542              | ALU            | 0.96 | Hehir-Kwa     | 27708267 | Supplementary Data 7   | N        |
| rs2820037               | ALU            | 0.91 | Hehir-Kwa     | 27708267 | Supplementary Data 7   | N        |
| rs2681019               | L1             | 0.92 | Hehir-Kwa     | 27708267 | Supplementary Data 7   | N        |
| rs10496262              | ALU            | 0.92 | Hehir-Kwa     | 27708267 | Supplementary Data 7   | N        |
| rs6741172               | ALU            | 0.94 | Hehir-Kwa     | 27708267 | Supplementary Data 7   | N        |
| rs2163349               | ALU            | 0.93 | Hehir-Kwa     | 27708267 | Supplementary Data 7   | N        |
| rs10865924              | ALU            | 0.92 | Hehir-Kwa     | 27708267 | Supplementary Data 7   | N        |
| rs7442317               | ALU            | 0.92 | Hebir-Kwa     | 27708267 | Supplementary Data 7   | N        |
| rs10034228              | L1             | 0.95 | Hehir-Kwa     | 27708267 | Supplementary Data 7   | N        |
| rs1585471               | I 1            | 0.95 | Hebir-Kwa     | 27708267 | Supplementary Data 7   | N        |
| rs10053502              | I 1            | 0.95 | Hebir-Kwa     | 27708267 | Supplementary Data 7   | V        |
| rs4388249               | ALU            | 0.92 | Hebir-Kwa     | 27708267 | Supplementary Data 7   | V        |
| rs2523822               | ALU            | 0.92 | Hebir-Kwa     | 27708267 | Supplementary Data 7   | N        |
| rs1061235               | ALU            | 0.93 | Hebir-Kwa     | 27708267 | Supplementary Data 7   | N        |
| rs12185268              | SVA            | 0.93 | Hebir Kwa     | 27708267 | Supplementary Data 7   | N        |
| rs10948222              | ALU            | 0.94 | Hehir-Kwa     | 27708267 | Supplementary Data 7   | Y        |
| rs11757063              | ALU            | 0.92 | Hehir-Kwa     | 27708267 | Supplementary Data 7   | N        |
| rs848353                | ALU            | 0.92 | Hehir-Kwa     | 27708267 | Supplementary Data 7   | N        |
| rs1404697               | ALU            | 0.96 | Hehir-Kwa     | 27708267 | Supplementary Data 7   | N        |
| rs12344488              | ALU            | 0.90 | Hehir-Kwa     | 27708267 | Supplementary Data 7   | N        |
| rs12554999              | I 1            | 0.95 | Hebir-Kwa     | 27708267 | Supplementary Data 7   | N        |
| rs10771399              | ALU            | 0.95 | Hebir-Kwa     | 27708267 | Supplementary Data 7   | V        |
| rs1979679               | ALU            | 0.92 | Hebir-Kwa     | 27708267 | Supplementary Data 7   | N        |
| rs1612141               | L1             | 0.92 | Hehir-Kwa     | 27708267 | Supplementary Data 7   | N        |
| rs1436958               | ALU            | 0.90 | Hebir-Kwa     | 27708267 | Supplementary Data 7   | N        |
| rs2679073               | ALU            | 0.96 | Hebir-Kwa     | 27708267 | Supplementary Data 7   | N        |
| rs225212                | ALU            | 0.90 | Hebir-Kwa     | 27708267 | Supplementary Data 7   | N        |
| rs12373124              | SVA            | 0.92 | Hehir-Kwa     | 27708267 | Supplementary Data 7   | ı N<br>V |
| rs17577004              | SVA            | 0.95 | Hehir-Kwa     | 27708267 | Supplementary Data 7   | N        |
| rs17640552              | SVA            | 0.93 | Hebir Kura    | 27708267 | Supplementary Data 7   |          |
| 1317049000<br>ro1864205 | SV IN<br>SVI A | 0.24 | Hohin Vm      | 27708267 | Supplementary Data 7   | 1<br>V   |
| 151004323               | SVA            | 0.94 | 1 ICIIII-INWA | 21100201 | Supprementary Data /   | 1        |

| rs1981997  | SVA | 0.95 | Hehir-Kwa | 27708267 | Supplementary Data 7 | Y |
|------------|-----|------|-----------|----------|----------------------|---|
| rs2942168  | SVA | 0.94 | Hehir-Kwa | 27708267 | Supplementary Data 7 | Y |
| rs3077     | SVA | 0.94 | Hehir-Kwa | 27708267 | Supplementary Data 7 | Ν |
| rs3790672  | SVA | 0.91 | Hehir-Kwa | 27708267 | Supplementary Data 7 | Ν |
| rs393152   | SVA | 0.94 | Hehir-Kwa | 27708267 | Supplementary Data 7 | Y |
| rs8070723  | SVA | 0.95 | Hehir-Kwa | 27708267 | Supplementary Data 7 | Y |
| rs9303525  | SVA | 0.94 | Hehir-Kwa | 27708267 | Supplementary Data 7 | Y |
| rs12530    | ALU | 0.91 | Hehir-Kwa | 27708267 | Supplementary Data 7 | Ν |
| rs2300747  | ALU | 0.92 | Payer     | 28465436 | Dataset S3           | Ν |
| rs1335532  | ALU | 1.00 | Payer     | 28465436 | Dataset S3           | Ν |
| rs2779116  | ALU | 0.81 | Payer     | 28465436 | Dataset S3           | Ν |
| rs857721   | ALU | 0.81 | Payer     | 28465436 | Dataset S3           | Ν |
| rs857684   | ALU | 0.81 | Payer     | 28465436 | Dataset S3           | Ν |
| rs426736   | ALU | 1.00 | Payer     | 28465436 | Dataset S3           | Ν |
| rs1367228  | ALU | 0.77 | Payer     | 28465436 | Dataset S3           | Ν |
| rs12463617 | ALU | 0.91 | Payer     | 28465436 | Dataset S3           | Y |
| rs7561317  | ALU | 1.00 | Payer     | 28465436 | Dataset S3           | Y |
| rs6548238  | ALU | 1.00 | Payer     | 28465436 | Dataset S3           | Y |
| rs2867125  | ALU | 1.00 | Payer     | 28465436 | Dataset S3           | Y |
| rs6711012  | ALU | 1.00 | Payer     | 28465436 | Dataset S3           | Y |
| rs10189761 | ALU | 1.00 | Payer     | 28465436 | Dataset S3           | Y |
| rs2903492  | ALU | 1.00 | Payer     | 28465436 | Dataset S3           | Y |
| rs2667011  | ALU | 0.80 | Payer     | 28465436 | Dataset S3           | Ν |
| rs6738825  | ALU | 0.92 | Payer     | 28465436 | Dataset S3           | Y |
| rs16857609 | ALU | 0.95 | Payer     | 28465436 | Dataset S3           | Ν |
| rs11177    | ALU | 0.91 | Payer     | 28465436 | Dataset S3           | Ν |
| rs2251219  | ALU | 0.96 | Payer     | 28465436 | Dataset S3           | Ν |
| rs4256159  | ALU | 0.93 | Payer     | 28465436 | Dataset S3           | Ν |
| rs2712381  | ALU | 0.88 | Payer     | 28465436 | Dataset S3           | Ν |
| rs2362965  | ALU | 1.00 | Payer     | 28465436 | Dataset S3           | Ν |
| rs9877502  | ALU | 1.00 | Payer     | 28465436 | Dataset S3           | Ν |
| rs2087160  | ALU | 0.72 | Payer     | 28465436 | Dataset S3           | Ν |
| rs6825911  | ALU | 0.84 | Payer     | 28465436 | Dataset S3           | Ν |
| rs10034228 | ALU | 0.96 | Payer     | 28465436 | Dataset S3           | Ν |
| rs11748327 | ALU | 0.82 | Payer     | 28465436 | Dataset S3           | Ν |
| rs9472155  | ALU | 0.95 | Payer     | 28465436 | Dataset S3           | Ν |
| rs441460   | ALU | 0.96 | Payer     | 28465436 | Dataset S3           | Ν |
| rs204247   | ALU | 1.00 | Payer     | 28465436 | Dataset S3           | Ν |
| rs11759769 | ALU | 0.89 | Payer     | 28465436 | Dataset S3           | Y |
| rs7809799  | ALU | 1.00 | Payer     | 28465436 | Dataset S3           | Ν |
| rs4609139  | ALU | 0.85 | Payer     | 28465436 | Dataset S3           | Ν |
| rs2293889  | ALU | 0.80 | Payer     | 28465436 | Dataset S3           | Ν |
| rs13281615 | ALU | 0.77 | Payer     | 28465436 | Dataset S3           | Ν |
| rs16901979 | ALU | 1.00 | Payer     | 28465436 | Dataset S3           | Ν |
| rs10505483 | ALU | 1.00 | Payer     | 28465436 | Dataset S3           | Ν |
| rs6983561  | ALU | 1.00 | Payer     | 28465436 | Dataset S3           | Ν |
| rs10512248 | ALU | 0.96 | Payer     | 28465436 | Dataset S3           | Ν |

| rs399593   | ALU | 1.00 | Payer | 28465436 | Dataset S3 | Ν |  |
|------------|-----|------|-------|----------|------------|---|--|
| rs7089424  | ALU | 0.83 | Payer | 28465436 | Dataset S3 | Ν |  |
| rs10821936 | ALU | 0.83 | Payer | 28465436 | Dataset S3 | Ν |  |
| rs2638953  | ALU | 0.89 | Payer | 28465436 | Dataset S3 | Ν |  |
| rs10771399 | ALU | 0.92 | Payer | 28465436 | Dataset S3 | Y |  |
| rs10843164 | ALU | 0.96 | Payer | 28465436 | Dataset S3 | Y |  |
| rs2066808  | ALU | 1.00 | Payer | 28465436 | Dataset S3 | Y |  |
| rs2066807  | ALU | 1.00 | Payer | 28465436 | Dataset S3 | Y |  |
| rs17788937 | ALU | 0.83 | Payer | 28465436 | Dataset S3 | Y |  |
| rs975739   | ALU | 0.87 | Payer | 28465436 | Dataset S3 | Ν |  |
| rs4900384  | ALU | 0.78 | Payer | 28465436 | Dataset S3 | Ν |  |
| rs1456988  | ALU | 0.82 | Payer | 28465436 | Dataset S3 | Ν |  |
| rs10519227 | ALU | 0.76 | Payer | 28465436 | Dataset S3 | Y |  |
| rs7178424  | ALU | 0.78 | Payer | 28465436 | Dataset S3 | Ν |  |
| rs8038465  | ALU | 0.83 | Payer | 28465436 | Dataset S3 | Y |  |
| rs10852344 | ALU | 0.75 | Payer | 28465436 | Dataset S3 | Ν |  |
| rs3729639  | ALU | 1.00 | Payer | 28465436 | Dataset S3 | Ν |  |
| rs4351     | ALU | 0.89 | Payer | 28465436 | Dataset S3 | Ν |  |
| rs2665838  | ALU | 0.92 | Payer | 28465436 | Dataset S3 | Ν |  |
| rs2941551  | ALU | 0.92 | Payer | 28465436 | Dataset S3 | Ν |  |
| rs11658329 | ALU | 0.96 | Payer | 28465436 | Dataset S3 | Ν |  |
| rs4343     | ALU | 1.00 | Payer | 28465436 | Dataset S3 | Ν |  |
| rs4329     | ALU | 1.00 | Payer | 28465436 | Dataset S3 | Ν |  |
| rs9894429  | ALU | 0.81 | Payer | 28465436 | Dataset S3 | Ν |  |
| rs6015450  | ALU | 1.00 | Payer | 28465436 | Dataset S3 | Ν |  |
|            |     |      |       |          |            |   |  |